<SUBMISSION>
<ACCESSION-NUMBER>0000950135-09-003035
<TYPE>DEF 14A
<PUBLIC-DOCUMENT-COUNT>6
<PERIOD>20090605
<FILING-DATE>20090423
<DATE-OF-FILING-DATE-CHANGE>20090423
<EFFECTIVENESS-DATE>20090423
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>RXI PHARMACEUTICALS CORP
<CIK>0001390478
<ASSIGNED-SIC>2834
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DEF 14A
<ACT>34
<FILE-NUMBER>001-33958
<FILM-NUMBER>09765011
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
<PHONE>508-767-3861
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>b73679dfdef14a.htm
<DESCRIPTION>RXI PHARMACEUTICALS CORPORATION
<TEXT>
<HTML>
<HEAD>
<TITLE>def14a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>SCHEDULE 14A</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>INFORMATION REQUIRED IN PROXY STATEMENT<BR>
SCHEDULE 14A INFORMATION</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the Securities<BR>
Exchange Act of 1934 (Amendment No. )</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Filed by the Registrant <FONT face="Wingdings">&#254;</FONT><BR>
Filed by a Party other than the Registrant <FONT face="Wingdings">&#111;</FONT><BR>
Check the appropriate box:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preliminary Proxy Statement<BR>
<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B><BR>
<FONT face="Wingdings">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Definitive Proxy Statement<BR>
<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Definitive Additional Materials<BR>
<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting Material Pursuant to &#167;240.14a-12

</DIV>
<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>RXi Pharmaceuticals Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Name of Registrant as Specified In Its Charter)<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>

<DIV align="left" style="font-size: 10pt">Payment of Filing Fee (Check the appropriate box):</DIV>



<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#254;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No fee required.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1) and 0-11.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Title of each class of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Aggregate number of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Proposed maximum aggregate value of transaction:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total fee paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fee paid previously with preliminary materials.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Check box if any part of the fee is offset as provided by Exchange
Act Rule&nbsp;0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the
date of its filing.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amount Previously Paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Form, Schedule or Registration Statement No.:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Filing Party:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Date Filed:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="b73679dfb7367900.gif" alt="(RXI LOGO)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">60
    Prescott Street<BR>
    Worcester, Massachusetts 01605</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">April&#160;23,
    2009
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dear Stockholder:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You are cordially invited to attend the 2009 Annual Meeting of
    Stockholders of RXi Pharmaceuticals Corporation. The meeting
    will be held at the Company&#146;s offices at 60 Prescott
    Street, Worcester, Massachusetts, at 10:00&#160;A.M., local
    time, on Friday, June&#160;5, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Notice of Meeting and the Proxy Statement on the following
    pages cover the formal business of the meeting. At the Annual
    Meeting, I will also report on RXi&#146;s current operations and
    will be available to respond to questions from stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Whether or not you plan to attend, it is important that your
    shares be represented and voted at the meeting. I urge you,
    therefore, to return a signed proxy card or vote by telephone or
    over the internet, so that you can be sure your votes are
    properly counted, even if you plan to attend the meeting.
    Information about voting procedures can be found in the proxy
    statement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    I hope you will join us.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sincerely,
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="b73679dfb7367902.gif" alt="-s- Tod M. Woolf">
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Tod M. Woolf,&#160;Ph.D.<BR>
    President and Chief Executive Officer
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="b73679dfb7367900.gif" alt="(RXI LOGO)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">60
    Prescott Street<BR>
    Worcester, Massachusetts 01605</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">NOTICE OF ANNUAL MEETING OF
    STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">To Be Held On June&#160;5,
    2009</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Notice is hereby given to the holders of common stock, of RXi
    Pharmaceuticals Corporation, that the Annual Meeting of
    Stockholders will be held on Friday, June&#160;5, 2009 at the
    Company&#146;s offices at 60 Prescott Street, Worcester,
    Massachusetts, 01605, at 10:00&#160;A.M., local time, for the
    following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="8%"></TD>
    <TD width="4%"></TD>
    <TD width="88%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;
</TD>
    <TD align="left">
    To elect two directors to serve until the 2012 Annual Meeting of
    Stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;
</TD>
    <TD align="left">
    To ratify the selection of BDO Seidman, LLP as our independent
    registered public accounting firm for the fiscal year ending
    December&#160;31, 2009;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;
</TD>
    <TD align="left">
    To consider and act on a proposal to approve an amendment to the
    2007 Incentive Plan;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (4)&#160;
</TD>
    <TD align="left">
    To transact such other business as may properly come before the
    Annual Meeting or any postponement or adjournment thereof.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Only those stockholders of record at the close of business on
    April&#160;14, 2009 are entitled to notice of and to vote at the
    Annual Meeting or any postponement or adjournment thereof. A
    complete list of stockholders entitled to vote at the Annual
    Meeting will be available at the Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors recommends that you vote your shares
    <B>&#147;FOR&#148; </B>each of the nominees for director,
    <B>&#147;FOR&#148; </B>the ratification of the selection of BDO
    Seidman, LLP as our independent registered public accounting
    firm for the fiscal year ending December&#160;31, 2009, and
    <B>&#147;FOR&#148; </B>the approval of an amendment to the 2007
    Incentive Plan.
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By Order of the Board of Directors,
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="b73679dfb7367903.gif" alt="-s- Stephen J. DiPalma">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stephen J. DiPalma<BR>
    Corporate Secretary
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April&#160;23, 2009
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 85%; margin-left: 7%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<DIV style="width: 100%; border-top: 1px solid #000000; padding-top: 11pt; border-right: 1px solid #000000; padding-right: 11pt; border-bottom: 1px solid #000000; padding-bottom: 11pt; border-left: 1px solid #000000; padding-left: 11pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Important Notice Regarding the Availability of Proxy
    Materials for the Shareholder Meeting to be Held on June&#160;5,
    2009. The proxy statement, the proxy card, and the 2008 Annual
    Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    are available online via the Internet at:
    <I><FONT style="white-space: nowrap">http://www.envisionreports.com/RXII</FONT></I></B>.
</DIV>
</DIV><!-- End box 1 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 85%; margin-left: 7%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="b73679dfb7367900.gif" alt="(RXI LOGO)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">60
    Prescott Street<BR>
    Worcester, Massachusetts 01605<BR>
    To Be Held June&#160;5, 2009<BR>
    <BR>
    <FONT style="font-size: 12pt">PROXY STATEMENT</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This Proxy Statement is furnished to holders of common stock, of
    RXi Pharmaceuticals Corporation, a Delaware corporation, in
    connection with the solicitation of proxies by our Board of
    Directors for use at our 2009 Annual Meeting of Stockholders to
    be held at the Company&#146;s offices at 60 Prescott Street,
    Worcester, Massachusetts 01605, at 10:00&#160;A.M., local time,
    on Friday, June&#160;5, 2009, and at any postponement or
    adjournment thereof. This Proxy Statement and the accompanying
    proxy card are first being mailed to our stockholders on or
    about April&#160;23, 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What is
    the purpose of the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At the Annual Meeting, stockholders will act upon the matters
    referred to in the attached Notice of Meeting and described in
    detail in this Proxy Statement, which are the election of
    directors, the ratification of our appointment of independent
    accountants and a proposal to amend the 2007 Incentive Plan. In
    addition, management will report on our performance during
    fiscal year 2008 and respond to appropriate questions from
    stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who is
    entitled to vote at the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Only stockholders of record at the close of business on
    April&#160;14, 2009 will be entitled to notice of, and to vote
    at, the Annual Meeting or any adjournment or postponement
    thereof. These shares include those (1)&#160;held directly in
    your name as the <I>shareholder of record</I>, and (2)&#160;held
    for you as the <I>beneficial owner </I>through a broker, bank or
    other nominee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What is
    the difference between holding shares as a shareholder of record
    and as a beneficial owner?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most RXi shareholders hold their shares through a broker, bank
    or other nominee rather than directly in their own name as the
    shareholder of record. As summarized below, there are some
    distinctions between shares held of record and those owned
    beneficially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Shareholder of Record</I>&#160;&#151; If your shares are
    registered directly in your name with RXi&#146;s Transfer Agent,
    Computershare Trust&#160;Company, N.A.
    (&#147;Computershare&#148;), you are considered, with respect to
    those shares, the <I>shareholder of record</I>. As the
    <I>shareholder of record</I>, you have the right to grant your
    voting proxy directly to RXi or to vote in person at the Annual
    Meeting.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Beneficial Owner&#160;&#151; </I>If your shares are held in a
    stock brokerage account or by a bank or other nominee, you are
    considered the beneficial owner of shares held <I>in street name
    </I>and your broker or nominee is considered, with respect to
    those shares, the <I>shareholder of record. </I>As the
    beneficial owner, you have the right to direct your broker or
    nominee on how to vote and are also invited to attend the Annual
    Meeting. However, since you are not the <I>shareholder of
    record</I>, you may not vote these shares in person at the
    Annual Meeting unless you receive a proxy from your broker or
    nominee. Your broker or nominee has provided voting instructions
    for you to use. If you wish to attend the Annual Meeting and
    vote in person, please contact your broker or nominee so that
    you can receive a legal proxy to present at the Annual Meeting.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What
    constitutes a quorum?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Bylaws provide that the presence, in person or by proxy, at
    our Annual Meeting of the holders of a majority of outstanding
    shares of our common stock will constitute a quorum for the
    transaction of business.
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purpose of determining the presence of a quorum, proxies
    marked &#147;withhold authority&#148; or &#147;abstain&#148;
    will be counted as present. Shares represented by proxies that
    include so-called broker non-votes also will be counted as
    shares present for purposes of establishing a quorum. On the
    record date, there were 13,821,629&#160;shares of our common
    stock issued and outstanding, exclusive of treasury shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What are
    the voting rights of the holders of RXi&#146;s common
    stock?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of common stock entitles its holder to one vote on
    all matters to come before the Annual Meeting, including the
    election of directors. In the election of directors, for each of
    the nominees you may vote &#147;FOR&#148; such nominee or your
    vote may be &#147;WITHHELD&#148; with respect to such nominee.
    For the other proposals, you may vote &#147;FOR&#148;,
    &#147;AGAINST&#148; or &#147;ABSTAIN&#148;. If you
    &#147;ABSTAIN&#148;, it has the same effect as a vote
    &#147;AGAINST&#148; the proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you vote via the Internet or telephone and do not specify
    contrary voting instructions, your shares will be voted in
    accordance with the recommendations of the Board. Similarly, if
    you sign and submit your proxy card or voting instruction card
    with no instructions, your shares will be voted in accordance
    with the recommendations of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a shareholder of record and do not either vote via
    the Internet, via telephone, or return a signed proxy card, your
    shares will not be voted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a beneficial shareholder and do not vote via the
    Internet, telephone, or by returning a signed voting instruction
    card, your shares may be voted in situations where brokers have
    discretionary voting authority over the shares. Discretionary
    voting authority is permitted on the proposals for the election
    of directors and the ratification of the selection of BDO
    Seidman, LLP as the independent registered public accounting
    firm for 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What Vote
    Is Required For The Proposal?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following votes are required with respect to the proposals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For the election of directors, the candidate receiving the
    greatest number of affirmative votes (a &#147;plurality
    vote&#148;) of the votes attached to shares of common stock will
    be elected.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For the approval of Proposal&#160;II, the affirmative vote of a
    majority of the shares present, in person or by proxy, and
    entitled to vote at the Annual Meeting is required.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For the approval of Proposal&#160;III, the affirmative vote of a
    majority of the shares present, in person or by proxy, and
    entitled to vote at the Annual Meeting is required.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An automated system administered by the Company&#146;s transfer
    agent will tabulate votes cast by proxy at the Annual Meeting,
    and an officer of the Company will tabulate votes cast in person
    at the Annual Meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Why did I
    receive a notice of the Internet availability of RXi&#146;s
    proxy materials (the &#147;Notice&#148;), instead of a full set
    of printed proxy materials?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    New rules adopted by the Securities and Exchange Commission
    allowed us, beginning this year, to provide access to our proxy
    materials over the Internet instead of mailing a full set of
    such materials to every shareholder. We have sent a Notice of
    the availability of the proxy materials on the Internet to all
    of our shareholders. All of our shareholders may access our
    proxy materials over the Internet using the directions set forth
    in the Notice. In addition, by following the instructions in the
    Notice, any shareholder may request that a full set of printed
    proxy materials be sent to them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have chosen to send the Notice of the Internet availability
    of our proxy materials to shareholders, instead of automatically
    sending a full set of printed copies to all shareholders, to
    reduce the impact of printing our proxy materials on the
    environment and to save on the costs of printing and mailing
    incurred by us.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How do I
    access RXi&#146;s proxy materials online?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Notice of Internet availability of the proxy materials
    provides instructions for accessing the proxy materials for the
    Annual Meeting over the Internet, and includes the Internet
    address where those materials are available. RXi&#146;s proxy
    statement for the Annual Meeting and 2009 Annual Report can be
    viewed online via the Internet at:
    <B><I><U><FONT style="white-space: nowrap">http://www.envisionreports.com/RXII</FONT></U>.</I></B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How do I
    request a paper copy of the proxy materials?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Paper copies of RXi&#146;s proxy materials will be made
    available at no cost to you, but they will only be sent to you
    if you request them. To request a paper copy of the proxy
    materials follow the instructions on the Notice which you
    received. You will be able to submit your request for copies of
    the proxy materials by sending an email to the email address set
    forth in the Notice, by going to the Internet address set forth
    in the Notice or by calling the phone number provided in the
    Notice.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What are
    the Board&#146;s recommendations?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The recommendations of our Board of Directors are set forth
    together with the description of each Proposal in this Proxy
    Statement. In summary, our Board of Directors recommends a vote:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>&#147;FOR&#148; </I>election of the directors named in this
    Proxy Statement as described in Proposal&#160;I;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>&#147;FOR&#148; </I>ratification of the appointment of BDO
    Seidman, LLP as our independent registered public accounting
    firm for fiscal 2009 as described in Proposal&#160;II;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>&#147;FOR&#148; </I>approval of the amendment of the 2007
    Incentive Plan as described in Proposal&#160;III.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    attend the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may attend the Annual Meeting if you are listed as a
    shareholder of record as of April&#160;14, 2009 and bring proof
    of your identification. If you hold your shares through a broker
    or other nominee, you will need to provide proof of your share
    ownership by bringing either a copy of a brokerage statement
    showing your share ownership as of April&#160;14, 2009, or a
    legal proxy if you wish to vote your shares in person at the
    Annual Meeting. In addition to the items mentioned above, you
    should bring proof of your identification.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    vote my shares in person at the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares held directly in your name as the <I>shareholder of
    record </I>may be voted in person at the Annual Meeting. If you
    choose to do so, please bring proof of your identification to
    the Annual Meeting. Shares beneficially owned may be voted by
    you if you receive and present at the Annual Meeting a proxy
    from your broker or nominee, together with proof of
    identification. Even if you plan to attend the Annual Meeting,
    we recommend that you also vote in one of the ways described
    below so that your vote will be counted if you later decide not
    to attend the Annual Meeting or are otherwise unable to attend.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    vote my shares without attending the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Whether you hold shares directly as the shareholder of record or
    beneficially in street name, you may direct your vote without
    attending the Annual Meeting. You may vote by granting a proxy
    or, for shares held in street name, by submitting voting
    instructions to your broker or nominee. In most instances, you
    will be able to do this over the Internet, by telephone or by
    mail. Please refer to the summary instructions below, the
    instructions included on the Notice of Internet availability of
    the proxy materials, and if you request printed proxy materials,
    the instructions included on your proxy card or, for shares held
    in street name, the voting instruction card provided by your
    broker or nominee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>By Internet </I>&#151;&#160;If you have Internet access, you
    may submit your proxy from any location in the world by
    following the Internet voting instructions on the Notice you
    received or by following the Internet voting instructions on the
    proxy card or voting instruction card sent to you.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>By Telephone </I>&#151;&#160;You may submit your proxy by
    following the telephone voting instructions on the Notice you
    received or by following the telephone voting instructions on
    the proxy card or voting instruction card sent to you.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>By Mail </I>&#151;&#160;You may do this by marking, dating
    and signing your proxy card or, for shares held in street name,
    the voting instruction card provided to you by your broker or
    nominee, and mailing it in the enclosed, self-addressed, postage
    prepaid envelope. No postage is required if mailed in the United
    States. Please note
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    that you will only be mailed a printed proxy card or printed
    voting instruction card if you request that such printed
    materials be sent to you by following the instructions in the
    Notice for requesting paper copies of the proxy materials.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Can I
    change my vote or revoke my proxy?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may change your proxy instructions at any time prior to the
    vote at the Annual Meeting. For shares held directly in your
    name, you may accomplish this by granting another proxy that is
    properly signed and bears a later date, by sending a properly
    signed written notice to the Corporate Secretary of the Company
    or by attending the Annual Meeting and voting in person. To
    revoke a proxy previously submitted by telephone or through the
    Internet, you may simply vote again at a later date, using the
    same procedures, in which case your later submitted vote will be
    recorded and your earlier vote revoked. Attendance at the Annual
    Meeting will not cause your previously granted proxy to be
    revoked unless you specifically so request. For shares held
    beneficially by you, you may change your vote by submitting new
    voting instructions to your broker or nominee. All written
    notices should be addressed as follows: RXi Pharmaceuticals
    Corporation, 60 Prescott Street, Worcester, Massachusetts 01605,
    Attention: Corporate Secretary
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What does
    it mean if I receive more than one Notice of the Internet
    availability of proxy materials, or more than one proxy or
    voting instruction card?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It means your shares are registered differently or are held in
    more than one account. Please provide voting instructions for
    all Notices, or proxy and voting instruction cards you receive.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Where can
    I find the voting results of the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will announce preliminary voting results at the Annual
    Meeting. We will publish final voting results in a Current
    Report on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    within a few days following the Annual Meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">If I am a
    shareholder of record how do I consent to receive my annual
    meeting materials electronically?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shareholders of record that choose to vote their shares via the
    Internet will be asked to choose a delivery preference prior to
    voting their shares. After entering the access information
    requested by the electronic voting site, click &#147;Login&#148;
    and then respond as to whether you would like to receive proxy
    material via <I>electronic </I>delivery. If you would like to
    receive future proxy materials electronically click the
    applicable button, enter and verify your current email address
    and then click &#147;Continue&#148;. Shareholders of record with
    multiple RXi accounts will need to consent to electronic
    delivery for each account separately.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Proposal&#160;I&#160;&#151; Election of
    Directors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Proposal&#160;II&#160;&#151; Ratification of
    Appointment of Independent Registered Public Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Proposal&#160;III&#160;&#151; Amendment of the
    2007 Incentive Plan</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Stockholder Proposals</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Other Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Annex&#160;A&#160;&#151; RXi Pharmaceuticals
    Corporation 2007 Incentive Plan</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    A-1
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;I<BR>
    ELECTION OF DIRECTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors currently is comprised of six members,
    who are divided into three classes. Each director will serve for
    a term ending on the date of the third annual meeting following
    the annual meeting at which such director was elected. The
    directors in Class&#160;I, Tod Woolf and Rudolph Nisi, will
    serve for a term ending on the date of the annual meeting in
    2011, the directors in Class&#160;II, Mark J. Ahn and Stephen S.
    Galliker, will serve for a term ending on the date of the annual
    meeting in 2009, and the directors in Class&#160;III, Sanford J.
    Hillsberg and Steven A. Kriegsman, will serve for a term ending
    on the date of the annual meeting in 2010, with each director to
    hold office until his or her successor is duly elected and
    qualified. The term of the two directors in Class&#160;II expire
    at this Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is information concerning the nominees for
    election of directors, as well as the directors whose terms of
    office will continue after the Annual Meeting. Each
    director&#146;s age is indicated in parentheses after his name.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Current
    Nominees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that these nominees will be available and able to
    serve as directors. In the event that either nominee is unable
    or unwilling to serve, the proxy holders will vote the proxies
    for such other nominee as they may determine.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Class&#160;II&#160;&#151;
    Nominees to Serve as Director Until the 2012 Annual
    Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mark J. Ahn,&#160;Ph.D. (46)&#160;</I>has been one of our
    directors since 2007. Dr.&#160;Ahn is Professor and Chair,
    Science&#160;&#038; Technology Management with a joint
    appointment from the faculties of Commerce&#160;&#038;
    Administration and Science, Victoria University of Wellington.
    He is also a Principal of Pukana Partners, Ltd., a strategic
    consulting firm. Prior to that he was founder, President and
    Chief Executive Officer and a member of the Board of Directors
    for Hana Biosciences from 2003 to 2007. Prior to joining Hana,
    he served as Vice President, Hematology and corporate officer at
    Genentech, Inc. where he was responsible for commercial and
    clinical development of the Hematology franchise from 2001
    through 2003. Dr.&#160;Ahn was also employed by Amgen (1990 to
    1997)&#160;and Bristol-Myers Squibb Company (1997 to 2001),
    holding a series of positions of increasing responsibility in
    strategy, general management, sales and marketing, business
    development, and finance. He also serves on the Board of
    Directors of Access Pharmaceuticals and Mesynthes. Dr.&#160;Ahn
    received a BA and MBA from Chaminade University, where he
    currently serves on the Board of Governors. He was a graduate
    fellow in Economics at Essex University, and has a Ph.D. from
    the University of South Australia. Dr.&#160;Ahn is a Henry Crown
    Fellow at the Aspen Institute.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stephen Galliker, CPA (62)&#160;</I>has been one of our
    directors since 2007. Mr.&#160;Galliker served as the Executive
    Vice&#160;President, Finance and Administration, and Chief
    Financial Officer of Dyax Corp. from 1999 until his retirement
    in July 2008. From 1996 to 1999, Mr.&#160;Galliker was the Chief
    Financial Officer of Excel Switching Corporation, a developer
    and manufacturer of open switching platforms for
    telecommunications networks, and was Excel&#146;s Vice
    President, Finance and Administration from 1997 to 1999. From
    1992 to 1996, Mr.&#160;Galliker was employed by Ultracision,
    Inc., a developer and manufacturer of ultrasonically powered
    surgical instruments, where he served as Chief Financial Officer
    and Vice President of Finance until 1995, when he became
    Ultracision&#146;s Chief Operating Officer. Mr.&#160;Galliker is
    also a director of Osteotech, Inc., a medical device company.
    Mr.&#160;Galliker is a Certified Public Accountant and received
    a B.S. from Georgetown University and an M.B.A. from the
    University of Chicago.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE BOARD
    OF DIRECTORS RECOMMENDS A VOTE FOR THE NOMINEES FOR<BR>
    ELECTION AS DIRECTORS.</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Continuing
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a description of the directors in Class&#160;I
    and Class&#160;III whose terms of office will continue after the
    Annual Meeting.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Class&#160;III&#160;&#151;
    Term Expiring at the 2010 Annual Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Sanford J. Hillsberg,&#160;J.D. (60)&#160;</I>has been the
    Chairman of our Board of Directors since 2007.
    Mr.&#160;Hillsberg has been an attorney with TroyGould PC since
    1976 and is a member of the firm&#146;s Management Committee.
    Mr.&#160;Hillsberg was a founder and until December 2007, served
    as a director and Secretary of ImmunoCellular Therapeutics,
    Ltd., a publicly-held biopharmaceutical company formed to
    develop cellular therapies, including dendritic cell-based
    vaccines for the treatment of brain and other cancers, and its
    predecessor company since February 2004. Mr.&#160;Hillsberg
    served as a director and Secretary of Duska Therapeutics, Inc.,
    a publicly-held biopharmaceutical company, and its predecessor
    company from 1999 until January 2006. He previously served as a
    director and Vice President of Medco Research, Inc., a then
    publicly-held pharmaceutical company. Mr.&#160;Hillsberg is a
    member of the Board of Governors of Cedars-Sinai Medical Center
    and has also previously served as a Commissioner of the Quality
    and Productivity Commission of the City of Los Angeles.
    Mr.&#160;Hillsberg holds a B.A. degree from the University of
    Pennsylvania and a J.D. degree from Harvard Law School.
    TroyGould PC, including Mr.&#160;Hillsberg, has represented
    CytRx since 2003.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Steven A. Kriegsman (67)&#160;</I>has been one of our
    directors since 2006. Mr.&#160;Kriegsman has been a director and
    the President and Chief Executive Officer of CytRx since July
    2002. He previously served as Director and Chairman of Global
    Genomics from June 2000 until July 2002. Mr.&#160;Kriegsman is
    the Chairman of the Board and Founder of Kriegsman Capital Group
    LLC, a financial advisory firm specializing in the development
    of alternative sources of equity capital for emerging growth
    companies in the healthcare industry. He has advised such
    companies as SuperGen Inc., Closure Medical Corporation, Novoste
    Corporation, Miravant Medical Technologies and Maxim
    Pharmaceuticals. Mr.&#160;Kriegsman has a B.S. degree with
    honors from New York University in Accounting and completed the
    Executive Program in Mergers and Acquisitions at New York
    University, The Management Institute. Mr.&#160;Kriegsman was
    formerly a Certified Public Accountant with KPMG in New York
    City. From June 2003 until February 2008, he served as a
    Director, and he is the former Chairman of the Audit Committee
    of Bradley Pharmaceuticals, Inc. From June 2008 to the present,
    Mr.&#160;Kriegsman has served on the Board of Directors of
    Hythiam, Inc. and serves as chairman of Hythiam&#146;s audit
    committee. In February 2006, Mr.&#160;Kriegsman received the
    Corporate Philanthropist of the Year Award from the Greater Los
    Angeles Chapter of the ALS Association and in October 2006, he
    received the Lou Gehrig Memorial Corporate Award from the
    Muscular Dystrophy Association. Mr.&#160;Kriegsman has been
    active in various charitable organizations including the
    Biotechnology Industry Organization, the ALS Association, the
    Los Angeles Venture Association, the Southern California
    Biomedical Council, and the Palisades-Malibu YMCA.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Class&#160;I&#160;&#151;
    Term Expiring at the 2011 Annual Meeting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Tod M. Woolf,&#160;Ph.D. (44)&#160;</I>has been our President
    and Chief Executive Officer and a director since 2007.
    Dr.&#160;Woolf has 20&#160;years of experience developing and
    commercializing innovative biomedical technologies. He
    previously worked at numerous biotechnology companies including
    Ribozyme Pharmaceuticals (now Sirna Therapeutics), where he
    co-developed a number of lead therapeutic RNA compounds and
    developed
    Genbloc<FONT style="font-variant: SMALL-CAPS">tm</FONT> RNA
    technology, which was spun out to create Atugen (now called
    Silence Therapeutics). In 1996 he founded and served as Chief
    Executive Officer of Sequitur, an RNAi company acquired by
    Invitrogen Corporation in 2003. At Sequitur, Dr.&#160;Woolf
    co-invented and commercialized
    Stealth<FONT style="font-variant: SMALL-CAPS">tm</FONT> RNAi,
    one of the most widely used second-generation RNAi research
    products. Also at Sequitur, he established collaborations with
    over a dozen major pharmaceutical companies. From 2003 through
    2006, Dr.&#160;Woolf was an advisor to Invitrogen and more
    recently has served as an advisor to Signet Laboratories prior
    to its acquisition by Covance, and has advised ProNai and
    Praecis Pharmaceuticals. Furthermore, beginning in 2004,
    Dr.&#160;Woolf has served as the President and owner of IPIFINI,
    Inc., a consulting company focused on technology development and
    from 2006 to 2007, Dr.&#160;Woolf acted as a consultant to CytRx
    Corporation with a focus on strategic advising in relation to
    its RNAi assets. Dr.&#160;Woolf earned his Masters and Ph.D. in
    Cellular and Development Biology at Harvard University from 1987
    through 1991, where he performed work in the then-nascent field
    of RNA therapeutics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Rudolph Nisi,&#160;M.D., </I>(71)&#160;has been one of our
    directors since January, 2009. Dr.&#160;Nisi has held various
    positions at New York Westchester Square Medical Center. In
    addition to having been on the Active Staff in Internal
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medicine/Cardiology since 1963, Dr.&#160;Nisi is also Director
    of Medicine since 1975, Chief of Cardiology since 1975, Chairman
    of Medical Critical Care Unit since 1975, President of the
    Medical Board from 1977 to 1978, Chairman of the Board of
    Trustees since 1983 and from 1976 to 1978, Chairman of the ER
    Committee since 1984, and Vice-President of Medical Affairs
    since 1993. Dr.&#160;Nisi was the Chairman of the Board of Medco
    Research Inc. Dr.&#160;Nisi has also served as an Attending
    Physician at New York Hospital, a Clinical Assistant Professor
    of Medicine at Cornell University Medical College and an
    Assistant Dean at Weill Medical College of Cornell University.
    Dr.&#160;Nisi has also served as a director of Tempra
    Technology, Inc., a thermal research and development company,
    since 1997 and on the boards of Touchtone HMO and New York
    Presbyterian Hospital. Dr.&#160;Nisi holds a B.S. degree from
    Fordham University and a Doctor of Medicine degree from the
    University of Rome Medical School in Rome, Italy and is a fellow
    in the American College of Cardiology.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Meetings
    of the Board of Directors and Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Board of Directors.</I>&#160;&#160;The property, affairs and
    business of RXi are conducted under the general supervision and
    management of our Board of Directors as called for under the
    laws of Delaware and our Bylaws. Our Board of Directors has
    established a standing Audit Committee, Compensation Committee
    and Nomination and Governance Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors held 13 meetings during 2008. All
    directors were in attendance for 12 out of the 13 meetings, with
    only one director being absent from only one meeting. Board
    agendas include regularly scheduled executive sessions for the
    independent directors to meet without management present.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Director Independence.</I>&#160;&#160;Our Board of Directors
    has determined that Messrs.&#160;Hillsberg, Ahn, Nisi and
    Galliker each are &#147;independent&#148; under the current
    independence standards of both the NASDAQ Capital Market and the
    Securities and Exchange Commission, or SEC, and have no material
    relationships with us (either directly or as a partner,
    shareholder or officer of any entity) that could be inconsistent
    with a finding of their independence as members of our Board of
    Directors or as the members of our Audit Committee. Our Board of
    Directors also has determined that Mr.&#160;Galliker, one of the
    independent directors serving on our Audit Committee, is our
    audit committee financial expert.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table provides information concerning the current
    membership of our Board committees:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nomination and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Class of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Audit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Governance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Strategy<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Directors(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sanford J. Hillsberg(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    III
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tod M. Woolf,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    I
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mark J. Ahn,&#160;Ph.D.(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    II
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen S. Galliker(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    II
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steven A. Kriegsman(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    III
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rudolph Nisi M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    I
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Class&#160;I directors serve until the 2011 Annual Meeting of
    Stockholders, Class&#160;II directors serve until the 2009
    Annual Meeting of Stockholders and Class&#160;III directors
    serve until the 2010 Annual Meeting of Stockholders.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Galliker is the Chairman of the Audit Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Kriegsman is Chairman of the Strategy Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Ahn is Chairman of the Nominating and Corporate
    Governance Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Hillsberg is Chairman of the Compensation Committee.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table provides information concerning the
    membership of our Board committees through March&#160;27, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nomination and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Class of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Audit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Governance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Directors(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sanford J. Hillsberg
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    III
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tod M. Woolf,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    I
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mark J. Ahn,&#160;Ph.D.(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    II
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen S. Galliker(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    II
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steven A. Kriegsman(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    III
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    x
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Class&#160;I directors serve until the 2011 Annual Meeting of
    Stockholders, Class&#160;II directors serve until the 2009
    Annual Meeting of Stockholders and Class&#160;III directors
    serve until the 2010 Annual Meeting of Stockholders.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Galliker is the Chairman of the Audit Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Kriegsman was the Chairman of the Compensation
    Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Ahn is Chairman of the Nominating and Corporate
    Governance Committee.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Audit Committee.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has determined that each of the current
    members of the Audit Committee are &#147;independent&#148; under
    the current independence standards of the NASDAQ Capital Market.
    The Audit Committee assists the Board of Directors in fulfilling
    its oversight responsibilities relating to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The quality and integrity of our financial statements and
    reports.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The independent registered public accounting firm&#146;s
    qualifications and independence.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The performance of our independent auditors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee reviews our financial structure, policies
    and procedures, appoints the outside independent registered
    public accounting firm, reviews with the outside independent
    registered public accounting firm the plans and results of the
    audit engagement, approves permitted non-audit services provided
    by our independent registered public accounting firm, reviews
    the independence of the auditors and reviews the adequacy of our
    internal accounting controls. The Audit Committee&#146;s
    responsibilities also include oversight activities described
    below under the &#147;Report of the Audit Committee.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee has discussed with the outside independent
    registered public accounting firm the auditors&#146;
    independence from management and RXi, including the matters in
    the written disclosures required by the Public Company
    Accounting Oversight Board and considered the compatibility of
    permitted non-audit services with the auditors&#146;
    independence. The Audit Committee operates pursuant to a written
    charter, which is available on our website, www.rxipharma.com.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee held 10 meetings during 2008.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Report of
    the Audit Committee</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary function of the Audit Committee is to assist the
    Board of Directors in fulfilling its oversight responsibilities
    relating to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The quality and integrity of RXi&#146;s financial statements and
    reports.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The independent auditors&#146; qualifications and independence.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The performance of RXi&#146;s independent auditors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee operates under a written charter adopted by
    the Board of Directors on July&#160;11, 2007
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee&#146;s primary duties and responsibilities
    are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to appoint, oversee and replace, if necessary, the independent
    auditor.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to assist the Board of Directors&#146; oversight of the
    preparation of our financial statements, our compliance with
    legal and regulatory requirements, the independent
    auditor&#146;s qualifications and independence and the
    performance of our independent auditor.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to prepare the report the SEC rules require to be included in
    our annual proxy statement.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to resolve disagreements between management and the auditor
    regarding financial reporting.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee provides assistance to the Board of
    Directors in fulfilling its oversight responsibility to the
    stockholders, potential stockholders, the investment community,
    and others relating to RXi&#146;s financial statements and the
    financial reporting process, the systems of internal accounting
    and financial controls, the annual independent audit of
    RXi&#146;s financial statements and the ethics programs when
    established by RXi management and the Board of Directors. The
    Audit Committee has the sole authority (subject, if applicable,
    to stockholder ratification) to appoint or replace the outside
    auditors and is directly responsible for determining the
    compensation of the independent auditors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee must pre-approve all auditing services and
    all permitted non-auditing services to be provided by the
    outside auditors. In general, the Audit Committee&#146;s policy
    is to grant such approval where it determines that the non-audit
    services are not incompatible with maintaining the
    auditors&#146; independence and there are costs or other
    efficiencies in obtaining such services from the auditors as
    compared to other possible providers. During 2008, the Audit
    Committee approved all of the non-audit services proposals
    submitted to&#160;it.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee schedules its meetings with a view to
    ensuring that it devotes appropriate attention to all of its
    tasks. In discharging its oversight role, the Audit Committee is
    empowered to investigate any matter brought to its attention,
    with full access to all of RXi&#146;s books, records, facilities
    and personnel, and to retain its own legal counsel and other
    advisers as it deems necessary or appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of its oversight of RXi&#146;s financial statements, the
    Audit Committee reviewed and discussed with both management and
    its outside auditors RXi&#146;s interim financial statements and
    annual audited financial statements that are included in
    RXi&#146;s Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    and Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    respectively. RXi&#146;s management advised the Audit Committee
    in each case that all such financial statements were prepared in
    accordance with accounting principles generally accepted in the
    United States of America and reviewed significant accounting
    issues with the Audit Committee. These reviews included
    discussion with the outside auditors of matters required to be
    discussed pursuant to Statement on Auditing Standards (SAS)
    No.&#160;61 (Communication with Audit Committees), as amended
    and as adopted by the Public Company Oversight Board in
    Rule&#160;3200T.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee retained BDO Seidman, LLP to audit
    RXi&#146;s financial statements for 2008. The Audit Committee
    also has selected BDO Seidman, LLP as RXi&#146;s independent
    registered public accountants for 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee discussed with BDO Seidman, LLP, which
    audited RXi&#146;s annual financial statements for 2008, matters
    relating to its independence, including a review of audit and
    non-audit fees and the letter and written disclosures made by
    BDO Seidman, LLP to the Audit Committee pursuant to Public
    Company Accounting Oversight Board (United States)
    Rule&#160;3526.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the Audit Committee reviewed initiatives aimed at
    strengthening the effectiveness of RXi&#146;s internal control
    structure. As part of this process, the Audit Committee
    continued to monitor and review staffing levels and steps taken
    to implement recommended improvements in internal procedures and
    controls.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Taking all of these reviews and discussions into account, the
    Audit Committee recommended to the Board of Directors that the
    Board approve the inclusion of RXi&#146;s audited financial
    statements in its Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2008, filed with the
    SEC.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Respectfully submitted,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Audit Committee:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stephen S. Galliker, Chairman<BR>
    Sanford J. Hillsberg<BR>
    Mark J. Ahn,&#160;Ph.D.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Compensation Committee.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee is authorized to review and make
    recommendations to the full Board of Directors relating to the
    annual salaries and bonuses of our officers and to determine in
    its sole discretion all grants of stock options, the exercise
    price of each option, and the number of shares to be issuable
    upon the exercise of each option under our various stock option
    plans. The Committee also is authorized to interpret our stock
    option plans, to prescribe, amend and rescind rules and
    regulations relating to the plans, to determine the term and
    provisions of the respective option agreements, and to make all
    other determinations deemed necessary or advisable for the
    administration of the plans. Our Board of Directors has
    determined that each of the current members of the Compensation
    Committee, Messrs.&#160;Galliker and Hillsberg and Dr.&#160;Nisi
    are &#147;independent&#148; under the current independence
    standards of the NASDAQ Capital Market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee operates pursuant to a written
    charter, which is available on our website, www.rxipharma.com.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee held 6 meetings during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Nomination and Governance Committee.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nomination and Governance Committee assists our Board of
    Directors in discharging its duties relating to corporate
    governance and the compensation and evaluation of the Board. The
    Nomination and Governance Committee operates pursuant to a
    written charter, which is available on our website,
    www.rxipharma.com. Our Board of Directors has determined that
    each of the current members of the Nomination and Governance
    Committee, Dr.&#160;Ahn and Messrs.&#160;Hillsberg and Galliker,
    are &#147;independent&#148; under the current independence
    standards of the NASDAQ Capital Market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The principal responsibilities of the Nomination and Governance
    Committee include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    identify individuals qualified to become members of the Board of
    Directors.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    select, or recommend that the Board of Directors select the
    director nominees for the next annual meeting of stockholders.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    develop and recommend to the Board of Directors a set of
    applicable corporate governance principles.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the evaluation of the Board of Directors and its
    dealings with management and appropriate committees of the Board
    of Directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating and Governance Committee also established a
    policy under which stockholders may recommend a candidate for
    consideration for nomination as a director, articulating
    expectations to each director, reviewing practices and policies
    with respect to directors, reviewing functions, duties and
    composition of the committees of the Board of Directors,
    reviewing polices with respect to significant issues of
    corporate public responsibility, recommending processes for
    annual evaluations of the performance of the Board of Directors
    and Chief Executive Officer, reporting questions of possible
    conflicts of interest of board members and overseeing the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    maintenance and presentation to the Board of Directors of
    management&#146;s plans for succession to senior management
    positions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nomination and Governance Committee held 6 meetings in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nomination and Governance Committee has not established any
    specific minimum qualifications for director candidates or any
    specific qualities or skills that a candidate must possess in
    order to be considered qualified to be nominated as a director.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Qualifications for consideration as a director nominee may vary
    according to the particular areas of expertise being sought as a
    complement to the existing board composition. In making its
    nominations, our Nomination and Governance Committee generally
    will consider, among other things, an individual&#146;s business
    experience, industry experience, financial background, breadth
    of knowledge about issues affecting our company, time available
    for meetings and consultation regarding company matters and
    other particular skills and experience possessed by the
    individual.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Strategy
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Strategy Committee was established in March 2009 by the
    Board of Directors to advise management on strategic matters and
    to report such matters to the Board of Directors. Current
    members include Mr.&#160;Kriegsman and Dr.&#160;Ahn.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transactions
    with Related Persons</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee is responsible for reviewing and approving,
    as appropriate, all transactions with related persons, in
    accordance with its Charter and NASDAQ Marketplace Rules. We had
    various transactions with CytRx Corporation, our largest
    shareholder, in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of the distribution and award of our shares by CytRx
    described in our Registration Statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    that became effective on February&#160;14, 2008, CytRx&#146;s
    ownership of our common stock went from 86% to 49%. As of
    December&#160;31, 2008, CytRx owns 45.4% of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Reimbursement
    Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;27, 2007, we entered into a letter agreement
    with CytRx under which we and CytRx agreed to a
    &#147;fee-sharing&#148; arrangement for expenses arising from
    the preparation of the registration statement that included the
    Distribution and Award prospectuses, and our application for the
    listing of our common stock on the NASDAQ Capital Market.
    Pursuant to this agreement, we agreed to reimburse CytRx an
    amount equal to the sum of (i)&#160;$30,000 plus (ii)&#160;50%
    of the total relevant fees and expenses paid by CytRx to certain
    financial services professionals. Also under this agreement
    CytRx agreed to reimburse us 50% of the total relevant fees and
    expenses paid by us to our financial printer, our transfer agent
    and our legal counsel. There are no further payments or
    obligations owed in accordance with this letter agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    and Preemptive Rights Agreement</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On February&#160;15, 2007, we entered into a letter agreement
    with CytRx and certain of our current stockholders. Under this
    letter agreement, we agreed to grant to CytRx preemptive rights
    to acquire any new securities, as defined therein, that we
    propose to sell or issue so that CytRx may maintain its
    percentage ownership of us. The preemptive rights will expire on
    January&#160;8, 2012, or such earlier time at which CytRx owns
    less than 10% of our outstanding common stock. Under this letter
    agreement, CytRx also undertakes to vote its shares of our stock
    in the election of our directors and dispose of their shares of
    our stock in accordance with the terms of its letter agreement
    with UMMS. CytRx has further agreed in this letter agreement to
    approve of actions that may be adopted and recommended by our
    Board of Directors to facilitate any future financing. We
    amended this letter agreement on July&#160;28, 2008 to adjust
    certain non-material terms.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights Agreement</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;30, 2007, we entered into a registration rights
    agreement with CytRx. Under this agreement, we agreed, upon
    request by CytRx, to use best efforts to cause all of our shares
    issued to CytRx pursuant to the two contribution agreements to
    be registered under the Securities Act, with certain exceptions,
    with all expenses incurred in connection with any such
    registration will be borne by us. We amended this agreement on
    July&#160;28, 2008 to adjust certain non-material terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Transactions between us and one or more related persons may
    present risks or conflicts of interest or the appearance of
    conflicts of interest. Our Code of Ethics requires all
    employees, officers and directors to avoid activities or
    relationships that conflict, or may be perceived to conflict,
    with our interests or adversely affect our reputation. It is
    understood, however, that certain relationships or transactions
    may arise that would be deemed acceptable and appropriate so
    long as there is full disclosure of the interest of the related
    parties in the transaction and review and approval by
    disinterested directors to ensure there is a legitimate business
    reason for the transaction and that the transaction is fair to
    us and our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result, the procedures followed by the Audit Committee to
    evaluate transactions with related persons require:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that all related person transactions, all material terms of the
    transactions, and all the material facts as to the related
    person&#146;s direct or indirect interest in, or relationship
    to, the related person transaction must be communicated to the
    Audit Committee;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    that all related person transactions, and any material amendment
    or modification to any related person transaction, be reviewed
    and approved or ratified by the Audit Committee, as required by
    NASDAQ Marketplace Rules.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee will evaluate related person transactions
    based on:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    information provided by members of our Board of Directors in
    connection with the required annual evaluation of director
    independence;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pertinent responses to the Directors&#146; and Officers&#146;
    Questionnaires submitted periodically by our officers and
    directors and provided to the Audit Committee by our management;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    background information on nominees for director provided by the
    Nominating and Corporate Governance Committee of our Board of
    Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any other relevant information provided by any of our directors
    or officers.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with its review and approval or ratification, if
    appropriate, of any related person transaction, our Audit
    Committee is to consider whether the transaction will compromise
    standards included in our Code of Ethics. In the case of any
    related person transaction involving an outside director or
    nominee for director, the Audit Committee also is to consider
    whether the transaction will compromise the director&#146;s
    status as an independent director as prescribed in the NASDAQ
    Marketplace Rules.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our related person transactions will be disclosed in our
    filings with the SEC in accordance with SEC&#160;rules.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Recommendations of Director Candidates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The policy of the Nomination and Governance Committee is that a
    stockholder wishing to submit recommendations for director
    candidates for consideration by the Nomination and Governance
    Committee for election at an annual meeting of shareholders must
    do so in writing to the Corporate Secretary. Such
    recommendations must be received at our principal executive
    offices not less than 60&#160;days and not more than
    90&#160;days prior to the anniversary date of the immediately
    preceding annual meeting of the stockholders. The written
    recommendation must include the following information:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A statement that the writer is a stockholder and is proposing a
    candidate for consideration.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The name and contact information for the candidate.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A statement of the candidate&#146;s business and educational
    experience.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Information regarding the candidate&#146;s qualifications to be
    a director.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The number of shares of our common stock, if any, owned either
    beneficially or of record by the candidate and the length of
    time such shares have been so owned.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The written consent of the candidate to serve as a director if
    nominated and elected.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Information regarding any relationship or understanding between
    the proposing stockholder and the candidate.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A statement that the proposed candidate has agreed to furnish us
    all information as we deem necessary to evaluate such
    candidate&#146;s qualifications to serve as a director.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As to the stockholder giving the notice, the written
    recommendation must state the name and address of the
    stockholder and the number of shares of our common stock which
    are owned beneficially or of record by the shareholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any recommendations in proper form received from stockholders
    will be evaluated in the same manner that potential nominees
    recommended by our Board members or management are evaluated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Nominations of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Bylaws specify the procedures by which stockholders may
    nominate director candidates directly, as opposed to merely
    recommending a director candidate to the Nomination and
    Governance Committee as described above. Any stockholder
    nominations must comply with the requirements of our Bylaws and
    should be addressed to: Corporate Secretary, RXi Pharmaceuticals
    Corporation, 60 Prescott Street. Worcester, Massachusetts 01605.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Communication with Board Members</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stockholders who wish to communicate with our Board members may
    contact us by telephone, facsimile or regular mail at our
    principal executive office. Written communications specifically
    marked as a communication for our Board of Directors, or a
    particular director, except those that are clearly marketing or
    soliciting materials, will be forwarded unopened to the Chairman
    of our Board, or to the particular director to which they are
    addressed, or presented to the full Board or the particular
    director at the next regularly scheduled Board meeting. In
    addition, communications sent to us via telephone or facsimile
    for our Board of Directors or a particular director will be
    forwarded to our Board or the director by an appropriate officer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Member Attendance at Annual Meetings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has no formal policy regarding attendance
    of directors at our annual stockholder meetings. All our
    directors attended the July&#160;18, 2008 annual meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Section&#160;16(a)
    Beneficial Ownership Reporting Compliance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers and directors and any person who owns
    more than 10% of our outstanding shares of common stock are
    required under Section&#160;16(a) of the Securities Exchange Act
    of 1934, as amended (the &#147;Exchange Act&#148;) to file with
    the SEC initial reports of ownership and reports of changes in
    ownership of our common stock and to furnish us with copies of
    those reports. Based on the Company&#146;s review of copies of
    such forms it has received from its executive officers,
    directors and greater than ten-percent beneficial owners, the
    Company believes that during the fiscal year ended
    December&#160;31, 2008, all Section&#160;16(a) filing
    requirements applicable to its Reporting Persons were met in a
    timely manner, except that Ms.&#160;Khvorova failed to timely
    report one Form&#160;3 and one Form&#160;4. Ms.&#160;Khvorova
    subsequently filed the required reports.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Beneficial
    Owners of More Than Five Percent of RXi&#146;s Common Stock;
    Shares&#160;Held by Directors and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following tables set forth information with respect to the
    beneficial ownership of our common stock as of April&#160;1,
    2009 by:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any person known by us to be the beneficial owner of 5% or more
    of our common stock, including any &#147;group&#148; as that
    term is defined in the Exchange Act,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each director and our named executive officers&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers as a group.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beneficial ownership is determined in accordance with SEC rules,
    and generally includes voting or investment power with respect
    to securities. Shares of common stock subject to options,
    warrants and convertible securities that are currently
    exercisable or convertible within 60&#160;days are deemed to be
    outstanding and to be beneficially owned by the person holding
    the options, warrants or convertible securities for the purpose
    of computing the percentage ownership of the person, but are not
    treated as outstanding for the purpose of computing the
    percentage ownership of any other person.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise noted, the information below is based on the
    number of shares of our common stock beneficially owned by each
    person or entity at April&#160;1, 2009 and the number of shares
    subject to any options and warrants granted to these individuals
    that are exercisable within 60&#160;days of April&#160;1, 2009,
    which are indicated by footnote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amount and Nature<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Beneficial<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ownership</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CytRx Corporation(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,268,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Investment Funds affiliated with Fidelity Investments(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,855,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tod Woolf,&#160;Ph.D.(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    228,105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen J. DiPalma(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Anastasia Khvorova(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Konstantinos Andrikopoulos(6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pamela Pavco,&#160;Ph.D.(7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,048
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dmitry Samarsky,&#160;Ph.D.(8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mark J. Ahn,&#160;Ph.D.(9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen S. Galliker(9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sanford J. Hillsberg(9)(10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steven A. Kriegsman(9)(11)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.8
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rudolph Nisi, M.D.(12)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All executive officers and directors as a group&#160;&#151;
    11&#160;persons(13)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,101,342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than 1% of the outstanding shares of our common
    stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address for CytRx is 11726 San&#160;Vicente Boulevard,
    Suite&#160;650, Los Angeles, California 90049.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Holdings as of December&#160;31, 2008 as reported on
    Schedule&#160;13G filed with the SEC on February&#160;17, 2009
    by the Selling Stockholder consist of (i)&#160;shares owned by
    Fidelity Mt. Vernon Street Trust: Fidelity New Millennium Fund
    (&#147;FNMF&#148;), (ii)&#160;shares owned by Fidelity Trend
    Fund: Fidelity Trend Fund (&#147;FTF&#148;), (iii)&#160;shares
    owned by Fidelity Advisor Series&#160;I: Fidelity Advisor
    Strategic Growth Fund (&#147;FASGF&#148;), (iv)&#160;shares
    owned by Variable Insurance Product Fund&#160;IV: Growth Stock
    Portfolio (GSP&#148;), (v)&#160;shares owned by Fidelity Mt.
    Vernon Street Trust: Fidelity Aggressive Growth Fund
    (&#147;FAGF&#148;), (vi)&#160;shares owned by Fidelity
    Securities Fund: Fidelity Advisor Aggressive Growth Fund
    (&#147;FAAGF&#148;), and (vii)&#160;shares owned by Variable
    Insurance Products Fund&#160;III: Aggressive Growth Portfolio
    (&#147;AGP&#148; and, together with FNMF, FTF, FASGF, GSP, FAGF,
    and FAAGF, the &#147;Funds&#148;). FAGF holds
    1,101,923&#160;shares, or 8.0% of the Company&#146;s total
    outstanding common stock, and FNMF holds 744,517&#160;shares, or
    5.4%, of the Company&#146;s total outstanding common stock.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Each of the Funds is a registered investment fund advised by
    Fidelity Management&#160;&#038; Research Company (&#147;FMR
    Co.&#148;), a registered investment adviser under the Investment
    Advisers Act of 1940, as amended. FMR Co., 82 Devonshire Street,
    Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR
    Corp. and an investment advisor registered under
    Section&#160;203 of the Investment Advisors Act of 1940, is the
    beneficial owner of 2,049,622&#160;shares of the outstanding
    common stock of the Company held by the Funds.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Edward C. Johnson 3d, FMR Corp., through its control of FMR Co.,
    and the Funds each has sole power to dispose of the shares owned
    by the Funds.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR
    Corp., has the sole power to vote or direct the voting of the
    shares owned directly by each Fund, which power resides with
    such Fund&#146;s Board of Trustees.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    The Funds are affiliates of a broker-dealer. The Funds purchased
    the common stock in the ordinary course of business and, at the
    time of purchase of the common stock to be resold, the Funds did
    not have any agreements or understandings, directly or
    indirectly, with any person to distribute the common stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 228,105&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 60,056&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 23,750&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 16,500&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 86,048&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 53,726&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 112,500&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    The shares shown do not include shares owned by TroyGould PC.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (11) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Kriegsman is the CEO and a director of CytRx, but
    acting alone, he has neither voting nor investment power with
    respect to the shares beneficially owned by CytRx. As a result,
    Mr.&#160;Kriegsman disclaims beneficial ownership of such shares.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (12) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 23,375 shares of common stock underlying stock options
    exercisable within 60 days of April&#160;1, 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (13) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 1,101,342&#160;shares of common stock underlying stock
    options exercisable within 60&#160;days of April&#160;1, 2009.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers of RXi Pharmaceuticals Corporation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Set forth below is information regarding our current executive
    officers (other than information relating to Tod M.
    Woolf,&#160;Ph.D., our President and Chief Executive Officer,
    which is set forth above under &#147;Continuing
    Directors&#148;). Each officer&#146;s age is indicated in
    parentheses after his name.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stephen J. DiPalma (50)&#160;</I>has been our Chief Financial
    Officer since August 2007 and was promoted to Executive Vice
    President of Business Operations/Chief Financial Officer in
    January 2009. Mr.&#160;DiPalma has over twenty years of broad
    experience with emerging life science companies. He was founder,
    President and CEO of Catalyst Oncology, Inc., a specialty
    diagnostic company, from 2004 until its merger with a public
    diagnostics company. From 2002 to 2004, Mr.&#160;DiPalma was the
    Chief Financial Officer for Milkhaus Laboratories, a drug
    development company, and from 1998 to 2002, he was Chief
    Financial Officer for Phytera, Inc., an international biotech
    company involved in natural products-based drug discovery. Prior
    to Phytera, Mr.&#160;DiPalma was the Chief Financial Officer at
    Aquila Biopharmaceuticals, a public biotechnology company. From
    1988 to 1995, he was the co-founder and Chief Financial Officer
    at Athena Diagnostics, a specialty diagnostic testing firm in
    the neurology field that subsequently merged with a public
    biotech company. Mr.&#160;DiPalma began working in the
    healthcare industry in 1985 in financial positions for a
    subsidiary of Baxter International. Mr.&#160;DiPalma earned an
    MBA from
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Babson College and holds a BS in finance and information systems
    from the University of Massachusetts. He has also serves on the
    Board of Directors of Neuroptix Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Anastasia Khvorova,&#160;Ph.D. (39)&#160;</I>has been our
    Chief Scientific Officer since October 2008. Dr.&#160;Khvorova
    has contributed significantly to the RNAi field. While at
    Dharmacon (ThermoFisher Scientific), she made major technology
    advances in RNAi and microRNA. Dr.&#160;Khvorova was also
    responsible for establishing and managing several drug
    discovery/development collaborations with major pharmaceutical
    companies, including Abbott and Alcon. Her groundbreaking work
    has allowed her to author more than 150 abstracts, 30 patents
    and patent applications, several book chapters and over 40 peer
    reviewed publications. Dr.&#160;Khvorova received her Ph.D. in
    Biochemistry from Russian Academia of Sciences in Moscow in 1994
    and after 10&#160;years of working in academia and industry she
    joined world recognized RNAi leader Dharmacon in September 2002
    as an Associate Director. Dr.&#160;Khvorova was promoted several
    times before becoming the Chief Scientifc Officer in April of
    2005. Dr.&#160;Khvorova held this position for six years
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Konstantinos Andrikopoulos,&#160;Ph.D., J.D.
    (43)&#160;</I>has been our Vice President, Legal Counsel and
    Chief Intellectual Property Counsel at RXi since November 2008.
    Dr.&#160;Andrikopoulos brings a broad range of experience to
    RXi. He was previously an Associate General Counsel at
    Transkaryotic Therapies, Inc., (TKT) from September 2002 to July
    2005 when TKT was acquired by Shire Pharmaceuticals, and
    continuing there as Senior Patent Counsel prior to joining RXi.
    While there, Dr.&#160;Andrikopoulos was responsible for Shire
    HGT&#146;s extensive patent portfolio encompassing two marketed
    drug products and a rich pipeline. Prior to his work at Shire,
    Dr.&#160;Andrikopoulos spent five years with Wolf,
    Greenfield&#160;&#038; Sacks,&#160;P.C., a Boston firm
    specializing in intellectual property law, as a technology
    specialist, patent agent and patent attorney, creating and
    managing patent estates for a number of biotechnology clients.
    Dr.&#160;Andrikopoulos received his law degree from Suffolk
    University Law School in Boston, his Ph.D. in Biomedical
    Sciences from the City University of New York (through Mount
    Sinai School of Medicine&#146;s Graduate School of Biological
    Sciences Program) and his B.Sc. in Biophysics (Hons.) from the
    University of East London, London, U.K. Dr.&#160;Andrikopoulos
    was an Irvington Foundation Postdoctoral Fellow at MGH, Harvard
    Medical School in Boston. He is the author or co-author of
    numerous scientific publications and is a member of the
    Massachusetts Bar and a registered patent attorney with the
    United States Patent and Trademark Office.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Pamela Pavco,&#160;Ph.D. (52)&#160;</I>has been our Vice
    President of Pharmaceutical Development since March 2007.
    Dr.&#160;Pavco brings over 16&#160;years of research and
    development experience in oligonucleotides to us. From 2002 to
    2006, Dr.&#160;Pavco was Senior Director, R&#038;D Project
    Management at Sirna Therapeutics, previously known as Ribozyme
    Pharmaceuticals, where she was responsible for the discovery
    research and development of Sirna-027, the first chemically
    modified siRNA to enter into clinical trials. Dr.&#160;Pavco
    also managed the alliance with Allergan that was initiated to
    continue discovery research in the area of ophthalmology and
    take Sirna-027 forward into Phase 2 clinical studies. While at
    Sirna, Dr.&#160;Pavco served various additional roles including
    Director of Biology Research and Director of Pharmacology and
    managed numerous corporate collaborations and internal programs
    developing therapeutic oligonucleotides in the fields of
    oncology, anti-angiogenesis, Hepatitis, respiratory disease and
    Huntington&#146;s disease. Dr.&#160;Pavco has authored numerous
    scientific articles and contributed to approximately 48 patents
    and patent applications in the oligonucleotide therapeutics
    field. Dr.&#160;Pavco received a Ph.D. in Biochemistry from
    Virginia Commonwealth University in 1983 and did her
    post-doctoral work at Duke University prior to joining Sirna
    Therapeutics. She is a member of the American Association of
    Cancer Research and the Association for Research and Vision in
    Ophthalmology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dmitry Samarsky,&#160;Ph.D.&#160;(42)&#160;</I>has been our
    Vice President of Technology and Business Development since
    June&#160;2007. From 2005 through 2007, Dr.&#160;Samarsky was
    with Dharmacon, Inc. (now part of ThermoFisher Scientific),
    where his role was to develop, support and expedite technology
    development for the company&#146;s RNAi platform. From 2003
    through 2005, Dr.&#160;Samarsky was employed by Invitrogen,
    formulating partnership models and providing BioDiscovery
    platform solutions for the drug discovery process. From 2001
    through 2003, Dr.&#160;Samarsky was employed by Sequitur, Inc.
    where he had the role of developing and promoting Sequitur,
    Inc.&#146;s antisense and RNAi technological platforms.
    Dr.&#160;Samarsky received his Ph.D. in biochemistry and
    molecular biology from the University of Massachusetts, Amherst
    in 1998. He then performed postdoctoral work with
    Dr.&#160;Michael R. Green, a Howard Hughes Medical Institute
    investigator at the University of Massachusetts Medical School,
    Worcester. During postdoctoral training, Dr.&#160;Samarsky was
    awarded a three year H. Arthur Smith Fellowship for Cancer
    Research. Dr.&#160;Samarsky has authored many
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    publications, including research articles, reviews, book
    chapters and patent applications and has frequently advised,
    chaired and presented at various industrial and academic
    conferences and symposia
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ramani Varanasi (39)</I>&#160;has been our Vice President of
    Business Development since March 2009. Ms.&#160;Varanasi has
    more than 15&#160;years of experience in structuring,
    negotiating and executing strategic alliances, licenses and
    collaborations and in providing business development, management
    and strategic leadership in the pharmaceutical industry.
    Ms.&#160;Varanasi spent nine years at Millennium
    Pharmaceuticals, where from September 1996 to July 2004 she
    served in a variety of management roles in the areas of
    technology licensing and technology and product business
    development. From July 2004 to June 2005 she served as Director
    of Business Development at Millennium Pharmaceuticals, and
    cultivated her business strategy skills, executed several broad
    technology and product focused deals with global pharmaceutical
    and biotechnology companies, and grew her network of connections
    in the pharmaceutical industry. In June 2005, she then joined
    Momenta Pharmaceuticals as Director, Corporate Development,
    where she successfully led various business and corporate
    development activities for the company. From January 2007 to
    March 2008, Ramani served as Head of Business Development at
    Archemix Corporation where she was responsible for and lead the
    strategic development and execution of several strategic
    technology, research collaboration and product alliances,
    including the partnership with Merck Serono, a multi-year
    alliance with a deal value greater than $600M. Ramani holds a
    B.Sc. and a M.Sc. from McGill University in
    Microbiology&#160;&#038; Immunology and Biochemistry,
    respectively, and an MBA from Northeastern University.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXECUTIVE
    COMPENSATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows the compensation paid or accrued
    during the fiscal years ended December&#160;31, 2008 and 2007 to
    our Chief Executive Officer and two most highly compensated
    executive officers, other than our President and Chief Executive
    Officer. Amounts included under Options Awards below represent
    the fair value of the award calculated under SFAS&#160;123(R)
    and as more fully described in &#147;Management&#146;s
    Discussion and Analysis and the footnotes to our financial
    statements incorporated herein by reference to our annual report
    of
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Bonus(1)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principle Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tod Woolf,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    236,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,302
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    573,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    275,481
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,814
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    444,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    450
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    774,824
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen J. DiPalma
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,893
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    201
</TD>
<TD nowrap align="left" valign="bottom">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    154,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President of Business
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    229,173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    450
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Operations and Chief Financial Officer<BR>
    and Secretary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pamela Pavco,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,522
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,677
</TD>
<TD nowrap align="left" valign="bottom">
    (5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    335,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President of Pharmaceutical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    212,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,539
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,759
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    450
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Year-end bonuses were accrued at December&#160;31, 2008 and 2007
    and paid in January 2009 and January 2008 respectively.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of $33,000 in consulting fees paid in 2007 by CytRx
    Corporation and $302 in life insurance premiums paid by us.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of $450 in life insurance premiums paid by us.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of $201 in life insurance premiums paid by us.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of $29,375 in consulting fees paid by CytRx Corporation
    and $302 in life insurance premiums paid by&#160;us.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RXi
    Pharmaceuticals Corporation&#146;s 2007 Incentive Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The RXi Pharmaceutical&#146;s Corporation 2007 Incentive Plan,
    (the &#147;2007 Incentive Plan&#148;), was adopted by our Board
    of Directors on February&#160;23, 2007, approved by our
    stockholders on June&#160;19, 2007. During 2008, the 2007
    Incentive Plan was amended to increase the maximum number of
    common stock shares authorized for issuance from 2,750,000 to
    3,750,000. The amendment was adopted by our Board of Directors
    on June&#160;4, 2008 and approved by our stockholders on
    July&#160;18, 2008. Under this plan, we may grant incentive
    common stock options, nonqualified stock options and restricted
    and unrestricted stock awards. As of December&#160;31, 2008,
    2,223,452&#160;shares were subject to outstanding options under
    this plan, and 1,526,548&#160;shares were available for future
    grant under this plan. The Board of Directors has appointed its
    Compensation Committee to act as the administrator of our 2007
    Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to board approval, the administrator has the power to
    select the participants, establish the price, terms and
    conditions of each option, issue shares upon option exercises
    and interpret option agreements, and the administrator may at
    any time modify or amend the 2007 Incentive Plan in any respect,
    except where stockholders&#146; approval is required by law or
    where such termination or modification or amendment affects the
    rights of an optionee under a previously granted option and such
    optionee&#146;s consent has not been obtained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a change of control in which there is an
    acquiring or surviving entity, the administrator may provide for
    the assumption or substitution of some or all outstanding awards
    by the acquirer or survivor. In the absence of an assumption or
    substitution, each stock option will become fully exercisable
    prior to the transaction on a basis that gives the holder of the
    stock option a reasonable opportunity as determined by the
    administrator, to participate as a stockholder in the
    transaction following exercise, and the stock option will
    terminate upon consummation of the transaction. In the case of
    restricted stock, the administrator may require that any amounts
    delivered, exchanged or otherwise paid in respect of such stock
    in connection with the transaction be placed in escrow or
    otherwise made subject to such restrictions as the Board of
    Directors deems appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately upon termination of employment of an employee, the
    unvested portion of any stock option will terminate and the
    balance, to the extent exercisable, will remain exercisable for
    the lesser of (i)&#160;a period of three months (90&#160;days)
    or (ii)&#160;the period ending on the latest date on which such
    stock option could have been exercised without regard to this
    provision. The 2007 Incentive Plan provides exceptions for the
    vesting of options upon an individual&#146;s death or if the
    administrator determines that the termination of employment
    resulted for reasons that cast discredit on the individual.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows vested and unvested stock award grants
    outstanding on December&#160;31, 2008 to each of the executive
    officers named in the Summary compensation table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price ($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tod Woolf,&#160;Ph.D.(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    167,302
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    149,692
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5/23/2017
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6,888
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    48,219
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    7.50
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4/18/2018
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen J. DiPalma(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    62,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10/18/2017
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President of Business Operations and Chief
    Financial Officer and Secretary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    2,428
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,001
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    7.50
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4/18/2018
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pamela Pavco,&#160;Ph.D.(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    63,573
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    81,738
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5/23/2017
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President of Pharmaceutical Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5,228
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    36,598
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    7.50
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4/18/2018
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    The stock option grant to Dr.&#160;Woolf with an exercise price
    equal to $5.00 vests in 36 equal monthly installments of
    8,804&#160;shares beginning on June&#160;23, 2007. The stock
    option grant with an exercise price equal to $7.50 vests in 16
    equal quarterly installments of 3,444&#160;shares beginning on
    July&#160;18, 2008.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    The stock option grant to Mr.&#160;DiPalma with an exercise
    price equal to $5.00 vests in 16 equal quarterly installments of
    6,250&#160;shares beginning on November&#160;28, 2007. The stock
    option grant with an exercise price equal to $7.50 vests in 16
    equal quarterly installments of 1,214&#160;shares beginning on
    July&#160;18, 2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    The stock option grant to Dr.&#160;Pavco with an exercise price
    equal to $5.00 vests in 15 equal quarterly installments of
    9,081.94&#160;shares beginning on June&#160;7, 2007, with a
    final installment of 9,081.90&#160;shares vesting on
    March&#160;7, 2011. The stock option grant with an exercise
    price equal to $7.50 vests in 16 equal quarterly installments of
    2,614&#160;shares beginning on July&#160;18, 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pension
    Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have any qualified or non-qualified defined benefit
    plans.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Nonqualified
    Defined Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have any nonqualified defined compensation plans.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination-Based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have agreements in place with our named executive officers
    that provide for acceleration of option vesting and severance
    payments upon termination of such officer&#146;s employment or a
    change of control. In the event of a change of control, as
    defined, certain provisions allow for acceleration of vesting in
    full of the options granted in such employment agreement.
    Pursuant to the change of control provisions in
    Dr.&#160;Pavco&#146;s employment agreement and as more fully
    described below in &#147;Termination Agreements,&#148; if such
    officer is terminated due to a change of control, she is
    entitled to immediate vesting of the greater of (a)&#160;50% of
    all unvested options or (b)&#160;12&#160;months of unvested
    options, as well as any accrued but unpaid salary and unused
    vacation time as of the date of termination, twelve months&#146;
    of salary from the date of termination and continued
    participation at our cost in our employer sponsored group
    benefit plans in which the officer was participating as of the
    date of termination
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Termination
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tod
    Woolf,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon termination of Dr.&#160;Woolf&#146;s employment by us
    without cause (as defined) or by Dr.&#160;Woolf with good reason
    (as defined), he is entitled to payment of: (a)&#160;any accrued
    but unpaid salary and unused vacation as of the date of his
    termination and any unpaid bonus that may have been previously
    awarded to him prior to such date, both of which are due and
    payable upon the effective date of his termination, (b)&#160;an
    amount, due and payable within 10&#160;days following his
    termination, equal to his annual base salary for the period of
    time which is equal to or the earlier of either (i)&#160;the
    <FONT style="white-space: nowrap">12-month</FONT>
    anniversary of his termination date or (ii)&#160;the remainder
    of the term of the agreement but in no event less than six
    months and (c)&#160;continued participation, at our expense,
    during the six-month period in any of our sponsored group
    benefit plans in which Dr.&#160;Woolf was participating as of
    the date of termination. In the event that Dr.&#160;Woolf were
    to be terminated by us without cause, the value of his severance
    package at December&#160;31, 2008 would be $1,250,500 including
    salary and benefits of approximately $584,300. In addition, any
    options issued to Dr.&#160;Woolf under the 2007 Incentive Plan
    that would have vested through the earlier of (i)&#160;the
    <FONT style="white-space: nowrap">12-month</FONT>
    anniversary of his termination date or (ii)&#160;the remainder
    of the term of the agreement but in no less than six months
    following the date of termination, will vest and become
    exercisable as of the date of his termination without cause.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, in the event that either (a)&#160;a covered
    transaction, as defined in our 2007 Incentive Plan, occurs or
    (b)&#160;CytRx votes its shares of our common stock to elect
    individuals who are (i)&#160;employees, officers or directors of
    CytRx, (ii)&#160;employees, officers or directors of any entity
    that has a contractual business relationship with CytRx, or
    (iii)&#160;employees, officers, directors of any entity that has
    a contractual business relationship with any officer or director
    of CytRx to constitute a majority of our Board of Directors, any
    options issued to Dr.&#160;Woolf will vest in full and become
    exercisable. The fair value of stock options that would vest as
    a result of any of these events occurring is approximately
    $524,000. The fair value of the options, based on the following
    assumptions, was estimated using the Black-Scholes
    option-pricing model. Due to the fact that we have limited
    history of stock trading, our company&#146;s expected
    stock-price volatility assumption is based on a combination of
    implied volatilities of similar entities whose share or option
    prices are publicly traded. We used a weighted-average expected
    stock-price volatility of 105.3%.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The expected life assumption is based on a simplified method
    provided for under SAB&#160;No.&#160;107
    (&#147;SAB&#160;107&#148;) regarding the Staff&#146;s
    interpretation of SFAS&#160;123(R), which averages the
    contractual term of our options (10&#160;years) with the
    ordinary vesting term (four years). The dividend yield of zero
    is based on the fact that we have no present intention to pay
    cash dividends. The weighted average risk-free rate of 3.92%
    used for each grant is equal to the zero coupon rate in effect
    at the time of the grant for instruments with similar expected
    life. Dr.&#160;Woolf&#146;s severance payments will only be
    triggered in the event that his employment is terminated by us
    without cause or by Dr.&#160;Woolf with good reason, which, for
    purposes of his employment agreement, means any of the
    following: (i)&#160;a material reduction in
    Dr.&#160;Woolf&#146;s duties, position, or responsibilities in
    effect immediately prior to such reduction, (ii)&#160;the
    reduction of Dr.&#160;Woolf&#146;s base salary or bonus
    opportunity by more than 5% relative to his salary and bonus
    opportunity in effect immediately prior to such reduction,
    (iii)&#160;a material reduction by us in the kind or level of
    benefits to which Dr.&#160;Woolf is entitled immediately prior
    to such reduction with the result that Dr.&#160;Woolf&#146;s
    overall benefits package is significantly reduced,
    (iv)&#160;without Dr.&#160;Woolf&#146;s express written consent,
    he is relocated to a facility or location more than
    35&#160;miles from our current facility in Worcester,
    Massachusetts, or (v)&#160;CytRx votes its shares of our common
    stock to elect individuals who are affiliates of CytRx to
    constitute a majority of our Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stephen
    DiPalma</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon termination of Mr.&#160;DiPalma&#146;s employment by us
    without cause (as defined) or by Mr.&#160;DiPalma with good
    reason (as defined), he is entitled to payment of: (a)&#160;any
    accrued but unpaid salary and unused vacation as of the date of
    his termination, (b)&#160;six months&#146; salary from the date
    of termination (this period shall be referred to as the
    &#147;Severance Period&#148;) in the form of salary
    continuation; and (c)&#160;continued participation, at our
    expense, during the Severance Period in any of our sponsored
    group benefit plans in which Mr.&#160;DiPalma was participating
    as of the date of termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event that Mr.&#160;DiPalma were to be terminated by us
    without cause, the value of his severance package at
    December&#160;31, 2008 would be $211,000 including salary and
    benefits our approximately $139,800. Mr.&#160;DiPalma&#146;s
    severance payments will only be triggered in the event that his
    employment is terminated by us without cause or by
    Mr.&#160;DiPalma with good reason, which, for purposes of his
    employment agreement, means any of the following: (i)&#160;a
    material reduction in Mr.&#160;DiPalma&#146;s compensation or
    benefits,
    <FONT style="white-space: nowrap">and/or</FONT>
    (ii)&#160;any change in Mr.&#160;DiPalma&#146;s position or
    title that is not agreeable to Mr.&#160;DiPalma. In addition to
    the payments upon termination of Mr.&#160;DiPalma, all options
    issued to Mr.&#160;DiPalma under his employment agreement will
    vest in full and become exercisable as to all of the shares
    covered thereby upon the occurrence of a covered transaction as
    defined in our 2007 Incentive Plan. The fair value of stock
    options that would vest as a result of a covered transaction is
    approximately $71,200. The fair value of the options, based on
    the following assumptions, was estimated using the Black-Scholes
    option-pricing model.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due to the fact that we have limited history of stock trading,
    our company&#146;s expected stock-price volatility assumption is
    based on a combination of implied volatilities of similar
    entities whose share or option prices are publicly traded. We
    used a weighted-average expected stock-price volatility of
    106.64%. The expected life assumption is based on a simplified
    method provided for under SAB&#160;107, which averages the
    contractual term of our options (10&#160;years) with the
    ordinary vesting term (four years). The dividend yield of zero
    is based on the fact that we have no present intention to pay
    cash dividends. The weighted average risk-free rate of 4.09%
    used for each grant is equal to the zero coupon rate in effect
    at the time of the grant for instruments with similar expected
    life.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Pamela
    Pavco,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon termination of Dr.&#160;Pavco employment without cause (as
    defined) by us or by Dr.&#160;Pavco as a result of an
    involuntary termination, she is entitled to payment of
    (a)&#160;any accrued but unpaid salary and unused vacation as of
    the date of her termination, (b)&#160;her salary through
    September&#160;7, 2009 and (c)&#160;continued participation, at
    our expense, during the severance period (as defined) in any of
    our sponsored group benefit plans in which Dr.&#160;Pavco was
    participating as of the date of termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, any options issued to Dr.&#160;Pavco under our
    2007 Incentive Plan, that would have vested during the severance
    period will vest and become exercisable as of the date of her
    termination without cause or as a result of involuntary
    termination. Furthermore, upon the occurrence of a covered
    transaction, as defined in our 2007
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Incentive Plan, all options issued to Dr.&#160;Pavco under the
    2007 Incentive Plan, will vest and become exercisable. In the
    event that Dr.&#160;Pavco was terminated from the Company
    without cause at December&#160;31, 2008, the value of her
    severance package would be approximately $406,800 including
    salary and benefits of approximately $248,800 and the fair value
    of stock options that would vest as a result of this termination
    of approximately $158,000. In addition to the payments upon
    termination of Dr.&#160;Pavco, all options issued to
    Dr.&#160;Pavco under her employment agreement will vest in full
    and become exercisable as to all of the shares covered thereby
    upon the occurrence of a covered transaction as defined in our
    2007 Incentive Plan. The fair of stock options that would vest
    as a result of a covered transaction is approximately $304,000.
    The fair value of the options, based on the following
    assumptions, was estimated using the Black-Scholes
    option-pricing model. Due to the fact that we have limited
    history of stock trading, our expected stock-price volatility
    assumption is based on a combination of implied volatilities of
    similar entities whose share or option prices are publicly
    traded. We used a weighted-average expected stock-price
    volatility of 105.3%. The expected life assumption is based on a
    simplified method provided for under SAB&#160;107, which
    averages the contractual term of the Company&#146;s options (ten
    years) with the ordinary vesting term (four years). The dividend
    yield of zero is based on the fact that we have no present
    intention to pay cash dividends. The risk-free rate of 3.92%
    used for each grant is equal to the zero coupon rate in effect
    at the time of the grant for instruments with similar expected
    life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Pavco&#146;s severance payments will only be triggered
    in the event that her employment is terminated by us without
    cause or by Dr.&#160;Pavco herself as a result of an involuntary
    termination, which, for purposes of her employment agreement,
    means any of the following: (a)&#160;our breach of any material
    term of the employment agreement; provided that the first
    occasion of any particular breach shall not constitute such
    cause unless we have failed to cure such breach within
    60&#160;days after receiving written notice from Dr.&#160;Pavco
    stating the nature of such breach (b)&#160;a reduction in
    Dr.&#160;Pavco&#146;s salary (c)&#160;a reduction in
    Dr.&#160;Pavco&#146;s title, (d)&#160;the reduction of
    Dr.&#160;Pavco&#146;s duties from those typically assigned to a
    Vice President of a similarly situated biotechnology or
    pharmaceutical company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the above, in the event we undergo a change of
    control (as defined) and Dr.&#160;Pavco&#146;s employment is
    terminated by us or by Dr.&#160;Pavco for involuntary
    termination, within one year after the change of control (other
    than for cause (as defined)), then: (i)&#160;the greater of
    (a)&#160;50% of Dr.&#160;Pavco&#146;s unvested options shall
    vest immediately, or (b)&#160;12&#160;months&#146; unvested
    options shall vest immediately, and (ii)&#160;Dr.&#160;Pavco
    will be entitled to (a)&#160;any accrued but unpaid salary and
    unused vacation time as of the date of such termination,
    (b)&#160;12&#160;months&#146; of salary from the date of
    termination, payable in accordance with our normal payroll
    practice, and (c)&#160;continued participation, at our expense
    and cost, during those 12&#160;months in any of our sponsored
    group benefit plans in which Dr.&#160;Pavco was participating as
    of the date of termination. In the event that Dr.&#160;Pavco was
    terminated following a change of control, the value of salary
    and benefits Dr.&#160;Pavco would be entitled to receive during
    those 12&#160;months would be approximately
    $&#160;&#160;&#160;&#160;&#160;. As any options held by
    Dr.&#160;Pavco&#146;s at the time of the change of control would
    vest immediately, the accelerated vesting provisions described
    above would only apply to options that may be issued to her
    after the change of control. Because the terms of any such
    options are unknown, the current fair value of stock options
    that would vest as a result of such termination cannot be
    calculated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tod
    Woolf,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We entered into an employment agreement with Dr.&#160;Woolf
    under which he was engaged to continue his employment as our
    President and Chief Executive Officer through December&#160;31,
    2008. Dr.&#160;Woolf was entitled under his employment agreement
    to receive an annual base salary of $250,000. In October of
    2008, the Board of Directors voted to increase
    Dr.&#160;Woolf&#146;s base salary to $375,000. On
    January&#160;1, 2009, we extended Dr.&#160;Woolf employment
    agreement through December&#160;31, 2009 at his then current
    base salary. In addition, on May&#160;23, 2007, after our
    initial funding and pursuant to the terms of his employment
    agreement, we granted Dr.&#160;Woolf an option to purchase
    316,994&#160;shares of our common stock at an exercise price of
    the then fair market value of $5.00 per share. This option has a
    term of ten years and will vest in equal monthly installments
    over three years, subject to accelerated vesting if any of the
    following occur: (a)&#160;a covered transaction, as defined in
    the 2007 Incentive Plan, occurs or (b)&#160;CytRx votes its
    shares of our stock to elect individuals who are
    (i)&#160;employees, officers or directors of CytRx,
    (ii)&#160;employees, officers or directors of any entity that
    has a contractual business relationship with CytRx, or
    (iii)&#160;employees, officers, directors of any entity that has
    a contractual business relationship with any officer or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    director of CytRx to constitute a majority of our Board of
    Directors. Dr.&#160;Woolf also may be eligible for an annual
    discretionary bonus, which will be determined in our sole
    discretion. Under Dr.&#160;Woolf&#146;s employment agreement,
    CytRx agrees to indemnify and hold Dr.&#160;Woolf and IPIFINI,
    Inc., an entity affiliated with him, harmless for any claims
    which arise from his services as our President and Chief
    Executive Officer prior to the effective date of his employment
    agreement. In April&#160;18, 2008, we granted Dr.&#160;Woolf an
    option to purchase 55,107&#160;shares of our common stock at an
    exercise price of the then fair market value of $7.50 per share.
    This option has a term of ten years and will vest and become
    exercisable in 16 equal quarterly installments beginning on
    July&#160;18, 2008, subject to accelerated vesting in the event
    of a covered transaction, as defined in our 2007 Incentive Plan.
    Provisions in Dr.&#160;Woolf&#146;s agreement related to
    payments upon termination are described above in
    &#147;Termination Based Compensation and Termination
    Agreements.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stephen
    DiPalma</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into an employment agreement with
    Mr.&#160;DiPalma under which he is engaged to serve as our
    Executive Vice President of Business Operations, Chief Financial
    Officer and Secretary. Mr.&#160;DiPalma is entitled under his
    employment agreement to receive an annual base salary of
    $220,000 and an annual performance bonus for the achievement of
    certain company and employee performance goals to be established
    by the Compensation Committee. The bonus for top performance
    against such established goals will be 30% of
    Mr.&#160;DiPalma&#146;s annual base salary. In October of 2008,
    the Board of Directors voted to increase Mr.&#160;DiPalma&#146;s
    base salary to $265,000. Pursuant to the terms of his employment
    agreement, on October&#160;18, 2007, we granted Mr.&#160;DiPalma
    an option to purchase 100,000&#160;shares of our common stock at
    an exercise price of the then fair market value of $5.00 per
    share. The option will have a term of ten years and will vest
    and become exercisable in 16 equal quarterly installments
    beginning on August&#160;28, 2007, subject to accelerated
    vesting in the event of a covered transaction, as defined in our
    2007 Incentive Plan. In April&#160;18, 2008, we granted
    Mr.&#160;DiPalma an option to purchase 19,429&#160;shares of our
    common stock at an exercise price of the then fair market value
    of $7.50 per share. The option will have a term of ten years and
    will vest and become exercisable in 16 equal quarterly
    installments beginning on July&#160;18, 2008, subject to
    accelerated vesting in the event of a covered transaction, as
    defined in our 2007 Incentive Plan. Provisions in
    Mr.&#160;DiPalma&#146;s agreement related to payments upon
    termination are described above in &#147;Termination Based
    Compensation and Termination Agreements.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Pamela
    Pavco,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into an employment agreement with Dr.&#160;Pavco
    under which she is engaged to serve as our Vice President of
    Research and Development or Vice President of Pharmaceutical
    Development for a term of one year. Dr.&#160;Pavco is entitled
    under her employment agreement to receive an annual base salary
    of $198,000. In October of 2008, the Board of Directors voted to
    increase Dr.&#160;Pavco&#146;s base salary to $270,000. On
    May&#160;23, 2007, after the initial funding and pursuant to the
    terms of her employment agreement, we granted Dr.&#160;Pavco an
    option to purchase 145,311&#160;shares of our common stock at an
    exercise price of the then fair market value of $5.00 per share.
    The option will have a term of ten years and will vest and
    become exercisable in 16 equal quarterly installments beginning
    on June&#160;7, 2007, subject to accelerated vesting in the
    event of a covered transaction, as defined in our 2007 Incentive
    Plan. In April&#160;18, 2008, we granted Dr.&#160;Pavco an
    option to purchase 41,826&#160;shares of our common stock at an
    exercise price of the then fair market value of $7.50 per share.
    The option will have a term of ten years and will vest and
    become exercisable in 16 equal quarterly installments beginning
    on July&#160;18, 2008, subject to accelerated vesting in the
    event of a covered transaction, as defined in our 2007 Incentive
    Plan. Provisions in Dr.&#160;Pavco&#146;s agreement related to
    payments upon termination, a covered transaction and a change of
    control are described above in &#147;Termination Based
    Compensation and Termination Agreements.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the discretion of the Board of Directors, each director may
    be paid such fees for his services as a director and be
    reimbursed for his reasonable expenses incurred in the
    performance of his duties as director as the Board of Directors
    determines from time to time.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of the compensation
    paid to certain of our directors in 2008, other than
    Dr.&#160;Woolf. Amounts included under Options awards below
    represent the fair value of the award calculated under
    SFAS&#160;123(R).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>in Cash&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Compensation&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mark. J. Ahn,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224,475
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    315,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stephen S. Galliker
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224,475
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    325,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sanford J. Hillsberg
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224,475
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    339,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steven A. Kriegsman
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224,475
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, our Board of Directors approved a director compensation
    plan that provides that each director who is not an employee
    will receive the following cash compensation for service on our
    Board of Directors and committees of our Board of Directors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $10,000 for each director, payable
    quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $12,000 for the chairperson of each
    committee of our Board of Directors other than the audit
    committee, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $20,000 for the chairperson of the
    audit committee of our Board of Directors, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $32,000 for the Chairman of the Board
    of Directors, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $2,000 per board meeting attended by the director
    ($1,000 if attendance is telephonic),&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $1,500 per committee meeting attended by the director
    ($750 if attendance is telephonic).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;18, 2008, our Board of Directors approved a
    revised director compensation plan to be effective as of that
    date that provides that each director who is not an employee
    will receive the following cash compensation for service on our
    Board of Directors and committees of our Board of Directors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $24,000 for each director, payable
    quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $12,000 for the chairperson of each
    committee of our Board of Directors other than the audit
    committee, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $25,000 for the chairperson of the
    audit committee of our Board of Directors, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual retainer fee of $50,000 for the Chairman of the Board
    of Directors, payable quarterly,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $3,000 per board meeting attended by the director, such
    fee payable for meetings attended in person or telephonically,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fee of $2,500 per audit committee meeting attended by the chair
    of the committee, such fees payable for meetings attended in
    person or telephonically,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $2,000 per audit committee meeting attended by other
    directors who are members of the committee, such fees payable
    for meetings attended in person or telephonically,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $2,000 per all other committee meetings attended by the
    chair of the committee, such fees payable for meetings attended
    in person or telephonically,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $1,500 per all other committee meeting attended by
    other directors who are members of the committee, such fees
    payable for meetings attended in person or
    telephonically,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of $750 per each written consent.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Equity
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;10, 2008, as part of their annual grant, each
    non-employee director was granted, an option of
    25,000&#160;shares at an exercise price of $5.00 per share.
    These options were fully vested at December&#160;31, 2008. These
    options have a ten year term and will be exercisable for two
    years following termination of service as a member of the Board
    of Directors, unless the director is terminated for cause, in
    which case the options are terminated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;18, 2008 each non-employee director was granted an
    additional 25,000&#160;shares at an exercise price of $7.50 per
    share. These options were fully vested at December&#160;31,
    2008. These options have a ten year term and will be exercisable
    for two years following termination of service as a member of
    the Board of Directors, unless the director is terminated for
    cause, in which case the options are terminated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Reimbursements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Directors will be reimbursed for their expenses incurred in
    attending Board of Directors, committee and stockholder
    meetings, including those for travel, meals and lodging.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into director indemnification agreements with
    each of our directors. Consistent with the indemnification
    rights that will be provided to all of our directors under our
    amended and restated certificate of incorporation, we will
    indemnify and hold harmless each director to the fullest extent
    permitted or authorized by the Delaware General Corporation Law
    in effect on the date of the agreement or as such laws may be
    amended or replaced to increase the extent to which a
    corporation can indemnify its directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Tax and
    Accounting Implications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Deductibility
    of Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of its role, the Compensation Committee reviews and
    considers the deductibility of executive compensation under
    Section&#160;162(m) of the Internal Revenue Code, which provides
    that corporations may not deduct compensation of more than
    $1.0&#160;million that is paid to certain individuals. We
    believe that compensation paid to our executive officers
    generally is fully deductible for federal income tax purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for Share-Based Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for share-based compensation in accordance with the
    requirements of SFAS&#160;123(R). This accounting treatment has
    not significantly affected our compensation decisions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation in Compensation
    Decisions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no &#147;interlocks,&#148; as defined by the SEC with
    respect to any member of the compensation committee.
    Mr.&#160;Hillsberg (chair), Mr.&#160;Galliker and Dr.&#160;Nisi
    are the current members of the Compensation Committee. None of
    Mr.&#160;Hillsberg, Dr.&#160;Nisi or Mr.&#160;Galliker have ever
    served as an officer of the Company or acted in such capacity.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;11, 2007, we adopted a Code of Ethics applicable to
    all employees, including the principal executive officer,
    principal financial officer and principal accounting officer. A
    copy of our Code of Ethics is available upon request. Such
    requests should be directed to Attention: Corporate Secretary,
    60 Prescott Street, Worcester, Massachusetts 01605, or by
    telephone at
    <FONT style="white-space: nowrap">508-767-3861.</FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;II<BR>
    RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED<BR>
    PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Appointment
    of BDO Seidman, LLP</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BDO Seidman, LLP (BDO) currently serves as our independent
    registered public accounting firm and audited our financial
    statements for the year ended December&#160;31, 2008. BDO does
    not have and has not had any financial interest, direct or
    indirect, in RXi, and does not have and has not had any
    connection with RXi except in its professional capacity as our
    independent auditors. BDO also audits the financial statements
    of CytRx Corporation, our largest shareholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee has reappointed BDO to serve as our
    independent registered public accounting firm for the year
    ending December&#160;31, 2009. The ratification by our
    stockholders of the appointment of BDO is not required by law or
    by our Bylaws. Our Board of Directors, consistent with the
    practice of many publicly held corporations, is nevertheless
    submitting this appointment for ratification by the
    stockholders. If this appointment is not ratified at the Annual
    Meeting, the Audit Committee intends to reconsider its
    appointment of BDO. Even if the appointment is ratified, the
    Audit Committee in its sole discretion may direct the
    appointment of a different independent registered public
    accounting firm at any time during the fiscal year if the
    Committee determines that such a change would be in the best
    interests of RXi and its stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any material non-audit services to be provided by BDO are
    subject to the prior approval of the Audit Committee. In
    general, the Audit Committee&#146;s policy is to grant such
    approval where it determines that the non-audit services are not
    incompatible with maintaining the independent registered public
    accounting firm&#146;s independence and there are cost or other
    efficiencies in obtaining such services from the independent
    registered public accounting firm as compared to other possible
    providers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that representatives of BDO will be present at the
    Annual Meeting, will have an opportunity to make a statement if
    they so desire, and will be available to respond to appropriate
    questions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Audit
    Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fees for 2008 and 2007 billed to us by BDO for professional
    services rendered for the audit of our annual financial
    statements,
    <FONT style="white-space: nowrap">S-1</FONT> and
    <FONT style="white-space: nowrap">S-8</FONT>
    Registration Statements were $281,000 and $587,000 respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Audit
    Related Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were no audit related fees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Tax
    Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were $7,500 in tax related fees for 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">All Other
    Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No other services were rendered by BDO for 2008 and 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pre-Approval
    Policies and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is the policy of our Audit Committee that all services to be
    provided by our independent registered public accounting firm,
    including audit services and permitted audit-related and
    non-audit services, must be pre-approved by our Audit Committee.
    Our Audit Committee pre-approved all services provided to us by
    BDO for 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE
    &#147;FOR&#148; RATIFICATION OF THE APPOINTMENT OF BDO SEIDMAN,
    LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE
    FISCAL YEAR ENDING DECEMBER 31, 2009.</B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;III<BR>
    APPROVAL OF AMENDMENT TO THE 2007 INCENTIVE PLAN</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The RXi Pharmaceuticals Corporation 2007 Incentive Plan, (the
    &#147;2007 Incentive Plan&#148;), was adopted by our Board of
    Directors on February&#160;23, 2007 and approved by our
    stockholders on June&#160;19, 2007. During 2008 the 2007
    Incentive Plan was amended to increase the maximum number of
    common stock shares authorized for issuance from 2,750,000 to
    3,750,000. The amendment was adopted by our Board of Directors
    on June&#160;4, 2008 and approved by our stockholders on
    July&#160;18, 2008. Under this plan, we may grant incentive
    common stock options (&#147;ISOs&#148;), nonqualified stock
    options (&#147;NSOs&#148;), restricted and unrestricted stock
    awards, deferred stock awards, performance awards, stock
    appreciation rights, securities convertible into stock or
    otherwise based on stock, and cash awards to all employees,
    officers, directors, consultants and advisors who provide
    services to us and our affiliates. A maximum of
    3,750,000&#160;shares of common stock are currently authorized
    for issuance under our 2007 Incentive Plan. As of
    December&#160;31, 2008, 2,223,452&#160;shares were subject to
    outstanding options under this plan, and 1,526,548&#160;shares
    were available for future grant under this plan. Because we
    anticipate that our needs under the 2007 Incentive Plan over the
    next several years will exceed the number of shares of common
    stock available, our Board has approved, and we are asking our
    stockholders to approve, the amendment of the 2007 Incentive
    Plan, which serves to increase the number of shares of common
    stock under the 2007 Incentive Plan by 1,000,000&#160;shares for
    a total of 4,750,000&#160;shares of common stock authorized for
    issuance under awards granted pursuant to the 2007 Incentive
    Plan (the &#147;2007 Incentive Plan Amendment&#148;) and to make
    corresponding changes to related amounts in the 2007 Incentive
    Plan with respect to limits on the number of shares of common
    stock that may be delivered in satisfaction of awards under the
    2007 Incentive Plan. A copy of the 2007 Plan, as proposed to be
    amended, appears as Annex&#160;A to this Proxy Statement, which
    we urge Stockholders to read in its entirety.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purpose of the 2007 Incentive Plan is to advance the
    interests of the Company by giving stock-based incentives and
    other incentives to selected employees, directors and other
    individuals or entities who provide services to us or our
    affiliates who, in the opinion of the Administrator (as defined
    below), are in a position to make a significant contribution to
    the success of the Company and our affiliates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Administration</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The 2007 Incentive Plan is administered by the Compensation
    Committee of the Board of Directors (the &#147;Compensation
    Committee&#148;) or by such persons to whom the Compensation
    Committee may delegate such administration (collectively, with
    the Compensation Committee, the &#147;Administrator&#148;). The
    Administrator has full authority, consistent with the 2007
    Incentive Plan, to select who will receive awards, to determine
    the type of awards to be granted, as well as the amounts, price,
    terms and conditions of any awards, to issue shares upon option
    exercises and interpret option agreements. The Administrator has
    the right to determine any questions that may arise regarding
    the interpretation and application of the provisions of the 2007
    Incentive Plan and to make, administer, and interpret such rules
    and regulations as it deems necessary or advisable.
    Determinations of the Administrator made under the 2007
    Incentive Plan are conclusive and bind all parties.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Participation
    in the 2007 Incentive Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Employees, directors, consultants and advisors who provide
    services to us and our affiliates, who, in the opinion of the
    Administrator, are in a position to make a significant
    contribution to the success of the Company or its affiliates are
    eligible to participate in the 2007 Incentive Plan. However,
    only employees are eligible to receive ISOs. Approximately
    100&#160;employees and directors and approximately 20
    consultants and advisors who provide services to us and our
    affiliates are eligible to receive awards under the 2007
    Incentive Plan. The maximum number of shares for which stock
    options and stock appreciation rights may be granted to any
    participant in any calendar year is the total number of shares
    of Stock authorized under the 2007 Incentive Plan. The maximum
    number of ISOs which may be granted under the 2007 Incentive
    Plan is the total number of shares of Stock authorized under the
    2007 Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The future benefits or amounts that would be received by or
    allocated under the 2007 Incentive Plan are discretionary and
    therefore are not determinable at this time. If the 2007
    Incentive Plan Amendment is approved, the Company does not
    expect the award of benefits to change from the current practice.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Types of
    Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator in its discretion, may award (i)&#160;stock
    options, (ii)&#160;restricted stock, (iii)&#160;deferred stock
    awards, (iv)&#160;performance awards, (v)&#160;stock
    appreciation rights, (vi)&#160;securities convertible into stock
    or otherwise based on stock, and (vii)&#160;cash awards, on such
    terms and conditions as it determines.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Performance
    Criteria</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Awards under the 2007 Incentive Plan may be conditioned upon
    satisfaction of specified performance criteria. In the case of
    any such award that is intended to qualify for exemption from
    the deduction limitation rules of Section&#160;162(m) of the
    U.S.&#160;Internal Revenue Code of 1986, as amended (the
    &#147;Code&#148;), each a &#147;Performance Award&#148;, the
    criteria used in connection with the Performance Award shall
    mean an objectively determinable measure of performance relating
    to any or any combination of the following (measured either
    absolutely or by reference to an index or indices and determined
    either on a consolidated basis or, as the context permits, on a
    divisional, subsidiary, line of business, project or
    geographical basis or in combinations thereof): sales; revenues;
    assets; expenses; earnings before or after deduction for all or
    any portion of interest, taxes, depreciation, or amortization,
    whether or not on a continuing operations or an aggregate or per
    share basis; return on equity, investment, capital or assets;
    one or more operating ratios; borrowing levels, leverage ratios
    or credit rating; market share; capital expenditures; cash flow;
    stock price; stockholder return; sales of particular products or
    services; customer acquisition or retention; acquisitions and
    divestitures (in whole or in part); joint ventures and strategic
    alliances; spin-offs,
    <FONT style="white-space: nowrap">split-ups</FONT>
    and the like; reorganizations; or recapitalizations,
    restructurings, financings (issuance of debt or equity) or
    refinancings. A performance criterion and any targets with
    respect thereto determined by the Administrator need not be
    based upon an increase, a positive or improved result or
    avoidance of loss. To the extent consistent with the
    requirements for satisfying the performance-based compensation
    exception under Section&#160;162(m), the Administrator will
    provide in the case of any award intended to qualify for such
    exception that one or more of the performance criteria
    applicable to such award will be adjusted in an objectively
    determinable manner to reflect events occurring during the
    performance period that affect the applicable performance
    criteria. In the case of a Performance Award, the Administrator
    will pre-establish the particular performance criteria no later
    than 90&#160;days after the commencement of the period of
    service to which the performance relates (or such earlier time
    as is required to qualify the award as performance-based under
    Section&#160;162(m)) and will certify prior to payment whether
    the performance criteria have been attained.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rules&#160;Applicable
    to Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No awards may be made after the tenth anniversary of the date
    the 2007 Incentive Plan was first adopted by the Board, but
    previously granted awards may continue beyond that date in
    accordance with their terms. Unless the Administrator expressly
    provides otherwise, awards may not be transferred other than by
    will or applicable laws of descent and distribution, and
    generally only the participant may exercise an award during such
    participant&#146;s lifetime. The Administrator may permit awards
    other than ISOs to be transferred by gift, subject to such
    limitations as the Administrator may impose. The Administrator
    may determine the time or times at which an award will vest or
    become exercisable. Without limiting the foregoing, the
    Administrator may at any time accelerate the vesting or
    exercisability of an award, regardless of any adverse or
    potentially adverse tax consequences resulting from such
    acceleration. Immediately upon termination of employment of an
    employee, the unvested portion of any stock option will
    terminate and the balance, to the extent exercisable, will
    remain exercisable for the lesser of (i)&#160;a period of three
    months (90&#160;days) or (ii)&#160;the period ending on the
    latest date on which such stock option could have been exercised
    without regard to this provision. The 2007 Incentive Plan
    provides exceptions for the vesting of options upon an
    individual&#146;s death or if the administrator determines that
    the termination of employment resulted for reasons that cast
    discredit on the individual. The Administrator will determine
    what will happen with respect to an award granted to a
    participant that is outstanding upon the cessation of the
    participant&#146;s service relationship with the Company,
    including disability, death or retirement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator will determine the exercise price, if any, of
    each award requiring exercise. Unless the Administrator
    determines otherwise, each stock option will have an exercise
    price not less than the fair market value
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of the stock subject to the stock option, determined as of the
    date of grant. A stock option intended to be an ISO granted to a
    person who owns (or by application of attribution rules is
    deemed to own) more than 10% of the total combined voting power
    of all classes of stock of the Company will have an exercise
    price equal to 110% of such fair market value. Awards requiring
    exercise will have a maximum term not to exceed ten years from
    the date of grant and will vest, either quarterly or annually
    and all within four years of grant date.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Effect of
    Certain Transactions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a consolidation, merger, or sale of
    substantially all of the Company&#146;s assets or a dissolution
    or liquidation of the Company in which there is a surviving or
    acquiring entity, the Administrator may provide for the
    assumption or substitution of some or all outstanding awards by
    the acquiror or survivor. If the holders of stock will receive a
    payment upon consummation of the transaction, the Administrator
    may provide for a &#147;cash-out&#148; payment with respect to
    some or all awards or any portion thereof, equal to the excess,
    if any, of (a)&#160;the fair market value of one share of stock
    times the number of shares of stock subject to the award or such
    portion, over (b)&#160;the aggregate exercise or purchase price,
    if any, under the award or such portion (in the case of a stock
    appreciation right, the aggregate base value above which
    appreciation is measured), on such payment and other terms as
    the Administrator determines. In the absence of an assumption,
    substitution or cash-out, each award requiring exercise will
    become fully exercisable, and delivery of shares of stock
    deliverable under each outstanding award will be accelerated and
    such shares will be issued prior to the transaction on a basis
    that gives the participant a reasonable opportunity, as
    determined by the Administrator, following exercise of the award
    or delivery of the shares, as the case may be, to participate in
    the transaction as a stockholder. Any shares of stock so issued
    with respect to an award, in the discretion of the
    Administrator, may contain such restrictions as the
    Administrator deems appropriate to reflect any performance or
    other vesting conditions to which the award was subject. All
    such awards will terminate upon consummation of such transaction.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Equitable
    Adjustment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a change in the outstanding common stock
    resulting from a stock dividend, stock split, recapitalization,
    or other capital change, the aggregate number of shares
    available under the 2007 Plan, the number of shares available
    for individual awards, the terms of outstanding awards,
    including stock option exercise prices, will be appropriately
    adjusted by the Administrator. The Administrator may also make
    adjustments in other circumstances if it determines that the
    adjustments are necessary to avoid distortion in the operation
    of the 2007 Plan and to preserve the value of awards; provided,
    however, that no such adjustment shall be made to the maximum
    share limits, or otherwise to an award intended to be eligible
    for the performance-based exception under Section&#160;162(m) of
    the Code, except to the extent consistent with that exception.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the Administrator&#146;s obligation to exercise its
    discretion consistent with qualifying awards for the
    performance-based exception under Section&#160;162(m) if such
    awards are intended to so qualify, the Administrator may at any
    time or times amend the 2007 Incentive Plan or any outstanding
    award for any purpose which may at the time be permitted by law,
    and may at any time terminate the 2007 Incentive Plan as to any
    future grants of awards; provided, that except as otherwise
    expressly provided in the 2007 Incentive Plan, the Administrator
    may not, without the participant&#146;s consent, alter the terms
    of an award so as to materially and adversely affect the
    participant&#146;s rights under the award, unless the
    Administrator expressly reserved the right to do so at the time
    of such award. Any amendments to the 2007 Incentive Plan shall
    be conditioned upon stockholder approval only to the extent, if
    any, such approval is required by law (including the Code and
    applicable stock exchange requirements).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The existence of the 2007 Incentive Plan or the grant of any
    award will not in any way affect the Company&#146;s right to
    award a person bonuses or other compensation in addition to
    awards under the 2007 Incentive Plan.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Price of
    Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The closing price of the Company&#146;s common stock on the
    NASDAQ Capital Market on April&#160;16, 2009 was $4.96.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Certain
    Federal Income Tax Consequences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following discussion summarizes certain United States
    federal income tax consequences of the issuance and receipt of
    options under the 2007 Incentive Plan under the law as in effect
    on the date of this proxy statement. The 2007 Incentive Plan
    provides for the grant of both ISOs and NSOs, as well as other
    awards. The summary does not purport to cover federal employment
    tax or other federal tax consequences that may be associated
    with the 2007 Incentive Plan, nor does it cover state, local or
    <FONT style="white-space: nowrap">non-U.S.&#160;taxes.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">ISOs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An optionee realizes no taxable income upon the grant or, for
    regular tax purposes, upon the exercise of an ISO. However, the
    exercise of an ISO increases the optionee&#146;s alternative
    minimum taxable income by an amount equal to the excess (at the
    time of exercise) of the fair market value of the shares
    acquired upon exercise over the exercise price and this increase
    may give rise to an alternative minimum tax liability. With
    certain exceptions, a disposition of shares purchased under an
    ISO within two years from the date of grant or within one year
    after exercise produces ordinary income to the optionee (and a
    deduction to the Company) equal to the value of the shares at
    the time of exercise less the exercise price. Any additional
    gain recognized in the disposition is treated as capital gain
    for which the Company is not entitled to a deduction. If the
    optionee does not dispose of the shares until after the
    expiration of these one and two year holding periods, any gain
    or loss recognized upon a subsequent sale is treated as a
    long-term capital gain or loss for which the Company is not
    entitled to a deduction.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">NSOs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, in the case of an NSO, the optionee has no taxable
    income at the time of grant but realizes income in connection
    with the exercise of the option in an amount equal to the excess
    (at the time of exercise) of the fair market value of the shares
    acquired upon exercise over the exercise price; a corresponding
    deduction is available to the Company; and upon a subsequent
    sale or exchange of the shares, any recognized gain or loss
    after the date of exercise is treated as capital gain or loss
    for which the Company is not entitled to a deduction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, an ISO that is exercised by the optionee more than
    three months after termination of employment is treated as an
    NSO. ISOs are also treated as NSOs to the extent they first
    become exercisable by an individual in any calendar year for
    shares having a fair market value (determined as of the date of
    grant) in excess of $100,000.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restricted
    Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator may award stock options that are exercisable
    for restricted stock. Under Section&#160;83 of the Code, an
    optionee who exercises a nonqualified stock option for
    restricted stock will generally have income only when the stock
    vests, equal to the fair market value of the stock at that time
    less the exercise price. However, the optionee may make a
    so-called &#147;83(b) election&#148; in connection with the
    exercise to recognize taxable income at the time of exercise.
    Assuming no other applicable limitations, the amount and timing
    of the deduction available to the Company will correspond to the
    income recognized by the optionee. In the case of an optionee
    who exercises an incentive stock option for restricted stock,
    the tax consequences described above with respect to the
    exercise of incentive stock options will apply except that
    (i)&#160;the optionee will have no alternative minimum taxable
    income associated with the exercise until the stock vests,
    unless the optionee makes a timely &#147;83(b) election,&#148;
    and (ii)&#160;in the event of a disqualifying disposition, the
    ordinary income recognized by reason of the disposition and the
    Company&#146;s corresponding deduction will be measured by
    reference to the fair market value of the stock at the time the
    stock vested.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Deferred
    Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A promise by the Company to transfer shares of stock to a
    participant in the future does not itself result in taxable
    income to the participant. When the participant actually
    acquires the shares of stock, unless the shares are
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    restricted, the participant will recognize ordinary income equal
    to the value of the shares at that time. If the shares delivered
    to the participant are restricted for tax purposes, the
    participant will be subject at that time to the tax consequences
    describe above with respect to restricted stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Performance-Based
    Awards</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No special tax consequences exist with respect to the use of
    performance criteria. Where stock is transferred to a
    participant upon the satisfaction of specified performance
    criteria, the participant will recognize ordinary income equal
    to the value of the shares at that time unless the stock is
    restricted stock. If the shares received by the participant are
    shares of restricted stock, or if restrictions on previously
    awarded shares of restricted stock are lifted in connection with
    the satisfaction of performance criteria, the tax consequences
    discussed above with respect to restricted stock will apply.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    Appreciation Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The grant of a stock appreciation right does not itself result
    in taxable income, nor does taxable income result merely because
    a stock appreciation right becomes exercisable. Generally, if a
    participant exercises a stock appreciation right for shares of
    stock or receives payment in cancellation of a stock
    appreciation right, the participant will have ordinary income
    equal to the amount of any cash and the fair market value of any
    stock received.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Deferred
    Compensation Rules</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Arrangements under the 2007 Incentive Plan may involve the
    payment, or commitment to pay, deferred compensation subject to
    special rules under the Code. Awards that are subject to but
    fail to comply with the formal and operational requirements of
    these rules will be subject to a 20% excise tax, in addition to
    ordinary income tax, as well as, in some cases, to interest
    charges. Failure to comply with these rules may also result in
    an acceleration of the timing of income inclusion in respect of
    such awards for income tax purposes. With certain exceptions,
    awards of restricted stock and stock options with an exercise
    price that can never be less than the fair market value of the
    common stock subject to the option at the time of grant will be
    exempt from these rules. Other types of awards, however, if
    granted, such as deferred stock awards, would have to comply.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">162(m)
    Issues</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Code limits to $1&#160;million the deduction a public
    corporation may claim in any year for compensation paid to any
    of its chief executive officer and four other most highly
    compensated named executive officers, subject to a number of
    exceptions. Generally, the $1&#160;million deduction limit does
    not apply to certain stock option grants awarded under
    stockholder approval plans or to other qualifying
    performance-based awards. Stock options awarded under the 2007
    Incentive Plan, assuming an exercise price not less than fair
    market value on the date of grant, are intended to be eligible
    for this exception. The 2007 Incentive Plan is also designed to
    enable the Company to grant other performance-based awards that
    will be exempt for purposes of the $1&#160;million deduction
    limitation rule.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Golden
    Parachute Rules</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the &#147;golden parachute&#148; provisions of the Code,
    the accelerated vesting of awards in connection with a change in
    control of the Company may be required to be valued and taken
    into account in determining whether participants have received
    compensatory payments, contingent on the change in control, in
    excess of certain limits. These tax consequences, where
    applicable, apply to change in control payments that exceed an
    individual&#146;s &#147;base amount,&#148; generally, the
    average annual taxable compensation of the individual determined
    over the preceding five years. They do not apply where an
    individual&#146;s total change in control payments are less than
    three times his or her base amount. If these limits are
    exceeded, a substantial portion of amounts payable to the
    participant, including income recognized by reason of the grant,
    vesting or exercise of awards under the 2007 Incentive Plan, may
    be subject to an additional 20% federal tax and may be
    nondeductible to the Company.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Company
    Deductions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, a deduction will be available to the Company for any
    ordinary compensation income realized by a participant under an
    award. The deduction will be available in the same year as that
    in which the participant realizes income for income tax purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, the Company is not entitled to a deduction for any
    dividends paid to its stockholders. However, if stock has been
    transferred under the Plan subject to a substantial risk of
    forfeiture, and if no effective 83(b) election has been made,
    dividends on the stock would be treated as deductible
    compensation until such time as the substantial risk of
    forfeiture lapses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Information with respect to the 2007 Incentive Plan as of
    December&#160;31, 2008</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Equity
    Compensation Plan Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining Available<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>for Future Issuance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Securities to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Under Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>be Issued upon Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plans (Excluding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Outstanding Options,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options, Warrants<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities Related<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Plan Category</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Warrants and Rights</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>and Rights</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>in (a))</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity compensation plans approved by security holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>2,223,452</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">
    <B>6.11</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>1,526,548</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity compensation plans not approved by security holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>&#151;</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>&#151;</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>&#151;</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>2,223,452</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>$</B>
</TD>
<TD nowrap align="right" valign="bottom">
    <B>6.11</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>1,526,548</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE
    &#147;FOR&#148; APPROVAL OF THE AMENDMENT TO THE AMENDED AND
    RESTATED 2007 INCENTIVE PLAN</B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">STOCKHOLDER
    PROPOSALS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any proposal which a stockholder intends to present in
    accordance with
    <FONT style="white-space: nowrap">Rule&#160;14a-8</FONT>
    of Exchange Act of 1934 at our next Annual Meeting of
    Stockholders to be held in 2010 must be received by us on or
    before December&#160;24, 2009. Only proper proposals under
    <FONT style="white-space: nowrap">Rule&#160;14a-8</FONT>
    which are timely received will be included in the Proxy
    Statement in 2010.
</DIV>
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Expenses
    of Solicitation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will bear the cost of soliciting proxies in the accompanying
    form. In addition to the use of the mails, proxies may also be
    solicited by our directors, officers or other employees,
    personally or by telephone, facsimile or email, none of whom
    will be compensated separately for these solicitation activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Miscellaneous</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our management does not intend to present any other items of
    business and is not aware of any matters other than those set
    forth in this Proxy Statement that will be presented for action
    at the Annual Meeting. However, if any other matters properly
    come before the Annual Meeting, the persons named in the
    enclosed proxy intend to vote the shares of our common stock
    that they represent in accordance with their best judgment.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Annex&#160;A</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RXi
    Pharmaceuticals Corporation<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">2007
    INCENTIVE PLAN</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DEFINED
    TERMS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Exhibit&#160;A, which is incorporated by reference, defines the
    terms used in the Plan and sets forth certain operational rules
    related to those terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PURPOSE</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Plan has been established to advance the interests of the
    Company by providing for the grant to Participants of
    Stock-based and other incentive Awards.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ADMINISTRATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator has discretionary authority, subject only to
    the express provisions of the Plan, to interpret the Plan;
    determine eligibility for and grant Awards; determine, modify or
    waive the terms and conditions of any Award; prescribe forms,
    rules and procedures; and otherwise do all things necessary to
    carry out the purposes of the Plan. In the case of any Award
    intended to be eligible for the performance-based compensation
    exception under Section&#160;162(m), the Administrator will
    exercise its discretion consistent with qualifying the Award for
    that exception. Determinations of the Administrator made under
    the Plan will be conclusive and will bind all parties.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">LIMITS ON
    AWARDS UNDER THE PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Number of Shares</U>.</I>&#160;&#160;A maximum of
    4,750,000&#160;shares of Stock may be delivered in satisfaction
    of Awards under the Plan. The number of shares of Stock
    delivered in satisfaction of Awards shall, for purposes of the
    preceding sentence, be determined net of shares of Stock
    withheld by the Company in payment of the exercise price of the
    Award or in satisfaction of tax withholding requirements with
    respect to the Award. The limits set forth in this
    Section&#160;4(a) shall be construed to comply with
    Section&#160;422. To the extent consistent with the requirements
    of Section&#160;422 and with other applicable legal requirements
    (including applicable stock exchange requirements), Stock issued
    under awards of an acquired company that are converted,
    replaced, or adjusted in connection with the acquisition shall
    not reduce the number of shares available for Awards under the
    Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Type of Shares</U>.</I>&#160;&#160;Stock
    delivered by the Company under the Plan may be authorized but
    unissued Stock or previously issued Stock acquired by the
    Company. No fractional shares of Stock will be delivered under
    the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;<I><U>Section&#160;162(m)
    Limits</U>.</I>&#160;&#160;The maximum number of shares of Stock
    for which Stock Options may be granted to any person in any
    calendar year and the maximum number of shares of Stock subject
    to SARs granted to any person in any calendar year will each be
    the total number of shares then available under the Plan. The
    maximum number of shares subject to other Awards granted to any
    person in any calendar year will be the total number of shares
    available under the Plan. The foregoing provisions will be
    construed in a manner consistent with Section&#160;162(m).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ELIGIBILITY
    AND PARTICIPATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator will select Participants from among those key
    Employees and directors of, and consultants and advisors to, the
    Company or its Affiliates who, in the opinion of the
    Administrator, are in a position to make a significant
    contribution to the success of the Company and its Affiliates;
    <I>provided</I>, that, subject to such express exceptions, if
    any, as the Administrator may establish, eligibility shall be
    further limited to those persons as to whom the use of a
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    registration statement is permissible. Eligibility for ISOs is
    limited to employees of the Company or of a &#147;parent
    corporation&#148; or &#147;subsidiary corporation&#148; of the
    Company as those terms are defined in Section&#160;424 of the
    Code.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RULES&#160;APPLICABLE
    TO AWARDS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>All Awards</U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;<I><U>Award Provisions</U>.</I>&#160;&#160;The
    Administrator will determine the terms of all Awards, subject to
    the limitations provided herein. By accepting (or, under such
    rules as the Administrator may prescribe, being deemed to have
    accepted) an Award, the Participant agrees to the terms of the
    Award and the Plan. Notwithstanding any provision of this Plan
    to the contrary, awards of an acquired company that are
    converted, replaced or adjusted in connection with the
    acquisition may contain terms and conditions that are
    inconsistent with the terms and conditions specified herein, as
    determined by the Administrator.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;<I><U>Term of Plan</U>.</I>&#160;&#160;No Awards may be
    made after the tenth anniversary of the date that this Plan is
    first adopted by the Board of Directors of the Company, but
    previously granted Awards may continue beyond that date in
    accordance with their terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;<I><U>Transferability</U>.</I>&#160;&#160;Neither ISOs
    nor, except as the Administrator otherwise expressly provides in
    accordance with the second sentence of this
    Section&#160;6(a)(3), other Awards may be transferred other than
    by will or by the laws of descent and distribution, and during a
    Participant&#146;s lifetime ISOs (and, except as the
    Administrator otherwise expressly provides in accordance with
    the second sentence of this Section&#160;6(a)(3), other Awards
    requiring exercise) may be exercised only by the Participant.
    The Administrator may permit Awards other than ISOs to be
    transferred by gift, subject to such limitations as the
    Administrator may impose.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;<I><U>Vesting, Etc</U>.</I>&#160;&#160;The
    Administrator may determine the time or times at which an Award
    will vest or become exercisable and the terms on which an Award
    requiring exercise will remain exercisable. Without limiting the
    foregoing, the Administrator may at any time accelerate the
    vesting or exercisability of an Award, regardless of any adverse
    or potentially adverse tax consequences resulting from such
    acceleration. Unless the Administrator expressly provides
    otherwise, however, the following rules will apply: immediately
    upon the cessation of the Participant&#146;s Employment, each
    Award requiring exercise that is then held by the Participant or
    by the Participant&#146;s permitted transferees, if any, will
    cease to be exercisable and will terminate, and all other Awards
    that are then held by the Participant or by the
    Participant&#146;s permitted transferees, if any, to the extent
    not already vested will be forfeited, except that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (A)&#160;subject to (B)&#160;and (C)&#160;below, all Stock
    Options and SARs held by the Participant or the
    Participant&#146;s permitted transferees, if any, immediately
    prior to the cessation of the Participant&#146;s Employment, to
    the extent then exercisable, will remain exercisable for the
    lesser of (i)&#160;a period of three months or (ii)&#160;the
    period ending on the latest date on which such Stock Option or
    SAR could have been exercised without regard to this
    Section&#160;6(a)(4), and will thereupon terminate;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (B)&#160;all Stock Options and SARs held by a Participant or the
    Participant&#146;s permitted transferees, if any, immediately
    prior to the Participant&#146;s death, to the extent then
    exercisable, will remain exercisable for the lesser of
    (i)&#160;the one year period ending with the first anniversary
    of the Participant&#146;s death or (ii)&#160;the period ending
    on the latest date on which such Stock Option or SAR could have
    been exercised without regard to this Section&#160;6(a)(4), and
    will thereupon terminate;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (C)&#160;all Stock Options and SARs held by a Participant or the
    Participant&#146;s permitted transferees, if any, immediately
    prior to the cessation of the Participant&#146;s Employment will
    immediately terminate upon such cessation if the Administrator
    in its sole discretion determines that such cessation of
    Employment has resulted for reasons which cast such discredit on
    the Participant as to justify immediate termination of the Award
    or are otherwise determined by the Administrator to constitute
    cause.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (5)&#160;<I><U>Taxes</U>.</I>&#160;&#160;The Administrator will
    make such provision for the withholding of taxes as it deems
    necessary. The Administrator may, but need not, hold back shares
    of Stock from an Award or permit a Participant to tender
    previously owned shares of Stock in satisfaction of tax
    withholding requirements (but not in excess of the minimum
    withholding required by law).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (6)&#160;<I><U>Dividend Equivalents, Etc</U>.</I>&#160;&#160;The
    Administrator may provide for the payment of amounts in lieu of
    cash dividends or other cash distributions with respect to Stock
    subject to an Award. Any entitlement to dividend
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    equivalents or similar entitlements shall be established and
    administered consistent either with exemption from, or
    compliance with, the requirements of Section&#160;409A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (7)&#160;<I><U>Rights Limited</U>.</I>&#160;&#160;Nothing in the
    Plan will be construed as giving any person the right to
    continued employment or service with the Company or its
    Affiliates, or any rights as a stockholder except as to shares
    of Stock actually issued under the Plan. The loss of existing or
    potential profit in Awards will not constitute an element of
    damages in the event of termination of Employment for any
    reason, even if the termination is in violation of an obligation
    of the Company or any Affiliate to the Participant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (8)&#160;<I><U>Section&#160;162(m)</U>.</I>&#160;&#160;This
    Section&#160;6(a)(8) applies to any Performance Award intended
    to qualify as performance-based for the purposes of
    Section&#160;162(m) other than a Stock Option or SAR. In the
    case of any Performance Award to which this Section&#160;6(a)(8)
    applies, the Plan and such Award will be construed to the
    maximum extent permitted by law in a manner consistent with
    qualifying the Award for such exception. With respect to such
    Performance Awards, the Administrator will preestablish, in
    writing, one or more specific Performance Criteria no later than
    90&#160;days after the commencement of the period of service to
    which the performance relates (or at such earlier time as is
    required to qualify the Award as performance-based under
    Section&#160;162(m)). Prior to grant, vesting or payment of the
    Performance Award, as the case may be, the Administrator will
    certify whether the applicable Performance Criteria have been
    attained and such determination will be final and conclusive. No
    Performance Award to which this Section&#160;6(a)(8) applies may
    be granted after the first meeting of the stockholders of the
    Company held in 2012 until the listed performance measures set
    forth in the definition of &#147;Performance Criteria&#148; (as
    originally approved or as subsequently amended) have been
    resubmitted to and reapproved by the stockholders of the Company
    in accordance with the requirements of Section&#160;162(m) of
    the Code, unless such grant is made contingent upon such
    approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (9)&#160;<I><U>Coordination with Other
    Plans</U>.</I>&#160;&#160;Awards under the Plan may be granted
    in tandem with, or in satisfaction of or substitution for, other
    Awards under the Plan or awards made under other compensatory
    plans or programs of the Company or its Affiliates. For example,
    but without limiting the generality of the foregoing, awards
    under other compensatory plans or programs of the Company or its
    Affiliates may be settled in Stock (including, without
    limitation, Unrestricted Stock) if the Administrator so
    determines, in which case the shares delivered shall be treated
    as awarded under the Plan (and shall reduce the number of shares
    thereafter available under the Plan in accordance with the rules
    set forth in Section&#160;4). In any case where an award is made
    under another plan or program of the Company or its Affiliates
    and such award is intended to qualify for the performance-based
    compensation exception under Section&#160;162(m), and such award
    is settled by the delivery of Stock or another Award under the
    Plan, the applicable Section&#160;162(m) limitations under both
    the other plan or program and under the Plan shall be applied to
    the Plan as necessary (as determined by the Administrator) to
    preserve the availability of the Section&#160;162(m)
    performance-based compensation exception with respect thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (10)&#160;<I><U>Section&#160;409A</U>.</I>&#160;&#160;Each Award
    shall contain such terms as the Administrator determines, and
    shall be construed and administered, such that the Award either
    (i)&#160;qualifies for an exemption from the requirements of
    Section&#160;409A, or (ii)&#160;satisfies such requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (11)&#160;<I><U>Certain Requirements of Corporate
    Law</U>.</I>&#160;&#160;Awards shall be granted and administered
    consistent with the requirements of applicable Delaware law
    relating to the issuance of stock and the consideration to be
    received therefor, and with the applicable requirements of the
    stock exchanges or other trading systems on which the Stock is
    listed or entered for trading, in each case as determined by the
    Administrator.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Awards Requiring Exercise</U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;<I><U>Time And Manner Of
    Exercise</U>.</I>&#160;&#160;Unless the Administrator expressly
    provides otherwise, an Award requiring exercise by the holder
    will not be deemed to have been exercised until the
    Administrator receives a notice of exercise (in form acceptable
    to the Administrator) signed by the appropriate person and
    accompanied by any payment required under the Award. If the
    Award is exercised by any person other than the Participant, the
    Administrator may require satisfactory evidence that the person
    exercising the Award has the right to do so.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;<I><U>Exercise Price</U>.</I>&#160;&#160;The exercise
    price (or the base value from which appreciation is to be
    measured) of each Award requiring exercise shall be 100% (in the
    case of an ISO granted to a ten-percent shareholder within the
    meaning of subsection (b)(6) of Section&#160;422, 110%) of the
    fair market value of the Stock subject to the Award,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    determined as of the date of grant, or such higher amount as the
    Administrator may determine in connection with the grant. No
    such Award, once granted, may be repriced other than in
    accordance with the applicable stockholder approval requirements
    of Nasdaq. Fair market value shall be determined by the
    Administrator consistent with the applicable requirements of
    Section&#160;422 and Section&#160;409A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;<I><U>Payment Of Exercise
    Price</U>.</I>&#160;&#160;Where the exercise of an Award is to
    be accompanied by payment, payment of the exercise price shall
    be by cash or check acceptable to the Administrator, or, if so
    permitted by the Administrator and if legally permissible,
    (i)&#160;through the delivery of shares of Stock that have been
    outstanding for at least six months (unless the Administrator
    approves a shorter period) and that have a fair market value
    equal to the exercise price, (ii)&#160;through a broker-assisted
    exercise program acceptable to the Administrator, (iii)&#160;by
    other means acceptable to the Administrator, or (iv)&#160;by any
    combination of the foregoing permissible forms of payment. The
    delivery of shares in payment of the exercise price under
    clause&#160;(i) above may be accomplished either by actual
    delivery or by constructive delivery through attestation of
    ownership, subject to such rules as the Administrator may
    prescribe.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;<I><U>Maximum Term</U>.</I>&#160;&#160;Awards requiring
    exercise will have a maximum term not to exceed ten
    (10)&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EFFECT OF
    CERTAIN TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Mergers, etc</U>.</I>&#160;&#160;Except as
    otherwise provided in an Award, the following provisions shall
    apply in the event of a Covered Transaction:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;<I><U>Assumption or Substitution</U>.</I>&#160;&#160;If
    the Covered Transaction is one in which there is an acquiring or
    surviving entity, the Administrator may provide for the
    assumption of some or all outstanding Awards or for the grant of
    new awards in substitution therefor by the acquiror or survivor
    or an affiliate of the acquiror or survivor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;<I><U>Cash-Out of Awards</U>.</I>&#160;&#160;If the
    Covered Transaction is one in which holders of Stock will
    receive upon consummation a payment (whether cash, non-cash or a
    combination of the foregoing), the Administrator may provide for
    payment (a &#147;cash-out&#148;), with respect to some or all
    Awards or any portion thereof, equal in the case of each
    affected Award or portion thereof to the excess, if any, of
    (A)&#160;the fair market value of one share of Stock (as
    determined by the Administrator in its reasonable discretion)
    times the number of shares of Stock subject to the Award or such
    portion, over (B)&#160;the aggregate exercise or purchase price,
    if any, under the Award or such portion (in the case of an SAR,
    the aggregate base value above which appreciation is measured),
    in each case on such payment terms (which need not be the same
    as the terms of payment to holders of Stock) and other terms,
    and subject to such conditions, as the Administrator determines;
    <I>provided</I>, that the Administrator shall not exercise its
    discretion under this Section&#160;7(a)(2) with respect to an
    Award or portion thereof providing for &#147;nonqualified
    deferred compensation&#148; subject to Section&#160;409A in a
    manner that would constitute an extension or acceleration of, or
    other change in, payment terms if such change would be
    inconsistent with the applicable requirements of
    Section&#160;409A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;<I><U>Acceleration of Certain
    Awards</U>.</I>&#160;&#160;If the Covered Transaction (whether
    or not there is an acquiring or surviving entity) is one in
    which there is no assumption, substitution or cash-out, each
    Award requiring exercise will become fully exercisable, and the
    delivery of any shares of Stock remaining deliverable under each
    outstanding Award of Stock Units (including Restricted Stock
    Units and Performance Awards to the extent consisting of Stock
    Units) will be accelerated and such shares will be delivered,
    prior to the Covered Transaction, in each case on a basis that
    gives the holder of the Award a reasonable opportunity, as
    determined by the Administrator, following exercise of the Award
    or the delivery of the shares, as the case may be, to
    participate as a stockholder in the Covered Transaction;
    <I>provided</I>, that to the extent acceleration pursuant to
    this Section&#160;7(a)(3) of an Award subject to
    Section&#160;409A would cause the Award to fail to satisfy the
    requirements of Section&#160;409A, the Award shall not be
    accelerated and the Administrator in lieu thereof shall take
    such steps as are necessary to ensure that payment of the Award
    is made in a medium other than Stock and on terms that as nearly
    as possible, but taking into account adjustments required or
    permitted by this Section&#160;7, replicate the prior terms of
    the Award.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;<I><U>Termination of Awards Upon Consummation of
    Covered Transaction</U>.</I>&#160;&#160;Each Award will
    terminate upon consummation of the Covered Transaction, other
    than the following: (i)&#160;Awards assumed pursuant to
    Section&#160;7(a)(1) above; (ii)&#160;Awards converted pursuant
    to the proviso in Section&#160;7(a)(3) above into an ongoing
    right to receive payment other than Stock; and
    (iii)&#160;outstanding shares of Restricted Stock (which shall
    be treated in the same manner as other shares of Stock, subject
    to Section&#160;7(a)(5) below).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (5)&#160;<I><U>Additional Limitations</U>.</I>&#160;&#160;Any
    share of Stock and any cash or other property delivered pursuant
    to Section&#160;7(a)(2) or Section&#160;7(a)(3) above with
    respect to an Award may, in the discretion of the Administrator,
    contain such restrictions, if any, as the Administrator deems
    appropriate to reflect any performance or other vesting
    conditions to which the Award was subject and that did not lapse
    (and were not satisfied) in connection with the Covered
    Transaction. In the case of Restricted Stock that does not vest
    in connection with the Covered Transaction, the Administrator
    may require that any amounts delivered, exchanged or otherwise
    paid in respect of such Stock in connection with the Covered
    Transaction be placed in escrow or otherwise made subject to
    such restrictions as the Administrator deems appropriate to
    carry out the intent of the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Changes in and Distributions With Respect to
    Stock</U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;<I><U>Basic Adjustment
    Provisions</U>.</I>&#160;&#160;In the event of a stock dividend,
    stock split or combination of shares (including a reverse stock
    split), recapitalization or other change in the Company&#146;s
    capital structure, the Administrator shall make appropriate
    adjustments to the maximum number of shares specified in
    Section&#160;4(a) that may be delivered under the Plan and to
    the maximum share limits described in Section&#160;4(c), and
    shall also make appropriate adjustments to the number and kind
    of shares of stock or securities subject to Awards then
    outstanding or subsequently granted, any exercise prices
    relating to Awards and any other provision of Awards affected by
    such change.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;<I><U>Certain Other Adjustments</U>.</I>&#160;&#160;The
    Administrator may also make adjustments of the type described in
    Section&#160;7(b)(1) above to take into account distributions to
    stockholders other than those provided for in Section&#160;7(a)
    and 7(b)(1), or any other event, if the Administrator determines
    that adjustments are appropriate to avoid distortion in the
    operation of the Plan and to preserve the value of Awards made
    hereunder, having due regard for the qualification of ISOs under
    Section&#160;422, the requirements of Section&#160;409A, and for
    the performance-based compensation rules of Section&#160;162(m),
    where applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;<I><U>Continuing Application of Plan
    Terms</U>.</I>&#160;&#160;References in the Plan to shares of
    Stock will be construed to include any stock or securities
    resulting from an adjustment pursuant to this Section&#160;7.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    CONDITIONS ON DELIVERY OF STOCK</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company will not be obligated to deliver any shares of Stock
    pursuant to the Plan or to remove any restriction from shares of
    Stock previously delivered under the Plan until: (i)&#160;the
    Company is satisfied that all legal matters in connection with
    the issuance and delivery of such shares have been addressed and
    resolved; (ii)&#160;if the outstanding Stock is at the time of
    delivery listed on any stock exchange or national market system,
    the shares to be delivered have been listed or authorized to be
    listed on such exchange or system upon official notice of
    issuance; and (iii)&#160;all conditions of the Award have been
    satisfied or waived. If the sale of Stock has not been
    registered under the Securities Act of 1933, as amended, the
    Company may require, as a condition to exercise of the Award,
    such representations or agreements as counsel for the Company
    may consider appropriate to avoid violation of such Act. The
    Company may require that certificates evidencing Stock issued
    under the Plan bear an appropriate legend reflecting any
    restriction on transfer applicable to such Stock, and the
    Company may hold the certificates pending lapse of the
    applicable restrictions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">AMENDMENT
    AND TERMINATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Administrator may at any time or times amend the Plan or any
    outstanding Award for any purpose which may at the time be
    permitted by law, and may at any time terminate the Plan as to
    any future grants of Awards; <I>provided</I>, that except as
    otherwise expressly provided in the Plan the Administrator may
    not, without the Participant&#146;s consent, alter the terms of
    an Award so as to affect materially and adversely the
    Participant&#146;s rights under the Award, unless the
    Administrator expressly reserved the right to do so at the time
    of the Award. Any
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    amendments to the Plan shall be conditioned upon stockholder
    approval only to the extent, if any, such approval is required
    by law (including the Code and applicable stock exchange
    requirements), as determined by the Administrator.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    COMPENSATION ARRANGEMENTS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The existence of the Plan or the grant of any Award will not in
    any way affect the Company&#146;s right to Award a person
    bonuses or other compensation in addition to Awards under the
    Plan.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">MISCELLANEOUS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I><U>Waiver of Jury Trial</U>.</I>&#160;&#160;By
    accepting an Award under the Plan, each Participant waives any
    right to a trial by jury in any action, proceeding or
    counterclaim concerning any rights under the Plan and any Award,
    or under any amendment, waiver, consent, instrument, document or
    other agreement delivered or which in the future may be
    delivered in connection therewith, and agrees that any such
    action, proceedings or counterclaim shall be tried before a
    court and not before a jury. By accepting an Award under the
    Plan, each Participant certifies that no officer,
    representative, or attorney of the Company has represented,
    expressly or otherwise, that the Company would not, in the event
    of any action, proceeding or counterclaim, seek to enforce the
    foregoing waivers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I><U>Limitation of
    Liability</U>.</I>&#160;&#160;Notwithstanding anything to the
    contrary in the Plan, neither the Company, nor any Affiliate,
    nor the Administrator, nor any person acting on behalf of the
    Company, any Affiliate, or the Administrator, shall be liable to
    any Participant or to the estate or beneficiary of any
    Participant or to any other holder of an Award by reason of any
    acceleration of income, or any additional tax, asserted by
    reason of the failure of an Award to satisfy the requirements of
    Section&#160;422 or Section&#160;409A or by reason of
    Section&#160;4999 of the Code; provided, that nothing in this
    Section&#160;11(b) shall limit the ability of the Administrator
    or the Company to provide by separate express written agreement
    with a Participant for a
    <FONT style="white-space: nowrap">gross-up</FONT>
    payment or other payment in connection with any such tax or
    additional tax.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;A<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">Definition
    of Terms</FONT></U></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following terms, when used in the Plan, will have the
    meanings and be subject to the provisions set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Administrator&#148;</I>:&#160;&#160;The Compensation
    Committee, except that the Compensation Committee may delegate
    (i)&#160;to one or more of its members such of its duties,
    powers and responsibilities as it may determine; (ii)&#160;to
    one or more officers of the Company the power to grant rights or
    options to the extent permitted by Section&#160;157(c) of the
    Delaware General Corporation Law; and (iii)&#160;to such
    Employees or other persons as it determines such ministerial
    tasks as it deems appropriate. In the event of any delegation
    described in the preceding sentence, the term
    &#147;Administrator&#148; shall include the person or persons so
    delegated to the extent of such delegation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Affiliate&#148;</I>:&#160;&#160;Any corporation or
    other entity that stands in a relationship to the Company that
    would result in the Company and such corporation or other entity
    being treated as one employer under Section&#160;414(b) and
    Section&#160;414(c) of the Code, except that in determining
    eligibility for the grant of a Stock Option or SAR by reason of
    service for an Affiliate, Sections&#160;414(b) and 414(c) of the
    Code shall be applied by substituting &#147;at least 50%&#148;
    for &#147;at least 80%&#148; under Section&#160;1563(a)(1),
    (2)&#160;and (3)&#160;of the Code and Treas. Regs.
    &#167;&#160;1.414(c)-2; <I>provided</I>, that to the extent
    permitted under Section&#160;409A, &#147;at least 20%&#148;
    shall be used in lieu of &#147;at least 50%&#148;; <I>and
    further provided</I>, that the lower ownership threshold
    described in this definition (50% or 20% as the case may be)
    shall apply only if the same definition of affiliation is used
    consistently with respect to all compensatory stock options or
    stock awards (whether under the Plan or another plan). The
    Company may at any time by amendment provide that different
    ownership thresholds (consistent with Section&#160;409A) apply
    but any such change shall not be effective for twelve
    (12)&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Award&#148;</I>:&#160;&#160;Any or a combination of the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Stock Options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;SARs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;Restricted Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Unrestricted Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;Stock Units, including Restricted Stock Units.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vi)&#160;Performance Awards.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vii)&#160;Cash Awards.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (viii)&#160;Awards (other than Awards described in
    (i)&#160;through (vii)&#160;above) that are convertible into or
    otherwise based on Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Board&#148;</I>:&#160;&#160;The Board of Directors of
    the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Cash Award&#148;</I>:&#160;&#160;An Award denominated
    in cash.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Code&#148;</I>:&#160;&#160;The U.S.&#160;Internal
    Revenue Code of 1986 as from time to time amended and in effect,
    or any successor statute as from time to time in effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Compensation Committee&#148;</I>:&#160;&#160;The
    Compensation Committee of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Company&#148;</I>:&#160;&#160;RXi Pharmaceuticals
    Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Covered Transaction&#148;</I>:&#160;&#160;Any of
    (i)&#160;a consolidation, merger, or similar transaction or
    series of related transactions, including a sale or other
    disposition of stock, in which the Company is not the surviving
    corporation or which results in the acquisition of all or
    substantially all of the Company&#146;s then outstanding common
    stock by a single person or entity or by a group of persons
    <FONT style="white-space: nowrap">and/or</FONT>
    entities acting in concert, (ii)&#160;a sale or transfer of all
    or substantially all the Company&#146;s assets, or (iii)&#160;a
    dissolution or liquidation of the Company.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Where a Covered Transaction involves a tender offer that is
    reasonably expected to be followed by a merger described in
    clause (i) (as determined by the Administrator), the Covered
    Transaction shall be deemed to have occurred upon consummation
    of the tender offer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Employee&#148;</I>:&#160;&#160;Any person who is
    employed by the Company or an Affiliate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Employment&#148;</I>:&#160;&#160;A Participant&#146;s
    employment or other service relationship with the Company and
    its Affiliates. Employment will be deemed to continue, unless
    the Administrator expressly provides otherwise, so long as the
    Participant is employed by, or otherwise is providing services
    in a capacity described in Section&#160;5 to the Company or its
    Affiliates. If a Participant&#146;s employment or other service
    relationship is with an Affiliate and that entity ceases to be
    an Affiliate, the Participant&#146;s Employment will be deemed
    to have terminated when the entity ceases to be an Affiliate
    unless the Participant transfers Employment to the Company or
    its remaining Affiliates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;ISO&#148;</I>:&#160;&#160;A Stock Option intended to be
    an &#147;incentive stock option&#148; within the meaning of
    Section&#160;422. Each option granted pursuant to the Plan will
    be treated as providing by its terms that it is to be a
    non-incentive stock option unless, as of the date of grant, it
    is expressly designated as an ISO.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Participant&#148;</I>:&#160;&#160;A person who is
    granted an Award under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Performance Award&#148;</I>:&#160;&#160;An Award
    subject to Performance Criteria. The Committee in its discretion
    may grant Performance Awards that are intended to qualify for
    the performance-based compensation exception under
    Section&#160;162(m) and Performance Awards that are not intended
    so to qualify.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Performance Criteria&#148;</I>:&#160;&#160;Specified
    criteria, other than the mere continuation of Employment or the
    mere passage of time, the satisfaction of which is a condition
    for the grant, exercisability, vesting or full enjoyment of an
    Award. For purposes of Awards that are intended to qualify for
    the performance-based compensation exception under
    Section&#160;162(m), a Performance Criterion will mean an
    objectively determinable measure of performance relating to any
    or any combination of the following (measured either absolutely
    or by reference to an index or indices and determined either on
    a consolidated basis or, as the context permits, on a
    divisional, subsidiary, line of business, project or
    geographical basis or in combinations thereof): sales; revenues;
    assets; expenses; earnings before or after deduction for all or
    any portion of interest, taxes, depreciation, or amortization,
    whether or not on a continuing operations or an aggregate or per
    share basis; return on equity, investment, capital or assets;
    one or more operating ratios; borrowing levels, leverage ratios
    or credit rating; market share; capital expenditures; cash flow;
    stock price; stockholder return; sales of particular products or
    services; customer acquisition or retention; acquisitions and
    divestitures (in whole or in part); joint ventures and strategic
    alliances; spin-offs,
    <FONT style="white-space: nowrap">split-ups</FONT>
    and the like; reorganizations; or recapitalizations,
    restructurings, financings (issuance of debt or equity) or
    refinancings. A Performance Criterion and any targets with
    respect thereto determined by the Administrator need not be
    based upon an increase, a positive or improved result or
    avoidance of loss. To the extent consistent with the
    requirements for satisfying the performance-based compensation
    exception under Section&#160;162(m), the Administrator may
    provide in the case of any Award intended to qualify for such
    exception that one or more of the Performance Criteria
    applicable to such Award will be adjusted in an objectively
    determinable manner to reflect events (for example, but without
    limitation, acquisitions or dispositions) occurring during the
    performance period that affect the applicable Performance
    Criterion or Criteria.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Plan&#148;</I>:&#160;&#160;The RXi Pharmaceuticals
    Corporation 2007 Incentive Plan as from time to time amended and
    in effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Restricted Stock&#148;</I>:&#160;&#160;Stock subject to
    restrictions requiring that it be redelivered or offered for
    sale to the Company if specified conditions are not satisfied.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Restricted Stock Unit&#148;</I>:&#160;&#160;A Stock
    Unit that is, or as to which the delivery of Stock or cash in
    lieu of Stock is, subject to the satisfaction of specified
    performance or other vesting conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;SAR&#148;</I>:&#160;&#160;A right entitling the holder
    upon exercise to receive an amount (payable in cash or in shares
    of Stock of equivalent value) equal to the excess of the fair
    market value of the shares of Stock subject to the right over
    the base value from which appreciation under the SAR is to be
    measured.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Section&#160;409A&#148;</I>:&#160;&#160;Section&#160;409A
    of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Section&#160;422&#148;</I>:&#160;&#160;Section&#160;422
    of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Section&#160;162(m)&#148;</I>:&#160;&#160;Section&#160;162(m)
    of the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Stock&#148;</I>:&#160;&#160;Common Stock of the
    Company, par value $0.0001 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Stock Option&#148;</I>:&#160;&#160;An option entitling
    the holder to acquire shares of Stock upon payment of the
    exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Stock Unit&#148;</I>:&#160;&#160;An unfunded and
    unsecured promise, denominated in shares of Stock, to deliver
    Stock or cash measured by the value of Stock in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>&#147;Unrestricted Stock&#148;</I>:&#160;&#160;Stock not
    subject to any restrictions under the terms of the Award.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="b73679dfb7367906.gif" alt="(PROXY CARD)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">000004000000000.000000ext000000000.000000extNNNNNNNNN000000000.000000ext000000000.000000extMRASAMPLE
DESIGNATION(IFANY)000000000.000000ext000000000.000000extADD1ElectronicVotingInstructionsADD2ADD3Youc
anvotebyInternetortelephone!ADD4Available24hoursaday,7daysaweek!ADD5Insteadofmailingyourproxy,youmay
chooseoneofthetwovotingADD6methodsoutlinedbelowtovoteyourproxy.VALIDATIONDETAILSARELOCATEDBELOWINTHE
TITLEBAR.ProxiessubmittedbytheInternetortelephonemustbereceivedby1:00a.m.,EasternTime,onJune5,2009.V
otebyInternet<B>&#149;</B>LogontotheInternetandgotowww.envisionreports.com/RXII<B>&#149;</B>Followthestepsoutlinedonthesecur
edwebsite.Votebytelephone<B>&#149;</B>Calltollfree1-800-652-VOTE(8683)withintheUnitedStates,Canada&#038;PuertoRicoany
timeonatouchtonetelephone.ThereisNOCHARGEtoyouforthecall.Usingablackinkpen,markyourvoteswithanXassho
wninX<B>&#149;</B>Followtheinstructionsprovidedbytherecordedmessage.thisexample.Pleasedonotwriteoutsidethedesign
atedareas.AnnualMeetingProxyCard123456C0123456789123453IFYOUHAVENOTVOTEDVIATHEINTERNETORTELEPHONE,FO
LDALONGTHEPERFORATION,DETACHANDRETURNTHEBOTTOMPORTIONINTHEENCLOSEDENVELOPE.3AElectionofDirectors&#151;The
BoardofDirectorsrecommendsavoteFORthelistednominees.1.Nominees:ForWithholdForWithhold&#043;01-MarkJ.Ahn,P
hD02-StephenS.GallikerBIssues&#151;TheBoardofDirectorsrecommendsavoteFORthefollowingproposals.ForAgainstA
bstainForAgainstAbstain2.ProposaltoratifytheappointmentofBDOSeidman,LLPas3.Toapprovetheamendedandres
tated2007IncentivePlantheindependentregisteredpublicaccountingfirmoftheandreserveanadditional1,000,0
00sharesthereunder.CompanyfortheyearendingDecember31,2009.CNon-VotingItemsChangeofAddress&#151;Pleaseprin
tnewaddressbelow.MeetingAttendanceMarkboxtotherightifyouplantoattendtheAnnualMeeting.DAuthorizedSign
atures&#151;Thissectionmustbecompletedforyourvotetobecounted.&#151;DateandSignBelowPleasesignexactlyasyourname
(s)appear(s)hereon.Allholdersmustsign.Whensigninginafiduciarycapacity,pleaseindicatefulltitleassuch.
Ifacorporationorpartnership,pleasesigninfullcorporateorpartnershipnamebyauthorizedperson.Date(mm/dd/
yyyy)&#151;Pleaseprintdatebelow.Signature1&#151;Pleasekeepsignaturewithinthebox.Signature2&#151;Pleasekeepsignature
withinthebox.C1234567890JNTMRASAMPLE(THISAREAISSETUPTOACCOMMODATE140CHARACTERS)MRASAMPLEANDMRASAMPLE
ANDMRASAMPLEANDMRASAMPLEANDMRASAMPLEANDNNNNNNN22CV0219581MRASAMPLEANDMRASAMPLEANDMRASAMPLEAND</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="b73679dfb7367907.gif" alt="(PROXY CARD)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">3 IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. 3Proxy &#151; RXi Pharmaceuticals CorporationPROXY
FOR 2009 ANNUAL MEETING OF STOCKHOLDERSTHIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF
DIRECTORSThe undersigned stockholder of RXi PHARMACEUTICALS CORPORATION, a Delaware corporation,
acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement, each
dated April&nbsp;23, 2009. The undersigned stockholder hereby also designates Sanford J. Hillsberg,
Stephen J. DiPalma and Marc A. Rubenstein, or any of them, as proxies and attorneys-in-fact, with
full power to each other of substitution, on behalf and in the name of the undersigned, to
represent the undersigned at the 2009 Annual Meeting of Stockholders of RXi PHARMACEUTICALS
CORPORATION to be held on Friday, June&nbsp;5, 2009 at 10:00&nbsp;a.m., local time, at 60 Prescott Street,
Worcester, Massachusetts and at any adjournment or adjournments thereof, and to vote all shares of
Common Stock which the undersigned would be entitled to vote, if then and there personally present,
on the matters set forth on the reverse side.THIS PROXY WILL BE VOTED AS DIRECTED, OR IF NO
CONTRARY DIRECTION IS INDICATED, WILL BE VOTED FOR THE ELECTION OF DIRECTORS, FOR THE RATIFICATION
OF THE APPOINTMENT OF BDO SEIDMAN, LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE
COMPANY, FOR THE APPROVAL OF THE AMENDED AND RESTATED 2007 INCENTIVE PLAN TO RESERVE AN ADDITIONAL
1,000,000 SHARES THEREUNDER AND AS SAID PROXIES DEEM ADVISABLE ON SUCH OTHER MATTERS AS MAY
PROPERLY COME BEFORE THE MEETING. THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THESE
PROPOSALS.CONTINUED AND TO BE SIGNED ON REVERSE SIDE</TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>b73679dfb7367900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b73679dfb7367900.gif
M1TE&.#EA4P!3`,0``(N+BS\_/W]_?[^_OU]?7S0T-)^?G]/3TQ\?'WQ\?/#P
M\"4E)>+BXD)"0D]/3ZBHJ&YN;N_O[]_?WP\/#[:VMF]O;YF9F<_/SR\O+X^/
MCZ^OK\7%Q5%14?___P```!<7%R'Y!```````+`````!3`%,```7_(">.9&F>
M:*JN;/DU;2S/-%E\WW9L?.__P*#0Q^@8CYW+8,EL.I_0"P"WX>"NV*QVR\TN
M%$@CP4,NF\_H=&":LW;?\#<@W#&D[WCSFNJ.^_\%=`-YA&IL57^)6@M:!W2%
MD&5[;8J5.`E:"8^1D).(EHIL6`UT&)R%GGV@<00$6V!(`:>$J:M_#S=:&V&R
MLWBUMG$,7'.QOK^'JL%;#0=<FL;'AGS+;PD;7!R\TM.4U5P4HEFD2`C<:,#?
M6@SB66'GZ,GJBQT07>_P>O+S6-K*6$@NY--'C=\53?^N(!DTD$RZ44$L)"36
M86*.(QE."=@HH->9AU>TT3'RX,\NB[N,_U0XA41`MT]91(ZLY^?DO2,>(;5\
MF5!FAP..CCB+X\@BDED[XQ6,B<0*!21^C-CC<D0@RR,NE7IC>L1*,2-1.[0#
M:,1.0X?[N!KQ"C6.$0I<`HDYBW9IOZ8?OG8(.VR+3%-T0>+PR?:(GR(=<F4A
M8"0"W;I;[W;-VQ9.RJE9BFGPQ;$C3[]X]=8T@DV+A;E(L7[60IBRX3BGC2B^
MDM)<:B-9/Z:5O-8UV#C0.I3,`D;"L:2Z[88,7?F-S]ER,_I"3C#R\LFBPY+&
MPKA#3D[4)>V^WCL[4228<)QV?%RU5IB\*_K>ZT>O@ER.S$YWG]SZ8.:OQ4'.
M$=@L8(0#TH0'&?]\Y,EGGC!A<-#=!`GR5QV#_V%WA`*)!"?5`W5PHZ`'@GW0
M6DK")6(@$E]T@&"%N*VFUD^P=*``(XF`^!9C[,'806X7]C22`@_@F(A<'1``
MH@&VM1?C>T*.=(`KE8#(P(H.9`#D54_VAZ&),QF1GHH*`*")8Q)XY^2/,L;'
M00&(=="7(A#`60<"1DA`X6UL0@F:A@$J(I(#%5@8R8@EMO9@(D\YID$Y?&ZY
M8)3E-0=(61.$H=^AAD[Z9Z6!_A&;`QC0T:1.G9(X7H:@_J8(+!1V=\2FA2"Z
M*IB`NOH'!$9L1H8!8>R):I=!?NJ@I>=UL!(9$Z1YQ++#]NDEI<>&"L?_@*<Z
M$!!XJ28*H*YQZ&C<&0-`&JVDJBK':K7@P@&+=&;@^2RGQ(JG+JZMTN<'KP>F
M`6RO]$I;+&O?ZAO'4T8(&^\1/1)BZ[V*(LO%BAV,FT:Y1IR*Q\/^X<NNP6_P
M&^(=VO9;:[>W1FPM.//B$4&]=W#\I<KM4H53'O_2&C/*$!?LAZP=$%(R0P[S
MW#'-(',16Q(G$YV'S-069D0#$`),2+D-;VSTS'B)+-\;2`I\AP!&G-MF@U;X
M-"870(]!2]DGPYQNQPWX0/4"/HR5Q=)J$B(O)$VX/:U!5"`!F,,6GU-B-?@4
M(H'3W"P>3-A!`PZY-)+;XE/6>`P`K^*W+N/A7^5W#("N+YFOHA?I%W^'>>C!
M(&P$ZVC0/DOJH*#8@>UF\,X)[I;H[KL'$T`+#_"5!#4[)!AH'#GLMH0Q?&#0
CK[+)8WD@K\CUV-^A?2+<=_]>F.27;_[YZ).O-^'L*Q("`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>b73679dfb7367902.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b73679dfb7367902.gif
M1TE&.#EA:0`Q`/<``/___P```/W]_?[^_@("`OO[^_KZ^@,#`_GY^00$!/S\
M_._O[_CX^&=G9PD)"1P<'/3T]/?W]Q`0$`$!`>SL[/#P\*6EI75U=2@H*.OK
MZ[*RLO/S\^/CXPH*"F9F9@L+"_+R\E-34T5%124E)=_?WPT-#=S<W$1$1#P\
M/$Q,3,O+R^GIZ3HZ.C4U-1X>'K^_O^+BXN[N[@4%!0@("/'Q\7IZ>AL;&P8&
M!BHJ*I.3DX:&AE)24@P,#!,3$Q86%B8F)BTM+7)R<A@8&(V-C104%'%Q<2\O
M+T)"0E%14<+"PL7%Q>WM[=?7U]+2TN3DY'=W=Z"@H+6UM;FYN;N[NQ<7%S`P
M,`<'!]G9V5]?7ZZNKBLK*\3$Q#X^/H>'A_;V]EM;6[.SLYZ>GJ:FIM34U*FI
MJ9>7EXF)B3DY.8J*BD!`0+R\O&AH:$9&1M[>WB0D))J:FDM+2WQ\?-C8V%14
M5)B8F("`@-K:VGY^?KBXN$Y.3KJZNLG)R8Z.CO7U]5E96=W=W5=75^#@X"<G
M)];6UK"PL(2$A%5553$Q,9F9F2DI*>;FYG!P<*^OK\#`P*>GITU-3<?'QZNK
MJTI*2IV=G5I:6K&QL6EI:3\_/Z.CHS8V-I24E-O;VQ$1$65E9>'AX1T='9&1
MD6YN;L;&QI*2DCL[.T-#0UA86(R,C$='1X*"@LK*RLC(R%U=73<W-V]O;^CH
MZ`X.#NKJZB`@(*RLK!45%1(2$GAX>%965H&!@6%A8<'!P1D9&<_/S\S,S$A(
M2'U]?6IJ:E!04&)B8F1D9#T]/4]/3W]_?W-S<[:VMB$A(1\?'X.#@S,S,S(R
M,I65E30T-)^?GZ&AH2,C(R(B(HB(B*JJJFQL;$%!03@X.'1T=$E)2;>WMVMK
M:\W-S5Q<7):6EIR<G*2DI"PL+-/3TWEY>;2TM(6%A6!@8,/#P[V]O=75U79V
M=BXN+GM[>^?GYZBHJ(N+B\[.SN7EY6-C8P``````````````````````````
M`````````````````````"'Y!```````+`````!I`#$```C_``$('$BPH,&#
M"!,J7,BPH8(OQ2(TG$BQHL6+"#D$"'`%H0$#&$.*')EP3X`/,0YR:#:,I,N7
M&,D$*"7@X),`/V#JW*D05X`+!PNP"X"$I]&C`.8%0'-0R8$`LY!*?3G@4@!,
M!V\%(%9SJM>0\CI`-2C'2H`W7]->U!"`@`J#-0+(D*.V[D1;`20L*!AA1(`=
M7>T*/BB`2P!F!0I"VHAL\,X*2S!2@!4@A$$^`83LK1MXX8:."V%@^(4Q"8$`
MS@H*0!&@2-T"P%`X8:B(18<D"@VP"/`"(Z(`-T`/;/*T5]T%IS<M'!!B8RJ%
M4WZ&=!7@C(*"70)@`*FVR802&Q3V_V&UT4H3``B,\3)XY%/*BR`$!4!4D(9\
M.G8K!6B5&&&&/!L%X(=`*@101T%,!+!,2)AUH$A!4`10RPIVZ1``+@E1T$(`
M#DPP`Q,"H1&`%`4=DP`)&'GR0`!L&"1"`'`T-(`&=0P!QA]]A#0`$@'HXA^`
M.\AQ`RD"#8!"!^\)](H$<V"4CA$;C5*0!:=%L1`"8!P1((>R`**).Q9!X(,,
MLQD43S-$,;!%`(L(Y(0,XG`G4"H!Z#&1(N=1<$&`$Q!"D`I$!'!"0@-L<0R4
M6R;JPBB13602$1`8I(8-`6!QG0<!B"&0!0$\0I`!LN!P'4,Y$&&%""X$D,B+
M!ZPRD!*4'O\P!4)[G#!!H@$V4(D.B6SDPBD3@5+=J`-]XT``PC``@`%NW`"#
M0`U(-]`+`4"1D`D62!%(=@&>@,P&"WQP%0`"Z"!6`%P<M$$-/&QDB2&):C&`
M0'V`X<=3>?RQD`"[M410%AO!(1$`;4S`PKP1*!,`.@2MT</``PE`@P;!B,MA
M@(=L,Q`$M;1&P0X!<'*L:P;=L1$1>""`10`VA)!``-08M$6O5&2AD&D!:%)0
M,0$<DL%`C`3PA$"B<!C+0`N40`E!@0!#S(J)GA9`(00)\`B'*V)P!92:&H3#
M1B/\,HT@?,#@20(H>''0*Y9LU`#$!#&@Y0%*%.1(`R80M,B(`E'_@I.R`N40
M0!@$18LK,WI`<1H0:@]DAU4L;A*#`S+8<=`Z6Y[PWAH!J*&0!9\<D#<`"ZCB
MR!!![!;``8TL5,"&W0``R<LIS`M``4`<@.)`\"2*R@-E`#!)`#J(8"=!--11
M!@(`@!%`%?T5!($K5$CP!04")3%!"@A%`()`&?3"!",AT/(RKH0KY,6*)E10
MQ4:A#,2I(:I-TL-&^%5A!@!P)```-SE0R$WNH!`05(`@/-)`04`0"0]@P`?:
MB$,GTC`#7&U$&5`:FD($T)QVE")`:`&`D7HPB(.(@`#!^TTC5B`!`IS#!7A(
MR!(>,(,23H0$!\"&G#90#BU8D`#/,(,%_[ZP$7+,(0!1$,-?&$*(`(U``@%P
MA$`B5(.#J"`!Q@"`B,X`@$"<JP2-.L@0`@"(BH!C<`)A0#:$$"!I!"$-&RD$
M!T85ES:Q(B?4T@+S%%(`-@1`"W^X1@#>`8`,"`$(V#-()P*`"F^P;#T`.&(`
M/)`0`WS-9A,IS`QVIZ$2;.00*'K!K2`Q$!5\X`$(D$DT")8`'M"`(28P0QL`
M8(J?K$`2O$%('`+DBS$,9!!<2$&9#A*%`.QB,PV)3C`^Q8%4=0T:>:&00(01
M@!&8+!,@44`+"#".B@0A`#Q(AJ!L9Q`$A*(%<2"G0#IS$$QAH2+14F#<=C')
M#&C`#0$8`D%R$?^@&[A*(.8(0!<J(H4M>8Z/%Q'`,\Y"$1CTP`>O),@`X'62
MC=A"G70H3_H$`H,?2(*="D$`$#:2BZ/$@A,$\.5$"E&I@ZR@"SB0`0:J4<X+
M^*)U!?'"`2LRA2J8(E)&B40`W`#2A+0B`*I("`/L$)ZO[/$HT2H"!ZS$D*!Q
MSS%V(44`U$&((Q25(`48P0Q4BM6T*"$!0@!``S`0/80HP!D^*JM:EB$@"/!@
M#7+-:T$&D((`A`,/`2"#7@=+.@DD@`EI\`$R"5O6HMT"8$%@K%Z%]85,4($#
MDI6KU0(4P,R6%02TV`@5=NI9QU3`DY,L;5DK0)D`;$&U6&6`.`%!+-@)"N84
(U@#J0@("`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>b73679dfb7367903.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b73679dfb7367903.gif
M1TE&.#EAR@`U`/<``/[^_OW]_?O[^_S\_/KZ^M?7U_CX^/GY^?;V]D1$1/?W
M]^_O[S$Q,=O;VU=75X:&AI>7EW]_?^OKZ_7U]65E9=34U.[N[E555:VMK>7E
MY>GIZ?'Q\=[>WNCHZ//S\T!`0&EI:6%A86]O;[*RLFAH:)N;F[:VMN+BXGEY
M>5%14?3T]#@X."DI*4)"0O+R\N'AX3,S,U-34SX^/L/#PTM+2VIJ:M'1T=W=
MW7%Q<6!@8.WM[7Y^?N#@X+N[NZ^OKT]/3ST]/86%A965E9V=G=K:VM_?W\+"
MPL#`P*6EI6YN;IB8F(*"@JZNKF=G9U965EM;6U]?7\7%Q8B(B-/3TUQ<7%A8
M6%I:6C\_/]75U6UM;3HZ.AX>'EU=71T='>SL[,'!P=S<W`T-#69F9JNKJ]C8
MV+^_OZ2DI$E)27-S<WAX>#0T-$I*2HJ*BD5%17)R<EE96;R\O%Y>7I*2DI^?
MGX"`@#8V-GU]?3P\/'Q\?#L[.S<W-V-C8Z&AH2$A(4%!04U-33(R,L3$Q+JZ
MNKZ^OL[.SGM[>YR<G(N+B\S,S'!P<-G9V8V-C8.#@T='1\_/SQL;&VMK:U14
M5%)24BTM+71T=#`P,#4U-2<G)Y&1D0\/#^?GYPD)"?#P\)F9F2PL+!@8&+>W
MM\O+R[FYN2@H*&QL;*JJJ@```$Q,3*FIJ2,C(\C(R,?'QXR,C*BHJ-#0T*"@
MH.;FYLK*RI:6EIZ>GF1D9)J:FM;6UDY.3DA(2(>'A[2TM"LK*^/CXQ,3$Y"0
MD"8F)K"PL(^/C]+2THF)B>3DY$9&1K.SLY24E"XN+A\?'X&!@9.3DZRLK(Z.
MCLW-S7IZ>B0D)'=W=Z>GIQD9&2`@(`<'!RHJ*D-#0\G)R1(2$J.CH\;&Q@H*
M"KV]O186%K6UM0,#`Z:FINKJZKBXN'5U=79V=B4E)2\O+X2$A`@("`X.#@0$
M!!P<'`P,#!45%0("`@$!`:*BH@L+"Q$1$6)B8CDY.;&QL08&!A04%/___P``
M`````````````````````"'Y!```````+`````#*`#4```C_`/,)'$BPH,&!
M=I0<7,BPH<.'$"-*G$BQHL6+#7N8^H*QH\>/($.*'"EPP*@V`4BJ7,FRI<N%
M`/"8,O&RILV;."$:TL-`0<Z?0(.N]`)%62FA2),JG6A,U:T!2Z-*E:H"198&
M4[-J!?H`%(BM6U78J``5K$HBC%A-,2L5@!P9<2@EP%26[4<"]%Q0(<CCD-V@
M.Z2DS#<AEY]M`/YVE$(HPIR!`%)449QS`HRZ`H7!4#*8\L0,*!0D4#$04Y)$
M"SM[#HD(QT$/DI0E7AU1!+$EC`9J@"(G"L$!(^C\632;]L<7A!8*P)%&M?&#
M7Y8M0.9!(``08"+E.^"#@@QN:X89_]'UO"8`"A2*ER=H((Z!!TL&+G`2(08%
M:@R@*%F@?KW+`4V\<8!_!#U@`P$K$*+(+#NL`$\Z?XC@B``$_C1`#&Y4F,\7
MP900B2F9)--%%4_LD(1''&2H844&)/"810;<P$%_%B8Q``GO/'````!0<@(0
M@F`$0`,L-+&B11L`0D1%@9Q10PPY)#7'$?F8@<9LL(@1RB@T2G3#%2B4<:1%
M/JQAP$3'Y,!!``,D8(%01M203P"5O&"=-@6(L`A&`]R!A!84CEF1`X9(U,P.
MLPFP1@4WK7*40$>@D-@S5LR6`0@Z;+$`1DT,X4`@@EJ4`0/.'02`&/'-1L0D
M7:Y$0P0";?]PQH`$;,%H/@"@40`;)&#DPZ<.E!J4`'R(4`X6PKI$`28.!8!"
M$(D%H$``(6"@G"T<B&0`-6;@2L$-`ID!1%F1YG,%'!?Q,(HB6IRP%``S?$!#
M&1'T\69.!70Q04,XE,`CK@#TD$>@!1U``1=]8-:1()/EPXHO`@G0A2B)*2`)
M`N)D@\!%#D#P0*%*$8!&,48,]$PT*UG0"0&F6C((0X-`P>/,ND!3Q$&<?-"*
MHLE6U(I?1N`QT`A^)`8`#B/D<\0;%_7`P@BX]'R3!G<(07`^4:@AM44$G)%%
MJP^@L)`'%W`2```#!%"*&C<;I``#3`#P@HH@/>##`A<+1,`NH.;_,P8I`I7`
MA*FM1FP)(S#LFQ09*=!4D`"/N#L2!-"<N5`M>RS4Q"H!=!Y`!&WH8&H3F/"8
M!KHA/5!&#3P,),TIB1GA@.5_*`X9)S$80Y``:7PP6"MZJ$&&4CPP`,9"6V`E
M$@#GK-(0&YD;-`:B;*J20`@*#X3!'CPBH$7A%3V00"T#"6#)\2:XL7$^KJQA
MT`9Y`&%[/EQ@T`++`$RR2=\&`4"&G2_!!@P*T"4!)*,#(PE'$L`7A!`81`/8
M`P`BJ)`'&S!$`E>P`(],((21*",'G4%%#@`0!18,2"`[2-I``J`+0*AA4_GH
MP35@8`(/W$(@<-B$*"!C@D!YX0E4Z)5`_Q80"0GD(P/@FP@16N`"AE3@$3X)
MB06@D:V&!`$2!:$6.991CSLPX6H&`4'<T!:')H9$&-Y(PT!<\(LB:$`-%B1(
MHHHQ#5-880,"*<4%7F`-1<@!%7/ZP0XSXP!/I(0'IRB`(U@A$$TD``1>N$`O
M3NB1*50B%@TYP@J2.)%"R,DA08@/02JP!3L\(!;9*P@9&C$S/.1")#R0@=.0
M"(`2<*$(5@`73`IP@1C,!@-X($`.9'&$.`!``%#X@4`LD(-FM`$+^6B`#&X`
M@2808`!#V,(I-/"&;S@`))9TAD-((;20",`3!7A('%`GD`#08`P-@04$%)(/
M0?*(#2E(C"]>)O\D":C!-[YX0#X(D``'M$`"X+M!.S0A$$-((1\00`($)G&"
M$Q3C$X30`0EH8`PC&"(`H!B%'FI0"P!D``A9D,$/$H`(!#"`1@$8QP6,^)`%
M7(*?`E$!$>#0B2EL#`"?$&=(0I&`AVS@$@@<"!P8P!"-.D$$U2``U01`@"5<
MP"=12``A&+H-A7GA%'G@!4,,$`,^"&0"87B&"-81AWLUY!A8/$`69`&`(H0`
M`%JP0;PR\`9',"`(*;$#)5)0B`@(P0/8O$,/\@$#)]`T$6(800^`,00AD&,2
MC0`&1`#@!+/B"AMOV,09GD#:#U#`#/A8'TCH$(^'S$`&N/(`VJ[A@X7_&*$+
M&%"$*QX!``R,P04_X`*%),""`D"!!V#0`\MR6@@HI*`3,S"5`+2`CN*@H`T1
M(`(G\Q&#,OB`!O:8$RUT,(%,%*(*;R+!&X8G$"8D`IJ@``(5VL`&RQ&#D@$8
M!@W:H(<KB`$),(0(,R!`FGQ@(`PBT$1Q)%@'&FPW(A\074,.P((2Y","FY"`
M"3)Q/.G)HQHM\(,0Q)`/-^QA!1B8S3+"(80LY",$XQ@(`G#!!Q78X1>2FY,M
M@G&!#]`!!ZIQA&\D,@A2O,(+`AE&*`"PA!8@8K,#&,"#+2(&+E@P&'5`HASS
M88LP*"\?`L`"&"FB2X8`H`8.```$KF""#K0`_PG(*$@1>G<L3YQ@#",PP30P
M8,9\H&(-$,B!"Q@A@J$E`0PVJ,,%7*&`&9#`"CL`ABJ62Y(9+`$`$KC?5H;@
MB2_+L0DGBM@*MI!.@I1@%B*9`PO*<`5P@((3U@`$+%)`D%4X00,Q6(050A"%
M0C1B")*X5P<4D`QU9(,==:C"%P#`#!+DX0"'X``W9!"!7>"@&V,F"2TT`(!%
MH%HK!0@#1VA4@3"4.0",L'!!W%`ID(Q@'H[0@B720(H?W$(.)4"#0`R``RE0
M*!4P0$,BT+"R?,B"#E](A`P\H`1!-``#"F!"*E*P@Q/T`@B,5`4E8J%:EW``
M!``P``/PJ)4_1,-HUO\Q&@4N`!$=K``2E(91,W;!##FP0`=FJ,)1OV$.1KV@
M#G%46I\'0H!CU$`0E)1/`09S-J`,H!$+"``$]J25*=R#&%E,3`=ZL1:(>.`,
ME0C%16;P"QIT8`4@T(!U)'`)5.#BB!>X%8&8,`2Y`:'C40&``T30'QX)X`\U
MF/(`E/"))[S@P1Q@`S)@((W$)#T?%?A$`H:W!T_[)Q?#_D&0M.(,=R35($A@
M``*F'*MH@*,%=BB#E@LR@1E`X`-A"$$W>F:`+-06S$?B@CAP0`>PT**#!^E`
MSS%R@E<XH0^9\(8?2``)*CCA'(]@``7FX-90/80*C8A`MI6R@"Y$L2`(.,.2
M0T&B`"(TH`@<:$`#-K!]ZS>$``7>BC9"73`V)*`Z[L__2`#@AU++\1"`H';Z
M-X`@(0$KT#\ET`=B18`,V!$%\`0%`0"OD`K^UX`62!&'$`0%P0==`$T7^($3
M@0)(8!U>D`,IL(`@F((/$0'=D@^*D`H@@'<J.(,&T0I]$`0@``A(0'HT:($#
-(`61H`3STX,2$1``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>b73679dfb7367906.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b73679dfb7367906.gif
M1TE&.#EAT`*D`^8``-[>WO3T],[.SKZ^OO=_OTA(2/11I_O-T@\/#_9QM_B1
MQSDX.>/CXZZNKE]?7YZ>GMJMU7Y^?M75U6YN;HZ.CO(RE\7%Q;2TM/O'X_W?
M[R@H*._O[Z6EI?N_WY24E(.#@_CX^&-C8_57=/$2A_[]_OWL]/FGTG-S<_-!
MG_>)PU-34_F?S_WGZ.GIZ?[T^?FGL/5IL_WE\O5OA.\G5/B2G^C9YOS6ZO(4
M39\IDMC*UOJUP/JVVO(ID_[P]XT!?OS0Y_5@K[)3I_O[^_[X^[:JM)>,EJ:;
MI/(ACXA^A_(]9/JPUWAX>/`"?^_<[*Y#E?S8V_4#0_?M]>*\V8B(B,1ULO'5
MZ?&]W6AH:'1L<UA86,N'O-2;Q[YGJIV3G*RAJV-<8KRONO&TV?S@X/C#Q.[(
MXD]/3\J]R$!`0/[V]?+.Y=+$T?S!S3`P,/[[_'EQ>/&LU%Q;6[&EL,.VPB`?
M(']W?FYG;6EA9RTL+3T]/>#1WAL:&Y&'D/:!E?+B\````/___R'Y!```````
M+`````#0`J0#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<
M2;*DR9,H4ZI<R;*ERY<>;2CY80/#GQ(87'1HHT2)BYXZ>_S!D`%#B1\SD?Z(
M\>-/C!TEE/0`ND-)B1TN_NR(T:&HD@P9E!"UV:.#"ZA*L`*U.O0HTZ0S_W'>
MQ%!VJL^>;<S^Z8K!!E(;,FUD:)H!ZHZI.[1*W3J4J=<,,L?^Z9'3[-J[0NEB
M>-O4(0B8H'L18`*$`(J]*#)4Z,&$28;6JINB6&&@`Q`F"6XG4`+DCY(C'9C\
M@'V$28<C&?X<45)!@0$F"A0P,:#@](\*&8`S00[;^)_:0)0D(#T>2`<#>PU<
M'^ZZ=0_L?RJL0$'@-H'1!%8D^+,"^(CA(_PQ@G`C*/$'"KS-Q\0*HU%G76K8
M==>>;#\8(!YN#PD0VH:YC%;::1U`R%I[KE4@&VVVX:8;;[YIQUYVQB&G''/.
M02>=@W]<EUUPW+77P7>V70A$>>>EMYZ$[R4G'_]]]N&G'W_^`2@@@08B"(2"
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MEXTV.S"T4%HJI::<6HEEJ`]R6VK$**`Z9L5$@W9QK%_..INZ<[8(LFMXBNSK
MO";O>&]W^8:WKWDM+PISP$Q&ZF3!-A^,L\+7,JPMJ1"'.7'1<+-T=,9)I\MQ
MT[G>R6N\)`,+J-4H9WTHR\F^Z![8SHY=\[0(Y[QPMJ*R3:S;0\=M.4ISGUOW
MQG*RZ[2N4.\]\J\-GXPOD%JOS'7ARRHIL-@$+WYSM3ICRS.7/K<M<>67]SY2
MYFW"IG2<MGK\N=[PCDYUL("?;JSJ_;IL.!,QO_XLI093F["U.S<L>7>4A^O[
M__@?`:_QTG=[GG?(O<I;,O.".J_RD(3[.WWU85]/-N-G<V^[][F;W.[$1[X"
M:L1\FT-?YXRWOM`E;VKO^UO\L(:ZP:W.?JUS5/X4)ZW9;:]V:HM<`,$W0%49
M\(060:";AL<T];G+@5)SG]_JU3P*/H]^%Y1>!F4&.YIUT&RT>]SM'-8M4P4-
M7"9$H1(CHD+AV6V!N'HAC!XHP]+5T$<5W%KTO'8XUVTP=C_4GN/2!KF>/4R`
M1WS;$M?XD":6Z(G%B^+3IAC#OEEQ@EB\(;(P"#`O)@Z,V6L<VKJWMA%Z*XV\
M8Z,B%>+&-RDPCA\#'1W;9\>JX9%0681>UU[610W^T?^'@>P?",N(NS.2$)$$
M7*0J"Y*!#@BF*3WXP1!^D)<.#*$#MOQ!5I9B@Q[8H"N_S$`);#"7LNC$EACH
M`&6&T!9>=B`&7+$!4_[@`EG2I0,8N*4ME?F'7MJ@!*T4C"M].1D;5/.8VFR#
M+'/DF&"V,@,Q2$X,-*,3FR33!4;)T3"9\LQP3K.:L]2F0/6BRV^^,VYG2*A"
M%\K0ACKTH1!UZ!P8L,J*6G039P#``S;*T8YZ]*,=Y8`0!A$`D)J4HP*8`P`N
MRM*62N(,#_"#3&=*TYK:M*8-&(00]'#3GLHT`BIUJ5"'F@B8^O2H-ST#(32`
M5)L"=:5$C6I4C=I4GV9AI@C_:,$@'%!5FCY5JF`5*E6[:M,KT/0"6R7K3X,:
MUK9:=*QJE2D"(D!3#Z15K5]UJUX7"=>X9H&K,U6J(`!+UKSN];!*[*M:I[``
MFBY@I'\@;%<-B]C*DD^Q746`!>904ZA*MJJ4M:QH+8?9JJJ4LS2%ZE7QRM;1
MNA9N?9V#;.?`4ZL"P*9016UA6_O:WHX+KG,@!`@N@(">.N"VG?W#3GVZA`$,
MH`!>Y:UOIWLFX!K"`CWU``-P^P?D]O0!@XTN5*E+WC)9]P\,6,(&!'&&FX)7
MMS)=*0>."M[(BK>\^-W0>0'`UO;:]+W)G<)1$2#;XLXTM/E-L$KVVU_W_F&U
M<M5J_QGBZ@<$*_C")6$P5/U;4_`*.+!_`$%M>TK@.1AXK>/%L(I)HF'VWG0)
M?\#N3+/PAP$@M;Z2M?"*=\R1%O^!PS1U@'+A,%/P3N#&X3VP='G,9(WX&,@S
M78!6&6!@"P@!O@ZVKY)3W.0N7^3)-]6#!)+,`._Z%,?W];*:+0+FFTY!$"V8
M@P;^X(&FHGG+:\[S1-ILTP(,P@)7>+"=DXQB/1OZ(0RFJ!`:>U,$4+2[#6C!
MB<],Z`HO^="8+LAY0:"A&A_US7^(0`MB.F@M%SK3J#;(>?^,Y9KJH04!F(`0
ML@#E+.?XTJG.-3_.*X3/>/JH(6B`!"3P`$DCV=26YK*NE_^MC_WB0:L_'O`)
M_D"!E9*:TLC6,;.W/0\^]Y0##QX$=+%]:V5S^]SQ\+9-LQJ`$`RB`?2MM+;1
M36]UJ+NF$?@#!S0K""&P@=QIKK?`VW%OK(ZYO1,5Q!(`CN>!.]S>U_9#<+O;
M8./^P=A^$#+%ORMO7#_\X]\HN$QS>@&L*AK"'>ZXN4'.<FZ('`$!^,/"9PJ'
MD=;9U@%ON<Y='O&)\W?#/2V#(,8]4PO\00`<S[;'=\YT:8@<O,NEZ030F_1R
M-_WJURBX!BAJ9IGJ8:2M]L.=3XWULD>#P6..=ED%47*;CCGL8T^VV>?^#`;7
M%^5%%D3$\PYWE=/][\NPNR#FZ_;_H=\TT'U7^LH!S_A?P!4!#G"`"A"`A\BK
M8-TQ5WM-RP""L%?>`?"==^-'GXO2(G7.?P@`4VUZVMTNGO2PMX7ICZKQKL]4
MI2-NJN@;'T[(E!.@N!1H-H<22U\"LROQ=`H]L8G/G`S?*)OY03]=^<\?4*8$
MV!SH+EU@T*Z\,P;$'";PM_FCYS,%_,\,9O+GB9.RV`27^,Q,+/D93U?Z/I9#
MR&;P]Y^5G'CS^/`4?M97&6:!2T/1!FVQ&;\$3=0G3YMQ33:1$;/G4X'673TU
M!S(V64LW>N5!`%V3&K*B)"&2(LZ"/67S'R.`@NU#2)'3`16@!%=S2$*#&V.R
M`G2B'B!(_R+*H2?S01O081\*$"TOJ!T!TAJ;\B/`,1O_4QJ)\CW>8B*U`BD)
M8(.^@0+'P1[LH1Q"H3Q^`@0*0`#\(1^"XF1[UU7U97LR-0<WIX&OQX&DX8%&
MDH,K)()6:!_V88+3LBDJ&"\L^"`N"(,H$SX)4(,WN"T2LH/*T8-]`H1"F"M%
M2"!(&"+=PX3F4D01`X4DJ!M4J`16>`18V!I:R#>DXX5@N`)BR"-D2&%B)PAH
MZ`<+<`*LU8:-UX$?6$3,,H)V"$@GJ(>;LH+_LS9_&(-&-(.#B!N;B(/=@HA'
MH(@_&"E!&(:.^`=&.`*1J(0,0XD88TI/6"&9:(QTTHF?R`2AR/^%TD&*85@I
MVY&*%':&/<4&=Q"+L7<(M!B'MDB'W0A*NYB"O<B'O]B"+RB,0$.,A.@;R'B(
M(L.,"L"(T$B$T@B)RB&)2PB'V6B)38&)N3B%WWB%1@B*1["%$%2.7WB.8RB!
M95A5[*B*3K6!L_B&M1B"\8&+D7*'^P,@O#@"OAA"?OB/@5A"`ZD$!:F#![DT
MS4@`SVB*T3B-U3B)$NF$IF*1,>F-5:B1H#..'TD:(6F*Z'@$ZAA7];5=*(EO
M*LEX\Z@H<B@\]IB+^)B'^FB3_(B37!*,.XE*Q8B1!&F(0,F#0IF0SMB(#(F4
M#VF-68*-3'F)W'B1FPB.&RF.'2F*\V+_CE@YDAAQ!@(0`919F99YF9;9:7_P
M`)C9F9YIF0,0EH`WEC\YAR]9AT^9EC2YEC=)2J,"EV@DD%#IDW;I)<J(D`II
ME'WID$FHE$UH2$U9F$])EYPHE5FXF.1HE:5XBNF8$;/UG-`9G=(YG=19G7X@
MBV+)DO3HDA4`DR4XDYA2DZTY1%:HD[&)1#U9FAR)ESZHET3)E\'QB$?XE[Y9
MB3]3D<(IA8=IG!SID57DF,RIE1E19@!0H`9ZH`B:H`JZH`R:H)`5CX1`FK5I
MEJ=YCWBXFGNX)WWXEN9Y2K))G.JIF.RYB'NYD/'9D//9FQ'YF]H8G%&HB1GI
MB8E)E?]YE0$*_Z$5):%E62)GF9H7&IZLV9:N69Z`>)ZIDIX3*J*)F)>Y.80G
MZI<J>HU+"9R$^:*SB9A3B9Q5":!9R0@9``/F(0AM8`)_,`1!^'XP$($DL`).
M<1\*X!LP8$OW00!2<1]#0`(ID``E@*,=H:/U6*%H^:,HF*',L:&OV:$RB)ZS
M&:*WR:0EJIM/RIL0*:4L2I'QD9\P&I4RFJ7^:4=<"IF(T`8&D`$]@`)&`02]
MH0`I4`+8@0(N4`$QP!_HH00P0!-?Z@(HP!05@@$$L`,[,(4K4`()0`)\NA%^
MRIW>*9.R`Z2$NB1N>:A%ZJ&*"J))VJCMV:1'*:F`F2:5>I^7:J7$B?^EQ]FI
MHVBC7:H(-@"&0V$#.T"%^60`PT0"J1$#N?$'T=$!)*`$V)0!S%0",/`'!(`!
M&``#!!"K0!"KX7`"#G`%'#`!#1`"%`!>#Q!Y'C!ME]`"#M``H#8(&&MTQ1JA
MVDF6?]J=J/F=RSJH^ZBA_9B3T9JH1[JHU1J4U_JH3GHP4#JI@3FE+5JEW1BN
M_*F8Y-J8Y@JJAZ`$;%H(O2$()I"T"6``+I``/]`;*4``*>"%!I`"*"`4*=`4
M'<`#)K("*Y`!/-`9X#`'!8``(>`'=\`&<"!DH*<'>H``Q38`#V`!(=4`D?8`
M>3L`+<`!`W`!%G`!%.`'97`&Q"8!=%MR$2O_4A_[!\>:-#UJLF$DGD)*GK`I
MK2]+K3MJK23ZGB9JL]I:GQ/IK4ZIGS$:CC3JJ4.+BHK0`6\Z&5GQ!TF;`?`J
MI@9@@^?12W]``D>@`&1J`-D$!,0*`X"!`B5@`$!@`,04#G/@``CP7'[0`)$7
M66S`4P2F!VR@`3QU!P1&8&J+!WY0`'B``-E;7`YP!O^6O=BK!QJP>GY`8(]6
MK(]KFB1KH>")LFRILL]*I``IB$BZN3+;N459L_))C?2YHO:I.Z6;J<6YJ>/*
MF%VXNLV9""Y@`,1Z)8+0&S9@O-V4`HZ;`M%1`3N0`BXP!$>P`[\KL$DKO$/`
M`T1!`C#`3,Q[!ED%_UT<,+V@YP!`Y;P<]@#-.P<Q!0<\Q09ZBP#>>[YT15=^
M,``<$`(&!KYLD'GR&[(ARBV`ZJ/W2[GZ.Z27Z[)C\K_)&,!#.<#9FJ(XRZT)
M+$`+?*4_F[KENISGJ@@>F``H(,.]0<>H6@(\H``5L*>RRQ\HX(5#T!PH,*9D
MXAPPH``5D@!D*@YS$)I.S`9LZ[9"YL-<1;XR9<E`+%/MM0!.K`=X4+W52U=E
M$+<3YHIR!;X#T+@8L`(8('U.T0%7X0)@2\LK\!-9H01/,4\K\`.M_`-%\0=A
M$0,F4`(K4,PF@,RY'!:%$;8_L`*NE!A7$0-?L0(^4<O!JA785Q2NW,J2T?]*
MLXS-;.H3OE$8K;0"-='+-2',7Z'+Q\P?P6H"L:K+.]#,@^'*L/P4N"S.M+RG
M5O%,O^S-P5P8U&S,P0JVOL%,[?Q+Z&P#KNP7[#S,UMP(@T&L@K"GX`06)*!.
M,GP3@@!^@E!-".@"0B$(8&'2RRL.U48!$4`!$A`!>OL'>'MT%-``%+`$E2D`
M-4T!DQD!$Q`!'O#3%C`!//W3`T"9#]"P'!`!)T"901T!#]JX4CW55%W55GW5
M6)W56KW57-W57OW58!W68CW69%W69GW6:)W6:KW6;;6F!+"\&9`?Q.H"4RL4
M)-`!O6K2<KV[#+*\'9``B>$4*;`"=JT?*2T(2A#_L(+P`P30R"Z@J@@K'A&8
MKBO`3&9:L(^`L*20V!$8`T1IV5^(L+QJ(&V:`I:=V)WQ`XS\T:H:NY)-"'=-
M`#\BS'M-RP20''L!V"8]V(7]UH_@QVQ-$3ZY`S99`BBP`P9`I@E`M;,JPO!A
M)61:'WQ\$]W)+%7[K[RQ`Q5`""8P&SS@`FT@PE;X'8.('J_YW6VPC"C@P4%(
M&XY@`TD["J.R`RX<WC;(WE/HM#]PPA5@$[>;`.P]&R,`WB3KWX/HA]\]",Q!
MW,EQW$"@W%[(`]2-`<]]W;X!!-KM"#$0W\$M$4"0'(E,A3&`'BA`K&.+P2:@
M`!G0&S'``[P+XL_,IB8`_P,94.(Q4.(?_@>U.@CCG0+Z"H84[@(#/@3P*MM_
M,-A_34VNZJK?@=L?_14W$:N^A-Q.'@I&GJ<A4J:GP>060K5#D0"XJN6E^B-T
MN@-`#@2X6L(=F0`_XN.#@.(JSN(NGAK?$>-_D.(K3@(W+J\P3@A104P]D!S<
MAP&CVN&*,`1YF@`V0:_+G1RJG0"OF^@&\K2#F!R"H0ZGP1\P`.""X*KH\1W=
M;1,_``,C+`@V&2#V.N.BS@.EWN29'AV#,`+^#,)DRAHV\.F*7KL^Z;N"4`$;
M+`B0/@@8P`,IX.LU+KM*P,>D+0JZC@(*\*_Q<2#`G@+*.QDH8`/0WM\<K`0I
M`/\#M3X"V)[!PS[K/"[JWN[!`G+K@N"[:9HC!M#JRHOJO"X(PU[LRN3B^6&*
MC6SHAT#A8(L>7VB#8!CB67OC8'L:.P`#^M$;=-H#1VL.F6X;B=SIQYO!\T$8
M#_ZZ1X`!`OKOA'$$*2[NF<X@L2X4>.WFTH@!22O;!F#RZTW:IIKI]S$(R;T7
M8/@A)!"UI=#RJ)&GG2[M`.N!N&VJ9&*%66OS%B((3(`!9"+;(V#RZGHJPNR%
M&D_H@N#QPHP"(2^[&(#J""T(,.#!*^ZXIC$$8\_OB%`DWV&O/Q*20"`4;W_V
MLSK.#/\5'$X.F<X;P7X@/?#IU](4\)WL@N")'6^#@+__'*\+!*-R]>@N('MJ
MY@I@($,@'"M_'H_O[#"_^`#;^$?@M3R`'C;`!(FA\Z10NSO@[$4/]/=1Z$,0
M-$4?(H]?'Y(O'&3"YD<0^SP.^%>B\15R]8;?30B2^)OB^SQ^!!5P_).Q(%./
M]FG_Z0#?]C</]X&>M'-_X0!K`J0/\<PTM3,OKVV0Z<<]WKR*U[O[]"/`3+UJ
MY!A@A?LAKZ6*_LM^!,24X@@=`\BQW3H.W_,/K)T."!DH?W\P2H1_/"L='3]_
M*T<$?S]`B):7F)F:ED`V?R9`*Y5_@X.%"D`[?S%`&:,H-K"?"@0KJQ6NA`:Q
MGB8*B"@=?Q@$'9(D(STH0W\$_SO%PPG&?R0H/2/,SL#%'1A_'4>5N9ODY>;G
MZ.GJZ^SM[N_P\?+S]/69'0:Z?PK"M']`/?[U&)=/B2TEE1`:J&"OH<-UM4A4
MV-%AF1))NV(<Z4$`1IL$.UPLVP&#E(D8UCJ43&#"Q9$,.P81,-'&FHM#,%*X
MV)7!0!L%"?X<P?`#!8D5*?[PK-`#X3\,(ML@`I+@*`$7%4J@R""HQ,-+2$D8
M6)%A(X9*0*#"6F&`1`I;UBB1`*(35D\2"GZA('KD:-)=?Y0,Z=@&1LB1)0V<
MW*CR#TB1,&72M(:(@,\=0*K%,("AA($87T.+'DVZM.G3J.?AZ]$CGX(=/5)(
M:M4#H/\KU@45]`"%:%SJW^TR5$`!9,B0!"@J>%(RW,0?02@,N'"<W%.'X4&'
M1%_6;/@AX2B""G^.@CB)?^6]KJA0X9=6`YG15_"&8?BOWN5QF9`DRF70T5H1
MYQ4!*/!`GWTD!)C5/LG15UY\0!B`@E<*L&?+>_%9`QUWR"D7V'"2:&>`=(YY
M]QQVEO34X%G?2,?#*,#%*..,--9HXSPE)``$$,[9L",,WF!&%0G'[?A+###L
M*`PA+CAWXY.63(>(E(00&6644E7)#"(!(3)$EM10B0@)8KIP'B%M;$E-ETR>
M^4<;8D[I)G!D1NEFG5-&J2:>A/3@9IICLGGEE&!:R:4E7X[_&2>34#;JZ*.0
M1BKII)16:NFEF&:JZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJKL,8JZZRT
MUFKKK;C2^(Q7?W!T""%YG6D#`8[T2L"O?^R0`J\V)%#L/DJ<N>LEQ&1`2`S0
M$++""EMBD("U?PRFBK8$J&F.N:)5B^9,B.RW);;>O%D+(L1T&8,T:&Y+[[>7
M#`NNKX@HFV6SQ?:@0+2$3(L.F+DV[/##LF*``@%9M4:@,"D``4-)$E/LE0$7
M/T)</LIXK!00$P\S<3Z(5(3<EQ.CX$@"(XH3\Y<5)%"!+288H",Z&?PWFB`$
MVM"&SRCP['-Q&?!`L2<PT,QS>#S`_UQT(2.61#1WA'3,P\<AIX`"#(,HD\*"
M\*7<,<OFE"")IT?$+??<=!\A-,1XYRUK)Z>(LDH^1B7B(\\*Y!(##T)!;8.^
M)L`@'`DH_:,X,*JD0)$D];4Q@@M#&,!1Y29T$)1(VDUG`+B(Q,`P(924IDT*
MT@RB'2FF/X-Y`K-KIXPJSDR#`0RE#['1Z^/^0[CAB,NR"^.%9Q:Y+#!X8@EH
MF/C&*1/89Z_]]DS`J/?WX*<:^`H)$/#V,J88H$0PDTCS]@@QC'!>"DK@^T,%
MTRB%TORV$/)28`K05PE&(`A"P(`2UD*(OD@1"P/VCSP2B@&+"$"+(]Q'-*T(
MS%A>00H#HO_"&Y[Q$2%DMA4`)N!"1Q#A/^Z7P`NR[P<@>=_^_D`_^P$A?Y^1
M'PV1U9.%V$`05DG!$9+2*488\8A(9(3TPL?$)H;*%!W0V'TFQ+)0R.PY/+K/
M4(Z@+;8XHBR^($1:3+&"M_TA&=\@`/T(P006-6,UWT#!&DDA,4*8#Q&*2>,_
M"$2"UI'&<W&$W0@[V`S+@&LO_PD&98RA/C9ZRXX=0&/^2/%%(.3%?QA@V;8,
M\$44A/$I(^@B(G*"1<<0:`C6V]2.5LG*5N[H@4Z,I2PO90K,)&"*GA'C"J[H
M"B5H\0=<?(0HOG@$7XJQ*.1"A"0I>`@2,,&/Q0!D10XV0F06$A'_X=!1/C#`
M!.?X<3321`%0!FD*\YV.&C)+9$4"8@P@-/.9_RG&1O1832RNX)>:'"9YC+G"
M4`H3&#[3V7-&D)14:DH)"$VH0A>JA&>51IR$.(X2=K(C`Q#12P984KM&=,YP
M`4:#U#/!(&@VH@24@)\CY.C=9LG23'%'-G>L1DU&&!-A$&,:R+A&-IYATV`$
MI1JD:P:R4C@+?6ED/(7P42].V+^MF,(0B%`$(QP!"4E\$X.]"`4'GXH*5;!B
M'+"0A2_F%0-<C&(78G6A38MQC&1PQQG0\!9.4>`";#2C>!-CA#?`(0[OJ=*5
M@'TE:I@`10LJHTJXL$1%V!8N`B9K%!49_X4"1M`_(#"!%,T4YSB!T=+.=BH!
MWE#,^B91$KIJ[EZ24(`)#ON#?,SG:#&XR#YT<P07(!.T^FL#:/((VA^41`GY
M@)]6?N(<:;26!#;(QV=(H28#_$)T$A&."Y);&M4Z)@4_X$&"E`N:O2C@MTFI
MP':/YIRT^#8PDJA`#`9(7,=X(P8D*!\-5SN(UM*Q#3R(;6KI:]M!I$5_B$B`
M>)0;B_7Z55-Y2;""%YR7XI6&"8YSC"4/^Z:/4J,3^?72$5;@)VM5PP;PV\>.
M_N`"&%P6!;\JWV8'Z=D68PH\Q3E.=3[D2?)$AQD=L@Z*1/36YIPH/">R,832
M\PCVN"<Z0Y[/,/_LDZ+\9&`_CP""?T@3("`,J$`'$F>"\D.A!JG,//^0$(4L
M]`<,G4=#Y>'0C)F3,A&1J$/?05%O)#0?%N'#!2]RL2:88!#CZ68$Y3E"21"!
MS'LJ%@4C.&=V'?,+U;9E!R8XL24),`(,K/@/3!B!ILVHYTX[BE>$`'6X!"7J
M$JAI"(*B7I].K>HQE1I,+J"2;BU1`EB+&A$EF--O$D1K,+6AU+2F$J]3!VM9
MMQK7M#ZUH%#7*U9GXM:C$K"TITUM`3O)-$S`R@\.IAMKV&`BEM!9A!@2:FNY
MH"(E&C>T^)$`%YRX&%#9Q]U,X>EZV_O>3`QL8&%)FLN.R`:^I'!9W%3_@6)]
M]'[,F*EX=6&#@R6W$B=&EKPM06]\6_SB&)\5@S>>8`>3)I0F8,@.=,.V6[).
M:#VK3`4D9`(8MHN"JMC9&97BX`J-2!)'X.B!,\[SGOO\>MP+.O9V7BET_?SH
M2$_ZJSC*]*8S_8)*C[J>82*E(>Q@B1CHP)E*L`/J67V)-NB`E+BN:@S80%@A
MN40&.M`E%^P`=3_`0)9@TJ4V=`#N'5@=.?3^%;I7J0-+_$'>F=3UO\?K.1W8
MDMO!U<?#^YW6L(GHU1$1]JT7/EQF1_NB-J%K!'-\XQZ7NNAGV;&*@8Q]&=N8
MRDQV>F'L,D*]FAC:4(:YE1WZ934AT,QJ1IY3_[8A9S+OV<_.$;32;,UH2%.:
MCE#I-`]%;2R?H)K5H)>UWG-M]5]32MC&5C8YSEYMMC^'VSXE=*$3??3H!Q]N
M19N/\])5>$%+BFISB<SY="X#2I#_LGC07_<J!76*$5]$\5MM(5S+8%W&U1;)
M!5O5("B]TGE7%1H(2"S:E4N?40V6]EL$4`W;U3DF,!<#B%Z:40)',`0(>'@)
MD!0I8`+T5PH8,`2XD'_[P(+2@4S_U5&'4CWG9RE.UX,<!76D83X4!!K8(H1'
MDC$$X!4=,"XD`0,K,!T[$"]-$5'EL@]">"QQ1P@J`57?L"2[$26_4"[&((3,
M-BQGH@#Q\@-*T`'7MO\"/\""Z3=+XU,^YS,[2K$^P@!#^0,_.E1#>8@_;_,9
M@?,6V-1"`D1`3X5`@1$*3=5`A?!`@A!!$U1!0/@0&01<?M-!7/5?(?0*1=%"
M)U1F*30*0,!"``0,>1A#A``_@U@_>7A#@1@_\\-#(Z(<0%1&0G11F_(#O-B+
MOOB+/\!L_98"0/$9P)1@MN`S]5,5!!`4ZV,"/2,)R"$5XP`)PN`+Q/$:AK8^
M*R!285@!U,A8AL8$'*%9"M!J!'`$Q3(<YR$*(&8MWQ8#2!&'LE1+5(%+5;1+
ME<1/ZAA,VU**SU%,]U&*9&1&RT1-S@1-<#1-OT)"=F1&,+"!]U0-.U`!MK7_
M@_403IM5"@]Y3M7@<J2P3FGD3M0`3Y`T3Y/$2Z&`3UT$D(+`3Z7H3PO4#)FQ
M`T&142@0`P:5*>S1DS[YD^S!:?W6)>5S/Y<P%(30$LUX#:!F"]I42HFP`SY!
M"*'X"`J@.=+3`T>`+1%"`CUA"2Q#CLV8"1\Y:-D891I4#=;2.49'CWICCR9'
M"KED/"K)C\#4DL0$D]941LK$3LQ4D@JID0UI37=$""_RE-SD31A)#QJ92(1D
M3AZ63B,DDNWT3B`I3WX)#)5D:$)A7\+DDB@VD#\@DP\4'0+&$!E`4%#9*5S1
MFJ[YFEP!;:)!CMK"22,@A*Z7:$_8#*"%.*O`%>Z%_S^YT$#LXQC]<T]E80F&
M40P5H`1?>2VC()858#X.]DC@2$<\T`&9>'.5<7AN"3Z!`Q2%B3ZZ@(?1\`RK
M*(L[A"_U@9[Z,X@/]#^^<(B.>$`9!`H+%%8.A$T1R2X=P`2V$(%?<9\;1$X>
MQ(F[X(DEY`NA2((JQ$F)]4DA&0VR=48SY(?#D`JQR`2S"`Q`8#Z_D`%,(`D[
MB2EU<Z)RLU*C09LBEEV]"!HD8'=BDP'-B`'!E#&AY"QEU3J602"C4)7WI!%N
M`HL=4`(%QS;$P$8<D5%W!Y8?VIR45)&9.)IJ0DW?&3[KMP+`]0<B]'XOD8+[
ML`*YU$"O=3HRJ`#[UW_KE_\!L\9;C5`24HD,ZW6`Q;4#Q[6`RT49NF`+EH:!
M%DE=I#&!V;5=`!8,@O0,-=&!>71#OY,L!%`3,:!3*^@8P@!?8!I`8^J"OX=_
M\B>F-3@(G/%_HT2B&%$1,<`*%\>BSF64O;%P=]B,6,E9SD)#%5`)N)`!&%`U
MQJDMOW`$2R*B+@`-;(&D_R&6*FH#+[%VVG5%9S,*R8D(5GJEWS.:"V$<$J*.
M^\`#<C0).:>K$L(#CF`"1Q`=X=*MS+`0//`+P#0B`<FEXTIN*[>5S<`#.2.*
M"T$(PS$"A[`#VGHWR&H`(Z"&)9$Q)<`$*NH0)+@0H($RQ90LXUH5`P2PH`%G
M#IO_'.<1KQ-+KY*0L/#:`^M:@DIA`."Z#^.:#\(CLN=:`>G*K>Q*>3P`L`U5
M$,4Q`HLI*:QQLSB;LZRQ>:$QHI8!`QY[FT(89D`!$&/9,2G`KK-*46[4#,5U
MG+\@,<188]#P>VRS$THZEI>@M5%Y14.09^TZ2L(HK7AC`VE'8I-'#5EW)C%P
M>6[W+&$G);%%/230")H7+M(#$[S2`V]'+W)'"/C'*U]'+SNP.FUK+9%*8HY@
M`TLD&GJ+)G9*:(7;)WW[)E'8&V?;%.#2!AC@>$K`+.?1MKSRME52>=>B!-1S
M;C]PMY;`MYZP7F_R`VU@`PZE*>47=#5;#R_*)+\(N'8:_[I>AP&7%P-2X@(9
M`+M]@KB\4@*"RPAR*R4#P0G3L;JG6CU4<KP9(+?@,@1+])QD^[W@FS>P.;ZM
M*9L/8Y,/08CAN[[L>RNWRSVY:RMC.P_'UK[V>[^K\K[;$[_XV[_^^[^_0;[D
M:[ZA<6X#8T12DG7=T'G`"<`._,"BEV82/,$2K(NEH025I@O1,2+3`6@2<A51
MDC00/,(D['/ZJSW\.P^*<59+PA9G!"X?.B4+P6\E7,,V[&))E,-&U+BD<5C<
MD5'7$DJ.]0ELDR:A<,-(G,0M1<%,G&86/!H;$T7.`<1E=EE#/%J<0,-*3+86
MX`!>[,41\`</$,;H(`$!T`XMX/\`#4`.#^``$D`(0O`!$0`"F2``?\``5S``
M["`!:IP.#+`![@``@#S&_7N%AGS(QW(:R+!*/D'%-OK"A)`QEW#$6[R^#^`'
MF(S);/`'#K#)YR``"```[0``?D#&FN`!?D`!A`#*#I`)'G`&?P#*JKP.`U#*
MZ,``<R#*>SP'=MS)_:MO@*7%7T$2B-"<SL6&[#,"H:./DRS,E>R6ETP!`##-
M#,#)GOP'`2`$EP#(A!`!?J#+?R`$=$P(9WP)0E#.("``+8`(V7P)I%P&A$`!
M?L`!Y*S-A'`&L!P`$K#.B+`!<U+.EU#+IHS-EB`$W/P'#?#-E@#0F7#0%(``
M=LP`;PS_QPP-Q^-,SA6==-NRT1S=T=OBG:-A`DMD$*A`%>"2)'3A@(\`TL]\
MI9?\`)?@RR1P!9@\RP)P!WZ``!8@`9B,``P`!W!P!GH0RW/@!WI@`7>,`!&@
M!WYP`DD]!7^P`6R0TQYP"7.``.>A`G[0`@&`!SE-SW"`R7<@`7-0U7A0`%JM
M`70,``O@!V50`'A@"0*]`7BP!&U]!W1\R7Z@`19@`0B0TQ<`UVW-``A0U1>`
M`/1,UD8]`!SPUP@@`5<0UW\P!7]]!G3L`0CPT//\!R!0`)@\`1?=TJ(]VFSL
M!WCPQ?3LRY>L`IXM`4*@`0AP!7.@`0"@`7Y0`"U0!GXP!R$0_P!Z@``.@`!Z
ML`&DC``3T-820,IA[`!^X`"V7<V(X,T"0`)Z<`="$-Q98-L70-D($`*R_`=3
MK0)9X`<P?09^,`&>?<U_,-=L`-SF_0`!`-Q3H`=L(`%M70`68-YS$->IC-#D
M#=ZQK0=Z<`$X?08`X,L)?0?C?05"(,\:L`1_#0(A@`!30--5'77`[$K.3-H<
M'@]ZG<D38,U_4`!8_0=S,`468,L"\``@X,VB7`:Y[-^)3=ZDW,JU_`#*_0<(
MX-0"0`'030@,D,H\?0("_0<MX-9_@,^QG-D`?AY*'0!(#@)^H-[LK0*Q7,I'
M7@`#T`)TG-"B;-[<W-\)_0`\#=,7`/_?#]W+FZS;@.S-`R#/:SP!WTSB%-`"
M_!QUU9;GTG9M'=[G\Q#-TRS((F[;^!S;8VX)+OX'98`'VBS/XXP`'T#*2W#E
M.%[*00[3FC#;E]P`FTX(])WDL/S=;*`!GAX!I!SB)D[EI2S55_`'RDT";>T'
M"T#/7I[D"(`(8D[>M6S'B)#F(LX&"T`(8R[/=NSB'-#3#@#.2:?G>L[GE&(F
M?DZ/+QW3FWP'>M``V"X`%]#?+7`!+:[0;TT(J%S-4B[-*D[CJ\[M#7#GA"#G
M&K```7#L,$T""!#72B[JGCP'$7#D<$`-"*#J$2#5(9[C(,`!$^X'&U#K0HWK
MJBSO*:['`'#_`0'@Z[Z\`!IP'IM.['^0Z`#P`9YMY5%WPMF3PO+PB7;T@^?!
M=#MP)P2P(_,;[4EWR1\@`#3_QKZLU78.!Q;PSD(P!5LMW4)0!O#\!RG.X*@\
M`#DN`.@>QG.P`!N`RFML"<?>U'\@`7J@`B!0RR%^!FJ-[X2@[T(@W`"0T``O
M\*Y>R@!0!G8<`G[```EM`2!P!G.`"#O^!TM`WD>N`D)`TP`@SQ9PW9O,]@,`
M`F6@!WWO!\7^S4L`!^*,`+",X1G.2AO^$%$3B,(07T'A6,KP0.AI33`O>A_>
MTR*>X@A0^J(<UG_=[WHM`4*/"+J-R05``DF_]&*<R1I0T1N`R7I<__N8K`?5
M'-9ZX/4F'L:8O=O_+M>KS@8#7\H@,-4XC0<DH/3S+/>N;]2V#=,T_=?PG-!^
MT,6;#`!_C<GTK/$NCLIS<-68KG0,M?X)5;NCT8#ILR0@!LG[P#8E`!J>__E1
M9P$3``@3@A-+?QQ3?X9960V)#!]E$PQ_+7!9#`\/B7\,$64GDQL3%YP3%J*D
M(%,J5Q:;KQ$3&XE"%*P2B1:L#$L#?U.(?Q^I#4L6<PNO`*,!4XVH?Q(A94L`
M?T(3*A8>'YL"62$6IG\;2Y_6&PXJ`(>)`R$J'D)_`Y)_%[)_#RHJ'""O``,*
M'$BPH,&#"!,J7%B0B<.'$",R`<*P(L`4!/_^).CPQP#'/SV8_!F1(9$2%`!M
MH+!AL:7+ES!CRIQ)LZ;-FSASZKRI@8T$"WZR[!Q*M*C1FT>2*EW*]$B"HW\J
M*'WJ,9&-$2-+_EEAX%4&'CN@BAU+MJS9LVC3RG3@IRT"5VKCRITKL(/=NWCS
M=F!I]`<*$G](\,!0-080!5G;J%2R*0:*&'0C2YY,N;+EFT*V>;!VN;-GFB-"
MBQY->@2,HRD8)TI``$CH(RD2'7D==I/KT!4^Z][-N[?OW\"#Z_Q!O+CQXS^T
M"E_.O+GSY]"C2V<HL?I#BM.S:]_.O;OW[^##BQ]/OKSY\^C3JU]/$T0$`8D$
M?.!,]A_!*?0)>N#_,-!^RP`5^>=-!`(*!$`P%@$007[LP53:@Z*=!E4,!/20
MB`D$9(A!(A@1D()RB720P`J`-6CBB2^=P0:`!90!(%D"E%$0`KX8Q(:,``50
M1HT6Z<+0`Q0$](`?LQ0T``(N#>`'CRBVE,&34$8I908EB$4`"HAUM,(/&*#`
MV`@[_+!#!1_]88,!)1!@0I-LMFD04/OY@8L$#7`F0`N<3+))`!<,`!B?%\S"
M```27/`B.1+\,R@Y%[@BQ!5Z6,-``[B\@D"?N!":B`1%_G$C"`)L,`!\0#T@
MA!`#7#`/`PP,,.@&`E@P#ZJJ/LI&?ALTF@@`K5;:`AM73"*`H?H0^8<`_PW@
M"6L+#4QR9*Z<Y0K7H'06:0&Q0#'IID(5=.OMM^!6D!%4*/S054<?=<!#5HD0
M(.$?,;"TP@K;UELO"7<LP$8R`NCAAP:N(.#!'U<4DL@&*K2ER15M70'"%7CX
M&\$F%NCA2@@1"%&&'P)OT!8<`2S@QQQ,(L#&R`-$,`<)(.@!7R(W,H#`QGHP
MD`7'&WC0%B)7%(#``P7`@<#/O^SLL1]P['D&QT'"@8<?$R2BLQ^](.!'`1L,
MN8$$_IX!P@4(%.#'`@$<N;$&(&C,,7]++#`'U/18C;4$;]F[D'7686>4$J<9
MP%)5((E$DDDHO9(`#WS9K?B)`E@]0`!XA,!``?]S_.%'D`Y$G<@4"$C@01;8
M``"V``X@P,`4E2="@AY+-&[!`WI(,.0`D`+@`1L;A*"!I4ML<$<!0`VK1XF>
ME@$`U0'H,46I%EPJ@1\,L'5!"V=@S<890%T@`)%7W+H)!1I(0($?,=+(V:_!
M+A!""\IKG<45`=Q!00.7<\V!DA=<X(<%$43Z`(T3\`,`_O>'!42`?5-H@088
MM+B!3.F!4*K245!@``(8(#:`BX'@M&*"<[VB2PT,(7O*@(=CT:A8+;C<'S*W
M"0?<X1424!D"2,>&/S0@=8F`PP(H@``A6.(/(+B<ROXP`39XP@_$.^$5Y@`"
M!-A"!:^XT?$:8<3C#6#_2$OX@!\>X(#=_>$,05+!&;"H10%$X`RO@,,5*+'%
M,B3C%6>8&`(<H#('#`D`=RA#!*Y'/VL4(`)'BL:2[B"4(%)@`I4+Y!SK"((%
M=$J$`@F7)+TUKJ+$X`A/LD$%,@`X!5!D<"0P0);^L`/&7!*2J#2/`QP0C4O]
M06<!4"$<-/>'$%1.5'3[P/](5\(!X-"&8Q/*%:`82P\,<0(+R,0#_.-*W?W"
M9YK8A!27],4%+6E('L@$#1,QQA6.T0_9?$`+(E#"380@!)SP`P?*@$8XRO$$
MF;BB`.]@QP<T@'ZX*,`'`FE%-A`3G!-X8>/^@`!X/L`72R!>*E^!M^KHC2@K
M_QBE*`T`!`ORP`4C80T*@(#11)2@`AU<TT)'^IU5`K$`Z\##[N;(``W0<GS\
MTP,'B+1+!Z#1EZ_8P,DTP8$9PC0"IO.`!EIP!1PE`@$A`,`<9+0].471>-2,
MX_$\<"1*:2!Z-?RB)FP*%*L&H']Z>J7+(B`G=@+D#`Y@P`)4L($Y9()(67!`
MR#A`O]8AH`'\7!+G!,!#<=1PH`LX05O%B1^2OD()B$VL8A>KA!\<)0,=A=>3
MB&.#$A4'1![=0>(,R]GI7&&-QWH;&^`SA9$5P&#D2-C/`G`RGUV@9W^PP`M?
M\0$V3$((JM5$X\ZP`9'IH1&;F$,6$'`'^*SNEW_``_\<9.:*`DRA90*<V@D(
M5LX"\*=G)"BM'Z:KOW;^(0!B(QH<"@"0\85@`/Y:``-ZNK7T;H!^2\,#"([!
MB;?@=FU_6$())9!(JZF7OW#A["0G6<G.&OC`%B'!(P^5(^(Q6"$!F$<BTI:(
M`"AT$R`HT>H0=)`7@>#!_3E4A`%"88*(."`*3D0?0?R*$9L8P9N8EXQG3.-Y
M;0C&.,XQ<"YP!P0\TC=]U#%,4$#D(AOYR"B(C9"7S.3*8*)2P6G!``K4Y(1D
MZ,I8SG*&5',4%W2@#5:Y2T<Q8!<,7#@1CJVRFM?,9AROX`BJ,4`"%)"""K!D
M!`100`)0@-D58*7-@$9+`R;_@">#B*)0J-W$``:F:$8+I!8AX(_J)@#<S9'"
M*!>(9D(N$(%.<W@3')!T62S`X254>G%:3O65N6P4`Y@`.X#C"KO^4-%7E,``
MN0FTKLGR-%$39(I`#0@%O/N'81-$?QIP:FS],#%I-KLHGEA(`-TB$).:Y0%9
M/2HM4:WJ5+.:*&?Z`PJJ!+@2;/!"A0L,$!RSZW8?Y7EZ$`H#7B8!7%S1%R`8
MP#B1)(0&/``7PY8`!V9A;!`TP!^OH,87NT&"DSW;4Q&X0`/F08),3Z)LL[@3
MK"3@IRN^;!.8X`"#*\YI&6T@U``H&Y[F+>&#$4IY.>6`!4S:@E!O0%2"@H\`
M#@J0_Y-SH-#DL``(I"R$LE&"`Y?.]\#U44.."T$/VU9<C:<NXQL;!08PZ``0
MUE3N<__A))M00FS2[>ZRYV0">@C!\,`&`A#,87E#FR&PD72"MLPA`!30PQVN
M1@)CCX_9+0<`GO`0I`=H0`\/WY?5^#.DL;5@>[Y@PT'G<#VPZ2%V('\:U6C+
M,0W("`YV9X`*/='R333`=*]@F-Y9*38_!&N+*X0#U_1PP@HO+2C>F&%I`>!+
M$FSLKL66FQ"PO0$]G(`$&DBTXAHJD8<.Q05'D#$*>@`XL`].(T])!!`,8(`1
M>-#LX)\)">9PA>/)RHE*$K@F=CAW$GS``J+GJ\7H-X!A!__@+<>[]/<0(/B[
MSB'Q>"`$_M0\XJ0!!0!YGG)0?C`?!7`)'/!Q,00"V(9AVR4$+4("$<!QY),%
MY(4'FO8*!?"!*>0!+3!'`;`$`<`!<P``:Y5"'-`]HA-@O"!E2*(Z`K,Q'+`$
M#O`L_U."\^$'F38'G@<8.R1"2':$1:9D1;$#V1<5':0`'6`"%>!8(V`"';`"
M=A809!=^7/@2ST-IB/<'8K0$>@!$'O`V%#!W?P``2V`U?(5&*00D9W`\<:5"
MBK9=OW`'``!U_F%$?]`B0X(G:(>`DJ<DKO!W#M`IJ+(QV39%?Q!M`G`";M@\
ML01E%!A6Q^('\Q!7L54Z*TB&^L/_`/KC!W/X"A8`>C68"`6@.W?0/Q[0A@Z`
M@Z18.A30>`83@B)$=51G=431`<I!9DJ@``JP`EHAC,-H(0'Q;5VXC`PQ/G&'
M.S-U!U&S`'A@`060AG[0`$"50E=`-WQ%-L?#`<-V//9$*9O`/EGP#VS1%M0$
M,Q-3!F4P4Y/010BH`0<U0]<P:'K@73S4`+<#<NKT!R=0!BGT`?0C`$^7!<CE
M#LCU/'B"5N3X`"O8/&6050-P`H=7(O1C3ZDH#'.@!V<H)RIS3PVP/2=P<+*#
M`!^```!"`0&V.,P7$<['C#09':N8"^J40M!#4)*C!]BHC9VC3D/"5PNX!'(R
M;"2`?JZ4_P@!!`<.D"P`L(<3T(?O:#QS<%X(\'H1,%/W*`#CEX@%\$8"B0!$
M-5N)L(_]4@;/(P"E!1\W$P(!P`BO<`+D]0I"@``J0#\.`!3E$"D6B(<%@#MM
MN`DZHR`=J218PS&9:$8^A@!9@#\3:(]_^&EV@X1(J(0UF9G.`0(:<&E"<`?3
M-0$XX@$(H`$J$`$,0#(4<`?W14*9I@)E@`"%\`!"T5,J*6$!,`>Z.0=!D@B$
M!X)!<D[TX"\.H(Y^4`8%T`"RA0L"D&P^X0UL@`!PP)JFIP?"%0)_J9"D,"0#
MUTTM%'6O9#)7<`(@\#1P,`>'N)-JA3*;``#1Z0!ST"DZT@UXP/]*1.0'>D`*
M*NB8_49>M[,!>-`-(:07!'H7FZ69")J@%5%:LW`_,:%?"=H4$CH5"EJA%GH0
M/C-=JD!E#'$RCI:9$`1!$G04.\`$:68`2>%]@#$"*9H""H4"H8&9%SJC[&$!
M?D(3`Z`M-0DA$/(N5\<:B5`5))``3S$X/8`"]+()WT>C3-JD3EH01TH"*#`$
MZ)((&8`5UR=KB1`#/``$Z_:D8!JF38H1&L$1@!,2LP9V5DH`-J``2RJF<!JG
MZ\&C#^*C0T$"1^"E7MH&@(,!1S!K*:`W/5`E),`$D26GB)JH[488FS`8A6$`
M]$(2;9`!%5`;?V`"3P%"BNINS3(00L#_0#GB:YL@`7?P8P)!*0ET:MHA<F(A
M`'>`)T(@`0S0FP)!`A]7$3=G`9;(''1:&G:Z$R9@=?.2`MRW==I7K+Q(`NX"
M`R.ZJ;KV'K1`"_/`5Q.&824B!*)@EXE``98((*<R88`!`!O@-9S1<BQ&"V=V
M#:_@'_91>@KAKB2FKM7JJ?,@"_[1<OB*80&1K^@*$!*VE_'A`#'2<@("`,2V
M"20`K_I:;!H7&!+VK<`1DQ`QD\Y:L3'Q'A_@`"[3`@M07+:T0O;8=QI`-J2:
M!;0D5`([!TG#"2HP!R>`!PL@!!>@`2OHDF<PJPUPGM?U.T5R`J>"FAU;;XTP
M76KW,A7)2B?P_UM=Y`&Y0T07P!\4T"D?@`N2@`=W`'^:<`)P<4@R=0>%<`4:
M`#K390&2QK%Z*)IS@)`JH`'\@;(BFP4DT``:(%<5-@$:P+1AR5L"L``%`&5"
M%0)<4Y?]\P!W\#LD,`"_4V@\=`4<(`'DI0(,<`8:4",@4`@YR@&FR0"1HYS3
M$#O4PPK`@1RB>UD66[HS\1X3(*LG$&IEPU>+5DN8\$H6@`<!(`Z)T`*L1%5I
MN"NLY#53(#LDL`V`-(<1\``<(`19$$-B6"0/8`&O(PD!``<[MT)_6&+DY9(N
M<@$#LX-3<`4?(`3H!%KN(#EGL`2)<@?BLT(U$G$"H`+(-RFUA+M"T/\[B5`-
M)Y>Z+7`"^_$'EY"[<BLJ#,":#\!HP(!;7`,"(7`!ZB4`H"4`U\L!`ANP`L`&
M))"\*R(`!F.PWR"1N;,\N%5HZ'0"+5";XKAS`W"S\O&8C@L<O4H:OVJZ,+P0
MJ'MS$Q`_%L-7*L,&"P0^)+,[)*`Y]7<L'K"[:S@Q44,!PZ(!&D`!PZL@/.<`
M$O>(1?(('T!4B1`"T\M*]LF4-L1%^@`?%,"T?H`G295H`CC`H%4&%X`YZQN5
M08([8!LI%/""YK0)^3`!<&`-6QDD`I!->-DX;'`'`CH!OO``%U!#8!C(.**-
M:S@%$7PL`BLC@&0RP+(K9T`"!C0%^S$!\Q#_#IL#`.4W,0>"Q`>%1@J".T04
ML1+K$!0;PZYL$#,L"G<"`-([Q_R1/Z!#`0.P`"#``)JS##;4`$2L(*E,`1>@
M`F7#Q"?LQ+X@L(B0B.:T1O!#`K7\!S*RQ?PKNZQT3T34`%,P`1/C`06@+1&0
M!0%`:']07-VP(XFP(`#PQBDC!`Y`*'%DQQL@@7>\3RLD`5'C;R*W!!R0##_1
MSIHP`1/<S:7*+.Z0-/[VR*03(X^XM]AZ:0:;7ZE[!YU@#7D<L!\0`*QT1:1\
MPD6L#0P`1;\QNJ.+6>#V&.U29$EJ`$1F`+Q(2A6`)J^L9K&<NC="@O&)!RJ0
MQSY]!GB%!WA`2\,D_U_#;,3%9@&+\$=-7+S-_`=.4ZIV/%U[*]3Q`[/4NPEZ
M@)PDP$H@<`8JL#Y"`0<M```]=`7ZU[YK:(#RP`8%,+GM[,:>(@%LD`5LX`O8
MXPW4*`ZS4,-X\`D$HP*TFP4J@#L30#F<,3DMHE/=W`#Z$DU?O;;I\#(<ZP&2
M+!]X0#(5EI_U@"^<P+>T^@<N(Y`JX$@-H`*E7,1JU2+`P7VP'=NRS7VC9!17
MDB60RB5>,A)A,B9E<FLQ@"$W767WO`$DD&(`X)5KB*T"\`]G'0``PBF=`BJS
ML`$/6]WD\&$2@*WWW`+8&@#.W0+P%P+^$7&[4BFO0@FOX`"<HM[DT-P@4/_=
M`=`)-L0CGG.[OL(I]F'=V,H))$`H`6#<<%"PZ``8L_!X\T#=0'0GF_)(6W/<
MH0`@K&*7`@`@+>`?+9#AV;V&F-@"Q>W>#"`!"L4`@"$$#/[?X`VK[U5OV,P;
MC/7BB95F1B&E1QJD'W$5L^:FFR",*Z`$Z3K<I0N^#H`@.:BP`T&9`@$"!3`)
M`%`B`X`U,'$%HVT>3)T%^M<;1)KE6K[E1"I2>],W?_,1:'I]:OH',(`"%J2,
M0&ZZO>Q@'!H30(=A<=X2<WX>-Q<<NCAU,ST4%;!1*$`5'W&ELZ:E&A$;+O!G
M:QYH@(&)`<'H!L$R#+`!=0X0+?`B&\!BCCX0/U[_JYN>Z')Q29FT29WT2241
M2J.D!!E1`G_JZ8"V,`4AO@?1`@_`"_YH$,N3"#(G$,IWY.<J$`_0ZZ_,Y<*>
MY5Y.%`K@Y3`0J!2$`C!`I4?`?5A"I:H#!#`@TZR>8QS'`9@P"]N0X6<@`4_9
M"'&+<&0K%+(#92!`5R3``'B"+&<@`))0;SOW#Z\S"[)#R(F@3+,P0-80-0,D
M`0$@XJX@KI2`GG$[9;MB#9RR<]YN`2G((P1_)SLW"9FR->88#0/0",D]`"='
M*ALP;_`1`*!J=GI:\B9?\DGJ&<UZ[0@65V<0"0>$!QXPSWG-!DO0MQP0`DN0
M0&<P!658`.*\"1&P!'#`_P%/?#OU\``1``]9\```@`?=:X$4P-E,]P&<W/,%
M@`TD`/2T*SEW=T!K*%,3,`W!\%K)M;=3L`!VS0$G<`+]X`Z:`+B$)R-'S,!J
MK(H.D`5#S`8>@`?D=)$>$`X,?>5<V&W>QO*>#K?<;$<1T`!8PTI"D?'8N4)(
M)]5?Q`&<$3_7$`)/3#K+H/3%J2`4,#_6A0B`E.^^4/1/R?FIBPA(1VD+8`'>
MA3ML(`2X6V&.=`8>X`IJ#9;^5D[EN0&K2PJM4_?%V4*A[9(M$#6OA3`3LP2^
M#.SMMLJLC/B)OLW-7(LY"@):3`\-`%J<[PI1TP*V-`^]=<6=/\\3`/I%O)4Y
M^O^ZNISO\.$`KYBCR]#']Z"-ZW\%Z`0(?W]L&WA_("&"?Q\4%Q02?TL-#AL%
M`P,"BF53%P\6?U,#$W\4`@Z*?Z,;;*4`4W\6(4)9KP-35ZBYNKN\O;Z_P,'"
MP\3%P`;(R<K+!@K&S]#1TM/4U=;7V-G:V]S4IPT#?PX#'R!7)%DMIP,-$18`
M5P(1&PL;$R`.`8(%`!81C@+P2%`A8<*#"*<`1&@P9<,5`'`"E`GWY\$'=0S@
M;%A2,``<$!,D7#BS0<\%16PDG+'0`)<@`1H"#)BW0$(6FR)'"6HP)X"`)0%4
M2-R0Q12J`A8X7"DE9`&#)10H1(##`(2&*2T@==O*M:O_,0)@PXH=2T")U[-H
MTZI=R[:M6VT-_D@`\"?N`SB?&CR("T!"@!,36E0,P:%NEKB"6DP`*F3)E`8@
M/`RX((#=GPT#2#QPD&D`G`=T_PAX$(+N@!!Q3WJ.&\`NJ@$>6IRXB*IP1<YU
M/0`X$4&?HBR"-G^Z`(=#"\2"X$R)(,2"8`%7'H#@$$!"W#)S3[[=SGT8D^_@
MPXMG`J2[^?/HTZM?S[[]M@`<7@D[%4P`&Q+N\Z\]PK^___]')*#?@`06:."!
M"":X`06^!?-),!QHE>"$T_Q@X8489OA#!A1VZ.&'((8HXH@DOH7"B2BFJ"(*
M*93HXHLPQBCCC#2>E\&-..:H_V,&)=3HXX]`!BGDD"]68.212"99`0%$-NGD
MDU!&*>645%9IY9589JG-CESBV*.68(8IYIADNC7>F>"55^::;*XG1`2*?/"'
M9((`)X@'%WAPQADA;"`(!QZ`LN<9!IUD@09SG-2`=O)5M.<$^A0PJ`6#GI$5
MG+!0IEU=>MPA85VV9;&G1BT,:N<?(31XJ$D[:;``11S`.<&@!@WZP`-[7B'8
M3GO*2>F>$;00J"`!A(!`""!8<-(%HP@A7P"OT/>`=A$,&D$$F?P!IZ1[ZA-`
MI19D`4"EKB@RQ:"[_CH!`X*<0!&W4S28H(;T7LBA5P<\T8,O3QS0@PO]\G*`
M&/LJ(O\&!BSHPL(/:]CPQQI/H*%+"0>LT4N^!?_QQ!-?"L+"`0E/#/+#/[C0
M"PE/K/%#QQISK$L/8ASP1\PL[[+&`34+XH(8:[#0AL=K9/"S($/P/#0O%#^!
M"@MK6"Q("1OGXD+#0_/,`GYM;I.%$'_,M$$(+LVAB$$3>(!9(G_<<4H`1&T0
M0`2>X!$`""H`0`$;=-&G+0<;7*#"'QIML($0&^"Y`0D?J)")7@,\H(@*0K2P
MM2!"\"G('(=?\`$`2PCNIR"$"&*!W'3WDRH`!8#PQQ5G",$VYF\+(#@($9@]
MP*D46+#!"7N9[38`.HD3SD@MX'+"`D((0($@&YR"0%QP$]O_MD04E0&XY_B1
ML($%#0DQ!^&`#JXW)8)CW0#?'HP20`'6_V&]$%<,.R&::*K951(BR-R+#$G<
M+,(,O+@!'_0G"#[,@`:Z>($(;B"#/T!!!DK+Q1J2<(->S"!_BA"!")PF"!H<
M<!<Z^"`4,,@+%\C@!B+0`2HTJ,)<C(%_?^!?"WL!A1EP$!4'X,,-:!`R&@BP
M8RS@`Q1RAHH)-E`1+X!"!06Q!@WFX@<,_)(.7S"$K&VC%'_(`DM.``?\B$T0
M9'.<^_Z`NB6P2QR"@)N[!#&`J%P!%WI;B"`TP`"]!8<B#O"`G!@GQC_@03`-
M$H`*KN`GS(DF`@K11>C^L,:N.8`C_\0Z1/P>]$5$*B)Z8Q0$%J>PESX"3Q`,
MN(,B[@``-J3B$1R@2/.RJ(<-8%(0])F((*QG1T4H[W([$>/X=-&`N'!@%`/@
M`/(R"94.T>],]N/*#"#H"QHD00=C2`(`=[',,:#B!1_,A0[XAT`46C,7!Y#!
M-'>1A"1\\P\S&"`JQ(E`7820#W]@8`1W,00/RH"`?TB"#&XH"!V((`E_<.8+
M?J'$&:+BA0P40P=G\(*,B4$&0_1%"-LIB!?<8(E_".<X!?&$`Q9,AS10G16S
M(8$/D``/0IB`(P+UQ50\P""SG),%V@C+-&[&-Q*(0.ZH$D?$G`$F92@#VAX0
M#N`!X&]\5/_$`,ZP@$U]X`(,^<,<"H`'?@!``T%='N@^EP]!J(02J+@`!W:#
M2VVQKPPMP"1827&&,F@```U@0U#'JA,!%.!Q=I7`$BSP`*`P[Q1YO%8?T>@^
M/`35>E@5*BIN*=5<UA26086#(AJP@#+,H3!78,"TI%H&/`2F0UWJ$A&W<0-S
M^N*$.GC"_P*H3D6P,X$4;.`RYZD('5#0@B1$9PJOF4UMBC"WND##"7>KB'(:
M5!!CX(,(8GB#@?H""E`X+D<-2(,O*>"'B@CB#3(&0@9>4XF*:.)&,QK%`C:W
MBB/-!AOX^@<]N->4+0VC(/Y6@#G,`0&JHP_<)O"@-I9"`E?HJ2#_[E#'7!!U
M=0BX+P.2^H<6T*42H5G`'/2``*EBYJZ)S,4B^<M&."PA-`((P!7T,`<-E-62
M-ITOUK`X@`+H11&?)*,I00>`#T2``R`XP0D4L<I3J`"FBHAE]0B;"\9^\<5$
MKF5=^%(`!OAAPHFP7E0[M*(JHZA%7IEM,Y\YAM52D[@530)%%?%",<<3N(+0
M:"^D.<,DM+:`O45%"!N8T%[4,YWXU.<YD?C//[P@"<ZEX0VD^X<N"["'#,V8
M:J$0!8G&V:(8#2=`4=%1&GQ4@!)++S9"(*Z<_H$$"VA!?%_J.(B`0+)_L`1A
MX=:`,N!G`LK+1!9:*D<)%(`$M3SP'03#_X%.-NXEDB5!W2Z#MI]BC@3NRC`J
M%MGJ5RLK`MK#CIT>TEAMA49;CF/`WS29B0N4`<EDU`D)"@`)"6B`!!+P5!:7
MP&/`=@T!@Q5R3)4L&JT>69=!YF5<;,V!':>:!._#PX/F=TSQ)',KI5W#$/`S
MA(6W`0U51.T!%MAP_#S\9P(\P,/QPP=`/_P/#6^#`O493PA>'.(D:")`*TZ"
M(:#A9Q=4>!5C3H*/8Y,&-7\YQ-LPT7SFKPTN_P/0&SX$$^)/!T,G@7%;KO,V
ME)FY`VUY%8G^<@=&=^A"'X(0<KA#%@Q!Y&XN0<C%(,022!WH(`^Y#KP+=)[/
MX`85%V_:O_X$??^*?0A31*^FK0$`ZW$@6U"5:QD>\)ASE4$%#!"`;2[P"DQY
MP"Y!#52$Y-*^.16@`'`0S%G+0)<&"(`!F/H+.P30UC($@`*20LQD1.>!`NC#
M(2HY[&^""J<'1#Z-<VV`5F>2ZCN=E0)Z.ORU.<`^<2TUJ.LR+':(HH)TJ'AO
MBGB;MF")G.FG(ENCV/RU)6";NW8-,<KWQV&UTN+#7R`"9WR$3AIP@BDC:`7P
MC[_\Y[\"#)SE@C1X`8=>\(*/T4"%S@1-"\1_/3(&-*`T%P1-^N=G;K8&`Z4#
M+R`&VV1F*'0`!T`#%]A_&C4$_,<"):`#&(@&Y91_UH1G);`&"$1=)6#_@#;`
M!SK``G.&3C(@!F+P`@@T!OSW`CI03_J4+SHH@OO$`B_`!P9X`",74(#V!T+X
M@&,`@DI34#6(=$_P`F-@:'S`?U.8:!"X,2(P1#;`?SCX!Q#X`D_0<PYHA#,`
M!1VH44(PAOGB41"X0'R0:7MG#=Z"-4(``IX3`'/#-H=S"%SS:=XB""`@4@QP
M1B`0B`VBAW]X&9[#-8F8A]%7B(13/G]PB(J0B()``FR#-0%0B8(3?8+C&YBH
M"`S@)X5(.:]'B'O(B+G`B/@!B@&@/8+#-0$```WB&ZFXB8/X!W.#"K[QB9'D
M.8.C"))X&90C4H_HA\7X!Y5HBYD(`K[A.M(X_R%69F58UA6E)4WPE%`6!4`2
MQTXV%%#IA$X#Y$$I.`/XLUS8%(?+5')3R$`W,`-C,$$WT`;.M`;1=&CKR%"Z
MM0;^!%#.A($+-%P'8%L(-$)&.(]BB#_\8T(H!(*)9EP'\';L]'3B-%!C\$$:
M]#_=&%U/T'%HX$$#!%)N=H$_M$P@`U$ET''KZ&<JN78-)`/[E$0'Q&7_@P:V
MM4$'$$7]2$5U&)1"^2(*4)1&>91(J0`[<'__9&8C-(7@94`"*$`W8#'H*(/)
MY8\>)`(RL%Q3M$WE6($W=P/1-7$S``(&Y#\'Q`+E1$$(I))K`$/4]00GI$/W
M]$YG!I4`A$T7-`-W)O\#!OA#^-,T2D1=$TB.#P@%\-213CEH$W<#((!-1'A"
MX@28Z%@"ZC@&#S5$SL257EE:.M!S+`1I4KF!'F1.%3F'ZBA-(364KOF:'L(,
MLID,SN`5^,.-#B0"97A1?]!Q_D.5%O-G\*22(-6;ZMB5`:6&"O2.*%2&^@1=
M.M!$D.E!3?-/?)`!Y32`^;1/V[1<Z#AQ#X0_!_E;/Y!$%81-^..7PP6".]0#
M++0&-71"-/!T':=".@`%",28\%1#8T"7-^`"]L1U/G1/U\4'F)D_+,"2G=EG
M/B0"]4AR7`F!T.5!T<D_:(">8P!%,E`";7E>L/FA($H@"3"B)%JB)IH`)G#_
M%C)``UVI0B)``V+090WT`O>40RO*3-ND0BMJA+NE!"+`!S0`3PHT!AB@7`,E
M`WSP!"]D`N+9@B(PDA`4DC)@`BW)!WP@`T?Z`C9P@4(J`SJ0`0*UHAD03@CD
M9C'J1-MDI3(P!";PH@>)I3T`I#^@6E@J`B^`@EUJ31.7@E;*!RFJ0?G"HFBP
M`R_Z!"QZJ#RJ`\(U0"Q``T^J`U;*HGZ&I!8XI0%%A+9UHX$J`T)`HT2H6B^`
M!GV*I7H7HJ9ZJE@R,/V2,!N#!E&0+TK(,5"S,1&CA/XR,QQ#,W^0-&*@-!OS
M+S'#JOKRJBL8,3LS!FW0JFA`,VW0JQNC4`<0`RZP_ZR^RC%#D`%C\#$9X')1
MHYEHT`-*BJO/2@(4(P9H`#5B``)/(`;3VB\Q`#(LL*ZVVB-H$#7/ZC(T`ZY/
M0`(],#"S2JLE\#$^TZLE4*]/T`;Q2H/5^@0L0*RQR@(LT)_*&C/-NC$L@`8@
M4['/>C2HVK$>JQ9`$+(B.[(D"P0K\+$HF[(JN[**<*(N2Z(IRK(R.R:_-`$,
M`@RK]PP,(#^[P`$-(`20<(N[P'V*`!J^T`(MD!2^,`5G!&.?,PP`(%*_@&ZY
M,'F\(%9<`;2*T`G6,`77=K6VL0B?LAXO^[(Q.[-HFR4.D`44@`!R\@L",'#%
M0'J^<`EZDFK5-UEZ(TN]@/\`HT%O*)$MBO!6Q:`!3^L+OY0+#I"WJ(`07.$!
MF*(ME3<-'-"TO."XE\.XZ5%P!I>VGGLE#N`X!1`"%#`!$>$`"X!C5,$)8A4`
M62!P\+,`[$8L6<`&@1("28LM&G`%-_%+9Q`!5]!D%(`K"#`%"'`&)'`%>.!+
M9Z`">WL">/!W#J`96G4!?A"Z"V`YI*<"3\L&H_$!9^`!%H``9?`U9S``+2!4
MI*&\$H`/>-`X"*`W2Z4X$N``!.&+*I`H'H`'<+*XZ4MN$G`"*A`1U5(`)]`<
M*F`)Z0N]`@`_9X`<HO"[#E``&[!9<.`*"^``('`&&D`1$<`&HPL"J,-YYO)&
M%H#_>6SSNG$!O84!:UTD`!.P`2KP4]I257HS!S/LL^SFL^A1LCXLLB?[N4(L
M)0Z`!UG@!Q[@`'<@#W`@``BP`1_`!GIP>K43#]Y+"!00B`V@`BVP/',`5S^%
M`'X#!Q&@`=9[`1J0Q(N!-ZS@;1(@-GX;8)J@`A;@!P+@!Q*P`,/2`GZ@%WCS
MQ6>@.6\["#"L17,@`28!O@.``!+@!Z&``*+P`1S0Q'2D!P.G!QRP!',P`'[P
M`/K@+!?\Q36QN+.QQ0.@!W9U!1%PR'BL`8Z!``#0QUEP`DM0!@+04KC2R';%
M+,OCM[#\`$]!2&FD!^;6``7@`12`-NYCQ0]P`JH<`@-@_\9G\,8!P`8#4!-+
MH$=+L%1O/"XW;!`(,+X@8,E#7,[F#`Q%[``,X@")L`!Q(7!.-@I2,0$9_,03
M-@&!"``(H`=P\L4-\%,H10'\RWE^4"H4X``V>P9_\,`4H#9^JP=UL;<G`<EZ
M?,B*8,=W,0@#,`>BHC?>:Q`;\,5?[``:``=^P,F)AP`D(!4?[``J;4@-!M%W
M;+U84Q&PI@<DO1FM5@`JP`;&;%93\0=V[+<`8,E^X$H34`8._3DO]0<5MK@V
MZ]2DAP!<+!67=%=0X0=!I="S--%P@`=LL+CX\0`:X-(#8,W`NP``X`!G``=S
M8'N1<,,-4-0,H`</@%_GG-=Z'?]D?830J/(!`?#%'L`&/<'29J0;J30'V6(=
MBWQ5$J`G`D#,5U`&$4#0&W`&!VVS*/7`=[$@&_#$'["W@6'''J`'RBS4?TO(
MZW4)@0O2(@T\V#$%C;P!3DP*.A487KPK0L#('`#)%5:T$P``<]`"P+RX>:1X
M&QT`#N``CFO'F'P!C'S4$3`!#I!Y%(`U3?W4#>`8#!#.'J`2.L4<:1039_``
ME\42FA`.FPQ5O)&^MM?%U3P`$H``IC0!LOT``G`'='/#'[#(D:$'V[;7`E[.
MH1MDHV`!>H`'K:,!E/(`4G'+F,<`<P`'AOL2$Z[?*K``V1O9>&#7E1W+EYW9
M=]T`64#_8#AL"&6P`&&M"6S`!F>@A_"&"GHP>*>`-Q&P`'>`'!_]`"$-`'?P
M*L>+!R!>VU+QQD&5-EPM#O85`8N,"@U@UR`\W(O+$_R[R!T^$Z=@QQ-`8@X`
MXM-M`5-E",$Q"MK-`5.%RAJ@`@QNWH@1`0G^RW>@`5KE/N$P`1J@`:E$WP4@
M:@7`!D)@S4*@!\`T!X02`!K`P3<<Y]9SQX,UX(Z.MBW0("WP.2W0P$+`+ALP
MZ7Z2>/A!VX=;Z=XB.RT``DB+Z2T@!`!``I,^Z4#K-I!0Z:H#`A*0Z8HPZA(@
M!)>N![O"/'XA&`S`-7.!"E7A-B3PZUEQ&0)``JA.`B"`Z7Y2_^E<<^R;*`'L
MTNRH0`*R`P*RTV#ZT!==4P:82.M1>XFIONRA".NB>(G<+A<M4!7:+AC)\SF9
M+@&[XNVUKCKH%AJ<CNSZ4!7K?HG)CNRT#DH;T+ZRK@<U_>@*O_#J$<M)WB$#
M,+E"T@!^$#P,?_$8_Q8D``"!F/&'P``)[_$B/_(D7_(FS_`F4`&HH``C@`)#
M8`/\X3#2<`0C4/,_T`M,(@QP@``\?WD\:PV_/0P78%_^I@@G0-\`$,T=7`D(
MX`$@4``(,`$A?_)47_5JH01,H/(DX`(DP`,=@`(*D`!`H``PD(FS'HW#ONNY
M,`(FT`,]@!\V$`."$`,9L/4C8#(QT/\C;>`"&>`"+E`"&<,V3QP`DSXWN-CN
M!+\+F,B)&V"Y@N`'OHCKA\.'(.^+EGL"16&Y?"P!>)`X$S`!*F#FG!S-?"RW
M5G_ZJ-\-*Z``*I\!%=`#(_`',``#!F`".\`#BJ#BJ#S>;+``4$\1:Y\`\/<'
M"5`!1Z`$K,\#(\H$*:`$/,`#2M`!_$$`/(`"(V!_BO#;F.T`):8!>(#'#:`!
M>I"WYCT'%/#99Q#.N0#YWKO1Z%^\"'X'+N$^)?TID4,"K&"[@_T!308(?AYE
M?WH/?XB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GD1T5?R0N)"-_
M"4`&'1U'B"3_`!(:$8@1'P!^`'@4C2,5*"@D&38&!`85*SU_L`88/[2K2A4D
MT8H(B&<4#E<#?D(+#0@6`@6*+1H2+7H;>B03AXI^?VP"`W/U)$P@%V*#GQ:(
MICR`XVX1!7IL'CQ@$Z&,00%^"O@IAJJCQX\@0XH<2;*DR9,H4RI2I6A$&R`P
M#*S8AD@(G@*\?%$(MD&<,26X$AAPEL'`"`/4_B1SU@&I$A1_O"4"]T><@PD#
MP)UIX.=,F26*`-`CX6?#G#_X$`$8\&=?OW]F`0QT,*=,&81_6H"8N$B`'@%_
M%E"@L&#*&09^&`SP,(>#RL>0(TN>3+FRY<LI698@X`)%`AX[%%0P_Y`"$0,]
M'.9$X-`@PLZRXC@\:,"1&A`"!#KP,(&"`(P$"GA0PY`@08H43?\\C;KB6[AQ
M6+4VR#)AR13:-554+V`6;;X!O#3\*;`D!,`Y<AU0T/#@C!!$;$(4<(#]SP8$
M;"9<F'#F3/03Z"%``0(,3,$69@@FJ.""##;HX(.1_`#$'S$`X<(V,"R33`:X
M9+%`"!1X(%$#+9P1P`0->*`0(8@8D`P*':3@F0(8H.`-:38D<PT!?Q#W!Q`[
M*-(0BE-XT`Y:%DBPP`("/.!`(@(L:4$`6?SAP06(!*#"'8=P<,<$65#9@HHM
MJ!!1(@,L4(8$#[`H07]G/-!.`0*`<`4;#?^0``>7:#4`X9^`!BKHH(06"M(%
M'D1F0:*',FKHHY!&*NFDE#[*``F1,;!!2)=6ZNFGH(8JZJBDEFKJJ:BFJNJJ
MK+;JZJNPQBKKK+36:NNMN.:JZZZ\]NKKK\`&*^RPQ!9K[+'()JOLLLPVZ^RS
MT(8J0!D@(/)`%I@J(@0#CPPF"0<L,B(!)YU&:^ZYZ,Z*V(%X7+'(!FP<V(@#
M3T82P3Z,#+1)=^GVZ^^_*+5@U\`$%VQPP?E4PH8[+?@Q0``>?#`N!WXL`4(+
M4U"P:2(.9.$!!0$`\,"F%EB0R+U_-""`BALPH`$>$I#`P0>`,7#!`!Q(8,$%
MP"#2P`<F4_Q`M0#_%VWTT:($,]C23#?M]-(+3'#)%0B`0($?`2SA!P(:,%"&
M'V4Y@``"$[R'B`-ZS$$V1A<(4<`')[NEP1Q^7`<V!1P@,`=`#:2=Q7IJL_%'
MWGKH(3#8&R.M^.*,1Q+,'Q&<P<;DE%=N^>0+9`'`59=<X/`9!4C@AP4@:%!&
M,`,TS`#J'"]`P@-^2##'!!8@`)@O;IWQQPF$G.&`$`C`'2=7'&RPGM5EZ7$"
M"&6\UOCST$,?#&)@5V_]]=A'P+DE!GT0/.QG:X"Z!7[L[4?"]/Z!T0`AL#$%
M5;CS\^0'O3O0L-X(G-#WN!3H3O']:KO"XZ)'P`("+!@8P9X"%1B"[5D"_P]Z
M&)WG$%(`/*!.="6[`%[^X`!"F$,`HLN<(E"6GS]0H'=P"$#%!'`!`#0`/28D
M!%<,,@$6`B`81#.@#G?H+`0N\(?6HY?4+D$Q!+Q'#PZ`W6M.<)\BK8-C?FA`
M&1`0@#_<01`C=(O43E@5-NSB#`-`S0L!$,.4E64!;+B`!CR@M"KR\(UP+)8/
M@0A$(6(B`'%"A`46H($I_$$((>A:`^YP!S\E8@J1ZP<B`$3&1+3G#R%(5&NL
MM$8&%&`.(1""!;*`D$E:P$0`4($&X``"MW4MCJA,9:_F2,<%VA$E*@B!*F=)
M2Z2QLI78>V5)5#BZ6OKRE^BZ)2Z#Z,"22(!;P/],IC*7)<QA@DV7RXRF-%79
M3&="<YK8S&8!JSG,:W+BF)_8H+8V<,-'M,!D[[`$"1(7"7E%8@-FTZ8\YVD)
M;N+2FYMX@#LUP8!>,$*?#3!D(P3@3XY98@`)BT2]),%$>CKTH8^P9ROQ64]'
MRNL!(?`3^Z;02"N%@"T>"$$$LN6!!00`HX8,P%4:$`(XL.4"2812!`!`@2PT
M0(WL",$'2'"!""Q&I+FXPA("$()P72`$)Q`";1P``!)$8`+A`H!.V_:!$-R.
M'P]HP00F($Z(>E6;P0B&,Z^WA&)BXE[HU"<B)+`$$CA@`%D`P0D.-(`I""%,
M)EW"N/X`@`BPU:T;`^C_!X0`AQ8XP*F-).@`DJH"#K8@KJQ9S086``*]%L0"
M%$!H(G9*`0O0CJT7>$``%I"(@O24`QP`06,1,8$-3."&0_RJ;+'YN"F.%6P:
M$(!9+W&UVZGU#P_`D@=.`)8&'"@")N/HDRAPN[X&UTJ^'4!`T<(!-CA@*XA0
M["&>]-8Y.$`%'Y@I!TT8)7J]-6$66((&!M!:UU)@7.XZFWTB$`%N7<%LK94E
M)&?+7VFB;@``#K"`!TS@`10@MII(W&\OX)@/>,!=O[W2[@Q+7K5$@,%_D)BU
MI.LGK/1"'MGUZ78Y*``XY$4"XEUNB?\``G_D@WD,\`![-^!:M2[T27V=PK@6
M_]K:P[JUOT!.)@/&1N0B&_G(1@8+*!XPGRN`(!WN@<,$UHN(#>"!`^Y0,2):
ML``N-T!W/KO"=*6V%3QL3+OC+8`%DJ@"@I)1Q1&8`HJ.]$<\7.`.,W9M"PK@
M`?$@P@,,\6L!.&!B7XAH"4MP5)`7K<H-!/31D(ZTI"-]54^T`,`F<V$++HU9
M=/*U`9L:%P/<^(<I:3H1($@=0LC8@@;L]0\AVP!"QG7#`%P`,`"HEJ@#((2;
ML6(`9I/`!1BP.B$(@8S"[B@[ZJJ^!I!Z`Q8@`8"SQ>AJQS$"&H"3MK?-[6U#
MD-JEV(`*LG"&'#[J`Q[JJ+77[<O2Y5H``MC4!D"H%O\!D%$($A``MX0`[TTM
M`$NH@'97#:5)=;/[X*J<0&/%^@":;NV&&BD```2@`3^H8.)@\Q,'3(3PCGM\
M4D+0`Y92;6`V9$&ZDS/0%-AP!QE'@.4`1D@`$."8RX1L$1(P-RCBN0D+M`#>
M,0M`SDD@@7D+?>`?3WJT!L`&3!G6`8!9<WS'48P`:.\0*H7ZV:IT&0$@^`]9
M0&8H&E#H36AI0&S00YCT@#<$-(SIM5&ZW*'U`+B!P@."ZX120:`+GCJ[WQ?`
M$@@#D"<6LX8$/[]IRDB0ZK7\83%D=+804%NM`;`)!`RP``<"(``.:&H`%AC:
M'R1@I-%K'@X+8`#I/2T$G"'_),91;Y($ILM6"EQA`Q0[T<*>Y#`VQ'WNP%_6
M!W[/B0N<Q1-@5$&;"X"G!13@`0L`8P'2P:(E9('/68D``H8A`+(/H`Q[G(([
MV"`7KY#2#W"(#^Q4\(\0W$$`"(##&99PFA/H02`:X$]C!"2^1=ZA#$Q"-@CP
M?1J0!?ES?ZQ!`<20!7B`>'Q$1KU'?,$W@<42`2<`;QB8@1JX@1SX`,?7"1&#
M``M`7R&P!'.0?Q-P`A-P!P@0`?FP``]04P96%0+P`7+&`=^7%1,P+N0W!Z-F
M.^!0$0^@!Y!4!FIT`0@`;7CP`4]R`A0P`7Y4$1CA4HFP`!Y`3A^@.R$`53-%
MA&6P_U@2\!!ILRDMP`:G%($4F(;'`BX'TX9N2##ZU0FR<P>7!'K>I0)S<%-U
ML3>-Q`;685R]`T)ZH`&75@9"X"14U(,_"'^04P8/<`>0)!@?D!5*6%6[\X2'
M4!$\136&Q`8>T`(\XPY;508S=19?.`="\(0!('*[HP'QT19PIX:R*$TD$'\G
M4!:%,`4?X(,-4QY!J%M+D(+?1X.%(#C?AV5A%`#D!P=740`@$(2.*#@<L$9Z
M4#M@LH.&,`=>EXF>B``7H`<-@")7L`!7L%Z"@`!25(I_X(CB\809-@<M("`/
MD(1H.(OVF$SZ)``<D3,24'-&PB:#`P`M@&CDY!A9-3A8`O\`')"*^F$E-!8!
M2X`0?H0S*X,('#!7\/<`#16.?G)KHU=#X>@!AV@!QK,$@+$?CH&#QH.0B;(S
M\\4!'A``>^%F'N!I]WB3.)E=\).3/-F3*(%[/AF40CF41%F41GF42)F42KF4
M3-F43ID@ND4OKY8R`5!SD0`8"04)E:8)(*`SKA<)61E1CH9THA"6C6"6A["5
M3[F6@L*1)#)"KC4)LK10D1"'/>>"F<5.\T()P"!>J$"7CP"8B,`6=LF6ALD@
MA&<V#9`P%\",&Q`!KB4$3'@"PN8V5B-J[`$'5W`Z+0`'<.!I%(!4%K!>%L",
MK38!+D54-H4+3A("("!+8S(!5AC_(BT0`475,IY9)PT$9J/GF?EV!7^3"&=P
M!;;)?O<04SY#+YR7!0XP:BUU`5,@D1>0!93)C$7G`$6U5A1@F1<@$`Z0*.1X
M!0S``=@)`E.`4V1W!:1VF.Q9&;=X(`V0;56B`M+F`9!).X3@`$<E`;8S`6[T
M)"IP3A]3)[^#"+(T-$]"2OI(`7F2!:%G)6O56,$E.'(Q`'CY6B8R&S,5`&+&
M`21`6HAP!9M6``,`%JL%.7WU,%<@`'Y$2B':>E)%3A'0`!Y:5F]V+?>P:1/P
M`1=@95ER!?SI=0T`%A;495,P!2'`4PS`76"7,@+5GE`:&:G12+0!`/;%8A-P
MGS%8:@^`_P</$`$>H&3CA6/0@9IX01A+(`1/@@=;Y1IO%@!E4```-Z2C1P$4
MZF$Q^%I/LIC4,0$Z-2ZQ%5_K-6*^T%=DA`_:40:W<P$+X``;<&#5P5%G<Z.]
M4`9;Q1_<$EM+4'<>(`[40:)2,P`.P`'DJ%+CE7]78)91NJHJL9@&Q0!+<)\-
M<`*#PP'\\60"Q:0TU5KJ8S8"0`(FF:`LIH^`T9P,4":#*4NAQP:<AZ=/N#DI
M@U'5TB1L478^-JCC5:CBA2)^(@!N!!BR86(DL#(FXP$.(`%W]:4<A"D"D`6`
M479?A@[X@"4D*4NS"A@>0)[C96+DQ*K^&AFNB@CAY:[W^:@?L/\`T$9:;+!!
MZD&FFT1?'#,%%J&?%'`";T4!*I!H`$"*M`IK5_`!!=!/V/E:@O&L>ZI/U$D!
M`A,!()HR(7`%.$BH5@('VVJP7`<Y$0`'33(!8A9*O]``L00'ZLI2^!!*_)$(
M#*"P`L!E(`LO)]!FQ*4"$@"@BQ4!4NN2_YJU)B$$Y@8`FP(")%!%N9`M5;2>
M%R.VU=(RVB(!500"FW*L)F0!R$1.U)8+1,,`0E!%&R"3`1"V?Y2VR!0`H_8.
M",&UL)8()#!JF-*V`,!S7KME>"&XI@$",DDTFU9E>ZL(98L+305K+2"VCUNV
M5:0I?ZNUIDLJ'C"5I[NZK-NZKONZL!O_N[([N[1;N[9[N[B;N[J[NVDX+6YD
MKN"6%V+'"-XB"0,0O&@A@8M@A+S;O(*R`3CS`:BG-ELS!VP`7OHTO);0,``7
M->\R@($IF(S@.8U@79*P$<Z;O@PB`5.@`A$T5@CP-M%F"0N3%PX#,1I&,1:#
M,1JC"!WS,2$S,J7F:5<01:/G8.]AO@"@$%5T:Q)1+7[@&B)I'W7'%GM1((4G
M`0BLOAS\$1;POK>%/890";<(`O=R5UNS?5]3%@4P-BH03PY0/@AP.E$D!#Z!
M"`C@!VP``H43//)S'Q$D2V<P-NC7%EQCP!J1P_&V-1%T`3RL!S[<P5)L"AH!
M1&FS-U!LQ>L)_PF>,P"@@T&E0\.IDQBL<S:N`SNR0SNVXTC[$`%Z``*#5(;?
M619Y0P)G0$H38$1^(#5O$PPQJ0*.Z@<]NA%N#,>0.,6('`KFH$`GUP+("VVW
MJ$!6&0DJI#4*@2\.(#X.0SY$["CILSY3]@%$R,9_H`(I/#K6=8M$S``^`3L&
M40P.X%-K3!@&P2T"8LI$G,BZ[`E9(,F34#O84W:2`$$2=!#C84$.@T$[P[`>
MY`<@Y`<BQ,:`I(T`IHP.\`'./`!./'\FA#7H&\OK\P=+P!VX*"#FX0_[M,OJ
M3`FUB#VHV![]06J/U1]2`P<B7`GFH`&8P@:-*LB(40`M,`>`/`>O)O\V*[@`
M[X$'?C#)%'.!^5,`!6#-&!$""W`'=HP`(:`'NO/-$2`$<P,'Z&@0FR(@\'<"
M$+W.*%T)]6`]&C")D%,]B0,`=-,5?Q!:<*`!.8P`=Z"7CX!'^;!'??1'@<0`
M@U1(BH!(DG,[C!06];L>3`))4T`"4Z`!_U85Y'8&@(%="O%X..%D>%1%!>`G
M3JV6*5W6B]`"'R`1";@`;5P]L4I?>0PVNI-V*J`0LL%5(Z%);,H)-VS6?ET*
M8D7$8(,`)-#+0`2)*WP]!N<1O&23F-#7?QW9H#!SV$,!L--*0)/#UJ,'/`<2
MX,0),BG9H@T*VE<]>B"2=(,`#^`!?N"(4S3_&-6C"UF@-GHSR:-]VZ3"=X\K
MSH.]VJW=)@)R-6#3$+A=W*ZRR&##<GZ@!VGG!QI0<=63SI\@`%ZAEQS0`E;9
M57);&P%@0930>8I@`6IF'\$)K$Z6"$)0'M427H=@8``'7!MC>4[EB:5F7E!G
M7G'W`)-7!MSB-8?PFFV580X@N-*=$"TP+A'@1M?="`BAJHC`$3KS#JF%=`^@
MNL9-BVP]V/81P9"#'F(%-GJ@O9[@-?Z@`>;V6K$%F'(2+K+1V8[``'=04.NX
ML?=@`1'0>;-1&PQ*&PP`!PTP)9J3!1O#&N&@)0VWJ9<VJM+%?I:7"/W(`"$@
M`29VK@+$HP^0@!9`_ZLRO@@7$`!GP08;,R5[*;Z)P"*:E0@!@%D2^%87KDV7
M73V"K=F"73W"O`GRDEEZ5%ETR``H;AH(4)-L@`<ML.*F8;T1P&?Q60#'-CD=
MQ0&(A+@F!@>`5*?WM5^L14Z:A#=A2T8:9A_N(@$2!Z(D,`=5)%[AR`B0J<%@
MES5%)\Z9%Y-NZRX?<*;0>PA513$KQWP6,`7]=`:G-#@T=P=J4FHODSAF/AON
M^P`%DG8<>@?%<`6$5.!M_DN[8#T#Z#EOA3:HA3T6?@EH%:(=)5=",`&V*A<&
M!0?0EM;38E$.H&.0178WU+'6(N-9``>-)4O]I%\+-1]?R`%9\%198HB)`/\'
M,:9/\KX`9&3J=5$&5BE+Z$"*#)`?W#$`>.!%ZG-E@W,@."AG!7(&,LT/H1>,
M`!`Z'%`;3])E-719?H0(Q[[:5"(7@Z&1<&H!AA@OTSY-AFT]$-D5D4,V$X`]
M)LX)7-%(?I4E)G0&AM#G\A5?(4#H&_9666&&]S(YQ`U<$5`B'@\62R!5?&6;
M9V,87\9X\=6D&Q`/5HW6&%5J94>(*)HR7_<'[D*CI<SU-S7@6I4=CY</!1*,
M/^[Q7PZ]6P6M%FI0RS4`=S`YO+E:H65C,/^$UJL',XH6TG[SLT39(5P]3YH)
MB8,HK+``<`6K#Z#T8PIK^+#N3S\`*W;@=_`>-OG_I2T&;XE2D\KZ`!$I!.*Y
MM)ED)\/V!R86`@`'0B#@65)C%J/;@&U_ZHMPH"9S>_8*4T+=`-Q2)1<@4#2[
M!.KI]_P`^'KZ>`7%I)EE8L&?""I01<'%^!,P&"ZH/CS#09-/^:G$%9=?/62>
M"7K"$-&)!TM`#*(_`2(""%<J`@\"97^(#P,.`R01$V42%W!9'(B)$9="*DM9
M0@^"+1(J<`.7`UE9%A)E5QX"<V5E`)<D<`V(`P57!;1_$;0-L643ER<!+65+
M)W_+90$<(:6C$Q1_%+Y_610<>']G`'@>;!L#$Q,`#G\#F8@+#>H4`P\.6::(
M%'@J9P&*?PX`)C18($#%_X0"(`I,T'#ODL.'$"-*G$BQHL6+&#-JW,BQH\>/
M($.*'$FRI,F3*#=.\<.RI<N7,%D6,+FA0:,_`BXP````1#8&`H1<L/"G10`)
MEUILD+#A3X`+`OZ0&#!`B,,6V?XP:,#@CY`&4=<UE$H5D84&0EI0'1#`(8"V
MB"0TR-:SZ-JP?QH0E=NT)E*A]\Y:/6$5$0"E2`7X%!!T`T\02!U?$B`!*8,-
M0LI>`G&V1=&F$GP&&`!BJ^<-%YBF7,VZM>O7L&/+GDV[MNT3,7/G/F.[MV\A
M4TAHW.#!M_'CR),K7\Z\N?/C$W1+=\G[N?7KV+-KW\Z]N_?OK:-/GUX=O/GS
MZ/_3JU_/OGUW\>-UEQ\)8"XBX0[Q7Y0$%V.`KA$!((!^(#`F@7X3(;@98P)X
MU@(())%@5$H*2K1!4P]5Z-Z&'';HX8<<#4#!B"26:.*)(^)"$BL/%,"8)0XM
M@=$'$XR#%$:+1%20`\49MD`$)Q10V$0R0@3``B/B8=I('"@"X$E%5M2`BI=,
M@2&(6&:IY99<QN:/!!1X$$)-)TC0`AX6;+#$!4Y%\,!#0ASRQP4/]//!3@(`
M\X<$)UQ`P@934.#`5R<\>4$6@5X2$")W5/8'41M\P*8`''B`Y@84L&F8.G\\
M`%8``42`2PL1X"54F:/)$P!1#!#U1P@A,'46!1)$X)G_!1,\*80'%*1E09F7
M!##%!Q!JA68+2YA"%&?KG-!"`Q2@@T@+!505IJ_`,K"$JUUVZ^VWX&+)P`(G
M$,7!MN6J`$`!$C""[@!3X+5GE'^<0`$]#^!QP1P;E&'!&8M$X\`#)PR@P24;
MX!%"?^D`8($&8/[SSP7)`GE!+Y78:]@9#7!0``/`5#N!P0,`G,@5`]P!@!X7
ML"$!&P%\`.,)2U!0T`/G-%"H`Q9D<8G,''PP@`H#R%GO/-84U8L*%EPA0#$;
M3"!!"!8XT(`]<""RP2!`"ZW"!8<P'<*3X99M]MEH6S=:`?*\.<`);*3SAP83
M./!!/F\Z5*M#('"@0@$/9#+'_YX1:`#/H^I<<`4"E\!AZ2N&:>``.@!8HP[=
M#A2@ISHA:%5=.`]HP&8$NG@%[Z/MK'.%'N'\,\`5BF-XK\U9-\"F`QP0PP:`
MG;\ZC\2(@$"!"JD[L`$S8$(]P0-$?85+,8A,L$'O(?S.,QN0P)CV]MQW[WU*
M#WC&`!OS#!!"`^JJ4^T`3$U"I5-9X^3!%4M<'?@?<ZS+P2V=5SW%R'JX1!9(
M0`$$>.8/BS+,%/Z0M?6Q@Q8.(,$5/+>I/17`$:7;0-!0AX@IE$(#`.`-(P1P
M`F;@XP$V4X=-_L&!*0R@`7"AGO4NX8H&%"\`R(N6$*+&O#U-Z0_0`^+T$%&]
M-_','O\7R,KWELC$)CK1(18`W,`L`(<I3($#<2.:U4:VA*#IY4;-Z"(;!)"%
M!RP!<((3`!PN<(<&3&`*#G#`"1[@`<8A(@L?<,`=8)1`IQ2``P?#G4#T5"T>
M72%O<ON%#0%0!GA8H(UH0L0)(N`!UHG0%"9#A`>J*``5FL(!#/A:&0HS(@^X
MT(@"',`2HE2`GEW``1((%(W2<8'S/>\2]0N3*6?82#B`\8G`#*8PPP6*7@5@
M"0)8@LRV\@`^]8H!$XC`JC3UATB-K%E3$H`I>O6!-0D``&Z:RPD\X('"2&`)
M'@#`/5#C$()9XIR]&D!3.,"!6GD`/S5!!`,N($\`C),$N.+_`'X`@$X.M.!-
M]KG"E0@Z@&?M*1A_X,`UM1:!)3@F*E0RA^TN0<^GO0F:#V`3SBJ#%&H28@,1
MB,!%\_*HY0WSI3"-J?=4\ZWYR?2F.,VI3G=Z$<CQ]*=`#:I0ATK4HAKUJ$BU
M"`GZXY`-:.@B("C6:@+PU*1:]:I898T$N(4(>CWD#AYY0!DT0(PK<-4BO7M(
M`53PJ`D^``%^6``8&:`!/X#0`G;$0TD1P"8&(."OY+`%7!$RA;\B8(&)`$DX
MJ`F1-TUP(]OR:E8G2]FATK.:OBC&?T@@A```P"K\.N!_O.+9PM0%(IQB!`"$
M(P1:++4KFPV64[)R!C](8!%"0`!:_\[`UNA-T`$+&(`?$#'&/RRN&`#P@P`V
ML``.[$L"R;5A%BY4+!!D`00D>$NPA!.`';H60E25R@4LX5GNKO8/U@6!`Y2B
MSP,BHK40@DQ;1A;$RMKWOCK-PA4`H()N`K%H)Y@`+#Y`CCE,``\=4P']#+:$
M.8"@#!%0P2\1D=H"R#&$'RC`!A"0!4,$^!)G8,`9:`1B/:#,`0(XV#KL&``V
M0`H$PGW``^80E3EP8'#)'0H;*/:!:?T"#S(&D`#(=X4(E`%`/:1:%E**4B&B
MMQ,,*,,4)G@'.'1ER`P^PP9P5KW&?4`%`2@#!<Y``OKB]\QHANF4,@4`G]6-
M`P"`@P4.T?\Q!]<*EB0@G\\`ME\*I.X2J6WH%2@P!0`([6!P@#,<BG6&(2\7
MQ!%`@`<8\;GA(I#&I_##&<Z``,J`U<;)9<D22!`":\Q!TA'0PZ:YY8``3!!7
M^EP"`*:PA*[`H<G2RT4#/$"4*P3`9X#61J?(R)/J@`R!&[B,ALV<YF8[>XE3
M>D1*@:C?E%9M'3-&8`2NX!DM?J,!FHL`8RE,87E&$PXI'?(?6I%21D>T#'`H
MS!D$A0!8ZL$JV48O'DQ1/DN/L8!S\,,L;+N`0Y#X4'[FE$.,)R,)`/M5KY@`
MA,:4B5RO`UI(64(+%"XQ=10BW$F+V`X-HF5F/_OD*"_;E"X[P0G_H!,$3D,T
M++0MD!;<(4=GD,`"A'"O"RV\W%'CP`3+Q(9?>`#F^#F#!8JC`;C,.[F78QL"
M3'B-.WA@#J3SMP``!X"W2L`/AT&`!0"`@"(CP,]L2&G>&/@'MCY`>W`C@0<:
MH0+U_D'#NJ93VTG`\:QYO)/)+I+=#UF<99L#&2E/O.*UQ%]7A^!-Z;P"CU+L
M@%'[[*!36Z,`%CB!%DRZ\YYR"&+C%0`/!*!NQ^B<JWETB0D$``ZLCQXN"/VH
M,VB`V\%R@.0"((#JA.!B?0'8&3R3J'QA;\N;/D,0#TF/*T@5?=4,@0/8-`$X
M+`P1`K``S!__!\0BXI`+3&(G?7D)"H3@_P,;@$.`&?`*7GM_\?"/OY8,`=.@
MR__^^"\J`Y(VS*==*?\`N!IR,24$6(`&>(`'*"\!N(`,V("L$0'Q$8$<YX`4
M6($6N!$0Z"D(N($;>`<3>($@&((B"(%*U!%G\($BF((JN(`D*!(GN((GP0`R
M%CX.H1AG)1%M<8-0-!%,A8,L=1*'$3PZ*`!P`0!D\Q!M\3XDH8./\BT;P"D"
M\7,;X6>7`&$384>7T`#S`40H:!+L@!)JH1'S(`$"\$,9P0840`)8MQ%=6!&=
MY!$M&!(O"(,ET0"/1X.7H%+U-1&=TX:=,A$+4!',52\HL0I:LX>(H">=HH0.
M$8B#<Q)=Z(<?\O^$LE<@XE--#2(5#7(E&V`![N5GJ@%A),`8TV(!;<$X[*45
M%Y`6HL"%I:4U1JA/2`$JBO$0&\![>](6G7@:`'`!$9!=W*6+M*B+Z!4`CN$+
MGK%##Y47UM`"%F`5&U"+3M$47;$!2L$-'4.$M4`9TRB-$84`#Z`'[M6)3<%[
M4L5[30%*O@``D>$4;=$"\#@@B/`?%^*-%Q&'(#&'=/@15](`:Q<04R`$>K@.
M`@$4?_`!))!$1<$&^T,!2Q!5-/(DN(`SQ=$TA:`'`Q`TV<=2$E`C%Z`'`F`-
M.!,5+60-3],C.#%2(.`!G5=1Y=`4>G$8]E(,(SDG)Y`%OH`S`I8:<V+_%0*`
MD7/@D!?B`4L`1AY@*Q)%%!Y%D!/Y`0#``1$P$QWY`"3``"?``9RR9>-$,+?X
M`7?2`K2V$Q/P`6FQ!+E"0!-@"4VC/<Y!B4#4`%>0892H!Q3`!B`0`1\@9N\%
M.(&(#PB@!PX&81_P5^'S5PO0`@BP,@>DA61W!WX@40Z@`FF%/8T$;M70`!I`
M8`\1E9GS`7<@!`7@`7)5!B-&23`B`3TF/6?P`&16#$AS!CVB#AGY`1%@#X*R
M`:'9.67@`<#6-`S@!PG1).?``4BB</8R?2VR;;505U2R=5<'`@O@`2KV#V,F
M`1IP`B$F=%=P+L1!`6KB`"%01MCG`!1P!TO0_Y<8@8\U"!%8(1'ZN(\<L1)A
MT0!X($=MIT&!$S4"L``!(#+)U9%-(019$``YYRD><`$M\%@2<P?IUP(+,P4V
M!P(<$S&M-EV2<@<@,`>JU&(`,$83H#BEAV0?\&OC\C2KD`53`@++@PI/.0$6
M@'[VD`4M``Z)<`);0T(!T#L@@*$:.B+H)`'Q\P<(D)''D`6AM`%7,!#]"0N[
MA@X:L`'D(&YX$)*<0G8,4``=PYL7H#A3P&N/4!-/PP#G)"*#6'=%:1UN*1"5
MP!3JP%;`D#46D#2\=Z3X$&]L(%818`$D]'@.``)W@@`+X'V,J0<.=PX:H`%2
M-:"O`TL`,`?^^`<,ZO\0;J)SD`H46X,^F:$"$70??>HT"Q0OKHE"#6%1$<``
M6=,"(_-V#]!F8>8H3@$[8T0^,O9";Y)6I,$!]X(+00I$?N!>`A)"`'`'V5<8
M7V,F;,4!BQ!5;<0.Y0(/#("JXTD!"#F=]PAV$:$'`QHL;+"%(":)\#D1$.@J
M=AAZJA=-/+1`\X!@&1-L64,(]!,!(49N60,,$Y"D?U!T9]!:EB,`G0,"4(H_
MM%(O#9`U]V)D`I4(1,$SQ=`[&N"@&:D(!W-Z=1,!;)`H3ID(M^,Z5%=T<T`"
MM<)N18<(`70%2X8'0N<4#X"N,R8$)X`+5*,!CS`%12<$C]4ZMA*2&K`$\'K_
M`7A``9X'.&FADU.`%%<P+A&0:-8A!/$S?8:V`->F#L"@#I6C-9J#=]<@(YH#
M86>DJ0ZI%2#@!VR@<(Q)#I,S`0@P!T]2#)VD`B3R0^0@J0,@-W%3`$%R.`.@
M#U)5(_)@"<X5JC9S"18P9<9%1$AC+Q0`8W`P$XFX+=$T#XKP0T&T!/1S+Y]T
M"5_'!@-D%@7P`5HF`5?PMH037)[T6!I@E69I*\83-=%J#2&;GM8*$1;@![WS
M>OGCGM[ZK1(AD6NG#LBBAU"9%]%0!M2B/>J@#NYZ&:1!;E#+CIVD;KPQ:]K0
M+@BD;G/`:\;U2M?03-"D(CV$8@M+`B1P,&<P)A#[_R<3T"?EX`$]=K&=DK%+
MT&7$A3_:)F?E<`F#LYV=:#Y[0H5UU@R6@&(:QHZ?Z6H;\PO12`&EJQ;0]0!R
MU0(?0`]Q6R,)FZ!+<83,40`!L*-@4GIY)#%O&@#08A;64`:R@R9S`#84RPY6
MHW0NA@`,H`=P,;9/>`X&$40?PP$G<`42<'IN:XV%03IR>P$C;+>41"4<(*P$
MU0QQ]@DHA!<M)B.+-J:>\B;>^28/!VX9JDVS"KF7P%;0X@_&J0&QZRIWTV)[
M$PGXX*>3EA>O<R&\@0<5-1.I"SV=-"+WJA'JZ1!7X`=$00&/.1'OB;L=\:B$
M*RIZ>"06L`!/672-DDK&^_]V0A,"A5&\O]!FN*)SO5=-97`!3<<(3I,_-,8(
M"\``\4`/%',/H/`ZT/K`.-Q]WJ`($=!"`L8SD4`TBIP(T]<YP'<)!(%C$?`_
MT(<(@X,*<]8"]F#+B=RH<X*B<Q``P?5[970"O1-"!AR28RDFP$RWN[8_<2HU
MN,,&).`OL=)0SU$T!<`F^^-ZUF`-!M4NU3"/(3!)`$(Q9=!C5]0-RR`$!U9.
M6>,!,&(!MJ+.,H8-*H`A=.LL`"!]%K#00.1JOE!/+6`-G1<"C6L-$L`!,`<7
MN"D<YF<-5Y,L"ODS4=%)"M4"=9?#;Q(!I984"S1JM\4*0_&'FG0%4Z`(2"&G
M.-G_#(@U-2<P!?M7>?CQ`.H7T8\"7>!)"RYT.A0`*HB4*=2'QZ\;$2'@!Q[@
M![UENX(,$@SP)/U@"A(@!):QJE)!%%PE"5&1;.O``?TQTKDH@Z;@,*YB`1QP
MUCU$&:9`")X1%49X4`U!1VH-UEXQ)591(%K1`D+``89("%WQE*:H3Q;P`$T!
MO8IB`:9P%$(@U^YU#X1`"YBG%6)]#W(!*8@M%0W@JJNR)]YU<=V5D:#"`0U0
ME<TD`*VBOP>U%__7'$,R)`]Q3QU3"P]!(^<0W,(]W,1=W,+M*IOJVP]1)PE2
M59I(=?KAW/>A(+G]$;I]$0ARW=>MW`\8U1#QPG8U80\1_\A9?3;^P!H,X#3K
M80XGNR&+\)`3L1,\,=_T7=_V?=_T#1=L*1';K1'JI8`_E<=-Y9@GX-SD7=YE
M<XNM<=KLD1-2A>!+)."MYP<%X`>,Z!`'#N$:ON$[)>&\BA9XH`>WC>&WR^$F
MCA[NY5XE,>)N883"P>(9H>(BD18BD>(3H8P5(>,.P0#231'^^AH2_@!^T`X_
MJ:`0D>$GGN3GD0D*QW\E@8@.86!7@`>J^Q$EC@A@01&D$C$9H5(.P7\H*"Q]
M-!%MZ'H6(2PZXN2K(>`"@``2QU%4C=5*/N?IT0!L8,QIR5(7(#6;43^=(@H-
MT`(T(P3:E"LNE!=^7@S;"Q%R4O\&YI`718L3A[0G]LI##G$!)\!6J*H]SV)6
M6B$0N(E8!J5.<W(!4Y*RPV<.V2!WO\B.P\:036,*N(#IFI[GFD00DX,+EGX)
MM%X4>6[I1Q=0DF!#4D$!17L!!-&1IA`U=IP+]BK$V9<K.+$\0@!-^TT1`LY^
M$/'`<D[GWOX=O;<!COH,L,0QBGMW#_!X7NE+21K+#Y`%HBE6<P,/B[)&(:!$
M&L8`C8(.TQ=!CJX"#/![QB,0$^5P#0##M\`SV&?N)OU*%A`",+(F$=:1L,(!
MJYD%,&VD'81.I8`+C:9TI>!WQGSP('`^`H8(8&.=6$SP]S#R>E#R;B0`28IB
MN\,QAK/_N='T`!_0`&5@"/QU-0$!ETFS-1?3GVMR!A>@98VD`A*E.#HN$1ZN
M$4C^[53_'.I`L.GPPM(TCU@G#=9E#2`PL)0[N.HP0?#2>6D7`BB)"`AP!M4"
M1)-&L?#(P&KD-#H')$72LJ_R\`C48SAA.7LN/W^K;;N`0GT:0NS``24+([VC
MH1Z?#KAY[RSDLA:0=F]TB(N2IS]",XC@VGMO^5,085'!!KU=/UF#6WGRI%)S
M!A&V!.K`Y9ZM,OWL`!2+H,1I[/[2Y=[M$5-?];ZO')2,#1%4*QCJ%.^@%QNP
M9*_R`;SB#\6@#J[Y/]0R)4ID-'`_!5."F_/3(/D`;MDD2;B`_S(3=&Q__P\Z
ML[^#7R^T;U92"S"Q+"KV,;AS\T)_@`>0#P"B2<J>;U8<`P@-$G]_&Q,`$W\1
M%@4-#0*$'`U_5Q9GCA(!#XUL#1Q_2PT.?P,.'E<-=X82#I@A?P`4A`P%'BH`
MHQY3G@`%%%<4&QQG%H3&Q\@1?@#(S<[-9Z//T]35UM?8V=K;W-W>W^#AXN/D
MY>;GZ.%G+:,4N):6((0+'!,?2Z<690(G%`\#?Q*-TE"*02(5`R98$#"(4)EC
M$UCI:Y%%P!D!62Q,$!#BPH=/?R1D&3!G`YP!5P#^$2#+00N$5P1X\&!LPH,+
M982,`D!L7YD!91I^F,)!A<@&"`"HP/]I(0LNBB0#C(QP@5"``@(216C1\2,A
MJ'.D#J":Q2,'-@S.<+@CBI2#"0,>Z+DJH<"%DQ,N]".4U<(=5B'Q6&"#T1(%
M!Q>6#+BPP9HR9NJDI9M,N;+ERY@S:][,N?.W#Q(^#1`FA$((D"OMM?"P08"D
M*P\:6&`VZ5.!"30G6;CR08B%AG\>')OT"^`4FQ(&A/A`0L*$)0&,/9@@2P!O
M(;,`?MI-@02`",8&2&!0NQ#KB`]0D?BZ9$(+(4N`;7C@H4$(FI^F5[\201ZA
M)0),<D$`SD$G'74K\0>"!%><L,$4`0RP1!:>P,(!@Q3TIM@%N,$"C$KPG?"`
M:X2D-\EQ-UG_$$($0C306#6/B1.-9S36:..-..:HXXX\=B-9CT"2TT(C*C`0
MI#+^/*#DDDPVZ:22&OP8Y)145FGEE5AF"4XQ6G8YS0`G0`:D,GZ4:>:9:*:)
MII1>MNGFFW#&*>><='H)P`!XYJGGGGSR"5R=@`8JZ*"$%FKHH8@FJNBBC#;J
MZ*.01BKII)16:NFEF&:JZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJKL,8J
MZZRTUFKKK;CFJNNNO/;JZZ_<0"#LL,06:^RQR":K[++,-NOLL]!&*^VTU%9K
M[;789JOMMMQVZ^VWX(8K[KCDEANM#^BFJ^ZZ[+;K[KOPQBOOO/36_VOOO?CF
MJ^^^_/;K[[\`!RSPP`07;/#!"">L\,(,-^SPPQ!'+/'$%%=L\<489ZSQQN\&
MX?''((<L\L@DEVSRR2BGK/+*++?L\LLPQRSSS#37;//-..>L\\X\]^SSST`'
MW7(?1!=M]-%()ZWTTDPW[?334$<M]=145VWUU5AGK?767'?M]==@ARWVV&27
M;?;9:*>M]MILM^WVVW#'+??<=-=M]]UXYZWWWGSW[???@`<N^."$%V[XX8@G
M3G@>9H!A1!%TN&''%UD48'D!"YQQN0I9V($%'7MT$8<9.2AN>A]PW*'ZZJRW
M[OKKL,<N^QUPG&[[[;CGKCO6:A3QQ1D:(/]P)@)WG/&%&W0@@401S#._A_*2
ME[&`\&?JL8`*=,BQN]\+X&'$]^"'+_[XY)=OOOEV++#]^NRW[_[?.72!!1YZ
M^($`&V5@L8<18*A1P]4UR($<O%`$-V2!?O9;P!>*H+WWR6T!6<!;$=2W-R(0
MX7]ED\,%CZ9!(C2!:#FPH!JN1@0P8,T,%A0AVM30A3T0X6IR,*$#9SBX/'1!
M!?6[0Q;V$(<\I*T&<BA"'::'@#,@P0PT9!L$)4C!O*FA3'$PVP+\,$*C3=$/
M2.P#'<KDAJD9P0M$\X,>L%:`ZM'!;'&H'Q>MMH`Q)O&->U,#'>[@!S9@P0L8
M?!L0Z5!&!-A!AG#_+-L2[S;!O6W1#U^0(A6/=L4B$&T.:XQ:%_R`!*)9CXQ^
MN,,"(.F'*(XM#L+#0QD16;4V!O*4="-"&?RP@"*4;FID2`/1K"#+/I"A"D5+
M`QGZT(0J5.&#NH1:#>*@`N)UX8-M:T(8K%`T*R"S"<SL0Q6B"4UD]L&9TO3E
M+#_HRU_:$I?2K"79!BFU8-JREN:4)C-[Z<VH%5)O9RC3'%YIM"98TVAY;%H^
MIUC%HDW1CWW(@9FZ2#1[(BV?2*#DTO))-(8:K8PO[$,\L8#/BF:-#0KM@Q'L
M9TV']B&?'S0E*D?JMB+X80Z`I%H%"-`'`C!A!&0(`Q.8$`:B&0`%?4C`_TQ7
M8(41,&$%4LM#&55P3[0U`04S34%.F8#3/BC@"-+T:0+Z@%0@$$VF9&C"3'$*
M`Z;*=*8)6,%,PQ"&(S!!`8*,X-108%6QTK0*/D5K2Z'JUJFZLXEW$Z@&ON"'
M*314#W"P@_#L0+0RZ*$(]<.##Y&@!R-8DH)N$!X"B-H'?C*2E0NHP48QVL4:
M9$%X"WBE&31@OTH:0;)=O*09#AM/!'C2#)"\0QWTX,FB091H>_!#[0Q;!S\0
MU@N01,`7/I@%/9QQ#WK(`F(KV8<TUL%H>;!?'NG@A0]&UGZ4!1Y?*>J&,M&!
M#6XDJ7C1]MEC7@VI!$C#"*P`A`3`8`4H@,$UF?]*50*\(0TH2(`"E#HU.=R!
M#?1$&P&.0(85\*`/,*V`%58P`J@J``9D@"D0WC""#R*5#%:HP!N626`8I.$-
M#+8"#Q1@`!@8``@#3NO4NBI?`YB``!,F`'RC"E48OV&7=]4;%B@YR0(0+;KV
MP^@B_SD]A7;7D7T08Q^>B(`KOM"R5M0M`N2P117XH8L)10`D:U>#^A69@&8B
MK)+E8#\]>+D&-8"D!CCIV(?Z(:)6?NX5_4"'/`A/C96,@QC3W,D:^.$,UO5#
MFXD&ACHFC<E.[@,=R[0'+Y3IBN$=KZ3%5F@D7PT&*&`IT5!LRR.DH`DWQ2D3
M>`"#)HR@O>*46@X0\%S_M9VX:!'N@P%6H(`4$XT,4.T##`X<A@L_M0)A($`%
MWDNT%.`4"`:H@+$)8`(FJ%AJ"7@UT6`LS5<3``50W34*4NVT=^*-M&:(+@+^
M!^32Q1.,4W1D;A-YY#".40UU0.*.'0EE?_HAMWLH8T*[2$<U-.&S1#`I8<GL
MXX0R=\R9#&#PS+!1/'P4DH,F6ADUR4D33M$--<A#%NB\9#T@0-YB](,*)(X`
M,-1`I$7;*%Z+)H=X]V'>BJ9DQJ?HV$E&>M(X[YH;5FZU3$][!+)\`P\(8.P$
MH*`*0%B!IT=@@*9;S0YW6!M;80W56?=!Z;<^@J:3C=\W,($,M4X`#Q(P@A0<
M_T&6P,YI!8Y0ZR-4@`G@%!LYHR9ML3+3"B<F0P6>VH<4*``(5LTQW@3J1HR"
M,;H:(!I?'3M%).HY@NU.<GC-4`?AT7N1428"(N=PV"M+WH*]18(=_(`%"YZT
M#P9W=Q_(?$:)3GF+K=]XQ/LP2C.U>HHR%!X&1^_(&D@6@PFE0Z%K9S1'\YSE
ME?>#(^F81=WW(0\:N'G.IX^UW/HP:S[O:4U_:6`4C.#[8?B@`1+`=J&S\0QK
M<SJHX4I5H&*=JCCM)56[:E8#\!+!*3@P"MY0A0,C.`S&=DT*,`+/)C6OIEYH
M)7\C``/?QP2?U@=OT%10XVUV8U+V0SV$%5U1UP>CQ_]XBZ1YD'=OJI<'=*0'
MI'5Y_40T4X1X?E``)N4&0'8F!H0F"(!Z&85PS%4`4]9=S-6!1Z-O)71]E85Y
MPE,T/$@T>)!)16,&?[9%7<!!IU<T2&!".5"")QASUU>$'P5>U->%69,'UB.$
M/4<`_5<!"?`&%0`$*#!K"H`"&G96(P!?:VA_5--=8*0V8D4`R=8';$=@5P=5
MS08#]N5I1_`&M79639<`%:!>9A=3374$F&8`UZ:&!4AW\@4$1Q!6;6AV8?!W
MZY5?0"!?@G<WM6<F<_!\2LB!@C:$(P2"?7"$?C9&W>58[59O*N@'>2!D;O""
M299X1M-;3V@TJ2=YJY=1.BC_!PE%6'V0A+-W6Y=519#T2E;F6(56)LS5!W.`
M`$DHAKPD/%GT1'Y0`V4$1NU&1]<'23ZD!F;FA>QH-3D`7GYU-<R&=TVW`E5P
M8K6T`BR%ABP%:@:`8U$C!\'30&N#A@80="MU5?)%8J_6AG(%:FG0!&K(3"N@
M;-?$7VG0=+J$;``I=VHE-7Y7!29F`)^&:375!V$@7V2PAG'W-!1(-TW@C7DP
MD_'40ZGH@Y;EB@E5.S:'.EA$>\K'BI>5!U:&1;R(41>D`@L@!SW6!T0P!\^5
M4'7@0SA(<G)`9K0U2:OH9A$5956T8UF0`UZ``!J0`S6`45N$`*\$!V7BBT?#
ME@M@_P1Q,$4.QWQ`N7RX6%BD5P,[)GWM^)=-HW':6`0>53=Q``?:2)"`Z31S
M1S<O.3<;]9%]D%MGH(%$@Y,?Z`<11&9EA@!CY&AB1%IG9(M#F`=3H&2\")K"
M`P?VU$=EXE@;)7+$2&8Y.&5:9":DU8QOAC10U@1"!D4OIYE]P%=J%9L4E32E
M>`>E8U):)CQG9(Y$HXYEH@><MYC6^31YX`;9>`9[D$5SDP-&@$,(``>*>9U,
MTYAS\YAR@P0%4%M+5@!9(([*6`0%8$)84``^9`8%P%QNH`%G8`1?D$A-\`5S
M4`!F4`:5=)_<>)]`5``4%0<%$(Q(L``:H`*O1)1SP`9%\/]!-0`\750`B:0&
M!=!F=*`"(]0$;E``>[!Q=U@T?.2=1:.@2U@&&K``>Z!X!:`]<E``*O`_.9";
M2I,#7W`'&E`&632@!>H%",J!!9!'7L`&=^`%=)!(YEFE08H$\:0'"+I!;-,$
M9K`'!)I)=5">5JHTZ"DWZEFF6`,&9]!J24BF8'-:F:6F=*HVP^0&9U`_>E``
M=M!H9E"85],$(51`-)I`=F`$`5:G9BJ9CGE\BDHUX!B@TE4V=@!)!/6HF%HV
M9M`%*;IH>L`&(.H&2-`%7D`$<J`&.3"31Y-Q>:`&C1,'+40'=B`]G#0'9]"G
M)I>I3;,`;*`\OOJKP!JLPCJLQ%K_K$JIJU@3!Z151RTZ-G1T!H"*K-+*-3G@
M.$A0!W"`.=%'/6HR/";(!F>@`G5`!Z+C;^MI9NB:KNJZKNS:KN[ZKO"JKJUF
M-?=Y.?9ZK_B:K_JZK_QZ.<<YK0`;L-27`VI0L`9;L-%:-T'4/`S;L`[[L!`;
ML1([L0[;E0)[L1B;L1J[L1S;L1[[L2!;-C@PLB1;LB9[LBB;LBJ[LBS;LB[[
MLC`;LS([LS1;LS9[LSB;LSJ[LSS;LS[[LT`;M$([M$1;M$8KLQR3M$J[M$S;
MM$[[M%`;M5([M51;M59[M5B;M5J[M5S;M?L2!6`;MF([MF1;MF9[MFB;MFJ[
MMFS;MF[[_[9P&[=R.[=T6[=V>[=XF[=ZN[=\V[=^^[>`&[B".[AO"RR&>[B(
MF[B*N[B,V[B.^[B0&[F2.[F46[F6>[F8F[F:N[F<:PT;\+F@^[G1T;FD6[J;
M&P"A&[KK82-S=B97T`T,,+J8`0(,@!W8L`%&$BD!T`*<(02U&PX,\"+B$+O3
M@+N>00+$VPVT:[OI\+F+T@*\:PTM(+S8L+O:L`'1>R,!D+O-L+R$0`(M(+N9
M`;W;L`1JH@$X,@#<.IW9&P$1T`!F`@D@,`<`L0"'4&2R<!%_4`;@`0M^T!B$
M$1Q^8`$,@`#RH`)+\)N0\`<-,`<@(``(P,`(X)D20`&F^!]+$/\2>L``%##!
M>!``JU0F#A!/93(`0L8&+\(!#P$">L`!?@`)$3`'W,M)?O``^EL&U&$FB4`(
MRS`'DW`&ZFLF#W`F?V"*#!`!;*`)%T$];##$9F(,RD`\+2``9G("MLNM3EPF
M&Q#`I&`F[ULF"*`D;%`($6P!$SP'%P``?O##B&`FLA`>7MP">##!PG$&_:O&
M]G,"QS#$Q3``?F`,$G`'PE/'4_`'#L`B$3#!!;"Z$V`FT9`(#5`&&V`F#T$(
MG'0&\VLF`!#">A`70FP!P8,`55&K@Z#&'X#'94+%?V#&6I;&:_P'9R`F*P'&
MLD##%OS$%CP()("8")`(+[R_PL$7"$#_$Y,L'/M`)G?`)7_`27H``%GL`+\9
MPY-@$_!;)G!0Q"VA$F121S:A"$#LR,9P!L)S!P(0`"<@/*]`PR2LQ64@/(DP
M`0A@`1?@!_U+Q?93%>?<9!M0S7[P`5F,`!3`!B1P!<)3`"#P`&A!$L;`!A10
M!F?`P#MLSV7R`'.P$@BP`33\(K?L!Q,0`7/!$Q*,`&7`#I*!%%H&`"#`!G0L
MT6/LQM)A)@[0P9_+!H-!"!K@`=PZR2KQ!R=@/PZP`602SUG\QL:P`<MJ)J*<
M(Q^`)E4!Q>\K)110$7.`"&P@!!*```%PPW?\OW\0P(@)'AK``20@RDV,#/![
M`A`\UMWQ`5G`_\,+_`<7@`!"\``:0,4"0`)GH,=_$,&P3-1-#`)E\,8%/,L,
M\,O3$\R$H+Z$<,/4\=#(T,-GD-4``11N;0R_7``?H`Q*LL3(X,-%_<(@4```
M\M``@`#`0=E%O,!;O,"HS<"C,`$+@-!D_`=X0!,GH`%J_-"QW,W-H-B$``=X
M(`00#`)V3`AJO`'JR[U?W<7&`-S"+=?QA`OOBP`,,+]OO<R-\18,+,D5W=D`
MH,86X-D.`1!PH`*R30AX<,T-@+XE00)W\`'!H8V$0`&._<=X(!RWG=NP+,L6
MP<#_*]Z$H-U_H(.R8`'+$->3#`EE@-A3(-(D,,EC?,S=`0>.O<SD[?\!TW$,
M`##&RSS-L3$*?AP`)T4"#K#3D\P,W1P!0,S7QZ"_>.#/%QT`>E`,-FP,K?`'
M%#`7&V#:C?P`'X``]?S0%'`'I3T``;``NP#B?A`=/X'C;.#'$B`$;,`!0QP!
M"DT(#+U*`;+#BRT+"@W!&+W3\]V_BE##($T0\^L!#B`-(%##/!T3>``"4X`'
MJFP,$7S5HWO>..X'P5#5%]T"?G#5.^T'*E':&R#C4Q`!94`")P`;;&(,!GXF
M&9PC&Z!&K+2ZA."^#7#?DV`5)D@3"_#&"S``6FW<?97C=ZT''X#"5Z`"5+S%
M64`!%.`?#1S/INT'1@(`,IS:GVT!#@`;Z!O_'-W-UV<0V'TN'#5NTPU``0N0
MX`R@!Q.@`L?@VWD]Y-0Q![+^UCU\TT!,"I7L!_T@'#5LP@V`Q$V\Q++>U``^
M``60V!?QY'3-O:@-[OZPVHE]![(N`0V0!1L0`K&M!Q30X'L='1!,Q6&]V['N
M#M,>Q@]@U#3Q!P>_U8U1!IU.`IT\QGYL#&%MTQ8Q!R=PR!-0R?YA#"5AR'A@
M&I(,T!2PTW,@`%0<WB$@Z_N[\GA@$W.@)""0U&/-`&A,$C2A`A^@!XU!WSP\
M\!9M\!;!WP\M!`,\!S'_QMK-P@W0[K_P!R00'?1^!XA=`(EL`9.,QA(NP21/
M\U1^\A10#!MNR1X^__4#\.-,C\8E_MDH'NL%L.*ROM-G\`%#CA+23@FOD.R&
M/`E9\`I_``?3P097D`5L4,]XL`&K7A2$T``JP/9!CQU-'M!3P.%3$`(4W<G=
MW=4-[?0-P.5]30H`?<X831T/C^.^0`$"$,-LP!.E;16&+`T&3O"QCP`%P`$/
MS.<44!5\/>4E`O!G3P%S4-=CO/L-(-"]3`$T0>B$8`N$T.H14``M<`6P$>H*
MWPRUAP#9BR,;K<R9_KYZ<`9M#<5Z(`]E/>`74.K^FP4.@``N_\$MC!04@`==
MC0=K/KJC#PAE#@@"?AM_+0@2?WX"?X]_"Q]S#11LCQP(CYI_9PL.#BUL#_]_
M#1J05RIE$1N-$W`7"$*0`YQG@G,3%'J@`Y!^`',><V>^`V6/?H(GC`A^2R01
M#Y]G`@B@%(^4D`W(?Q9LUGYZCK3>R@XG&^&/`W.@%@U^\QP/UUF:?H\2>A9^
MPV<`3,`#JEP[/V<"SB$5:<J9"(\`&/H#A\,C`7A(Z&$P0)\V7Y$L%$.@(H(#
M.(S\,-1VR($&![<V7'-@4=N\,R2(@?I3QMD$$/82!O`#LM\</7XH@!""((`*
MBQ3.)&.TK]\_8@`@_1$@]8^>"SH=/'(PX<\QI@$B0/R%BV$`0@66M/*`H("`
M"-DZ0IKC4\B#EPX:_`%PZ<^V"0\:.--@@9$'/2K_0/YIE76@`S;%_(!:>4L%
M@@<[_RPI\.=!US^!>9;]<\7#!`<+[H186VC>`-"/+IQ1[$=#5IZ^+$7HZJ'`
M@PA9',R!Q(9"F2F\5C\ZD_=:&4-S"CBX`LE2+Y,+/!1;#BFTWC\2YC`0X,"/
M7<T.LG'",^61/5"5RFB_-&4!XC]U;<<(2"8]LL1#\S3RP#L.&*15;7Y\H-6$
M%%9HX8480K+!'>Z1,*%:#8@UX0.%%5!63EPU5L!:$AT2SA1^.!,"`WZP8=$H
M$S8P@04(($"C(^`<THA6$;"A`0.9@/#'!X79DLTC.%*`$B9ZJ->*`!K$Z$=C
M[=CB2!FZG/9+,"TL@(`Q_^<8U,APT3Q`5S6<["78(Q;<85\97+6@P9SMI/G(
M.N4<PPV>+91VB4Q>916+!'ZTH`<"`JVD52V0+`"1$'H,\%!$AH!0S",?:,G!
M>9%(B"D``>$3`9-F&:?5'"V5U<T&Y+UZ@00>;O-(&0-XP`90A7E%BDP!P#I!
M`2!XH"5W44VEAZ**--KC;Q=)=:6N8Y4U@987F$8"`R<,]25#'3FS0"L,]'A7
M-@ON-4"1?DDW6&%S6'1%8J'H08H?Z9VI(3!__#<<I1-6$W`9)^#QB`H2FE:>
M8"&0UHF.4VC0'&WA,/#'!7@$\`<%@3G`0#^[!L?&,!Z>L,1QL=3:7!D47(&`
MO/_4F;6<-;1*]@@%:_UATIO$+CE`:(PJ6@TI'#3BT28?V1>L<YE<XL\=B_B;
M#$@<*/R'"@X,)T"AN&$(AQ]S%)KAV6BGO<\<'G\808@4DHB)'\<N0,()"YR`
MP)PM_A'.`@-L\)@0<#3EMXD3+%)*605H4H8&)VC@03(.RE36AG$AP*4M>$RP
M(QL%7$'RGPA-YH<\$FP0`3-=3O>E+GIXOA(PRUU`E%GGP.'YE4(((PT(Q%CC
M^1+:\"G$'9TC<`%7I<Q!K:",Z#X!8;I/X8[G'L#M]&2:+*'!$G-<(='&P!SK
M>0-3U$1P*0B<4`!IGGA>R!5GS*'D6X$_<$='GG-`E_O_\`,`HR+``#9D06\7
M>%6L2E$&RTU@"FUSWE[`-#U>D8`-(9";@1"P!#QP!U8RH8"E-L`/$#2+*DNX
M`_C$IX^D`8`"7!)`[/!PAYQ0,"MD:<&6-C"%`B0"#F>HX9#*P)`K4&`#%B"'
M(3IRE\[I@7@?N>`#2(2]>2U,A82`&P400!EY2(8R`2/%P.@V`0E-1W=Z.$%Z
MMJ.'0SAL+(+Q1PC@P+8)=,,!QZD6)(#GP2UI$5;`^1@;$E$&F0$@CPMPF7,H
MP``-T"PO-^/B'%3@.8U]S#^(,0GPI`('$_7#)9X#0`'N$(%Z`0`!]`L'&8E'
MMS(L`!+VP)YS2'"%2Y```>0A_TDE_4#)#P`/#J*S0`2\41I'3F!4-=$*\!RD
MMF8ZDQ85X@`'+/"D2:W&A'C`TV!<"<%'M*`,'IM>%CP&`#BT8`"KF4`9ULDE
M"Y#B`BAA0`@6<(6VE8%:CY@`2"3@RFI.:9CK1&<95$`!#T'B!*0(0!DX$`(Z
M16`6Z/EG5J;P@`NL\SF0*$,+&@J"+"Q"`O7AR46_F94'7&%4?_!`!,JYSBF%
M@$MT4@$>'@H`B'0T@?L(Z47OJ4XP\7.=$:`F+<H2`)1L-&\,^.8?.MJ"!UST
M`2<PHP2FM+,%E&$1`+WJ.D,`$@"`<YO'6"<%`O`!JV*U4"?=2AGHHR1(A,!C
M%""%!?\@>-$)M"T$9OM#""X*TD5PP`'HA$0+(K"`+&CLK7^8`G*X!`<)7&`M
MR&@!;$Z05&0P]0,X]6HA';'7=2XBK@)0P2PDH((`-*``O.+)1$&RA$4((0+'
M"``)'```#JSS`WD-@5_U>5&(M&`U`,A"WH0@U!:H0``:98WB_J!0L/F"`Q'X
M:1D:^@B`GB`KFMI-.WH&PS^0@`-G*$`"'^!.9$:D9V:1Z11(4%QM3F$1%RC+
M``IP!E(,P"(-H&[`+C"%\4HJ`@F40$/+&8#.WC,W%TU?-AH`$:_B@0,D<(YG
M)9LW)4T!#RJP@&;+@)*6&B2LJ^#O5E:SJD?`X:(;;NA\\=#_@.^&%'=BO6^%
M=/;,&MOXQCC.L8YWS.,>=V>G0(:9CVU,`1H/^<A(1O(#+)GD)COYR5".LI2G
M3.4J6_G*6'9R"P#`Y2Y[.:]9WH!!LTSF)A^BS&A.LYK7S.8VN_G-<(ZSG.=,
MYSK;^<YXSK.>]\SG/OOYSX`.M*`'3>A"&_K0B$ZTHA?-Z$8[^M&0CK2D)TWI
M2EOZTIC.M*8WS>E.>_K3H`ZUJ$=-ZE*;^M2H3C6%*L#J!/S!!:RN@!+^H(18
M=^`/)H@U!OZ@`%:CX!%`\/4C#,!J`PR;U03X@PU0P&H%_`$#L3;!LV,]ZP[$
M.@9_($"L7?"'!,0:V*U^1*Q=#6MD__\A!K:FM:YY'6L;L+L"*'"WMBM@[#\0
MF]Z/8'8%@"!N5DL;VO[^@[59/>M:LYK;WF8UN.&]<'+'.MGH9G4*E+WN7K/:
MW1:O@+M34&QLS[O>^N;W'\;=[PI(>^"R5C>K;YUKA?\AV`Q_N;#MS6H8G/O>
M$[=!K)T-\)3W?./7SO:VN\UJD9-\Y.$N=\H-7@&65WSF%O\US?$]]63_0=\\
MC_:T`XYRCP\]X15H>,D=;NZ(+_WI%W]WO(5.]7N#O.@E_[?645[PKW];YC&'
M.;GO#?%8YWSG6]?XNP7/<59[G>HA'WO<!4YME3<=UW>'N=0E?^P*V#P&.*=X
MLP,_ZY__H?_P%3A\!1`.=Z17P-6F)WO*?Y#NEE=@UU''^,S=7OFW5R#K`>_Y
MR8,.]@3X?@6O]GT"=HT!X?]`X,+/P!]VX'NK*Z#YCT@!]+/M>VG'@`"^W\$?
M,B#\6W/?][O^@?!+@&OA<WL%PG_$\Q,`_&[_/OC5_T,)C/_LY"]?^-AF?@((
M@&T33!_["3!QU)<`SN9^">!]W?<'X@=^]>=[YY=^O#9]ZP=\+B!\TC9_OC=K
M,6!_^I<`^8=_M-9\Y.=_`?@(`%B`PM=^";B`P]>`"7!\'0"!Z^=\TR=]!"A_
M`*B!PJ=]W]>"/8AM2C!^Y>>`?X!^-VB`*OA^%<B`Q>=[,,B!TZ?_?U9G@U8'
M@-(V@#R8@#UX:RPX@N97A#+X?D@(?PEP@<)'?%#H>Q^X?_WW?[XG@"?X"%JX
M@F?H@@_H>^HG@4IH@V:8@>>V@]L'@AT(A$)(@G#H>R@HAG3(A/07@W@8@?N7
MAY'X>8B(@WZX@=D7B`SX@R'H>UY(A$:8B.PGATI8ASWXA+ZG?%*XAE/HAB6(
MA9IX@+'(A4)HA*BG:KB8B[JXB[S8B[[XB\`8C,(XC,18C,9XC,B8C,JXC,S8
MC,[XC-`8C=(XC=18C=9XC=B8C=JXC=S8C=[XC>`8CN(XCN18CGO&,VJ1CNJH
M%C!ECN[XCO#89G.0(/18C]44C_B8C_H8_V7SF"!ZP`;UF!1M)@1MHXL@4)#9
MN`%MM8\,"67].`\/L`$+8(\4<F(CQ5!GPV4^@U,U!@`JL`#E8%'KM`0>PP%4
MA38"<&8^IE`[]0"*=38@Y@#+U4S\A$\3P@"><&:V-5`?<`B/U4S,I&=>-9,Z
M!@)&!@DL!52(,`%LL``<H"02-ETS&0".P`$O=B&Q%0%7^0A"P)$5$@+)=&,5
MT9#"^)"&(`0P0H_WN`ELX#D3H#JU8B%#(1C6<V,P<@%G1@%^<`4AH`=G(`0-
MP!UI4P@VN6,!X#E^X!_=("86<A\3L`#!TDQ,="$>L"<0%0$S,PC(,`!;B2$2
M$"=\5@A'>6,3P/^8#X(`%.0!P*,''[`M9:$<GH,`KP0)VN$SQ'0A#V`(4["6
M/A.9%#('Z&5C5\`G9.F+#WD)%\`C:DDA,T,DRQ$`'D`!BO,N#R`$_!,`M_('
M#$`!4Y`5`-``%O`!S"0!'^`!`:!0>]-6>GD(RB(``H!?X2D!+4`!%&`VT)5`
M,)(-T/D!B\``#\"9`7`<#0!1S>0'D'4&'/`!&@,4_*D5"P(M.>4!A^`7$0!A
M334`2G$!'Y";#A*>#Q``#)`%>P()I?0(,A,`CE4*<[4!`%">2@("#?`!@O$!
MGX$(T;D(+=``MP$4;Z,5_HFA),!@`^`A&T`!'Y`5)/!8`VI:`D`!#<#_0Q`F
M`#IZI.'I"'XAGMJY/!\`$H^5-`,0H#(Z(0/P`8R$E',"GEOAHAN`!XQA%@!V
MFGSB#Y-#`@6@![/E#4L0)XV$!Q(P3%9Y""[F(+FY`1?@"P+P`5/```%0`'/0
M&.^"4^0)%CVS`0UPJ'-"GD?T#1>0H#F:J'_``0(0H`)@/1Y"GM4Y&=Q9*((C
MHV-6G)KVD$=:0V.3(+R)`&U91CZS'`N@`6?`13R2!;P0*G?0`M11+',PD1(0
M%(UC$*=4`!I`-?.(6!\S$1)Q')K`%VPP`'I`0Z]$%YXQ!2I0.HS:.!P@#QI@
M(M^#`)UY-@:Z*WX`!W>@`K1$$D-B'S-#6-SA_P]XH`=W(`04,`<A@`"PU1OB
MI0Q98A!)TS@%8`%\D04D2AZ,TJ12<13#.@=E@$'S&JX-`)!GL`%Z8#&04@NQ
M<[%Z(QGF^F#OB@`>4"8+4#]DI0RH%`P:,#;QZ@>/Y1YF0D-Z(!KO@``YB@">
MT"C^X``<HBEM:35FH1EZ(#'H`0PZ5*[*,`<>]2@>P",RPY'6$`+T6:2-\@C*
M`@"PT0`-<`>S^0T(H`<,=@V\2A%ZT!/4,JBW4`ONLP".HJYT<;5O`3KM>A&V
M6@"-D"Y!5#:#H`(:@)K'"B`KA1#7`9Y^@`_,4``+`+G?=`<G<#JNRFD/:0%+
MT"A)0ZO,&2,(8">E1/\C#:`G\84,#-8*@D$=L;`!;[$RC<(H?,(JA0!=H+F>
M@Y$4F&D8#FL[`*!##+`B'_.?P%`(BP`Z\I!`*I"MN/),>_LXAB(3$J('+Y:;
M"0(1,D,"C&(!ZQ$`;`!8?F`1)S`'),"AM/E*23.?8E*BN8NA$TL:M<!>>L`/
M98%9UO"I_+(.UC,DV2$`^)2\6\,,65``+A0`XJ,!W*$WP3`YUS`4*N4'ID44
MRJ)#I."4BB$`3!0!"N-%_8M/&\`!0I`%D?E$\L``+9NT0R,55X`22T!,XC`/
M->4'$,6A[3$/<Z`S9R`6A#6M0I`4=#HY]F$(MY`T')`Z`7,);,#"5]`1&]#_
M"CU3"`W`#PTP#+D+&IKPKW]P`CLKL!(A`""0%%I<"AJ@0P`P%!S`!G@@`$1Y
MN9?6C_T:`!L@!*W@N1/2G`_K#U7R&6<@':K;"7%5&`:4FXA@N28F(GZ@6+<[
M$8QBK88!$<HR!WPQ`#AR$(?D$2XA#]B%%'J03-<1D&0S(<\K%1NK0[ADQZ7A
M/-9Y.F70%?4"#GP!OHZP$Y/Y"*24#-2TON11"!)K&&6AEY!\)@+)M],Z%DO,
M"1>@R3"%R9&`2_^HEUKA+QW!L((AL(S`,YK0`,Z3FWC,%TYZ)#S"'F(AF@^`
MS$C)J',0F1-P!PZ@,+E@.J`A%6S`S+5B#1S0Q"3P_[4[XP<,X``%(`$:<"Y:
MD<.V61J-$B-'T3-PVT`U+!9,Z17,K`+8K`U/O"5ZPF#>P$&7\3%2L;M<K,\`
M0@%90#9Z@+9DP\T<@!1(R\9M#)$;@`V10,?/+"^EQ"@7``(`0`)PH`*E<`5]
M3!T-H`="<$N(H0E];"!202.,W!T3H2Q]>JT0D;X@P`!"@`<2,@7["P`=H3$)
MH<P,L![$``EPW,1B+=:@?*"EP`9S@1X$^J#:F13*P5QGLB(D0!"3V=!)8Q#9
M]`W`<$+511Y7(,/-TLX_S5R%TCZ)!:J:D)L,X"FPI0DD```<<0?2H<P%("%E
MK-@D<%QS4!]Z&0S3#!&Z>__-V<POX:N=@(G6UB``HT$^`P#9%R#9D)"G(-#0
MD&`[F?('\=JT(:(PA80(!6D-<1HAWK4`.^L`J'O(`8T2PT30#FS:L"3$X"0!
MVUD^=H+`OET+!+FW6T$(ZU`)A^+6E]`L')VXAX``,7,*35P(+2`$4@W9`_`2
M*IUI_8@D\T`(H3(/M>J7"5%3<]`["Q`"_-(1(9`=0W$&.'E$MGH=[D34A+P5
M[YI(@Y7(>#"19;&[P*F=J%D&>A``T!&P)^`/.LT&WZL2RIP%<_"O(E*@9KVQ
M&U`&<["Y?)*;"["O;60[*G`']J,"9P`CD3$DMD.T]9I22JLP?.TS"`&0S!#8
MEX/_2FNU`84#X`_`*+0EFWXK`01S!\VA`=6DS%N$F1/``'=P"VU4N0$+!YZ-
MN-6\N]A<R1N0!7=`HU**VH3@#TQ)%!93,=5$H[MP"F#=(TJB+"$`.@7V&8HQ
M"6:TW7Q"`F?@'@"9#<;]!T+`!AM.FW/P6,@@R&<`.4B;T)FP!!/0%'JC4@@P
M"6.%`-E$S7R;DFS0`!*AX\^2T>*M"1U=WD[J!R=P!Z0!.J(C`+OZKZS@(_%=
M:?U8/PGRK#`-"8J5CN>4#>"2!3C%`2L"E67@GXTA`2OL"*.Z5-$U*6!R")RI
M%<*T*G/R[46V#R=AI3U$"D)P`G`@!+]5!M7."I/Q`060_ZG.!%N80`H2H)H;
M0.]A>1=JT9WMH`*4-1@$/\4U938/H`+\E5=!6MF'X$Z3HA9;ZB$23P$X%5HB
M,QG%\0`D<#=O9>T.T!@`$%)I01T$VJ<36AQC-1@Y[5K%89Y%N@AU&53?+@%'
M=!<'.1J"L>\@T`)3`#;BM5*#5>\$N@$G,/(?T*HREAL%H`[H042E<08?0*!`
M/Y/?50!P4`X-4!.#M5P#P/`R=A?,]0$+]2`1`!0680$JT%C;-#FF4?7?0$3_
M*5A!GRR+P/974"A3_`WV51_6HSH6YJ@(4RCR=%S:&0'U#@(@(._!/FEFZ<G!
M_/B47_GF&/F>S)N6O_F<GY!C_?_Y8KV0G3_ZI%_ZIG_ZJ)_ZJK_ZK-_ZKO_Z
ML!_[LC_[C38%X_DD$0!F%-("8?EI`0`*77/O```"@4$"4Q"8@]$"$F\?08D>
MK/.IDJ*-+9#T#K"N&+($@;,$"01;S!"J%I!,3EHAP@0)WT_[O=@1-%8+A1(0
M&&+3H]8*@A"<9Z,"'L`H*M!(%\`="I+BJ0$(?X*#`W.#$PZ#BHN,C8Z/D)&2
MDY25EI>#`',J#E.7!1$6?B%_>A(G?W,;#Q.#91&-#VR#K)BVM[BYNKN\O;Z_
MP,&2#W`#BP,.9W]G``]9#A(?(044*A$,'@TA*@]_2PY+?QQP#@$7#EDM#<;"
M[;L;?@+_@@$1&B$@(7!9CQ\%#RH:!B`04*"!GRRRV*@@X:#`'0_B[A1@4(A$
M"#8+$KG;R+$C)4T`!`FYHN$$B2EPRCQ:4H;"'38MY@3(<L$/MP5X0FPH@^?.
MAS\>)$J0)>0$FS*M/"I=RK2ITZ=0';`C]."$!69WA#2XXH##!95S`$1XP.$/
M'`;A0L'Y,^#!E0``&$"=^P>>'S\1/.C1Q$%A2$<-]$QH,&<*'H'PVK+9,(>!
M@U!LA"`8,&%!(0L:`+#12+>S9TB:[E*X`%.#!0?0'@W0\%C/@`*,`YAZ<*8%
M@@9ERM1DX.>""FYL!OAA4"#IY^/(DRM?3DGJL0<MLIP1@$I"_PBIE%.)?6!,
M:G$X#S1,N/+``IXR<IEOA,<=P)6U%(Q"?`3`SQT`*MA<$?@GWH-$;`#@0`.:
M`7`'6WX4TL!:B*CG(%-\#<#`%+!,X$%7D$BF00-G%+`$8ZFLTLH<N$4@0()Z
ML*6!+`\<6,N#,,8H8R0@`&#CC(\XITA;?T2````+_''!=0-D%]98W44CI`#[
M`#!`6190@*,O\,CSQP=!JD`!&]T\0@(""%SIAP?\^0>@@`0NAD``#\Q1R`!G
M@%``9U/6B0M(@CCS1T$#1K)`8R?XP0&(JM1"XBLGGMC"!V?(T@`")$Q@G)V4
M5DK7B7=9*HAS$00@"(\,_+A$"&4@4__DB-MU1T(6)Y1!SP1E2.#!%5E8L(ZF
MF%0IB`1L:*`'`USZB8>0?EC`GP:-GCF@9F;IH<<Z,LVA`6NX5@M:6((PQL8=
M`?0)":DD<!`/B&QP.6*))Y)0P!RWR;+!'2]-:NV\].Z"J1_U/A*`$)5L0$*V
M(&3K:;Z3D+`!OR(!P&\``4,2@*="^!OQ'P$P`(*G`9"PK\:",+#!'Q-7?#'!
M]!K\KR`@2+`PPH^,'#$)!M?5PL@',SSQ'PQXZC(#0@Q,\L]`.W)OT$07;?31
M2">M=#M#+^WTTU!'+?744S9-]=589ZWUUEQ38G778(<M]MAD5]K`V6A3<)<?
M:*,]5=EPQRW_]]QT\[+VW7C?/4O=?/?M]]]QYRWXVGL#;OCAB"=^=+F,]TIX
MXVSLHSBE4^1F^>68Y]8")0]D[KGED[<3P>>?^QP)!:1[_E?HDW_->J5E##[X
MZI%,(+O@KP-SQNUY?SR)`[SC;67NB+M._)2Q<R#`\LPWOSP;?M`.B>T7.&^]
M`-`?W\ONU5_?O`9^^"X)\`]XW_SNPVO_M_'JQQA[^H[L+OTCML_/R.[MZR*_
M)-"+'PGP;W/$^_*WOK4!30@L`P'+RC;`2.QO$O63!/Z6P[%?Q,P1^XK1`R'1
MO^8D2!(-)"#?V&<M":B@#!:@V'3BUZ4K2(D1$_#?I[HT"!#LY0\"_WCA(QA3
MA@+HQ#B66X`$YA+"1VRP=M&3(+X\8L)8S00.L&C$!0H@G0T(((6.&-8D)%``
M.!1@<XH``!7/,)]!3&$#>!!``Z:0GKD<T1$=_-T'(U%$$<Z-A-6:@@1:@(HE
M:`!^@U#!6C9`C3\`P`(@($$+)!##`/B/1XJP0!G"D4,+?&P#$I#>!A(AA#].
M8(]_4(F0Y,64.C;BC?1+H@.7V)$(`"`:/%*!(T)P@3],X0(>*,L&0M(SA?UA
M,>G9P.:$4*.&_6$"9>%`612QA`;4124D`&4$-L`&1[JR9S@;IC"5@DI&Q'%\
M<X2$*>T(-P"`CF0%V)0A'0#(39V!`1P(`?\%!N#"*VQ`/%<0`!S`.,-%+$$S
M),">!V2Y@'[0;I-_`,$?Y]`/(8CR#[*$RC@7T<U&1'"52B'%'SA)@H@R(@(J
ML`"_RG`%"UAC"85@5`#$4X`!7"`+(9A"`^ZPA#N<K',#,)T@/,JP*U1.`M,,
MS@-<&0();.4*ZU@`*CQ2445\\W_A?,1$R4G5X^Q-H^P4A,'\M:D/-&`L%```
M)K.P@2L<LR#/440`UG(""0C`$V;=!W<4L0$$S$$/'RBK-\SI"B+&0XGVLZ@J
M(3'!CFA$(QSX22-`X(%IK:(!*AC`!HHAU]5$DP(%L$`+!D0*!XA/%HU9A$HD
M@)H6#("Q7Z5F6T#_"A$X;&"3`RAC1YHZB*="`H`@_&M5=ZN<,O`+JU;J5CDV
MM8$3F&@T6E+!!EJ!".,(@`20%$1?'*""#^3PF!O]PUP'@=!LM<*5HNRH7]M)
MT<$B,;"**"Q'-$H*#\"!9:0:HI#X=8$I/(!#$XA`!+)SMED`8$M+B(!,6^%9
MZ7I*`.%0A$H"H$\`C&=`05WM>$*I7^[0<+;FA6/X/!C`1DR5MR!N"@4$P,=-
MD3<1#A@Q!1S0`D(N]YC1\=T)Q'(!1PH"J2`KP'4)K%W)-JR[=?DN7QFKV*=\
M6!"T5<1%"<M*CBR!`6)I@4<;$5FV4."^#JCE%%YS)>P9$G66'/!&?:<"_V<*
M(`+$',02R@*",C1@']F(\%`!L$^=@&">%^9(DG^Y83EVF!%'#K&@.;*!?*0G
MK(Z0T@,R63UP3(%-VF6P,PTYIP`\21!G%(1U:]D-*0U``AQ@1P!T"&D.M*!R
M*IB",9T2Z#T+8LE&;/)&&)"%?3:@`+EQA`2\"`>XJ*`%7.'.'<#Q!U*H`P#Y
M:(`%(/)H06R6BKND80"64`!_%'<"2[C``P(0`@%H>Y&+=@`<EE=+;F:X$;;-
M450%J-M!NYMJ%V@CC%I];D?`.GZRCA$RGK;G=#L"MW1L][L'_K0%SEO@^$;O
M(NY]RGS#:"C\KO<B_-T(@(L3X03/N+OIK7`E2_\\O0X?>+_[#,X_BQ;C&D\Y
M;V/'AC.X_.4P=SD"/KYP/RP@YC@_P\Q5CF2;YSSF,Y>ANEO^\Y?/G+P\3WK^
M0C"'ICO]Z5`/[20^$/6J.SWI6;"ZU87NB!-HO>KR5;K81=@"&YG][&BWD<%W
MF/:VFSWI97=[VT\FB;C+'>VK'KO>]\[WOOO][X`/O.`'3_C"&_[PB$^\XA?/
M^,8[_O&0C[SD)T_YREO^\IC/O.8WS_G.>_[SH`^]Z$=/^M*;_O2H3[WJ5\_Z
MUKO^];"/O>QG3_O:V_[VN,^][G?/^][[_O?`#[[PAT_\XAO_^,A/OO*7S_SF
M.__YT(^^]*=/_>I;__K_V,^^]K?/_>Y[__O@#[_XQT_^\IO__.A/O_K7S_[V
MN__]\(^__.=/__K;__[XS[_^]\___OO__P`8@`(X@`18@`9X@`B8@`JX@`S8
M@`[X.@]``1(X@10H@4CW@!A8+7,0/#J4@1XX+QOH!WK`.'J`-QT(-B/C;@\C
M#-CT@4\3@E'T!^%R-R?X!PC@"4Y1`&`")E?``5H$"1:P@WI``71G"7.`18T@
M`3/W%Q>P@VP@#QR``%S7""1`A)H2*N76"P$@6XQP!SLX+`RP`'?!#+:T@W.P
M3)]22U>08)`@`!L8=IAF"&M("5?P@\<1A'#H@HL`@S:(`%(R<Z+!"'CQ%-K&
M_P;^8`&R(`G"L03_42RV,!F/\`#1<S*/$H%ZH`$X%`%Y1Q\AAR/U,6F]$`&&
M\`AS$`(/<%\DP`8(P`&2F$[U<(IXD"*#X(<;14J,H#;\-`@^4HN4T`!<Z!G"
M<8$?R(=WD5<T*(@1T`(3<`99,$0<T"&<!@L28%:;U"A"T`(1<`8JD(>3@!1Y
MH@%+<`:U!`(G<`810'?"80P2\$&OT5(4$P+:*``,X%.PX0%G,`60*!(<@&OR
M@`>C,`B/LBO1<QKT@%GKD!OR``+A^!8?X`?E``#2`1$,<`)3$`("<@9OH0B=
M4`"C=@8%)@%E<`8<H#'VF`4A85]P$%F:,X_/>&5G(/\E('`%]X@S#D`;5\`O
MC!(!;%-H'BD^X0*-@T!:(7&*VE4`(14`JB@E4U`<_C,'-"0<RR2)&Y"-@E`3
M`&ESI*4"5X!"AJ0"!9"%`2"&J'!K[KB+#M`*3$(-0F!?0-%I'C!4&_4`1ODQ
MMV8A:'@*]K@$`?4!CW$29W`6MD0!7B0/P'8&'[`Y9.E,M.:1%!$/BSD!F^B!
M?*A52W",BX`7HG@!=^!:;/,!>^$`L\`?)"&)0S4'7[$6E^"-VN4'%)`%X0,'
M>J`7H"@<+3<'-]F$7"&%4Z`''#`'62``"&`/!A$!%N<!?D!M>D`"L1.#`2D(
M;".5T$,3"`!34@@'"!`>'V#_G->``(:9(">B`1324B6A"'[`!A,@B1ZP`*V@
M`=;`-I4Y!1BQ#'[P`&#2)E-P(ACI!V4`!WX0`%.P(@A@77Y`#0DB'+#"-A1P
M!@/`!CA(+!X0`I@X#V/2`G?``:)P`@40/3H7:C<H$8HP!T>A&\;Y%_!@`1$@
M&!-P!T'R*0,J('[X$B`P!V6`C[XC)ZS)&^]1+&8Y`22@!S0UGT;1`AJ`!S:T
M8K/@!QH0A100``@`"GY@',*AGFQC$&7@`;:S)04``KMC&+.0!4.(`.-VG12`
M`".!!U&(4O&0!5E0"+\HF7<!"_IE2248B)>I7PC03!%S$-"Q4:$9)CZ!/8]Q
MIPW`_S(24"2&:JA(*`BJV29_8!``H`?C!@=06IYG,`="-`%Z@$!ZL&V%J@%E
M`)QEL01D&@#A5`:S4"52"9!AXIRG&#XMAT/%4A.%8%86D$GX8A!#)$@G4A:B
MN%^764MP\$<N`0\AP0$,<`>R="(;<`:HX*&L<B*%FB#K2!SYQ!,G4DO/,@4+
M$`"BT``4H`<1D(4@XU83,(J"@`=E-ASAB#/S*8H],ATGL*J"T'3EP@&XF"T)
MHI,E>`=P2(L.0`I>=R+EXQJ#H#;:-0<:@P!V6HLG$A(+\*D(T(2NX0>;=:0_
M@2@4*P1S,*D7("?-A``!4XI_(`IP$B2B``(1^P?Q"IS<(/\7F'0!@A&,6:`!
M'Y"H>DB,Y3E9:U.#>-$"_.D':R&)?C`'I-6GI:`'3;=/5W`7J+E1@R.OBIH4
MB2@<]6%7MDD('X2R[[$W;'`"-=$K$&L,Y2H(^?@'YT&VVD9RS5FBT)D(->%T
MCQ*#];&:'S,!3_A!+>"/?K!4SBD/&4JO]2$^&UL7?B`!+_E+*#8!)X(@`E`?
M$K``5IM&CG@'7Z42GTA(;QJ4=S`'<&"NVH4`(1`DY."<%"*'5BL3@^"45XE%
MZR@69]!1"-"O4G*6/6*:(MATH&BP"3JO5["C_+%10<*>>."I00*:_=$-4/2[
M9P"E`U&+A$&VL%`?SVBYX?-7:@/_`H\B@EOH!V<0LXX)/7[0H#>;N2XW!4*P
M.W1*GOO%`=81%AZP`>+B%H80A7_P$.(@`$_"2.;J2*_5O_TK6E(;FM%SM9^&
MM<;`&]@FA77U9@Y``F<0ME>R)KPQ%3,K!(Z;JH(0D/ZY)FT+JRW```]P3[(D
M@8$KJ\N@N.SX:>M"GO+@`)B(OZ2*2`5Q<P@2`(>[&0R++\%8'^84#A=@`8GR
M2[YX!RU0$^OP:2I@KO@8`,];0WJ@L%?"!@$E*"?:(UEJ*Q]*0[R1!1?3O4)`
ME0*@!V8UBYY`NZ)X(@-``B%<L/C"`7H``BT0OCNZCB*E`?M@G5>@`@B`"L8[
MGQL5`>LX_P``@`"3R@$!@`=>-8KLV:@(<!4:(`3"(02;NE%[X0$,8!`"L`">
ML+'!:*$"@`=L``(",(4-.)EU(2X[BXRMJ`>>I0$XH0%#87/L`A1^@`?MTJ34
MDIH!C"``X`$(8,M3(1QK\T>:X2P+(`2BJH-I!(F/>E=E:P%--YUT>Y5K`Q$=
M3`(+<(DR(2YWL)-#"Y'!B0`,@,:?6P90/`A_)0J0^Q,.8%>P_"@;&`XWG+B+
MN\/1TX2VK#Q_Q08-8!O2PC916`9ZT*#BLBZ0H@@AT+PMX"R_#`+B`@=*J(J3
MHKJ#4!-KXTQ4N9I3P2[G\%T("YM_XC,&NU((,(+8&":T&SOL(O\/DFBOO<&G
MQ_O'>W*[DQK-`-#$CZ(!-^C`X6Q6:J/3'J`9+:<',Z$'.E@,\>`CYAS4;#.^
M0_MRJFB9BK!?(/``(7`-.'0%^507$6`5GN"?(3"HV'O5\D8)7B$(`@`18N$O
M#^H!="<6^G6?NR(I(<$`V.:MI_87]'0!B#8(%K"&FW-FQ@14$?`!',`O@IT-
MNW("GY0G*<8O4V!/4QD"QH"-(7%G*;9JR2B#VC!-.',"6RT$0Y)7VI5"BMT`
M%X"-AI2,4WDP%&"*?X"-F^,!0[05%P#(0G`AS38/K&"BJX:("$-/2[`Y"DD!
M0L`!5_`!IC-BB[`5$W`!_P))4PF*6V'_5+4T`%*R`:/R-B:*UA-P`G(Q`)Z`
MVC@3`?LA"&+Q2IOMBSTB#^L@!!*P97C`A@+A%F4A`3JD#<J]#`7P`1,@%W<6
MU@'#2"7U!],X!:P89?[I`!X0,8#LU+=3@WK("/#0WX)"",TK00\UX;Y0`)#S
MX6R`AASN"+MIU,;TR=S8""%@BR/>XB[^XC`>XS(^XS1>XS9^X]T'G^5B<I-@
M&)$03Y#0IMHE.1X@OHH@KK8$BMQW$8:("R"P`$(^")3=,D@^"*`@"!R9A`'$
M!BE.?RE*PB##,FOG"-T<=@F$V),F!">#0",+M8.@L4D4`9!90_]R#O,0W?*E
MYMNWO%<V#XHP_^:,(!S*(!)JE<%_X3,-XP$Q&$9#.Z\'4T-8WB4#0P%@%)GQ
MMXS+`Q1/[`'0S)N2```:<.7`V2L7@*G/X@%?"<JP[$=GR)]%AN%PL!;U`*)E
MM;D2\,2G<5=HH4P+H`%2K'V-(H]F$9S8X(66KF1>.D2[F05WP`"5*A-?60#9
MK!)E<`=_!"8V^P<4<`5/F`K=^P"@;L>BT,AWE4ZQBP>V3"?S9SM@(AE7YB:"
M0LJT$-;#L@3YQ#9Z5`;R=`:/XH9]@4P7\"AE;<5M0@(1L``&0A@-P+ZH$P`?
M``#B>)ZT,<@#3WTZ=Z>/RB02>!B30+G%(1FE"0#6!<O\_I=!:(-M,?^1&?GG
MNN%"J7"*SW('L04L-7M+_1D/^D$!GKONL"%,212Q;NX(&NO*P]$GSW("PYMB
M)?]+9.&%'_"[BW`'(ZBC!.:+3SP`#9`(5U``&R+QJ`+L%[`!EJ82<DD!;`@:
MW'M7Q"H!87%">B``)?^'/5+2^+WHGX(`O1XDJL##YLP,P8X'&5HE7-+$]0<K
M(G$;%N`:0=\()Z)?E,O8ZRCPJ)&@',+T9'(%,D^FBU!7^K4`%!`!!2`$>."M
M^A0!6<^D`5!F7J\=P,X.$J`!Y+@$GS\)#[``75VXJTAU04%-<,\A?[@!G-XH
MGV]P]6"G,7$!`B$`%GH;C4)MRHKS][7S\B?_#;1P5Q9Z()*`67FB`D!2`,]2
M!J%NBFNZ#P7QGRLRR'R;P6,\`%KB_1Q9#W>P/)-Q!@M0`(EU-C^!!Q4_?;4"
M"'^"$P@+&P\4@HJ+BB17#8)P#PUW)W,"=P5G%ED#60]_=W\.&FP,%P@#C`6)
M?UD1>%EZ%PQL&@X;A`]Z*G,,<Q(%#0-XC,;'R,G*R\S-SL_0T=+3U-76U]C9
MB@T<`7H6VN'BX^3EYN?HZ>HG`A<+ZO#Q\O/T]?;WR@(+<Q\@^/\``PH<2)"1
M!PUW.!1<R+"APX<0(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*E
MRY<P8\J<2;.FS9LX_W.:]."@E2(+9<K`D8`-E"`)&YR!2[1DBC$!`2*TT$:!
MJ"(``IYML,I(PB9!0;-`"A'4@R`+<,I\(*%H0($R%Q@]F/K'`KAI/GT"%7I7
MY[P6$Z[0%=0B:%"NYY:6"V"4$8?!RB2H8K9UD9"^C'P.<#`!1(`K@D%0<#!`
M@(/3=UOX=`;@%(!E055`:NQ7(^`_)Q@L:@`*P!S/4QD$^`,"Q&OB`-@&`""$
MN(3A$P0)64)T@VY%RX5L%2(D2P#A(3;X`]&\.X,S$HXO9ZN(@6[/R85D%R3\
MC_``&Z9.\4`^>7T2``P7P'=_7.!!<W\`.)P'`[#GP!^%_3''']-=L`$>#/\(
MX4%C60@!PAT,D%`?`R"0(`$'#13GWWC/_8'?=8L\*(B,?_#VAV^*"-&B<?Y,
M(\$<0`8IY)!SA.#,+T0F">0'SRBI9`'D4#!`,,8,`(J"BVSG8GT!M/!>?E@.
M1\)P#`S6'0@.E$D?C!0BY:)U.BHG@7)JVL=`=.L1QT`$Q_VQ'0G&B0F`E=)U
M:2=ANAGH(@`@M)"%/XS2%X",+;`AQ`4/A""``$L\$,$&<&C'P!U)W>B`B@A&
M*D1R;^IG00L#)@CI<(J40=P9`D2GY7>E6F.)DT1BI@P%P!()23,_%BOD:@PM
M]P>?NX$"`@(-E''"`UG`(8`'$\#1#1P.1."(`T[_G1!"A]'9=P8%`&0;UR!X
M7``''%-(H$$#$7#`!@5F>3`5`!H\<`8<!5P`PA5P:);6`![,2X$`983@``D/
MP*$"`!$($,(5!3!0AC!7E#$%9Z)E<04($810@`01="P(3PX4!D>I#X(JX5$3
M*.HB'+4*8&(`'F01`@!3,,"3,!YP'`$<:UT1`L]+.%!`GS,J0J.-TTIWVA4;
M1.#`"=0(X,?89)=MMA^V-@/`V6R3G6XS;;?-!CE)H54E*%.$$`*"+<SK5,17
MD)!R%@!4>P+,4=WX`">$'Z6!!7B0%8``6621E2`IJQ#`!RI_H,(#0ES1TQ]/
M%[`!)R2?9E;4"QS7=Q9%_ZN0[1\<I&44Q&50;CD`\PZ0U@8.9'%"`X_7KD(+
M`ZAP11:"3/Z'E1HT%\(2D)Q,NUF"`.!``UDH_T?#WIU&@1`;=RP4!RS_(4$#
M#<P[6-IE6#`!J.'^,6\9/5;C0-QL3\9,!/P[&VWR$4"S14`BOF-$`_#@@#-L
M"!+>L4"X.$"".3P@+BJX0!DD(``0#"!T=U($GW)#`N:!Q40`V(`*1L'"Z#C@
M,U;;`*X^$P$/;"`$M$J1`$X0`0J0@#0K],`%-$""'9*F#(?X``4>\`#^W.&'
M$CQ$!"(H):.@J4`.>,#E)%0&-C!O0GXZPP/\9T+UA8`-_<A""S@P@0GP[@^3
MR/^8!,#VP@&`(`LJ%`*A8F2U;3#P#$R"D`4"4(8!Y&Z+T1!;V@BXR&6LC4;)
M:(`?WL8,/X!1&1OPP]S(P8`"8&\15MK`%6AWK/2H\`]!]%V7KI6B!UW@`Q$P
MF@3@X*6W/<A6BPM!F4:9((,MP30M4!1I;(A#7&[&.!/P``=`-8`E_,&-1P%`
M"R[&LRO,LD9&&4!T=-F"1U!@`P*PTJ8*`[Q*G6X*;&B!HQ8!`#QL`(RG4<4)
MDI(%]ICJ`=%I73$P14Q#)O%A#YOG!RAW3D7,P0$JZ(P;D;)"6TT!D=/8G_^2
M(5%G`'"`Q[BH,Q3)C`'XX8`088`&V%0C=@UGC"2(3C?_H<4&:$6@`1^8PPD<
MH0$-`.!M?.(E+UG(`#RPX0PL?%!T<@:V&<GP-1-PP$_/0)<!9&("+WUF`Z+3
M``J84'2;@6,/F:B*!VUO#F<XP\C^((`J"J)K-RJ`%OOXARO@R#XAX(!"*+1"
M"NE&"`MH@!["&@$W&FD`^`(``!+A`"&00@/`>]X`:70UDRKBCG>8`_0Z-`V.
M+L.RS'@D,R1)R658DC*:-`<)]&!/05AIL&0U2D]_^DQLIBN+`T`K`%0P``Z,
M$@]\[>.#AJ&),[SM!'>X@VF>!XDL+K4%#QJCD9ZIU+!ZP"SLH@\><'O39P[`
M2`+(Y@%[.X$`%"`55O(8'DCE_P`!(,"Y&AC$8[^2WE'D[)D#6F[VLGC`3<CH
M`4N]0')[6%8!-.`"5Q``6!VHB*G197X%8,,['O2P:U1T&0_^GQ\P:@R--@.S
MR?`H2!TBA.,UCSTV$L0871&`ZT;@`2#0`(K^`)<&D$`%Z7,K3@&P!.:4\4$#
M%0*4O-K:!BS@7:,XZC,_X`&*(4@/0LA5#T$`!T/^X0,#B)X%HI953RUQQ%Z5
MH![U2U:S4HAG#;C"6JN&)AP)SD)X:`'%L*=C?Q0R@FQL%QP#BUH'6"`1>'R0
ME3S$5A8*(L2*P-0?"F"EE`IKHVAC!H:5H=EE</89GUU&)C<IC@A(``1SD`\H
M'Q``(_]=4!`YAI*M'N8=C(U1"&`>7T)'@9^Y!K5&UQ6/:J/S2ST7EV%P-"P<
M!W"%Y213(1[(54J/$^KJ3F"6)`CQ``X8'A",,4!-SE0#-F"ZF#U1,JUC@`F[
M<Q<8W]0#4YA473YYS_HRX!T/V`\<);!?@$(%#B=P%(#\U\AD-FC'?VBP-2),
M43],5!D6!OB$$=U(9&@8(@-``)#872I`C_@#!<##LME0!D[?(00J($'D5'"A
M$[`A5XJHF%<^T<<+J*"!@_Z`4/UD"$508`)G0"H(\`"',L)A`@6X0@0T4(8E
M)-P!Q8B`"N[`[BJ_5`]2"JH`KJ""!2"WR[ZYW`G@@*$Q_T'_X7KXXAP04-<'
M:``/"\@?!?1PAXPOH0P2=R/GV$!GPIX'N-I3[`!\H@<@-<`!0`H!H+.'APG<
M2W9G0%`B$WU9PF?6#Y!$QJ.=$6E,AG8<%J"X#8':%E"$8`)XZ)')48X`J:%2
M!3$?\=3=.6A05(O0!7[`;@?@EC(<:^8G6$!6`3L*(>#A!,Q++NL_UMT%Z,U^
M<)C#<4P.>F-O(&AWT.[SWM(`"3#0`[YY0`&R<`<0J(`#5M6`!"Z@"9[5Q9(6
M],H"+-!)%1R0`T`N]Q^`&K4[!(`-YQ*WIX@WT#_@`1)!6P!7ZFW($"S@A_D&
M4=+`;\A`@,D0<`<X<!=F>!GV42(1_P#-$0$#0"M^(AT;P!:><0SC08%9TB-\
MUAZ!]%B,0`*]<E:8PVG/@PO8(7B,P(&+`('&$`#VM`$LZ`P@4(*"<(,KF"6E
M]8(N""''$@VQDB`T&#8,B`R+E@R-I@R+!S>7E`R35@[:(6DL*!XS`H.GXH)%
MV((<R!U<N`@9B`PD`!D[2"&E,B:,<(''@(/802OXD8,N@B!>"(-QF`P!X(%L
MB$F*D(<_Z"+Y@PQW.`X&:`R#F%$**'`4=@Q)6"4.2!(4<&CI@`!4$PT4<"P6
M4%0Q42+_L(B,P(G&L(21-$F0]H3($(4+@8F86!LZ48@QXF\6=8@)F(A/<83'
M<'"J>(LJX?^)BJ"+[(1XFR6*C$>*:_AXN%B,!,&*5N.*S8"`R,",R<"+S].(
M&1&&QS"$C$"&6M&'T;`!VL@,V/B%9Z6#YD"-D=0"?\@,#(`95B@/T`B-V>.+
MC@:,3@A:E`80+5"#]C`8XC$8WQB#)<B-B\``I0("7`%1ZM0\5@$"`GA6/1@-
M_1@-XD@/R#@CRBAALBA"L,A('26-%K$^>W0,=G$,B?<,)Y8,G94,GZ8(3N$,
ME!=)0>A&02@.X=0.RR`OP?8,=W0L%\`R_Y8.[4B+R`"*BB>/E22,QF"*`>$`
MDV@/-/(P3O&4S8`OC:`M(9<%&P0`9Z!W+'8"G?%G*E`&TI1S"@'_;R?Y3'G8
M#$XQDI7%+/$PD:-0D<O@C!66D<\(E(Q@BQ=!92>P!.#`,D`F6"CR`5/!1,PC
M`!$0%QS01/B!"`Q0.!)8%U[S`,?'']L7`18@8)=C)1:`,9#0`A\P#!;`0=2S
M`7FU`4I$D$R$,0H1`%,@,(&V1,]#'("U!-`R`2T@`!HR!:42`!S`E^KSF(%%
M.]"B"A:P`5;R`5$Q`0P@`1:`+[J!?<?B*!]`?@W@`<UIF?RR"!SP`86#!UFQ
M`65``1'P`=0!F9`8#C]9<$H(CTQ(E)YEE&E(C.I@F$4V`!<@%;3S`8WS/!P0
MFH^Y;`W",I!@)=#W/`S03%O$FK'4`C#E_S\;,`7X^0#Z61=+$&!3L@#A1%:'
M>3T4,"#BN3X;1C!;%`(M@!93D!QL(`%.,0&38202D`4WJ2F),#^$<9H3X"F#
M>0+@@"\MX`&?0C$U=A08Z@`>@)P:\BD;P`'A-@7AUAJQB2\*L2=3X$.>0B+;
M>8[DX)9NB3ET.9<7N0C0B)<6\0%7,`!GP`',DP5H2A?LPP910P'R$@%WT`)X
MP`$%T`(:P#F(H'/#HP$>\!L+\`#)UU<GT)H+<!#V8A48YQ;2)P$AH'(A<&)7
MP`$7$R\4()Z\<7U7X`&:(J$1T)+[X@`7H"O;HU:G,@%EQ481L))HBE\!($;"
M57$!ED5&$AU\DO\%9`I3/N<I$P!+%J`"4]!>-R2>3G6C;(!.%,!49T&D(>`6
M1!$`GR!T24-(#Z`"6(J>=@FFV<H(0GD,35B4]"@/GY!!@;&J$O`Y=W`<3S,`
M@8H>WG(Q600'-W4%4THZYXJF"`)N'O!+>.`!4"((^\&DLR2HJ*0OIM%.[,8`
MU]<Q>O`!9P!3/*1W&S98(WHCON4/=\`-SS)71K(!+3456:00EBD(2W0"VG0"
M2L1NE/H'&I`OR61ID^I,-X('Y_H!$S`,-\HG:"2AK3D,+&1!9Q``U](3%B!F
M\]2R^"B(<%F`2QN+%DEP&[EA%F$EA(*J>$`!<?5G#<`&&W!3*H";<77_M7%%
M1#]4`#WTL-'!!G?V!ZTI5L'J*3?3DJ1A`7=``4TQ-Z$CJ67*0JQ``9*@"@M@
MMR='`CJF"*/TJZ3Z7Z,@/V7E?A!R5@,P!7IP71!BG1`"+2$``K;Z1F7%/E8"
M+0X`!^"P4UHD@9FV;*03@((P-:23"RYGF*HP`100GBIPGMF0GJS!GJ%8ELC0
M>%`HGS[)`6705QL`/#%Z'*=B`8%++F408`$0N!/`E6KF="=P`5E``<)`&#!5
M7H35'OA"I%FA2P<4;#SF`!QP0%:B!W!$`0QZ`JXGM?J6NN<1`FS!!BOV`4;1
ML6PP3Z/@`9``92)V?4(P/P,,`A=``>]035-:_P`"<+6#\2`\,UC`BKT8@TJ7
M*AM=93_/$G<2\')GZ[KJH*5-VXQ=R@ARJ8C;:EH<61%4"PH3`!2IJ;5<Z[59
M,0'"FYJB,`IEL"$HDK9S]SW2QT2\<4`3(K<#H+Q,I`^#<&(,@,!957%C-&)X
MP$07L%S_VEH"D%#:L3U=Q;@4$#V/"T<5IP$`YB<-U@*QU%::N\$/TKG#X"FO
M$;K@\#:E.P`3@KK1H6]GH!N"\38/\YB]FD5S<0ZXJS:Z.Y2\>PR^6XK`>PXD
MT'-0-3_`TV#0Q$(6H%9:1#0_)D:+0Z/7^U]B]@#'00%BQKU^]F3)U!,UO"=P
M-%Q>E6YU\0`3@@A+D/\P8@&_(ZHC!;`$27$'A$(]@F`D/76BI"-HY4D<TC=5
M2?'"*N`!MO(@(2#$`0!@\L5C@X7)#5#!GW-!/LMC?&(D@Q4"/`S"Z2#"/4G"
M7_HL)3R+ZLF(4EL1EUBU0I`[J"K#76O#)Z`O`/!QFC('V^D!*"LO4_4'Z>2=
M8K2IE`JW$Y*N,Q);'U>]S6PN)Z8MUR*ZU?M*(Y8%%M":%"!7H#H`^?P!',`3
M868:`8"J%$!DO2D(F]H`"-`"&'H&56P:^$(Y@];`<5=6K_2Y<;P9!"MBL'O'
M!Y3'EX,OG$#.R@3("BL`M$3(8X,`4!W54AW5*7P53SW56(T`[JD,5YW54MW_
MR.80`#!F?I)<7@'&!LCK)QI`.0WPM=L3/X=)HP*@!]^1!>=*%PYP(J9,(W8=
M-#LD`&SP8L$P7(23UQLT%+/LQ%/PL+A<('?B*1=DLMW%P%EP"G^P!$K:`)=X
MB=!JTY@#6"^WS`_0GW.37,$6`A9@:7P==X/51!I3P2_53+)=#`^24ZE=B0,U
M,]&1?N6P/UX]U6-SSH;XVU^]SIW8U<2]PA01`$,!#@IA2"M)5H;9)0HQ!9WR
M/.$I(4MP`C=8RYLBLB76S.275`'0G+BQL2)&%.?J3!6B=Q9@2`=T`?,T+^6M
MWL)#'`ZP!#YQ<DZAL$LD`%,`8[1SH.-"%[.$OR#P_ZL*00%?^RRY(\;^`@H'
M"CS,V0"#23M3X'UUP0#-!S;K0SL&*D)?RYM7,3Q$H1#5DL[6(`'$C=4:O@P,
MT.)3+;/-(.-270SQ,`5ED)C=P!AL^PET812_ZA354F19?'ZTT@K"ZVH0LT2#
M`D=M47%,,@4D!]T,``IR!0J&9!9@\][)DYC^!4JZP:(,\*B"L`2:4R/QTUI]
M([,14`93(;Q],4W>T0VTLP$F4V17,@$7@QL%T!=9#B$-,@%@R:`N$CQJIC<*
M87I>H@(`?'90L>#I<`4V'M6VRPA34.E0[6K+P.*:'MTR`9_B(`Q+0&[[QA`/
M4-'&N.H=82'-P-NL'NL:<?_IVG!\%]"0U(`8!($I9RGKOO[KP![LPC[LQ%[L
MQG[L;1%6NJX-;YX,1,&6Y@``%S`ERS"[.XSKS!"2EZ4"/F'J-P('>X,;<%XC
MJ-?DR'[NZ)[N#@&>=C$'O5X-<$!2?*26Y5!6T@1ATPX[T\`^S-!D92H$7F<,
M<94T%^!SDTTY"IO:G*[N#-_P#I\.DR`(4(%?:N0Y"6%!3(U&S\(&F3<R<W!G
M4_$!S<$!"-!#7L2V;&`6`8``67`::ZUC]Z((SK0M3A6T`+``*N8Q<\`6,`\)
M*L`&4!)EZ](``%X`EQ``8&=+2>$QS]2R<`3TK'D'H_2I^R)9/I80;*L!HQ2L
M<Y7_%%.`/CQA#.J]RU/ARZ!`/=A55P^_]FS?]M50?SGH3E/@.4V$1!IP7;8G
M`?WP4ML#%.R#QHK0&?4T!1)4G%6S/5G,&ZB&UZ(Q2R4V"<^AE&5P'8I/2TX7
M8'#`&$NT&<S9LS(40PE"6RHPSQ)@"%.@7U'AK!!Z4S!E?=HC.+,E`+VRM32#
M#/E,OP1]O]7*&"WI]K[_^\"_"`R2/0!>%Q+C7T1,>S<[,H'Z(%CI78L3^$03
MRY#$8S+D-7Q^.>DV2FS01O7B`$Q7P9C#&6[]+)3;VEF%,;;96D;E(MSN6W`@
ME635=T2:7++/Q:-``?2?58P`"!=P?W\.A(=_0A0>?Q,@_W]W#1Q_$1P#61%E
MB)N<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:Q%E.$!1=7?Q<3#@(-$7]S
M`P^%#5D`4P^&`&=_>`X!AQ,M)[\<AH>&AAMG%`)_%AN$``43?X,;$A,6`<S%
MA./E&X81`X8"%`_[?P!$H""!G;=S%[(\^/!'`(`L#3D4DR#!T`,!^!I<4#:Q
M13="'DA8T%2($P<XCZ8`(,%&@JXK`P;\6G>KILV;.'/JW,FSI\^?0'M>R5)F
MR9\05\H($$;,V``VP3846%)@"C1I#U0@6G=E21E\B")<`7>&08$3)QX1RM+@
M#X4)*OI-F##OD%FT(/(A"Z'"'_]`@0S*."C@K4"9,A*DGL`3X,J5,P`<)/7X
MYV)&=5-(.#A1)L#'/TO@E+%`R%"`$(?FG"D3`0">$!O+3$B[A.Z&!FV#ZM[-
MN[?OW\"#"_?9HH5=M9N0,2`48#FG`8PX`4".R/@F`)N6G/O#8/MT3]@Y,:!^
M*'')3^'_M!!":+PG(<X#DF]O;9.N3B#2%T0W?[C__P`&*."`!!:HB@6Y?3+`
M`O&]LL1GM$A0AD*\"9&>@1AFJ.&&'';HX8<@ABCBB"26:.*)**:HXHHLMNCB
MBS#&*..,--9HXXTXYJCCCCSVZ../0`8IY)!$%FGDD4@FJ>223#;IY)-01BGE
ME%16:>7_E5AFJ>667';IY9=@ABGFF&26:>:9:*:IYIILMNGFFW#&*>><=-9I
MYYUXYJGGGGSVZ>>?@`8JZ*"$%FKHH8@FJNBBC#;JZ*.01BKII)16:NFEF&:J
MZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJKL,8JZZRTUFKKK;CFJNNNO/;J
MZZ_`!BOLL,06:^RQR":K[++,-NOLL]!&*^VTU%9K[;789JOMMMQVZ^UP>,PA
M[KCDBIO,M^@2.H<?[+;K+KL4I"MOH.NRJX<'R+#A;KR;2.`<``V&PD!Z`.RW
M"0D@"-`?>-:1,._#/-;KQP4)Y[<O)P@L0,@9$(+R@0;.S:$5_R(D,`2`'Q>&
M<D8Q%R0(\<LUUJL""7?XP4S-\&+LATP<ER*`'\F<O!$B`_CQ1P`/U#?*RG\`
M#?/3--;+P<GOYKP)`GYHTK,$&OBA@A`;S-&`'W-L]P<)"*#V@!Y_>.`'`FUU
M78`$<S!`00$%^%',!EU/4/8A*W_P-D58,_)!`7@`W;5,2[Q]']20;UAO`S]7
M[0>_B""0]P`<@Z`''A3<NX$?H#M]2!ES%.+`R4M<X8<%KGL@`<H1^/$!'`A0
MHL$#^IJ]\@59IP.'!P@`,,'E-7M00!8M^,'!!PN8'?GT!$I--0)Z7'QU!&=H
MP+$%K_]Q^.@R74[!82VX;<$<''C`QO_9")Q0=$"TY_[S'V?HXK;OQ0`-?@1K
M.\$$V.8`#;CE#`'P@QY"8!WJ.5!`]3J!$++W%7U9+7.5>)L#BD8."BR@>071
M`P4<P*Z"(:`,?K`;'@BA!Y@8[60"8=O)\!>O!_B!?TU[`/!64P8/^*T0[Z,`
M5A;PMI0]\(C`D9@%&,"!#5#M@H=`0`1(D`4_.*!Y2VC!&28P.NS,`7.E\<,=
M_C``!`B@:/]`&0PCD+H97@$/%CC##0'7ORG0+6G"^*$#@@B9+#``?"Y#HB![
M(S$VF&,`>6L7&`DAQ898\0]5U(`9NVB,1;H--0&0I![8T(*3P9%V;30:^!#0
M-1QBSP)+^-S_'%J@1SYN0`\:6``"`C;(6@)%8I:#(B$L$!X+[,<"4TO$`!ZQ
MQ$UL8`#."0!NV%.."QPS/Z0!@4P09`$;,K,AV)%`$TEP`0X8!P"DD0`Y&$".
MVS1`:;9,YT]PF<M%!N4$<YA"N-1)SPXUX`'XS*<^\6FPW6S@!"J8`#GJ2=""
M&O2@"$UH3<#YB`TT\!5"*"8A'+H)!C`3!`]]12>_LP&':=06&+7+*4`@O4.4
M5*$!(@$`C!,``%R3$PZCJ"A:ZM&:BJ(%)SW2%$@YAW=TC!4?2U`(0(8(-H1'
M`-*0A3HF<`<+<!$6BZ2'*P!"B/>9HA^=H`E*!S0ZC0G.B(?0"@6T_R$*P9&F
M!;Z@`$-"X0"I)DD(L\0?!^AR@DDPX`H?((%&)M"6#4P`.N40*"(:$(+$+.`,
M^Y&`'N80G448%:T>.,,&'C".=Q0$=I-H0026\-)/D&0A7`3`"3:2#<Z"8`E3
M=$M:#G&!"#`".AQH```:<(4SLF&@"+K"<@906`%@9!(#J(\$KI`,(2SA`Q9Q
M7PM:6YDI=)0#2PA``$[P.`',IB`,X&LCU#.!)K:E`0X=Z%9[\TH]"&$.Q9MN
M8],"/GQ1;@!3Z.L'B(&<!<S!*!Z8PP.\=\P)+(<"P"`'*N%0C`]<00(`\(<$
M_\"!`P=6O#@"`-NNH0<2MH`-(8";`^:0!?\$@"`$92@`&S(Y`0W49WT;YMIM
M0<*&*VCE`AH(`<I4H((S0`8!>&C``HL7OSLD),1D#<57/.+##:C@)`*X`C':
M1]F65<(HA,##7"T0@;]NL``-0$Q9ZC&!!W!1!0-0@6@'P+8)Q%0#%UB`!;+@
M`3@X@!L>T(,`&#O6MW`@!!ZXPA2>)Y.&+"#+["#L.P(-DRM,T`(4(,UXR<N&
M,Q1M`<8KPY\;P(:`%BT"$7#`VC)L@1#<`87>N=?[IJ"'*<S!D&DKVQSPL(`"
M"``!5Y!B!%I=@#)NF`-S#@$;^%9`=-J(;EO)0A<W\`$$C'`"`.CI*B5@R#OP
M3M$38$0!JBS5`ES_@7@?9H0&`.#A.$J8P7IX@'X1X&PAJ$`/3U5/3-8=$^O8
M6!P@F(`$%A`!.%P!!`V``P4X(.4_=(5[A_`%`#[0FD(@HR0?L8<#+L`:Q$[@
M<`/0ZF0C,4;8A>`1>!``1!8P@5G#F!&139``&+&$IT0@!',Y2D`(CD@/+FS1
M/=D`&SC3Z&2_I0!(\8`!<Y?I!T!$;.R;W7:2PFUR2H,U^5W;!<3&.P]HC#5_
M:,`9V%!&2JA5%PR8@K,-J:,-(,`:(6A`5/PPYPC<X=C)GC,#F&T!#6`Z/-'^
MP[0[3@@0(.#N.PM!,K;=;<B,D0.R%D`O$/`!@<22$!*@@.(73Q!"D(00__)6
M`6X$$((/>(`"^':`!\*ND6NLO.`;3,8W#J'P"YP`-_]<PC/NPP`V>$#R[TOR
MQ>6^E#^PX0'+A%T!E)F%230D&27',N7,[`L&1.`"(6AP4F'NS]LC``Z0F<,)
M`,B7@?R!YYHV!-`Y('1"H!=K%SFZ:_6`:;K=DPT>_`-KKE"`#U"=YU<OQ\?>
MOJ,K?-J,8R_:!T3H`&27[0H+@`>[-@<?\#=D-`=^PTKT<`$%\`@?,`$P-@'%
MHP)94`"0\3[<M@0(8`$(L`1W,`5XDP4:(PJ/UP@;4`;(EV4"<`(4X`P-\`%\
MAAJ$L`"F1V78$7HE(6;U0`Y7%!>=<6<!H`>*)O\`!6`!D:`05Y!\R2=GAO`!
M2W`2#P`;],8!#Q`=1'@)?P!F$+@.<#``\O-*(%`&LJ5HS`<4,C<['``9(0`'
M!>`!'+``5S`(A-=SVD=;JC%'L[,<'*`4X:8""U!&&L@`3'=;"#!`W',8=U!U
M`[$^)2:(2V"`.<)*<+`1DA``7)1GL15;Q!8``J!Z[P.%AR`$4S")43<T`Y`;
M$N`!(#!]%+`!2U&%&W`?#:!Y),`-']`"UE5;HW`NA'!.$9<9M(5[K.1?`2`6
M!J,")Y!7SL1@X,1@E=%GR.2,#38)`+`1'E`?0A`!=;5$+'A.!.<!3'0T#X@1
M!K9$5X`-[4$!,%$.>"7_!&V19!_`'O'B30#09V7X$P$P!=.U`1[@1.>X`=/E
M``6Q6=T$3.(C3@#D!]8@`/1@?'>E0W#``&W6%A\@`;E``@]P!1QP`9U&#`!@
M%!<P`"6S00RF:4Y"17CC"ROR4_>8)EF@`05@0'JR`:CE:R="ABW))AM``1&0
M46%B`>P6E$(YE$19E$9YE$B9E$JYE$S9E$[YE%`9E5(YE519E59YE5B9E5JY
ME5RIE"^'(P'`E&!%2+E4EF9YEFB9EFJYEFS9EF[YEG`9EW(YEW19EW9YEWB9
MEWJYEWS9E^TRECE2.6KI5DED10YPF(B9F(JYF(S9F([YF)`9F9(YF919F99Y
M_YF8F9F:N9F<V9F>^9F@&9JB.9JD69J)F3V`"0*%!Q(Y%4B!]`FTU!Y1)PH.
M@0@4(5*$,`"NJ%6G\#-S$)EY0YB_L2XY>2MR!)BCPP@@@#*=`"$LR0DL.7JA
ML%*#E2`?(0"G`9BA\#,EZ`F7YA_$69RU<IR?$`Z^,`!X`$XAX``,\(L.0`(4
M4!\.L`0,9%PA8`[)0`%G)EM(81UM)P$JD(0!L`%)F![G\P`4,9^X`0=LT0`:
ML!\:L3NJP)VB\)W#$9[B.2ODZ0E^Y0LGL`0"$5&7QP&><7S>@&!/V`!"H`EP
M0%G>4`A.%&2&@$`Z%`&)H9+3T`+_4`VMU0"9`1$?T?\:STF;65.A>@.>1I.A
M&LJ<'#H!!,$:`-")?6$/=P")--%6RW%O960V#D"@A""#"$=&RS`7CV<1W/`'
M&Q`!N+%=01H9JT"AH6"APH&A2@HK&]H)?B4A'M`:*M`"B&8/<-")`0<"C0&H
M?R!`OE<(>4$"I_&BAG"*5V`-]F@1@D`"$J"F;;$.;3JDVUFD<7JD%YJD=6JG
M3(JG$W!>F@4`DA<"4Z!P66@=E;<$E*-I(;`!<!``,P-Y%]"J3W@(<_.HDG`"
M'@!E)?$/%/`@F+I=<T,(0OJFG@H*<AH<=#JJK7*GG``?W*$>)*6;*V4-R]$"
MSK%V`U6/)'4.[H&FEP5A#`#_KD=S#A;I4=D*D`,`3LYEKMQA'2T``K%)"G`*
MK:`ZIZ)*K=5:JAFR!%.0!3@Y"_VJ(/\JK0$KL*MBK1ABJ3XI"POKG0U;F!#K
M*A++(Q?;"=&JL1O+*AV[(Q_['!D[G`\[LJ=2LJSP.)X``OW4"98J!!#6"<5X
M"`!P&OOJK-T)LBGK&]/*LJ;BLIW069M0'S2!'"_EHHFP"4+`'L93>W^`'"3`
M3&#S$5T*&=?TE?Q*.DA)`4%+ED2K*D;;>1,0`'@`=?BU'Q>`!RJ@"\@6@(7%
M:G.@%@4P1G@#IA8@@`\`3WXC`8?#!D+0:D(X;Q:(>%]T!N$R-39&K!/*EL(I
MM"M;_[:C8K390`)*-@E9(`3K8`]1QP@0`8'QD`5(10(V2@B4]0!3(`178!U-
ME)T")9`0L9%U\SQ9,`!$>!!G8`%H97E",'NKP`"5^9J4:[FH8K2%<`&4A1T]
M^;D#U0`R80CRMK899PB@2UE_51FX56FK,[L-,`>'$;YDQ#T,0`):M;78$0QK
M6P`5"R-#B[RAHKQ4`0#_H*BH$0'1.PG4RQ8G6'O9VX+`%QX?A`]3ZP`6,`@4
MD3H#$`$JL$0041KAL+YU]0M(&R/Q*[^?HKP6H#'RP*K^!@<J`*$<DPP?D!5P
M(0':@*"(AP<;L)Y!-@4HEQ:]^\`C]!4KA&BJ.A:'\``1X/]'X@,`;A9D,5.Y
M&NPI'$Q6N,@>G+@!:B$)`A!3?Y`83FP<3JRS8",!3*LPQL$``8!3)"``75RU
MYMH=AY`?ZX&FZ.JU+9+!1\PI1FL6-]L)%I"P;>+&;ZPIRBLH>)S'F++']&+$
M?IPI@`PH?3S(E;+'E9`*:P5)4`9`GS`)^E@EAXS(DZ*\+1`"8+H!%V63)-`"
M#J-566!5!1`O)+`=G^PPGP&0$\7&0E+)EAPIRNO#M?I*]@<`+78&$N%%&[``
M2Q`]Z7L".*5O=Y%761`:F30%7&1MD"$(DM$DL!S+CZ*\]_D`VF%`?,5)8E=P
M93,=&9>^IXA/BD<.R1<O;DB]&P#_$;CA`$+P8=`LR-)\R01[,&S`H'<@<XU`
M:;?1<5X4&%>@`=;E#0%`%?V0:7/Q`$MU`>AL"+@A@[R9)-$<SXQBM(BV%A;P
M/MF\S\XP9U2820%=&H506Q30`!X@!"<@`2%0,A7A5V"!&Q$`E.P\LT82T1*M
M*$:+:X3031`Q!9<0EE.`5'&8#G0A`(]3#%/@2TWD9B%!GV:V>CD;$T(\`2&0
MLTI"TS6-*(4<%!0`3I,[T_!\U8Z2U4`A`'``!]HY)%8-UH4BUGV2UFH]*&S-
M)V[]UH$2UWLRUW3])W:M)^M2+G[]UX`=V((]V(1=V(9]V(B=V(J]V(S=V([]
MV)`=V9(]_]F47=F6?=F8?=@EQ"CLY)>>_=F@'=JB/=JD7=JF?=JHG=IG>=9Y
MW=JN_=JP'=O2<HJX4=NVC1NL+=MYW=E5XTZZ'=N\_2Z^_=NO72]2Q0&X--P-
M8,>'P*A1E]L2,#2B<!L/U0\/8*[GA`JN[`H(4MO(I*)V,0`7C`I"<+79;1/4
MX4LY80%S7+6@<`']A&CMS1,@,-YU!ZT]&PM?J;NI0-O+B!^N(`'VF`@7L&^/
M,%NF4-L74+'J'2K&30E3L';:LPD_HP?PN@FUUC3#O0D1D#NC\#/VR`%B='>S
M-<^B(`$K=!,%@#5OXVQSI+J[Y@H"8$"45!/.@`A0AQ,]LPD-`/^Y&"-5<,4+
MND$W.44(U`4*MV<3G8;DG.H);(!W>N"3$N(*/^0-8N0'A"&VIL`N6!/EG+!%
MHO+@[.(+7:-+A+!3?B#3A+`S&HY3A]`<UR0$[WLT#811('X(E>9(T<$<`=,<
M)G6^E>'A.'L.^GI1`%#D0F95-N1$G<6NQN12=F$V+<4>-B0>Z*2O>'H.;GZT
MA[XQO*A^$;`!9B-3)/,=A.#H=;<2)-`@,K7C+:"T-`$?-34>C3113.I0\$I2
M-#M1^2U=H%`<O?CB7KP)<T`/\.%KM\?*O'ZM.WL(P/X)^>$PYT,(*H4<7LP&
M3=X)Z%<."'`?CLX[A``?Y+'J#>+G$\7_2JD312NLD(@@ZL944D<:``@P-*^^
M,32Q`?E-*6+N!R.F`HK$"6K;X;IP,FTA#L=#=B-.=N*#-2##;57:X=?'Y6[!
M+E]#-U=NC^=&$/DZ-B;D!T0$`&7PY$=:.PK$`.T"XJ/S#^C5N]FS2@R@!WI@
M;*@0\JK+[_R.D;N&.Z1D-H`'\\/D[W[`"!>`-7?P:OS>12U0,QU("0N0/6"*
M/T\>/U@SKW-T.0,P!]F#3Q=4!EW3[7\P!>PR"(<P9V^S$2<0]CM);EC>-8/`
M!A:4#!PC!(GD#.RR05@S!RN1-Y(D52P><>RR`)RX258U06WA`'?@N>Q2!NZ(
M,J^&#)+4#29/_PYX8V1C;@QDTP(H-#&DQRX-H%AO\^EN?W?YR2Z\N71O$\55
MY`<7!_%K-`==HPGL@ECZ8D;^ID`5E@K;W@B$`0?LTE.QWP+KH@?2+7?L4@`K
M*O+%(.(\A0@:L#OK"I]&0P%W9V.VYP#@APA^@&P<*`!R[SCXLPZ"0SJ!\34%
M,`AXT-6<S2[]<_0D9.;`LX(K1/`T-#H<L)P0@0<?,#K(-G.L`P@2$0A_``(:
M920('Q)^`RIS(%..?Y4;"'Y^!0$-?@!7"T)7GF4(`1]L`5D/`'X-%`B&CAM^
M#P-^'``+FP44#PLD#Q25Q,7&Q65LE0]^%[<,#VRT%PQ9#,0J4W\G%_\<?A(<
M>G\+5P%S2Q1^#+0`']]+ZA%S&R=^Q6<J(',:`0@1K1O^^*%PX@X)#AP"+*`0
ML%*94`X0,/#CH14`8EGF!#B3Y=:%1A_2#>@D(-T&-GH"1-#PYXR#6Q8\(-C@
MP$&+`@M`Z(G@38(%/Q&(-;+PDX(%/1X$^)D@@1B<"7\T3.C4H-&%3H80#&#6
MX&*E,Q2$#$PGX)8$9A*FS*2`A]@&/1,".#C3`@X"(<38X`%Q1D,C#A-;$%NP
M0-626P(NX!I4R%.$;\S^1"C0XDJD$'`"-)OHX)CG8VR&299VIJR?DAI:3%FP
M045;2W@V8"T58(DR-F=`W)E3C%FF#W_2_4'_D"6`AC-_V-S1IZ)8IDQE_L#\
M@(#$F0FT6/DY,66.!#UWA"!H^KF\^?/HTZM?S[Z]^_?P/<_)%#13S@+/11>;
MX`K>AE8-M#0,)0/]D44$`R!@P1]3X-'*-8S]H4(LK3C`'P5LP/''3P,4L\$#
M*OCQ`5;G_#%;6QQ((\$'9[CR`"%*#9#=+20,M\`$"SB@%'$"$/-`34`&>0TQ
MR2SCQP;L1'.2'PM,`0(QCYT#P&,3C'))AWA%QDX94'W70`31>6`/,6=HPT86
M+4T`D$"^^*%'%CV>\0`R07G#3!83(!!@)1G^@=<$XHQ31CH@)&BB)V=N:(]+
MZ4S`'P"._C$'&Q,@_W*".(H$98DGS`AV!1Q*"49,BE8-@E<!2V`E@%8/L%0,
M!05<H(<$#KBJP0.=;&#7!%D00LP<$9SDP1^*]<CGG)-T8J%6Q""PA)_!+5`)
M7(Q9Q%@CP46'QQP3%,"&4GAIT%DQ<@49Y)[)B19!80)$P,9IT?P!!Z5X^%J)
M!1/<00J*RB!PP1^6&<,`!0MX8E(MP2''1E!G1$>,'V4(@X`P2X4(P'4)GHI'
M@A3HH6!U\84L\L@DEVQRR/,!)1!%BN1W3,J93`'@'W@,V&&!#D3PTX)3G+$F
M8W8VAFM5B7)8B1`:B"8N5AJ<\(<W`)0170/2Z%'&3PV\^$>,+=1BZ'!9-/_0
MP(+M8A)`)0-0H/;::XOJD#)_,!,0I])LD"+"E9#0`!P0#R)V`_W\*\&']K"C
M0I=Z7!!!9Y&1.0P;G5T'D%C#2,#?'2W-2>2SWGA#@=A#)M<<`"U<6LD"*@AG
M*%9L-/=32PZD\_<&D5HMM@6F"Z3I'^QXXVD(2AE#2Q:%N5-)`2-ZLNI6<!/3
M"AY7_!&"K1SD"L<<?Q<#;`!L#*L8><G-Z4XG0X>.@-,`;."!M'_H<4*UCO'6
M2K8T+R#V`(T\*:XQ(+#M_X)\$DT6X$"+$Y`D7G`H0_8J,9$'0$UJ)NI7@`+&
MP#DLB`2.2(=FAL6B\/T!@@_35!G`X@JQ;>`ZK_O_0P%R@P<-N*9U)XNA#&=(
MPQI^)F5!$8`$@O&<`A6C%1$0@`#.,`\_+,$""!A0L'`6+`2\A`U+^!D"6C"I
M!SR``>>S`!X$X``]"(`_'>(3]IB1JO@U``^DF!H;&JB8K#FB%1]@ABU\M0"?
M.4!L95"-'\[&GB+%[4@"`4`T&+"`7%"$&!.8P@;P4`!O;$4%UE'!4:[`#`NP
M0RT7X`\#%O?'>SPN<M@IX4"F0!D*L.0,)PA=,@0PH8E\8(BAZZ(%=O&3!RAF
M"JHC!.OT@#O,N40Q%_!``80P@3)(P%L7LT4SO+$[=C0B57IX0/",H:]G*<8#
M%]#*+1[P&.:]S!5_$%,#_WK2B0NH10(4@,JOLE"9!3P"`4_BT[<6P(9&>$`"
ML2'3'2Q0@"M@C2O,*$G\&A.<;UU!#P#@3C\\<`L',""*[#G3`Y:```XT0@)B
M$L`#O#B%>D;J7C-Q1]342+,MSH$WE0`!`MB@N&\(1P,+>)'"Y@3"2D#L`1[8
M"3!A)83K7.(#"7I6/2(P"OW8\*A(3:I2;V@?1^&HAS[TT0*&Q`'OA``!9RC`
MG%ID@3G,Z03#X(`&$+`)!LPC./L\Z4DM$`XG"F$#!4#`]0#XAQ:TR(D;&,`<
M&!"`,FA@%``(00BD4P"::.(.5YS#3,K@!P=@SP*8^X,$"L:&%IS039IC3P@*
M4/^)!IQUKPTH[`<\5EABZ)5)%A`"12>V-0WX004`^(X&-K#7`$SH5L%QFF>+
ML0H5.BT+P''`:Q%[3#<%Z#':J(1@3QJ@MD;/>?BY0X]DL@@0/(`WD)7.7MFP
M`(]U*`LG(,$5$)#$0X'J70NX"#R\I1_:7B.G;I4`2HOQF`M2]UD@0*,#%F"!
MT!YC)6<#P0G(.PP`("`E_$E<,4;!@1:@D0UT]:T>--"A<!BQ&$/T`QLN,H@D
MDH`O3MPK6_Y@U@TA8*HAFL-T-5R`$TA@G^PIP$G9\`$2"`$_&;F`@>^P$3_<
MX5\I+=A<!4O8#>GA3:^IQ`5<JP=M7%<ZC)P`<@H0("+__TJM*MB`>`\\#.`^
MS6/ET.Y(5+S4,IOYS#&$&51[:%3>N2T```@`""P0`,N2V`(@2%]=&\(`.OL)
M`#7:``/R#(!"/PD`J;6$`.`<3TL0!2]P%D(W6N"-#;1`,`%@``D"8,EU%$(`
M)-@`G>,,@M"UP`*B$K57VM."(<&Y1@`00J9)0`*?\-%YELR;$&MT9SY*8(>Q
M]I,%AF3I/\"Y&'9F@&#LS.E,!X337N&TVUH`YU7[I-&5D#8Q=LV[BY3:V+&&
MG`2,=>D_D$"'-1+"L'F7ZS_,6=`-,7>P/_VD//_7%$(1`%[876H09/H8@B;&
MN7=8B7&[VP+@RW:N1>TV!H)`_P*A\\F^W8)J71NKK@+(\UNO(02OZ-#8%O`*
M"89]Z7ZSAP&%CK>HG2W9BX@Z=)4X=9[KC.DAQ3;@R,9?H"_B`<"!B<1G*[?S
M"LV`?0^\1G:6;*+=#0!_SQO-4(^ZU,^CYC5GHLU39T\GV("`YF3]ZV`7&>2B
M+MS!AOWL:`]9B/3%@;2[_>UP/X8%!D#WNMN=[C"/^S&$X(%$QEOO@/\Z!\*(
MY@=,(>^!3WS8!W8"#V!;\9"/O.0G3_G*6_[RF,^\YC?/^<Y[_O.@#[WH1T_Z
MTIO^]*A/O>I7S_K6N_[UL(^][&=/^\\$``]E*(`'`C"LD/7<9'F5`+K"'I-7
M\9ID(/]09V=7_7N3J>`:#/``0RM1/<\DET&W)MGPB<%9]`B@N6@Z102RGYX@
M?N;[YYD"^3^#3_-OK??':,#%9[@)PIOG^NP1A&>"LKMC9+88Q&14Q0%_/F<B
M#")#_4<,`3!8(?!<-=05"6@R1+$>%L5`\&<>`S!_[Q$!";=_BD<3YK9/01%J
MQ/!F"F@,'T8NQT=^(#!Q'N(66T,!&O49\;9^)[AWV'9K\08"3\)'_E8)SV)L
M2F9_/'B#0IAMQ"!K1P,"'*`Y`>:`$?``MW9K\42%Y'(,#%`&PS(E$;`GOF"%
M?Z!.M!,0&[!O1?AW2&B#?#0N2'B%>?-X('@"N2$`'N``&]#_:%/(/\=WA&UX
M@YOF&>OW=PU`>`$P`!%(?@V1@H"84K?F-C7H/!&(;)6@3CIHA#;(AW+AAKS#
M)WW(.\K')QNP.W98"9U!B<;P5DMH#&I(BB"PA[R#')_XAYK8:`T!ANX6:*1X
M<=G'@@IX?$)`B\0``E'8AU:8@C)(?I=X-H/H;L!(C*HH/)H8C6\'@LEA`1'0
M`F5P!<-@(<-$5&5@70Y0!D,B`2H`!QXP!4VH`N7H`5F0#3ZBCA9``=53/7"@
M`H"3C5,0`5OT`'A0B$'(3PX0`M@8`LFU`<^"32=P!2I0&R0V!1=P'94P!>'X
M`!N0C9U1`'/1+0BG`@[0=E`Q!5=0_P8!0`]0LED#,`59T)'\=`5+``)+$`)9
M`(YE,``/Z2@/5P!P,`QGT!#Z>#@@4`8AX`!\$2MPT(`D<`(A<`8,@)%R8@P4
M<`&AP(5>B`=X\I,-2#LDD`57,%L_\GS"]`%XXC25<`4.@`<GH`(/8`'_<@59
M>04&Y!?+L%D`8!!`R5(J$`)X$&')(01@I5$6X`!P0&4,4(Z,X!*IL`Q94``#
MX$](628O265L)9$1TU<AP#Y_L`2#N5_$!I3C0A-PP`$6,`6!&0%'M`'E<)<J
M`)I[8X]:!`?1(S:5(`!ET!&K.38%,`'/X@!7,$P<$)AS^0M3$"!J(A37`143
MP`!%.0%"T/^`&S8!2=D.[3B.5^`!]>AX=\D;T:.;5]`:(2!)_M(`65`&QA(-
M',`Y%B`-F@(`MW(%$J`!#:"<KJE\%L"1%```*M!;A9"2$V`!SU(`#U6/`#`'
MFX5M)S0`;-!V<1.>"'J9`*J;#D`"<T$!9W`%<8&4*E`ZC92-!7`(1"49"FF0
MNXDN%AH`)]!(I.@`*D!W]WE/>*`"#2.9$V"50ED`NJ>.PC";AX>.=]EF2)D%
M_96!Y7@!`\F6*7D"MM6=^T8!"60!['D%>"D!2*F8Q.!/..F`TZ@'9W`'V!$!
M'K`@(0`"/7("]LD`**<A[5`)?4<"4_(`&F(!@](AD24O<%8`((#_""-'`@PP
M`1SP+QDH@P]P!1=@0`77`CKQEQL`/IUQ!2T`%6(#%5,R3E"R0W1Q$<W1'!Q8
M$B<@&"&@?Z!";>-`#`O"`1/`@5$Q`,,2`A?PFJ`I65W8=IW!`?G0%"$01EQ*
M`BPU#!-P`1KQ`<.R!!<0'25Q!A(P`&Q8"1H``EF@8Q'0A96@-J4Z)U$X`24A
M/;I2""&!9Y2Q:ED@!)#Z$@$RH\?&ACZ*)!8T#%?0`,_WGL8@GDN@45_J4`'@
MG&O)2L%A+*N0:0YP`8/%3<=)$UO!@1"ZIP:"2/9I(GO2`I1*#(-H2RS!`1$P
M`3+2D4YC`;9@`7@*L:>:?/%4#NIFL7EJ_ZK4&J82H"$H-P=3TE>B@&':@!T3
MP*N2`0`=\CD0ECX/.@!FQT5&(2];(2%_X``KLB&Q)03-P08DH`$?)H9J`A6V
M@)[$8(>=48K%%P'C*&=PT`#/XA4#L`EE`17"RED"8)\D`%0>`HN@*EG(86S1
M(P`<,`PR"$D"`!P3\`",.@$.$``!(*L-H"-".5A;T:_JM*@F4H>WE@42``!;
M)&NEP7_<U``D,`<7@*L7L)!3$!<`0`$=DEY1^"\:4@QU"P(A,(AA%@(`<`U9
MM@D`4)YQ`T!4=FDOX313P$5P)HH@N[EP5Y'H%HJ+XYRB4)DP2Z,&ZB@(ZI(+
M$86#%34RF!QYX?\H0=&`)I*<21&;?BH`2["=]Z("!R4$^K@$O*8S:J(-%.NH
M78@N_]`2=5&9/2L9&U`2%H*;;[LAN7<-\_4!X3BJ`<$&L#D!!.,HXP0'.0.;
M@Z4231*&>S*,<G(X_L0;Q50E?UI7$>`SQ%H,\N4`+2:5S3HG]OLO'I!.`]!V
MP4(I<7N\'@`]36LB'>*MY[L^V2D498`'\G45DI&WLO&)?_`!/"%@R#&*Q?04
M_M09QUL(^W4!'?DL7X(=_LI-%^$`SZM\:M(9L%E716F9"TLUA?"P$>L!FF,+
M>Q,"$#LG..6`9M>\%#H285@9E6D!7VRR08$'68-AT`HI"<R>SDEE`S#_0N?I
M***!LSUR1_\"%0Y`L0RDFY@C#0C@*+U'.Y`2-P8:BDT+@J7X`%QR!4-B`5H9
MDSBB.2"P/A#+M=8XPI8[MF$X*BEYMIN$-FVWIYTQ@\OJO?QK;$5IOWIKD)*5
M3DBB3@#@O4M0K$3,!@.`)Z4Q#%&(()("(E7REW6U!`N0P7&RIGEL#.IT1[NL
MO`"@E6V!PK!2)<8RLHK9D4[&15/<M#M;K&Y'C;S#$QQ``AP8%%G0#B2`33&)
M?D]S`20`!U'H4(Y\O,U#N.TBFVH"2?BR%<0D`*\[)PX`',I%I@B0&$7+1X<`
M.!IBN=NI.$W\LBU1/?EUOL%2$A^`9Q]0.@PB_P0">[8\.[E=6*`1D)4"D`5Z
M0Z\0/4'$P@'Z("_&0L!_20)+(%_AM`2J-5E"8$4.;(=#,@6J2\'!8<%02@*?
M>YQ.4P8;T,ZO(`#J,["D2,(]&X]\\=1H0KM&&A-[E1E49H?O66P51+J#A<-<
MJA+<W,-1Q`!D^0C)][!(\A)&/-7J9YE+;+`1"3A)MK`#,%OYN`1I>08#``>B
M8+G\O,5U=0?Z\0\M$`&%;8A9Z;"J``!UN\$FZS2M8FD*#16"/0$>@-,.F0AW
M5`X4X`$7>@&:@\<]*P@DT!8V89QQVP+2$AX+T&J%?)S;"K%,6PEPT`*=H2%,
M\2SJIUR"QII"L+FF:O^K;JH/NG`*',##`S!HED"VE=`<#WDTF?$!4^`T8GK*
M@@T'@1T<$KDA%$`"5`8J#XK2N$+$E-C00(P,=`<'</!PO2P9W-0A%O2@-<TX
MU!`:R1R%#P`"9MJTA98J`U#3`0"2,N(S'I"5%X`F%3&)#,`!)]#'VZJWW4R*
MWZQW)&D)#)$%!%F1$Z`"*^(`66`W">05$E`&.?DY<YQ`#]`4W?<TZC@`C/"V
M('D"2Z`*(>`!#M9?VT!X',`ELXV10>AN>B`8$8`9(!!:VDAWQ$`!UT"X7"*2
M3L,09V&?#C`G4*&D%[K83N&<[W.?=(<'L1.V)*X2;GD"3FZD`("3P)%/P1'_
M(#')OW7;%@P0E(,EOY1A#;ACB),83R<0CYT<-P%2`/'L`">P`<#AI#O9W+#U
MXO&LQ<3@-`.P((F.D7`0Z7P<1AS0COBT#7!@/XE.XR!+)C5R`FV7Z#/<`@/$
M@99-'@U0!BH0J#$QFA^`)('^"M=P`LM9EL3P`0Q`Z6&DSV6P;Y4^-IT>`C(X
MH2%0+N<:FFYY1'M2`'1%CCYZXX=!YE#.)2*^F@S0C^ZT`=)"`>0A``L0`L`!
M[$&IJ+=YKA&0F.CDZ05W`B^^#48]%]L0ABPYQ\5$.[80G@"DZ*J5!3Y:6/IQ
M!1'@-+%38X+E@+WI*%D(!YJ#G+H)5X')`!]0E,&>_[J'9PEH0M"2$0(E^NL:
M[Z1LZ33F/M#8BQDD>1/%U``?(/(,`I.*CB0@G^3Q+98.T8YTR(UG82(ULR![
M0><DZKY98,5-80V^@)-M]\4!*>*53HY5^P@A7MP6(A?=&4^.G*(N)I&EX30#
M,^D^KO.HIWZB"GQ7X(+F<4Q'=>N]L6KTA;7_9QZ;7(+XIWK1)P1PDE0UQ@WF
MD1BJ@&9+Z8K'L+/I,6?`(:306WLU-*U)Y0!P?S*VX",C?#)",`7BU7"S)U:;
M8#+RO!X+`&0UA$[%<(&](2J)L1[]UP":KWK78_HU)`]6ZAE\X9YHI@*P?PRI
MGQYSV13'!P#;Q_@F`_Q*-?\%K5\R%W!QQW?W)',")2+\T!_]TC_]U%_]8&=P
MQ#!HD4\RA!\RW?\9GLH[B!<R=>8>-3+^V7\>2&+][-_^[E_]&[H?41-#<+#]
M\<$!&F@>P+PU"PH(?X*#A(6&A`,1AXN#2W\.C'\/D7\-#928F9J;G)V>GZ"A
MHJ.DI::GJ*FJJZRMKIH7!0P6?P(!$P!E@QL1`K41`'\6%!822RU_#!^^%AP2
M$B<#&QH<`1X<0H,MO94/#((7#QXD)`]+#`P7%`X/``,GWP(G`"`64]8?`1$>
M\+,6`_D&76C@`42`!Q\VS#KWX%*+*0-("'H7@4$+"7^>"=I`88H0`!N$`<`C
M`,[_`PY_0%`8QZ#!`PL;'LBL-2]9A"F7_FQX%ZS%D@'"'@BX<*S6!WK#)KU:
MRK2ITZ=0HTJ=2K5J5`$J6DSX`PR7KC\!-`S`,R"+A3("\'CPL,#"@A8+RC90
M$>$"'@ML)+`9<,7#!T4ZQ9X9P*:BH#D</(BC<,%!@SL-3KB\<@&.!+-96JAM
MP-A#A!"-&TR8`*?!F4$://0]0>&!BL<-$'!8<%FTT@%BV0`H\&<"K=[J/@A]
MU*(```T7LC"0_`!GEL8!!C0HL`%SBRQR!0DH@)6$V0D2'$3@X+L7]C*:&X3X
M;;6]^_?PX\N?3[\^IJU;N^;2?N*/D`87_.$!!7!4$B`<_VO]<0%I@@"PA!X"
MG`$`&Q.$P-L?`TPA3`1LA"3(`OZ%\`<'%HKV!P4"/`"4`R<4,,%=!0J@000@
M1`#4!*)-`!0>@\Q!0B(@<*#"&29J\,@%=TR01183>0!<`1)<(1%8'I3!CB^0
M9"F)`"+^P88ECZ1T!@,<N*@6)`-I-TDO26;A@0,;3#-!"R<$Z,$`D(!IWYY\
M]NGGGX`&.M565W`%@%?:;27!`W:N8^`?68BCX`20N-4`6A(6,,"F@ECPP88=
M#@(B"%><L(0%69B(HHJ/G&#C!0!`$H`%$4Q@8V\Y`@7B81A&<,42IIG(QI%E
M#'#!;P,X29D'2U`P"!RM7?E'@?]:"M7EEY=`,H6S'+QZ@8AIUC+)$@(4"RN<
M0@@P11EU"HAG)3D)*N^\]-9K[[WP;55``PL<NE]*D+7U6AGA5?)E`0$L,->[
MES:@P78/7/'!$OV!!=E=H1[&;"P([;O5@*PZD,L%93"09P21W8KC:"IXH$*/
MO4:ZA,);#>M`60^$X"R&D)VQ`0D:!"-(L5>HP)<'O!5@`21"1="<!V`Z(,$"
M,K50!LD;A#!73FDUP&2J(0@`)P!P5";!P"WDV8`%[.'K]MMPQRVWW`%&QL$&
M%VR`4J?MB@;4)9&=@)$%DOT'UA0VNN,!`!]\\$VG$W!`0D&#W-'X1R=PT(`$
M`0*`8C#_@$]P`0B7U(C+`,%<P/EHYPSBK#OO$,2Y@)4`(,`2'G@(0&2^3#OE
MI"[5^$&`#5TB0`L^11"`1IM'X#SIHF=TP@,8U0*';[5,,$X#(`B(?60#D)Z1
M!`+T/O?YZ*>O_OJ!NL3*L*S@N(KS5^W,_OWXYZ___O$Q(+0J\5*%!1Z7BBG\
MSRD;J![_%LC`!CKP@1",H`0G2,$*6O""&,R@!C?(P0YZ\(,@#*$(1RB5=`E`
M@83X72&0IXGJM<!#`?@&"S-!`A1&PG8"D&$V2G'`/ZA0$#;\H2"$0$!"M*![
M#PP`!VA!1$T(D1$@*"(4RV>+9'PBAJ$``3)H^(D7^O"(@@C`_Q8+(1$I%L*,
M)$QCO390F`F4(0"$$,!6#$&"#^R0$A+8F].TP[0Q8L(!?F1$`:X0@<%$P$.D
MT!`A'%$(^#7B$!N88R$HT$/^D:`,_*"`$C,A@+UEX@20P`0`]."\,PA!DIQX
M%RA:$$!&L,H3`[`'+X3&`*`8PA&A7$0NJ1(E!P3H4YA(ER;T`8Q,3&$T%!""
M(CWA24\$8)F1`($--8&WC]1R$,W<!2NGB<U*XF\#H73,H4*P#0W4$@[FL\`2
M`D"!"5!`/2W@0,3$=@D.`$`"<#`)`VP%"<J$)$$CVAL'@+E$^T4"+;\XI,E0
M,DX)!.`$5P`!"980`C@*H@%+^-0%%/^SN`?<[#A[(X&MAO6`+'"``1IX0-8`
MHQ,57,$A#M`0);.VA#IB"``!"!#[&-"E!@3@$A0(`4H\ZB2R72$`<+@:1DX:
ML3],`0YCC-@N&3$A0>!B*PUP`"T$D(6:FLQ)+0C!`Z:$)UY,#@[!6!K@COD[
M`DD`;W^@6`-BPHZ,7&\#"\!1,.S)#Q)`U*(7R.$D&A!+-BPA`@1"QZ9**K1I
M-.8#(>C>4\?((D92=`,"`(J3EG('`#"@`/7@Y%09H8(+#*!`F#".@QK@R$Z,
M=A/"Q$0B/@$"VZ'(?MRTD?QT:4O^@5,0'CCF`X):IJE9``^/6\D&$."PB;WI
M5PM`4ES#0IC_B/%#!1MXS0.$<`84;>"P`&`<'#"KK$Q<C7$/B$`+]F*T"0SW
M"A1HC4P\L*!!X*%;%/"5!093VC+LIGKBX,`<TF8!A$%),A38FV-5P`#*?&``
ME*1,:[(``A6H*)OI<RD'0!!).1+F#\BACHZF(`[G94L`=^!`(@8@R>B\UA#'
MN2?"P(.=+(#3`CJ*"SJ)Y-Z).,`W%KC"`$*0W=.>31Q*.12M`("R*91I0K$(
MP'I0Q@X=/0(W!($:8`0PGCF<LC5&BP"PKB"`^$JF4"DQC@HXX.052Y)(PQON
M!8[Z&FBV(FBUD'(=602`$YS`,A8(P7,HH`$+!(@"$HB`"A+M@,U6_R*&J*7$
M5R`\+`]`"P2-0:?8R!DKD0W"`4+X``@\JJ&27&$GH.QMSI0W@5N$H*(4G=.0
MS1*!Z-)"O2<@&*5RTI*XQN0"W2))`:!UHG>H`)@)8]F:5=+H3R]I``'X`#OV
M28)3I^^WDLC'`\I0+`>4:0)LV!N.-G"'1T@@$3?CBY=`@)8"1:N&0O9``.Y@
M`>JUV0**&8J0@A'*1<GDW^T01`&LY`$A1,`"<R#-"0Y2AM?,80K>&0T"+%HH
M`)RAF(.9A,ARZ0")@(A6<P@3'D9SH>]*8@H4"@%\`2`B$@AU``4X@7+P1P)U
MCG<"4\#(5B`!C&<6@`(#2.^)"W2%$(`;$?^YK#?`9_('`"#``>OI38M>)(%M
MX*$!5QA,`!*^I(D@0$0?N-X='I#7F!=*""77`*<5W;VK]B9.'SA#>EF\HM/^
M(4D3N%!O(G`U=SY@`K/\`UKBBZ5/A\ES)S"Z(PM%)RG]040>F`,27X%PJOUA
M#J<EP0($,`<`^,4#SSB#V#QW90EQH#]7*")K,G'Q)=Q!`&S@Z40Y0`&\A>`$
M&[CGJ2/YZ2O`I%`Y=X`T23Q6)@D"$@-8;W-`H(<-Z.&AM)]%F*7S!PGAH04?
MP(8I?2@+!+"8RV66X[0>X5$A.%*W%&``'$[_A]0??[M9H(`=T0-9@\X-VUJ#
M@W"Z/5#I"*U.;/3_".X0`>E6,UR&3P*2,T(0)12`#&>P!`"@>0M'*@4@!)%4
M;F&2$4LG$T*#4()P<&0Q`"4A'.,E1_FT*0VP0X4B`06`<4$G@+ET!=E`&VNF
M"Y!0+)RB$XHP()H22Y0D(D(0`N%!,:VE/N%B8^[D"X7"<_AT$D`G=-,B-NU'
M6#KE8X.@=$O7(*TU`:YB+.5">PW0$GCP`&1Q+!-Q!C8F'-(Q9,82)2GQ%>E2
M)4P&)^UW*+T!`!:F&+H%%'#P+GN1@W_@*AP0*:T!>,4T>"B2@6$""8A'A8.P
M%3XA@X_'%1H02*M``@%`.L8Q!PG2"R&77O(`!Z(G,LYR,Y#P`67@1N:S_R"`
M-1JN.!K5TUU`YR7[Y49WXD8WLP#DE(H54CEW<!$C9V$C-P%+,!RY%'=3P$9+
M@!%XL`&GX32$HP+%8B.7("&0H')Y]SAG0"(4,`^]<%N]07Z*<!H?R&*7,`%Q
MIXK'AR71XP$"L%QW=#YXU8TJ$`!E@'5*LWD!4SUK$8`B@VZ;4C,>P`#FQR\/
MX"H3<&R=LBM78'PA@%HMXQ]H)FGF<TCA=H_W6#3=^``F,1[&]P<+H!K=$@P9
M)X!&<U&X(Q:B,P<!\!S30V(;D6+8=04<`"R4E#DH<WD20(QZPS[.&%R`APOQ
M!R(\5RYX,@5+DQQL(87FN$NJ1`E5]8BY<"D%%O\+IL$!I2%W.N-C$<)57E,<
M0F(!*I!?.D4VE<%D?(&*=C@!VW$!%I9?'D4!@\$TV5<Q`G("+=!YK8$[AUAF
MB<AQ[^(Y33D(!7"0%M``XS$!#08`A:(4K.",<$0,<X!U@L=YDA`!65`^H\@`
MBM!M`N(DT@`.H*8)7R$(>:$((H@>674!/R)M`6`X@F`9BMD?Q9`%)+`3C**(
M>>,;;+`2)#`'SL@5KN$.T_B"N@$))^`+V"`(4[!Y!6!/WUAFX<@.XS@(NG6.
M?H$A'G(SC[!'N+`.CG8^-8)8R+`@+A%M`+`@5:A.(.`D<^4.#1!>=I(3T,`!
M.20<X;(!:-8<'Y@3\(#_(?:W"!PP1N$##05AGG/U`7@9;?\I"%FP+=HI";93
M"1O@/BG1.`]0(\"2#@/I/!8U:DO0.1E5#PIQ`J(F"2)1H?>#8_"`:4KD*)<@
M#1=0)]`6`<J$$ZSD'^V$0KN3"1L0GG4C.D)0DR)X*)KD(+G3(`U``IKT=[[P
M#B@!+78T"![@&SMQ$#D#5Q?P4]$P0%,``A_P3CW*H`0$`+2P7190/C\1$@/*
M-L@0+P.@.3IA`4*PHP+Q`1`'IO!P0B-"`AB6"G"@`BVR=1L0<P_SB1&@?Q/0
M+P_#!A\@%I`P-12`!Q:U`*EH9XM0FEXB!`M``6B!24M"`7)%'HAE>-B%266P
M_P&-\U+;ACB#X";^I1MG<`(($)Q.,Y8.P!UQ@0<?H`>Q@B%X,*E3<AP@<`82
MP&06-PS3F5[5-P@1(S_@40:3:E$.D`7.4RZ3"@`+,`T;$&D01`)?6@KXM%7]
M(@S&UQBQ:8FM\&)J!`J!UD[HPZZ"4)-XZD&VTSW^DWS&\0T!L`$!8`O?`!()
MM`%:)`@@(`"3YS^>E0E^]`TU%!*8A44:T70HA`S^>K`><JR2T``"\#L'VP(D
MP``"8`$MH`$%ZZ__BD4XQ0!5)P1;E$`JA`P@:X%-UZ\Z\0<M8+-C1`(@`4<A
M<;"3ASP2(!$P:[/^BD8-A`ZEP`!*(0&_43Z=@A$U]_\4W-2NH:`.DR<W54L(
M\D1"#$`AY#@WK[0(L.<`$VFU:)NV:KNVB]!$#52P;(L*Y$-%=%NW=GNW>)NW
M>KNW?-NW?ONW@!NX@CNXA%NX?$H)"AM>BKNXC-NXCONXD!NYDCNYE%NYEGNY
MF)NYFBNYZDH(B;NYH!NZHCNZI%NZIBNY2.L><^`'K-NZKONZL!N[LCN[M%N[
MMGN[N)N[NKN[O-N[ONN["(`)J_N[Q%N\QGN\R)N\RONZ\NHER_N\T!N]TCN]
MMQMR];&Z#I"]VKN]W-N]WON]X!N^XCN^Y%N^YGN^Z)N^ZKN^Z>L'P4L)JWL&
M\CN_]%N_]GN_^)N_^KN__-O_O_[[OP`<P`(\P/G+!G[0O`:,!P2\P`S<P`[\
MP!`<P?OK!]9+'ZL;MQ:$`.\;"1>,P?<R``=,"0:,2!Y,+Q1L'QU<PA&DP<+K
M!RI<+R",P'Y`PB\<*"=\O2Y<PP_$PO";PSH<*#$LPC/\PX)RPQ;LPX"2D']2
MLC3,/SS,P4A,Q'T2Q)$PPE(,*$8\'RG\)\R'2GOR`!KP1/KSQ(RPQ5>\)U3,
M"%9\QGV2Q?)AQGTB8-XT'PR``.')0&2\"'#,QO.1QHNPQGQL'VX<'WML'P%0
M`(S4)Q[@!YT[QAM<QE$<R/+AQX<`R)(\'X,,'X5<'XN<NO'QFV?;0'E\")M\
MR59!_\F&8,FF#!^9_!ZE/!\+H'=\,@`(T,B.W,*KW,<A7,5#G,OQT<JJ&\GV
M(0`(4(5[`@(4(D&C;`BO[,M0@<J-U,O.[![`W![-#!]7``=B+!\-X`=;NS_+
M7`C7/,U,`<V$H,KD/!75;!7CW!YUW#9[4@"[LL*/K,?"G,[/O,MJ+,WXK,X5
MK,7W/!\J4(3V`0!^8#X0%,Z$T,[]O`KF/`CHW-!.L<Y5P=!4T0(($*#U$0&R
MG-#U3,H!+=&O\-"FR<\B/='__,8A#1]3,'%^0LS&[-&X?-+Y+,--3-.O0-%4
M8=%2`31W;!\GH`=9*],]C--/0=+.>]-&S0HZ/14\'14/(/_4?K)<P#1!"MTC
M*[W4IX#4$:W5JM#44O'43R$$<]`E<=QY%735AY'57DT*7&W2;?W5*4W(;%T5
M'.#-?\(&/TW44!S7KO#62NW7I0#642'63E$`8<LG=VW+>/S1S%S7@@U+^OS'
M<!W9@SW7F@S94F'0<RP?0..M5NW8XJS9EJT)@%W:J4#84&'83-$B?V(!?M!;
M%*36ET?:J$T)IWW;IJ#:3\':KR``?A#3]I%4V^Q`M.W;NCT(N9W<H\#;3H'<
MK3`!>E#<\,$`!XU!QVW;S&T(R[W=H.#<30'=JQ``"("I]5$&!!W:,^W=H-#=
M[-T)X,T4XJT*8/PG!NV8&2S:"ZW_W>^-(9-=R97=WY@0WTLQWZC@?.9-'[T:
MV'P-R0(NV3;]X/"-V:[,WZ_P`;7J)\PGW+.MWU@MX:GTWZD<X"!^"`3^"@9^
M"G?P,G["`2Z=0=E=XJ8MXM',X#(^""?N"BE>"K3,V.]!WBR%W1Z^UC<N6S1^
MSB1>Y(*0XZVPXZ/@<LT+']W\S?2\WDI^".Y]Y83`Y*S@Y*(PY7^R`%'>X/:L
MY8N0Y6;^!UR^"EX>"H0#*`VJ03&>YH6`YF:^YJK0YG3^!W.^YQ-QY!"=Y$J.
MYZF@YW3>YWYNYUI.Z*BPNG'RZ)`>Z9(^Z91>Z99^Z9B>Z9J^Z9S>Z9[^Z:#^
MZ8B^YXI^_^6,?@K#2[VJONJLWNJNWKI#7MNO/NNT7NO0*\.VGNNZONNY2^'N
M40!L$.S"/NS$7NS&?NS(GNS*ONS,WNS._NS0'NW2/NW3SB.4@`=SD.W:ONW<
MWNW>_NW@'N[B/N[D7N[F?N[HGN[J/NYVN0@%L.[P'N_R/N_T7N_V7N[6[N?Z
MON_\WN_^_N\`'_`"/_`$7_`&?_`(G_`*O_`,W_`.__`0'_$2/_$47_$6?_$8
MG_$:O_$<W_$>__$@'_(B/_(D7_(FG[89T`$JWP$Q\`<]H/(N,`AMH/(M7P(J
MWP-_$`,KWP$9D/,[W_(OWP%#(/,T_P=#H/(E\`<VO_(]K_,K7__S*C_T@C`$
M&,#S1H_T/O_T?Y#R*Y_T2Y_T@U#U/7_T'8#S3E_T7*_R8X_U86_U+G#S6:_R
M-A#W5D_V.-_V+>\"59_W.S_W2Z_V?_#V94\('8`!H5`",:_O+A#S+E`")9`!
M+3\()?`[/=#S+A_S)3#T/>`",9`!,7_WG9\!=S\$E9\!&9#Y+D_Z)"#Z,H_S
ME1\#)#`$IM_R;7#W2A_XEB\(D*_TIE_ZGA_X;9#ZD#\EIB_Z0V`#4N]#=T\"
M-I#XO[_U2=\#.%_[/3#T+C#TG6_TN^]#+5_\C[_].DP`3##^3*``?]`!X_\#
M@]`#X[\"?Z`$X]\!?[`"Y,\$!/`'"E#__^Z/_DP`"!E_@SU,3"M_&89*?TJ&
MA@1_"H^'C8:"@QE'3`F)BW\KE`I_!)2,CDR,@W^;D8I,':"BI)2=KZJ#(TR1
M/X:QDX]`LH^NOJM_NJ,_NHB]P9;$?\ZQJTQ'Q]C9JSTP(]X\)MJK+CP_JR4)
M1R,5B(,K%2/@)-@FUZLP%?D5&(1`ZB@Q_KC0IV_4'PSPCA"8EPC(B",P2JQ2
MPB,>-7$8,VK<B`U&"GHCV@T"(NR8MY,G>W#4MB*2`B`$5BB`,8@$"FH8/(X"
M,BI!.!@K>`*)$>D/3P7F_IB(H<"`@@3F%'0@H&"FQ#\[$I!XNL)`AP0*$,U<
M!<0&SZ)*%!#`_T!5`8:F"@2M$(249R=)3G.N@!'P((HV;1+L=0$41H84:EL*
M4Y(BYI\$'4P@7O&U\<$*;>`JX1ENI>?/H$.+'NVYU*-1'0PE_5.H$JI8H:(!
M,X0H-1-,K&E[2@4-DB1*B%#AUL1I-Z/8AD:9_H0*%ZM=NV'/6E[\EDGHTWX_
M0P[]U45D3)0QDT9I,25>QJK9\TR8!U(,0)CPTU8B_NIT2GYTLY%H!%0%(WP7
M@S?''&$``0AB0@`/2NR`0B=#((A@?#O\$0,*,/PP285_&'#$#@@9D,D(!/Q`
M0`6XD:9B1C!A$PH/+JQB@(C'K&`C"CS8N,(0HZV0P!`IM&C3(#8D\/]1(PJ0
MH`0)1I*R4TM8L35(4:L8%`E4DDQ%0`89]*56!@HP`D,'%\'4QDA3M:&*`C:X
M8.(Q5,XER0^,4!D)!A5.-<A3/^S0S%<6VH#"E`2(*!-5?XQ9%`$[Q.+2"N:X
M(M**E%9JZ:4848>::MOH]MHPOLU6B6VXM8:(=:B$"APTPVUBRR?<*6<*-,ZU
M$AVHX='RR*N\K:(+>K!H9X@PW!43K*^Y+E.),\/VAEUZ@U@#&@$C]/4'"170
ME`T&1SBT6@5'DC`":D`PQ,-=UZ)`;:??_5'"")C8<.0V1]SER%45O*I*+_PM
M6)-"F&+:8HU,5/#7(#.*D\"@*[;4P4L(HI#_E%3:DF`"#&X]1112,1F00`(N
M%`43`?S]<>25,!``Q%1$#34(6(@!@8()'<"DA`N"<5BN$AX-$C(0;"5(RBIR
M(N6Q2)&8($@&)4&&(#5*M$,4H0E@<*@")1"@)RF4F8R.E*X<V%G`9)=MMD::
M_F';:J9"(YULJY+::26HGB>L:Y>L0AROQTTW:W,%=F=,K+H:PO=UP/Y2'J[&
M?I>,-.,QRX1YT62G'F@H,+S1#HR,L-HQ+E1RS(`&*85"!B.L@@$/#YL0(RC7
M8-#!5<<`>)4-(U3X[D>IE5P"$^$8H&V'-)Y-VL!$PR)ZPMHL3.D*%^_0X@H<
M)E"H($KPB():@L4$_T34=DZ)C96/1345(S8T<R#&2G0P)C4[I"SR#A(QS`@)
MEJU"I1+]THG-G17:P4=<<*"5(8)S-,F`@PAE`B"80"T/;-2B&D4*`JIL:!F8
ME/$VR$%,I6UM<PO.X.PFJMKDC1"ZJ1O<'B'"V^C-5<;!E:P><8I/K,)6WI%A
MX:ICPUP\*UBB(I;=<H@L\2QK<:GZX7>D]1G_@,9SVN@&[4I@`/_PZ"#P0EWR
M'H2"(P0D`3PP&#PXY+,/'6,'ZQB!`7@4`]'MH!(5*)W,.B@:Y+F#":08@428
MEPWGK4@)&4@`.D;1!@.XH`>CR$`XS`(6@V`L`S#`0%K(0@`36$]K>\HDR?]`
M\18?\>4Q=%%`A0C`,P0ER6N@!$*3U/8Q##1F+9(XARI-8`,R9I($$CI3?D"1
M-03ACP`)Z$%6(..6B,B$BC;```8^UH&<^*0#YEA!"481`YB4CH[8S&9I9@%"
M%.(M6,6ZFPE=Z,U3,8>$JQ+."WG(&\)1IX:]&@0.1WB:'1X.68F[FQ"C040?
M&K$92+2;Y:*UGI4XL8F?NQ:`/N<"&Y@`.B1P3W]60:=Y8&M0"0#>GGA0NX+:
M`"(97-ZXZA&2/[#C'A70IF?L*(M!5,``).`C-ORH4A5IL*8XS:E.=[JB#W*J
MG&YCG#C5=L+<T.V<*_144?<60W?^K8?/:9P.J7/_3Q_F,XA"[2=X_DF>9R0Q
MGY?[S$NQ$8/YB`.*X_"066>:NA7D:`4I"$G)X)2Z!(R`(6V\"@GJ=0P8\(`A
M"N"H0@T`A&4PXD%DT1Q/L<'24`P"`^&1Z3%HNMB5Q.!UE<VL9C>+4Y\R@6U*
M!2<Z64A4<AK5G+SYZE#5F0D86L>I-*15X*0*6\/%$)]=5=QVA@BMK4+NB%X5
M:&^96)H18+9#*<4(6MV5N13!=14IP.,*,I<Y)J"`$0H86SJPPH0K*N)U-CC6
M2#2WC&MAX"J0Y0\,-)<MS4H,852ZH_Y&@(+BS52QG,VO?O?+7PYZ%K3??)NJ
M2"LWH*IPP*%M%3O[5L]W_\KVAH(3;8-K<5NKYE:?6>WMXY0%T.!6;K@%Y8@-
M>``$09`@%#<UR6K\88,>N)A'#S6'"S*'#2U."2#N.L(H(IHD_&GNH<<%D""&
M8(!!B2L2)`!"!>;A"/[@SCD\14&Y8I`C%^%Q$$-``1/L.UG\]O?+8`ZSF#/R
MWQ`&-9PE+&VI4HA4!']3P8>K;6JA.D\))\>>%0;/51<73JUN.'(!_;!X_T!<
MSU#9&N/)"%K;2`F(5A$%]+76B,8!#TB7Y"!,X($ZYDJ`$$>(OD<X`B;06($P
M]H4$W8#T*3/[1EWPX(K).T9XN;P*RI)&=IGLRE5,8(`4G%@:@OBDS`Q907?-
MJ/\$U%5`YDJ<N5&D8&8=4`DI`K*6(I=X$)RKB<S,$;5&5$@);)&R"]KQ;!3,
MAX(I.%-,ZGN5%-#E!\-^'9Y0RH]YA^4@C*EO#(ZD;!1PR-XJ:5!]YSKF@NN/
MFS\][9E'JYL"*_S`T$DS:Q/A6ECY+;:`@S!M+VY;Z^`V.UCMLX:3!6@/^V:@
MA`[Q2GK0`>BE2!P8>)T+R$3S#N"FY=G+QA#6Z@(_[>!,>C.!THZ1@;76!.?'
M39\)I'WTKG'V!RM0`NU6$8-V88#@1$^H:)"M/J^-H@<$<(%4(@'-'@AF:!@P
M09(_8H`80!WL/;"!`GK@)B4$IH)8NPL0$&$`)22-WS3_DJ38328,M9#"[\+T
M^Y1<#'0%?$25'2)`W+5U=J_<J3..GT?ZAC"*F>"26$^)^TL6WX,K$N`CUI,$
MI`)I\-9/">&?-?.GT!RWHK8-XBY)YU(KWDZ.SSF>4;V5G*NJYPN'G+>#_C-P
MFZ5:E!?:]="/?D:&$#6BA-W9:KM(`7^@M$C`)`')K)D++HU!L<$;F*2`S-!(
M88`,D')]L<`?FP2B2AMP7@%,B00I!5.UHEPR(&W0&#9`%39P(`@3(U11334#
M3"63`BG`#T,``UC2&&P!`ST@$T!!2B4A(8)032D0(8P2%H(07]+W964&5+/'
M<*-B>VSV>V[60G#65+X'3[42_V$"EBM4E6>_8GQ\AGR.0W++-SG.`E8$58)&
M>(03(1,OH2$F<Q"Z$TB*]`-@L48^01.-T7XT,H*)4"(98"(QX0(Q(#VQ1`HQ
MH00\DQ5GPC2(4@+"M!:S5!5RQS/9A4M3\@,_$"/2XQ225RA%<3!4(1-?$3]$
M0E@?T0,ED!549"1M@8%A,00;:(<QLADK0P!#`!9R0H)(F%\GJ'`IF%0K:%JW
MUV81IWNFQ52O-8,/)D\V.%44YG$6!G(]R$\CQU620SDG!V*9F(O05WWZ011I
M]P=M,";]IS9OT@&*IP2\E@@SD1:(X`I:@P'^DP"0!"B+PC3&Z!+.IA*=P!93
M\8&/@?\4*&`#BO<RS:0U'1`0!F"(J=<46B,34Z($?:<G9F@4E]4)`Q@T7[06
MI_,4,E*.9$)M`J$NC2`80C<ONLA9F]@VG?B":F9FN+=:N[=@K(AQ=+:*PZ>#
M2H1A(I=\0-AAS"=<@_9\!SF2_&4#21$+;,$0]Z@VB5!T?S`$9'(MU(-M^-,.
ML0!V"<@?/U!T5>.(@Q`+-F<#-\D(G<$AEE0"\(,!0[`"<7<1+1$F",)MV':3
M-.,8/\ER-I`!\1<.1<EDTM@.C5)U3E@E5+$#",(/U-`U)`!-5`%T)*E9"1E:
M-YA[!,:"1^6"HTA:$V>*%C=A%`E\=7:#,]1Q4+6#L+A;LLC_D;08:+<8DBKW
MEI`9F:"!`2\GF9;9>G$98$*59@X7BGA)EPFV3G&&BAFGBAOGEX0)?(9I#,>7
MF#^XF":7D6%UF;19F[9YF]&7F2TTET/5F2T(3PRYE[S'8'?F8*49?#ETD:Y8
M?(?9+!OYFK_ED4+8?+B(F]9YG=B9G3JEFPOGB>.T9G<)G'D9FJTED7)&@[,E
M?+Y'?*L)1+'H&W[6D5WUD8*V1(^IG?BY=1+1`UWR`S;`$!:R"CMW%9A0H&YB
M`VU0`C'B)CM)=0*A$I?EGZ]#`O'"H)@E:?XY"'WQGXE``OY)=QMJAW@U#P$!
MAEU(.P4J#3]`.W2G-Q@P#RV:`?M9_P)=&!!]T84_(&V'%*#N4@(-FI_^!7L`
MMIN;67N@^)M#")&E.)P3B50U>)K%V8J%F9&M"9^S&)WS.9T@:9]`VJ4]XA(V
M$Q29@&.'!P-#H`D!<00D0$53X2.0(@TYXS,5,`0_,*<E8@!!H1(]P%$9P#JD
M]$D=4C(F`%>QT'=_P`/\@`(]@*=`8)8C82-7!#0FU87`Y"/S$8XF910\XR4&
MX7X/)`D?D3*JAZ>,<A>"(2>2T!/8!5=5X:5GPYT+.9Z?")ZH)9Z@^6:B*8.H
M^7M/JIZ[RIY4^IZK6$186HM)ZGSWZ:K*F@T^T@-!$@D]P#!AX4@WLQ5O\0?A
M:`+FR#7FX/\_J^`G)B"%:O$F`L0:`!$4,2F-%C)ZH*``A\04(N(4!`1VDJ"M
MXD-UCO<8!N"%UW(7"3@H+H$)C1$CD,2&)F-(P!2`8II!_GH,;=`BA<(4E^BE
M$U`&%GNQ&)NQ91``VU1/W<2)],20OAF>22IQ$3F:NXJ>&N>K4;HK&+EGB&FE
MBEFLC"F;1;BL.(L1+;$#$$,`F/H8%Y,)08(S[O,8-B(5'A,UW6HS+^,@=&(]
M;[),K&&)*P,$!M`9@UH!,;*4*S.HAN04B/<@*;`U!W(R+Y$U-H(@@Z`M5*%X
M#Z(MD`0#JJ`$8,$-<OLT8>$Q"1`#IHH@`0$?AE$BDZ&%E`(`9W#_!EE@A&S@
M!XS;N([[N'ZP`1U[9Q^KD"$KJ]_ID*)XJS"8JZ>8LJF(G)<[F!+Y<:PIK%)%
MK!R6I;9HLRF7L[#+K#4#'W<"K5`!,D,3KK<;,C$A%6G9K;B0`?LJMX!T!&^2
M`N:`2(Q*)CCC`C'%?=CE`B[0&-#K%'M'KVJS*,=06#&Q$`?""^U`%6`Q-+@+
M`SN0%5&"2RFP`U*H-09@-9?6L-#U`PMH,C&1`958*0+`N'.@N)#[OXTKN2L!
MJY?+N0UI8)NKI#'XN2WKI.F9G.OYLCP8L\/J3S0;FT3XNK&[P8U`%&"W8T#0
M<T`9%1]#O\3H>)&A3(-`MXR2,@H`D^@C_Q5&81:GYS,/Q!8J+!53PWD'(8$\
M^Y)/\18W8Q"T&S\(XF*+=&^'`DQ7(14I$`ZH$0M:L17NDC(7,P]AX<'C:!0Q
M\4I1,1*)%";,I+_\Z[\`_+\"S!$$;&>8>\`/E\`FNZ3F29H5":4X**6J&:P4
MG+H6O+K&2IV."1H@P`$%P`8.(`#:(`$GL`!X,`4@H`U"<`$%,`=S4`8#D`T#
M<`8`@`T1\`!D@TN9LP(`J@T88``OE6+9D(P9D37--LJI3!(D<4W;8LJ%I<90
MQL'9N;]^T+\EN+AG#+EIO!%KS)N<:9>U6K*DN,!]V<"\^L"CBV?+V9ZZY9P^
M>!VP29^-R:6?X?\!"-#)9Z`'+8`-)+``=^`!%*`')Z`-%(``(?``'E``>K#)
MQP``?N#)JP`">G`!9*,`.A978Y,-5+9WW=`NV?!1R841W>"`1W#+VVL@,V*0
MV/`#/``4.')<VF`")87+^:G+O"Q]OOS+CAO,:".DLE?`O6G,,:1:<:S,O0>Z
MQQF835JZKWBZ>WPKJEMRV.RZ(JD1<[`$@Q``".`!V#``>B`!@_``?L"QQR`!
M?B#4JZ`">.#*2W`&QQ`!<^#*E-)&J@!&&#%'4T)^?10/!ZT-;50RJ5&9J\`#
M$*TP@J75&+&HH8;*&GV;'&W&(!W`DYLKE2N715J71TJR*IW,GKO,=_S_E[T*
MP;\JP<TIA,]IS1><TQF\TQDA``PP"$(0U-@0``+PR'_``4F-#1^P`$H]"``0
MSMC`U)4]"!HP`63S1E?1"Q9-=7.5`K1V#.:6`&.]+:DS"+]C2PX+/,J$U71U
M)N%%T!1E2"@@UW-=FW7=RW<=TGF]*;&'@B9=S']]S(&MER>KJ\RLLJ;)LH6=
MFLXAS1I9S3<=A*T;V<FZ$13@!_*L#2#`!@60#5EP!2MAR(.POX@<,(Y5#6B-
M#=SRSPJ3VS7&!.@E.@5M#3C"`[Y]#&:7+><BW-B0W)8R29;T2@8Q?J_C(UHQ
M8S$R*(X('X+!/W]0@..+,"7>"6SB,46QJ.::_Q.G=T41\5@)8!B)(@BGDRB+
MVDH&H4JX"TI&T09R]S%[.Q)[%'D_,@@FH`IFEP`5LN3?J!2;4>,#."4EO,+A
ML$E1Y\.AL0$(\.5@C@"-&^9?C@<&]]'/+=)D1M+4S<8&/++8K8*=6YXHV]VA
M"]/*.:4P2\VNZ=A^7+/J/1H#4,\8$0`J<`>CO0IEP-H<,04(,`\1,-_[O-NY
MH'784`(&PA&XK1&E9@,V4`$(#N`HDB[)RBUX6@%'P'080>&5XB/X,S`,$S\<
M0G;"Y.2L@)3OPZW2X!QF89)^^B91QQJO!H\Q62+7@C&#\($SAVHT0>&*&@EI
M>Z^UA@CJPJ_..A)VE_]2D;!+]ON3L<`(09)^)B.FTR2_M?81*K,5<H(NGK$!
MS]VX;'#F[\ZX:IXI;`ZR;G[2UYW2<LXJ@]W2=O[2%AG!T:S'?"ZST/GG&'QA
ML^D9)/`!",`!&-$""Z`!J8T-5P`'F9WHJT#/EWP'ETPVH<`0;6!:VK`#YZ+J
M&+'I&2&\1W!=&K41#R5IMDTC,\;NXL#JSP,5STH`0)'L;]((0.!K'^A]42,5
M(_.FY[<F3,-]4'LGG=`#C8JNJN2-S80"\P!)>]M,Y>(4^D%%*N.HD7<DU$,`
M;0!,9ED4;$LQV%KC/`(DQEZ)D12`4`%,A]$5*B.UC^&WB>`1(0,](KA^G^'_
MY60NYHQ;^&9><&A^U_4N#L/<UPV'T@^YTO].G.'=S"N+V,P,K'O.V.;=QSBM
MI?5Y#)*-$4)P`GH0\MI@`7/@`$(@#AQ0U,?@`7YP\<=P`E<@`7H@X2MRUC_)
M!&Z9#8Z`B2M/X!@17I8N#2+A"#3O*_/2%!NA\PWC(YOA$DG!$S3RY&8!_:<'
MB#L0(TJ/"UFF`/M@AA*S[8B@O.C:`?+R,DN(%:RA%C/Q`TXA&'"WEMHK(TTQ
M%8L*"`0$?T.#?P0**0J'0S!_?RD)"8,8/20$'0DI@BL)2BM`EG\)CX:/B0DK
M@PD**QF'C[&RL[2S`GY^<[6[O+V^O\"Q;+C$Q<:X_QO!ATS,3(L=S#^Q/<PK
M?TK,'7\KS4R#"MW6T$ROC]1,UAG,2M?=W^'MY+$91TRDZDSLW,V+!-WLV/+)
MJC<(G[9]S/IUN[=.U@AO?WYD^P.N&9!M[OX8=.@LXD-K$BW&8S8HI+983(XH
M>Q0!@0!>`304`,%K`P(5-/\PT'!EEP`-67JN5-9CA+4_0%#P^G%D!0EE"2KT
M(G'$1JD*;79Q*P>$Q]-:*`P\&H*"E"\41X?66F'#0`8@@WJ@:-/!&MM1G7[8
MM4$@@0D%'4ZJ6K$CE9(A'5)<2W&8QP\#*V"X^--#`0PE0`*/^E%";`G%*Q2I
M^O/9@!(8*WH8Z@`9`Y`5*_]<N!C40="HOGE+1>Y'49H!V:1L^$WQ^W;;#*!B
M02X,^]6@-BAHITJA2&VM6[FL:]\.;-BQ[\B4^>/W9YPT<]7B'<Q8,?VX<I33
MXP/('EY`^/3L:6R(L./XA@&Q$PM!^S&Q'GG_Z3<?1R5-U!X3%_57T$2Q/+3(
M#Q]%U,U%`9&DH8&RI+32!GX@,,>)<U`PBP=^Z('B'`S08L$<>A1PAA]GY%2+
M!GY8P)TO2HP`A`%,8,!+!2D=H>1%OD35Y`@PH#`"?+0,4<$1,!@PPDFU8'!$
M63R,4,(O:/T8BPMM6%)"#X^4T$8)0Q`R61LVE.!"G$.XT$,/0_`9YQ\N9)!!
M#X+_QD`"GW^08"=I0PCZU:%WPAFGGGVV^8B@E9(&IVR'CB5H"3$(VD:>B:Y)
M2`\E9#"9.7VRR6::I%GZ1PP_D!!#FSVD28(+8UZ:00RIJDK9(S&P25F@O9J)
MG2YF-ONC=^`=DTPP"3X3S33I!72@AP^*PPQ\YZ0#8'W-6'/?//4P)%!_"C5#
MGT`#0K01N\LTHZZ`CSS4((@/1IC11A5VA"$Z'S+#848FA:B2,BU0X/##/LHR
MP,,/3SM+PQ.<P$$`O4PLA+.[%$;`>5HI8++)^/+2@0F^#-$)`5;U4MDD,?.2
M05\*W/J+$C6#[///0`<MM-#+#FTT+=!&6XS%OU1;WK7H_Q&L+4;-O%/NT_)$
M+:Y`'4+4;3SXI5N@/MVT.RZ\CQ`X;]GU,G,O@Q]JTR_5'@*<K\`9AF3P2!`E
MC-+"1P<N^."$%V[XX8@GWDO1BH.<M-+A4<NV>=A*/9&$%,'S7N5;O\NM?=^B
MJR!_;"?X;LIJ7U[Z0F/#G?#<F-O]AX4>$:PWA'SOR^4?(C;N^^_`!R_\\,0O
MC@NSQ0]5P(O,-S\'T[XHH*22UGA9U31*LK.#DD8J,?T1BZSP/3O6ZTQ9]K,J
MN<,?VT\?_OCL*VE^#"@<,4@,ZE_SO3723[]^^^N+1?T6@;\C=&]_%/G>_?(7
MBRLMP@;<V\;W2.$]]Z7/@+*XDO\U;'`E=D!P>J1HGY(>&,$!*25Y*$RA"E?(
MPA9*@`UL*$`+9TC#&MKPACC,H0YWR,,>^O"'0`RB$(=(Q"(:\8A(3*(2E\C$
M)CKQB5",HA2G2,4J6O&*6,RB%K?(Q2YZ\8M@#*,8QTC&,IKQC&A,HQK7R,8V
MNO&-<(RC'.=(QSK:\8YXS*,>]\C'/OKQCX`,I"`'2<A"&O*0B$RD(A?)R$8Z
M\I&":P,9I!"%/DCADE7X0Q,@T(1'N$`*9/A#%#HYA%!6P0693"$``!"+&/U!
M`D*0`,<D0!,)_$$`+7A$"RY@2TCZ\I>`C`(5J+`%)S2AF%N0PA:"0`9FDL`)
M$-!"$*3_0(4V0/,/6B"#%J*`P@:$8`(#^`,')J`3!&P@`@W8`!Y\-`$*>.`,
M$I!``2P0@H@!\Y[XE&,?M$`%,G!A"U%(PR.X\`@<3,8%7%#F(RY)!2Z$4@M.
M"`(7($!,;@[O!`(`@`HDT`!R<F`!&[@`.B/P`0!X0`(;@(,%"F#+`/0RGS"-
M:1IQH`5/2B$(3G@*0?_@A%C\4PJQD((/'/H'*6A!"YTD`1>"0+P)`&`#9W@$
M.?]PA@T$8`D1$,`2.&!+"83@`FR`GDS'2E8P"H&B1IT,%?KPAYTZ@:U]H$(:
M:CJ$A%(A"L:4:!"VL`4J`)5X)["`!.`@U4=4]0\?B(`0(G`"GB$\0`@,6$((
MPLF`!Y3ULICE(@D@X`0G['2G30B":+D)46A2\P]5<((6]IDH%$I`!2IPY50/
MVX`I_*$!9?C#`,IP!@"`(`0%*$`N,TO<XE(Q4[-H0Q2^`J@_R<(%NUJA$'0$
MC`!\[!$;N*YQM\O=[GKWN^`-KWC'2][RFO>\Z$VO>M?+WO:Z][WPC:]\YTO?
1^MKWOOC-KW[WR]_^\C<0`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>b73679dfb7367907.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b73679dfb7367907.gif
M1TE&.#EAT`*D`^8``'5U=5555?+R\F9F9FEI:0T-#1\?'_#P\%E961,3$U%1
M47]_?^;FYN/CX^KJZC@X..WM[45%1=+2TC0T-%]?7^'AX4E)2=;6UMK:VF]O
M;]34U.#@X$%!0?JVVC$Q,<C(R-S<W-C8V,+"PLO+R\7%Q3\_/^CHZ*2DI+:V
MMOS8Z_WG\T]/3_B8R]#0T)R<G,W-S:JJJJ>GI[FYN2@H*):6EB0D),#`P(:&
MAHJ*BK&QL9*2DOFET;N[N\3$Q"$A(;*RLIF9F;V]O9"0D*RLK+2TM/B'PG)R
M<B\O+X&!@:&AH:*BHO9PMWM[>V)B8JBHJ/11IX.#@W!P<!D9&8V-C924E)B8
MF'IZ>HB(B'=W=P0$!&QL;%Q<7&!@8$Q,3/=[O(2$A#L[._[T^?O(XRLK*_5D
ML9^?GX^/C[^_O]_?W^_O[\_/SZ^OK_[^_OW]_?GY^??W]_(RE_7U]?O[^_S\
M_/;V]OKZ^O3T]/CX^-[>WN[N[JZNKKZ^OHZ.CL[.S@```/___R'Y!```````
M+`````#0`J0#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^_S]_O\``PH<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8,VK<R+&CQX\@0XH<
M2;*DR9,H4ZI<R;*ERY<P8[J[([.FS9M_^N#<R;.GSY]`@PH=2K2HT:-(DRI=
MRK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-HTZI=R[:MV[=P_^/*
MG4NWKMV[>//JW<NWK]^_@`,+'DRXL.'#B!,K7LRXL>/'D"-+GDRYLN7+F#-K
MWLRYL^?/H$.+'DVZM.G3J%.K7LVZM>O7L&/+GDV[MNW;N'/KWLV[M^_?P(,+
M'TZ\N/'CR),K7\Z\N?/GT*-+GTZ]NO7KV+-KW\Z]N_?OX,.+'T^^O/GSZ-.K
M7\^^O?OW\./+GT^_OOW[^//KW\^_O___``8HX(`$%FC@@0@FJ.""##;HX(,0
M1BCAA!16:.&%&&:HX88<=NCAAR"&*.*())9HXHDHIJCBBBRVZ.*+,,8HXXPT
MUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY/^23#;IY)-01BGEE%16:>65
M6&:IY99<=NGEEV"&*>:89)9IYIEHIJGFFFRVZ>:;<,8IYYQTUFGGG7CFJ>>>
M?/;IYY^`!BKHH(06:NBAB":JZ**,-NKHHY!&*NFDE%9JZ:689JKIIIQVZNFG
MH(8JZJBDEFKJJ:BFJNJJK+;JZJNPQBKKK+36:NNMN.:JZZZ\]NKKK\`&*^RP
MQ!9K[+'()JOLLLPVZ^RST$8K[;345FOMM=AFJ^VVW';K[;?@ABONN.26:^ZY
MZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_``<L\,`$%VSPP0@GK/#"
M##?L\,,01RSQQ!17;/'_Q1AGK/'&''?L\<<@ARSRR"27;/+)**>L\LHLM^SR
MRS#'+//,--=L\\TXYZSSSCSW[///0`<M]-!$%VWTT4@GK?323#?M]--01RWU
MU%17;?756&>M]=9<=^WUUV"'+?;89)=M]MEHIZWVVFRW[?;;<,<M]]QTUVWW
MW7CGK??>?/?M]]^`!R[XX(07;OCAB">N^.*,-^[XXY!'+OGDE%=N^>689Z[Y
MYIQW[OGGH(<N^NBDEZYJ&JBGCKH`$@N@NNILO/*`'[37[@<!DS`0QREN-"#'
M(P(TT$T<#*0B1P-S7-(`ZYDT8$<B$!2O2AL-[#[)&\B'DL<!UCC@0",.I!&)
M_P#?/Y)&^:_0(?PA;U20_!]MZ)Z*]Y%887OM8\`B0@+W2R']'PM8P!IJIX8_
MO*$&-OC#`S*P@0<4(`M3^$,)"KB"!0@"#7X0WQ$*F`0_B(`!"7##'Q0`@",0
M4!!KJ,$;U%"`/\`@`060P@7,4#L#"`(``/C#!?PWA0(4``QV6$'M*%""VIW!
MA'Z8@/C^$(,5_,$-4HB!'PJX@!JL[P\&J%T9)OB'%62`AK3+P"#\@`8#K$&"
M9RB`%FWWAQHR8`$>H,,664B[(Y2!C8)80!8*<`0&J(%V60#`[_Z@1MK=L79I
MV*`@SE`[`=*N`$`HPQ'^D(86BL"'/D`!!L]8`C1DH/]V9B`$(VFW``>`P8<N
MD*`%_X!!/Q3`"(3HH`C^P,A!7&`,#TQE"6[P!PHLH`YZ+(`%VB"(3]*N!!00
MXQI6D(;:.5$06?1#!-P033(*T0]2.,,A_5`&$<S`ARC`(NU\(($_;,`/4&@E
M[?[XATL6().;E"`:"/%'5T:PFF"DW1^$X(=RLF$+/M1"&RE8AD&T(`$ZH"0W
MNZB&!=!N#+.$)NVD`()M4@")?EB`&?^0@3(,T`]9V$(;0TF!,^2Q=D?H*`!+
M,$H_E&`0)7C@&-00!R,\L`GB/*;MTJ"`!T:!HP7X``JRL,IZ%N`'?[!I`1Z0
MAX]F`0G;+(`9CM`&`F0A"]/_+(,'&'`&&PKB"&98P4O7(,8_U-.0-F1A&JJY
MQ'QF8`%2H`,:7@H#'W;!!!2@P""&@$DTN,$#"4B`"\XZ24#R81`6-4,!4'<$
M$DSR#S6@02$SZ`>3"L((>VQ"'ASJ2A%L,Y2$R,,,[E>`<,(""O<S;1X%J%="
MF"$`+S``'K3@@3I<(`MVX&(%+YC!/R@2`05@PA]F<`(VE-:.A1B@$5C8A@+@
M@`U(0(`@IC@(%!1`#BZ8P0O\,`(V<`"6A!1$"4#KVS*XH0L)_0,(_S`"/S2`
MNJ=,Y2#2*%X*?O&EA2"C`4H0!Y;2\IG4G6X!+7`#AY9ACBTDQ$8%X8`LM."\
M5E##_TLQD(!R+A+`!:2D(O\[B#7H-0,/D"0E6UB"A!IA!AA\:2=5:@CZ"F(+
M)9A#"PK@AA*L$H-ID$$!KHB`!`BWEB^.\8SG4((LX,&7=67`'7R086B*+YE_
M6.9:#6$`-.#!#R18<!=-B@`%B%B\(LW!#+"8AC:,`0E_`,(/!6$&_/I!@JD\
M<8KE24^Z^N$`6NYE62U0@`CV(`MHT/$!J+N"@@H"!P7H0AN:.<D5--0,;=@"
M!P9A`"[KH`QEO>!C-]I1#_]!!GX0@!\,P(:2#J*9\U3I`EB:8$)PL01(<$$!
M(!`'*9#@#UL<!`7..`4I""`/"<!`!K(`A!L051`2_@,?CO\`@@+P(`X/P(&G
M0<VZ%9ATJD'P`P;<,`$8W'$!71T$6(6H!K*Z.I3A5FNE"V&&50*0FW.%K`BH
M286\"N(-68@S`5H`ACO@``SL'$0++U``ZWWY#S0T0R+G4`#R^8'@EFVC99M-
M:RG@8`$K:`,`!E"&UAY"!/?+82S2P#_:/2!V@PC@&L!0!A@,0@!2F$%"'Q#!
M/X!!!+J]L1]N8`8IJ*$-!KB!$@<0`#5D00!'0(`9S$"3*->@`)?$@'O_@`$?
M5&"@+\]"#R@P`"#40!!`\($@$EP"!2P=Z04M0P0&,0,8F.$!S51#!0R@A0"(
MDNP`,,,8OEB#I>MDNF6L@0[\>P;_`.<]E7YP`0\\`(,%3,`#"%XZ4K%X1D'(
M8.V?YH`:CG"&[/ZO\-,]?"(S?(8Q+/T":T``!`808BF8X08M+,#S1E``"?BA
M!C!8L=+-`(*['Q@",Z""(,9P`AOS5GPKR($@@!Z$"=#RS8)H^_`E4((:&,&7
M&7BF"!7\Y/$V@9D)6'H"H2F!]G[``$U8>A?-$(02:*$,!CBP&PI`!/CMV``_
MD($!JO"'`-P@`>+39M-%2+-7>[<W`IU49W\@!UD@`NBG?GKV!W<@!7JP=GPP
M`/"S.WZ0=V-@:'\0`4R0`#W03#6``HZV`*&T!@E`:>Q7`DZP14OW`:RT:6?4
M:1%P!E!0_P!U<'L_8&J"@&H<I701P%)9L'0R`%-(H`-C(`,$8'=_0``XE6N"
ML&M_@``86(5)D`$>T(034%1@D`9(T&U."`,*L`8W"`524`=;AG!'@`/.]P<X
MT`1E4`,&H'_B%E8UT`1#D&D2A&[A!P!9L%9:8`8T,`AF$`%^5T4>,%<@L()_
ML#OV]@<?X`>SYP'-%@$QX`9_)'GAY5LG(`AEX'IF\`%FX`,UT`>3%`$GL`9'
M8%R#6(B5)0@ZX(0$H``+8`$.0``$4`83L'2]9P@14#L%@#ZPD$\1E7(")`4E
MX(1Y%$+E)0@1\`,YQUL(0`$)H`8(2`<)$`,O)`0O=01@D%?60_]6*T`!!?!'
MX@-"Y11@@@`&4&``;O=8,>"(9#<!>>4`R#4$8R8(36B+<:<%6T`$US5?9-<%
M%&``7R0%>76$@&<`-+!?)@5Z;620L.1*?F`%;+``9?``1,1">95>6K9,@O`!
M$V!T62`%%G9ATT61H[=(!I!7(N!4)U`&"4`!P-5&@K!#(/>0*Q:.%/`"HI0%
M)5`"&!!_@O``-V!\K-1;6_")[%4";)``7`5]6&19#X!S9Y```;``32!2AL1]
MO30#%,`!S%0`>>64.14!0,<!]K8":J0%;E`&!3"4HF994G!^4N`'..`&<I``
M=!``,8!P;H:3.B0%.^D#"3@(R?8'4O#_`P;`EJT%93+0!770<`%$"'Y@D$;Y
MB`GP`A&`!<U$`PG0!8_V!T&0!93VEG-0!F))A6A`@QSE40\T`S+H!S0@!0$0
M<4"8`>%X!$285_(E05V@``F0!)&(!6LGA;UT1EXD"`.@`QG0!`\P!@-05(#D
M6:V%`A&P!K,Y3VLX5:LF"#00`67`!`%PD'>X`O\'93"%;F;9!8%H`!%``;C#
M9D>PD`M``0\P>.&F:ZT%9!=@12/0!-+T1Q_9B;L$BC6Y:V$UGY/DAE$`!(0T
MG[@3BP#46LC)65F@!G.85T!I"&>%9K-P`&.0F2B'C)Y6"%\6`0+%!C70`AP@
M@Q:@<QJD!CBP_T=9,``,D`43X`3/2`AD]0$^Q`#<U4X>D`=8-PA,,`$SP``G
MX(Q(X`%C)U[DA5QF(%*"$`-28``-$'<SL$=81I#UU47W90CZY0`.%)$8-D9]
ML``<D)%E(%D3U&K05'E_0`+Y\P=)H``2Y@`SH`>BM*8:1GK/%&6D^3TB5DE_
M$&Q_\`,%('4.(`4%X$D>>'>#,`'"U9<X1Z-W4`)[(`A?@*,G`&1_,`%?L(`)
ML`&=%``%L`!12DOD"990)F5>I6`H<`'$I&76I@,3\`8')UA_D`<-9P!IH`41
M\`95X$HY*I@#R*B."JD^Y)W(]E+-U`=Y!F5:`*8HX`)0R0!&(&H$9?]YRJI$
M[@5#I0E_E'8&CB<'F$8(KRD(/N"CN^AAD9H$;524!:";9!2;*^5BKE9`6M`%
M```&@J``:*:<5#@`72`(')`#&8`#,^`!4U!4)2D\*``&K,,'7.!A#'"7@F!M
M;/B0Q&0$5E`&"V!=M3IN9C``!<"'XT5+:;58Z^9:[I:?<@H!!4`'?X`$-A")
M%Z!MC<H!(V"O)["A5-F)!A`$H/A8"+<"\SA)))`%1W`!A!1Q%NH$!#M"7."F
M+8"H'H<(6S!JQ!@+%V``SU,(*O>U2RL(,)`%41`!)V<$#P``!3`$Q^=;:@`&
M,I`&0)``<[`%6:"S1Q`!&9`!%F9N$=!"73#_`P`060)&"!"0!6)T`(,+``D@
M@PA:`H7[`8,[`!XK")%+K7X``P^7!DP`7K1$=O;5<X4;G/KU!R@0BQ+I!PA0
MN!`P174061I)37-:N%A0IX,P!V,`!AE06LFF!S6``?,%8+6;`2"0=`][!CY0
MN#J0HK@V28IJ!36`!08P`!@$NV24`82;`7IP`X&9NAU6``#0!6M7`@N4`=M%
M`!S@`R(D``6PMT`P!CS@!X5[`FH&`!'0OFCPLPO0`!.``#8U>4X6@5+6L@^K
MLU@DK0;0!86+`=;6!AX@ATQK!0F`!6"`@<0JK&8`!@N0!A<00@*(DU9P!-SK
MO6]V`F2D`YBK!E+`_YMC`'04G`'*FTPFD`4?D`8X$`$.4``(4`*M2&B&1@!3
MD`8D4&$9M+\-Y7X&8`7IBL$NH%74.X."$`!'P,$CX&E\L%ADE`,6JE"I5E"K
M=@:2FP$B*D$(H`4&8`02X`/T*07B@[!G%+4#L`4&0`?DVP5R6%3X94"(:54Q
MJ5=\0*S?>00FD``K,``)4%$6]``I&U9F4`$SX++H%K-K%0"%NSYOU[KYR;M_
ML`4L>I<4D,DZ;`%'P`0&$`-XD``#$`$;Q+\9\+N2JP!9BVL)0+UAU08#,$ES
MD`!>50">G`'OY<E(\`8^L`4$8)@8AUBJ?`)!<+Z$<`<U\*&UP)"%$`,Q\/\!
MZ44(0?!33S0%8+`"(_`'(*#+5W"V#K`"SQ,%&(``SX,&6^``,B!0?Q`%*]#/
MF/L!J80"TM4``P`&!&`]*X`'A:`%#*D!*_``AR4(TO4'3-#/*S#.*Z``4W"B
M?P``$AI$)W"%'[``@R0!$\T$"GT#+O`#%LU+'^L`&.@&"%!.$N#2%KT"[ZS0
M+D``,:"T5(#2"-#/$ST`F"L(/:#+"S`'>"!<;X``JE73'VO1>,#/*Q`%$F#1
M3`#.@S#.?V`'TN4`TFD$#?#.3X0`#N`"%NT"1B"B)DT(.@`&7:`!%&W15[T"
M3:"T5`?/K&1M%JT#<0`%YRS73/`]/,U>70`&-[#_?<[Y/#J02A]P`T'4SU%P
MM@.`/@-`US=03DY``3Q`SG_@``OP``$@/`/P/#?`!`B`N5MP`3\@7%WTV?HI
MUF0MTPZ`!).'!_T\``5TV?U<3HVM!@'P.QJ@`'$P!!&@`$J;T']P`WB-!>4D
M!TQ0>';0!A2`!TVDGI:MV1G``UC]V>0\SV!@!'.@U0Z@`".`TT^8DD'T/2Z@
MM#'`!'7]R$K:ST:@T#S``1P`J*;IVG\@PW_`!L47`4?H`A\`!#U]ODM-"#P0
M`"7P7.1MWLM=3C_P4SQ@`24@H=7L0E>XSS]P`TA5!L%)T4@E`1B(!_3,V\K=
MJ"T=`PDU!,*USB[(!CI`_]<,$-LBE)0*T`.X+=1=M`);\'>FB=4=SE[DS`10
M(-%2;=$8R`-#J`=L$`,N'>3]K`,9;@C<G!8S?M-:'LZMH`/CQP\N<$634@%J
M4.9F?N97]PH0P-'Z``&F\^9P'N=R/N>@`@=VO@1_$`9V#@<=\`<=L.=]O@-[
M+@9_P`)[+@AD<.A_\`1V_@2"P.APX`5_D`)[S@)_(`9[O@.7#NA^ON<J\`=>
ML.=A\`=+H.B)#@=X_@=[CN=Z;N>2K@*<_N=V3NB&;N<I4.A[?NNA#@>.ONB-
M+@A[3@;`;N>:CNG$WNEVWN>R#@>C7NIVCNBF?N=YON>OON=%,.F#CNNVKNUP
M</_K1=#HG[[KO1[LPX[JY:[IRZ[LG"[HS_X'IPX'T-[ND"[L*@#IUT[I=F[I
MQL[GF[[MWV[GX2[JI&[GPJ[JTF[PYM[J_)[N?\#N<$#KBE[K\.[KO/[HKE[N
M^I[I_0X'Z.[IH"[PSC[QIY[JJS[M%P_KR8[L#\_MMR[QNO[K%#_N!'_N&]_Q
M*;_LS1[M[3[R>0[IU6[G]U[I&]_RN?X'_PX'`5_Q"%_P)8_P-K_PZZ[S(J_H
M\_X']0[TV)[O&]_G^^[M'K_KS#[P<,#T!U_R"L_U43_K+,_M%J_TD"[S<)#Q
MQ[[O3__I(;\$>&_I88#W2T#H8L#WM_[W>'_K'8#WDE[_Z(8O"$6`]]=N]'BO
MZ2K@!7C?YRG`]X1>^7A_^7S_Z3O`]Z/.`GPO"*"_!)9.ZGF?YWP/^8!_Z:M?
M^'C_Z:[O!9S/^(I/^Z!^^J;?]Y-N^;N?^:R/]Y\?^HB_!(<_^GJ?^E;/]WVN
M`JV_^7[N_*Y?!+._!(TO^:0O"'Q?^KR/^;HO^$L0^,(_^L6?^(Y__2JP^$NP
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M'4NVK-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_@`,+'DRXL.'#B!,K
M7LRXL>/'D"-+GDRYLN7+F#-KWLRYL^?/H$.+'DVZM.G3J%/G#5"BM>O7L&/+
MGDU;-O\#U;ASZ_Y:`LV9W\"#"Q\>7,W&-\23`V=@`,WNY]"C/RVQP(_UZ]BS
M:\]^1N,;*=O#6R_37+KY\^A_4A?/?ON*C0;::R?O/+W]^_A=KI<O?L7U`FEH
M1`%_V-&7WX$()OC1?@1J-^!UW0GR8(,&*FCAA?<QV.!_U5U7AH`;^E$AAB26
MN)N&(:XPH1\E@+CAB";&*"-I*&YH1@G8M2AAB##.Z../FM5(8`%HQ(==?2OR
MUR.03#8)F9#\&?"'D=<AR6-Y3F:IY6)0RK<"`UED5Q^5!"ZYY9EH]J6AE!JE
M@468VU&`AG9C]K?``D<4B&6:?/:)UYH=K1&>&7.*^4>AX7W_^,>*9OKIZ*-J
M`?I'&FN\(0B9'DYIZ!GL*<KHGI"&*FI9DLY9YWR:'OF'&>S-T!IX'H(ZZJRT
M;E6J'Z=F]Z%_JB:II*RU!BML5+?F6N`?'5K78I$AB@CLL-!&>U2QEVZWP!^<
M7M=B&>UYJF=]TH8KKE#4IIH=!7^\D>=X?V30[8ZQ@CONO/3B5"ZFR@JB!IS=
MK2N>M_'6*_#`,MV['9M_\(H&F.\N^BW!$$><DL';Q2`(&@5(R6W#G\HK\<<@
M<T2Q=N\)LL![[G+\<,@LLSQR=@#J&T,:L'8*[WC/MJQSO9*F88:^[/W<+@,Q
M*'FSLQ[OK/2\DFKT`;[8S?#&&S<D_^SOOT<WNO36PS:MT<;BT;"&&FB4<0&<
M6#L<,-=L2UOJ`P&:NUT!UYIA7,II=]SVWETGZP>;IE8;]**"I(%CWBOSK?BH
M+VN7!0-I#/"US6KCG/3BF//9>':2FQ%SNC6C6CG2F9?NY^;7/?X'CG`+@K?H
M>ILN^YFH6_=>&@58EP'0B6:=\^S`RUB[B-C^%Z"ZO8^N=?#,8UA[S'Y?^\<-
MR<?>_/4FUJXCK]9)85RVL">._?@6UFZQW'Y<BZBNOE]._OOVH0ZX=FQ"#;#E
M\.>?'^KH_B$HG>ACE_)^I[\"ZN96BK*?R;;S(04.T'T&C*!J$+A`[1CG#P_8
MSNX<:#T)>O\0-QJBVP+<M8([O<XZGX,:NJ!60CR)[X,P-$V7V,.F[QPL@/\B
M8`QWR)D9BJ=_Z\..E*"6*!WR\(B7\6%X@!@>`S"L3$9$HA0EHT0&7JR)X/L5
M!*?(Q<A4471!O,X1J$>A*';QC(GY(OL.%9X2$+&(6T2C'!&CQF.QL5D,-.,<
M]PB8.F;JCGC4E1[Y2,B]E*`,M:$-"C3"FD0ZL@0H&&0A)VD75SWRDIB<31;B
M2,E.WN4#R@FE*$<92DMY\I2H3*4J5\G*5KH2AF98P`UB8(8/+*`,:_A#&>ZT
M!J&U)`T+.$,N-P+,"[[RF&TQP`.RL((L/&`&`4!7":20,2F<X0W_%SB#;X#S
M@6ZFX0QJ0,X%Q*F&"WR@:!2@``/.P(!L?L`/-#C#!Y!)S[08X`8%.`..RI#.
MU;G1#UF0P@.D,(/X2"&@")5"GE9@@`)$8`8%*``%#!`?91:TH4?(7<:(5,^.
MDL4`&4V#?\[0SVF68``&H,`1L!"KB7+*A4<P@^>N,]'J=*B7K+).?`)@2H_Z
MU"O-,0`6"N"JDJ*+/`,JP+J0:H!LX:@$%*!F!%90@!+0S0\4*$`6!L1,Z\P@
M`EF(T$_'JI4`,(`U`4!D!JJVUC^@(``W6,%KWGJ#`*BA!&"80`E6,`$.W&`"
M`4#!`P[9&BP,X`$!X``86L-7#L2-K)"-_ZQD)TO9REKVLIC-K&8WR]G.>O:S
MH`VM:$=+VM*:]K2H3:UJ5\O:UG[PC8&,K6QG2]O:VO:VN,VM;G?+V][Z]K?`
M#:YPATO<V2*,*;`MKG*7R]SF.O>YT(VN=*=+W>H6][A+<8%,M\O=[GKWN^`-
MKWC'2][RFO>\Z$VO>M?+WO:Z][WPC:]\YTO?^MKWOOC-KW[WFU\7N/:_``ZP
M@`=,X`(;^,`(SD\<>IK@$J&4HCZ(P`FR2U&*?G6>%_!!#6[S!QH80`%_0((!
M&L`1"U2X!B60@2#`@%VHL"$'=O@##`S@2Y($8,0EH<$,E-6"HO`@QD^K<8,7
MPSWK9*$"2LDI=O]\`((_#,`/"/A#&W;L7W=Y[&I^*,!MXE,5)APA0-R27DEP
MQ,GB8:<`)A@*"K(0H)<.V3'^B0$:2)"GJB6%54U``QJ"D,$O_,$!N1L!2\'@
MAC]@X)H<R9,(\+`'#OA!<ERFRA&^_(=UEEDC9!X)`XZ0!2&\H0(3\(,5AC*@
M`'WSTF_^RT@%,04_-*%=)1A"`JYU@"X(-`>"V$()<BF"$FP!!Y`4!`E*X%^6
ML&IW@H""'Y#MKB[D[H(Z*`&'-9*G^@S!#Q'0%!K`((4I"*(-0/!!`CC`X2[H
M0,0Q"$``SN"#&:`!!$>0PB+_((<!2$$*`3B`("`0A034`->"<($4#%#_!C;\
MX:YVSH"TFQ!1,&``!8<4A`QFD(``.$#8$_#WA%>'JS^,(`(:[X@+_`!B0?Q@
M##`0!`@"H%`)Z*L$)`"#!T90@AO00`HEV(!&>C!0"\0-D1@P`!?^8(.,SX`'
M?]`!>,``@[LJJM8"[</+R\`$`W"`Q*G>RZK;M6R.@V<!:<A3F+*`:VX=H0U@
M\(,+3O!H01C!#R%HR;$%80(+^$$(@M@`G++MNHYOI-J"X(,?WA.?!,!J!'_`
M09;!DX`X_*$`!_7#$!H*>3](P0?Q*<`\F^"'!.0N`/3V0):SD(4D_`$(6<X=
M%(K7/S+[2PUA=BOI<^>!-@#Z;Z1W.9DAH-4'_R3`#_/6B!;\@`./5.#W82K`
M#XH'G@)<P`\^R$+N$G#Q'XS=#T?0`+(L[P<C2(#T!RT`!O!F!C=?0.P`Q36G
M?%"`W]<@ZUK']A8B8)TA<+P)%ZC`%KI/!Q@4X/UL('H9%`!M``%C\'YOD`4M
MAA*L(GVYPR(0H!%78!UB966)Y@<!L`5@$"8-Y`<3]G;>Q@34QW$NIU53\`$"
M$!_VEW9:P'4Z8`<!8`%MD`9^\'X_P")R$`+0%P=9D``'(`">QWJ"0&8,,`,S
M(`%N$'L)D`47,`=I)P)]4`-XIP=^4#5D1@1^``"5A@#+MQ$!0#P=,7Q-,`<R
MT'G%HWDO4"@CT`9=X/\'.O`'8^`'2?`&3("!V_<`$E`!,B`%IL<J-P`!7R@!
M`N!F^V<$;0`#-5@\"9`&<?![%P=_>%%D?@`&=\!Q02`(/N`'2,8&".`'%V!H
M8]=D7"<!(H!5&T$'$J`&JKB*K*B*T[8J`#5V"(!U?S`'H@=/&F&!?Y<=!*@I
M$2@HTM,&:!`#->`'QJ%4$:@I`?*%*<<JTE,'%Z`#?_,'7T!\@M`#$#`"V*9G
M]`<"G-)Z'3=I8)8^#>`'8R`($G`!;2`(`B`#`W(M9/9.!;`%+I",&Z$`8,@1
M'I``+O<'.W9H67A%[_<';#<`-#@&<O!GEK=]P?<'>9`#^'@MI58\UY*)FPC_
M'@[`*243:J@&B6GA'UA0!C$@`0G)<1@@"+FC$=6A*/3W`!JQ!ZY6'?:G$6KP
M@.PA9K"8`7)@!7XP`P*@$2.7.U+PDUQW9<17!C#P`0:G*8+@9B@0APGP>\=H
M`1H1:0/2'<ZH2^XWC>ZB*(*0`]HA`IRR!4,8CI069FK`(APA`%U`>CL&C[C"
M!@/P@`6P<<)7A1K1`$/@>"`5-R/%*4!P13JBD7/2/X_G!]MWDI7&`=(7'Q+I
M!VV6/H>):<;XC679D1YY%ENW$9GV!^`18W\P?$C'`+F3!=KW!P*0!4=@=[18
M:3=P)[`9F[`I5CGY!Q#P>S0@"&R000`0'XJBB]3F_W?P@9@4^0>A=@42X!_'
M6#),Z3!8F3YHH(!`4(Y2PI-X]P<?P`!E^`!ET)UEL$XD)P@9Y!SBJ$OI@P%^
MX`&"@`%](`=L%P%G@`*2F6ETX(Z9*`4<(8V@)PA)T'W^6`-8AR,OP"F*,B='
M8')8Y0!^0)5_<`?2MWWUH6P!\`$T()D3Z6:?*0AYXHVFR'&8F9EEL9F461_X
M>`-R(`(#]P=N$(<$8(YQ8W=9H)XN,7=_('A2@'B(F``"L&99X'+`J:'"697$
MZ6:=-P=SD"?+*:0[\IP+("CH@IY2<FT<(`=XT(,,\#=Q,`==@`!Q\$X3P`:W
M1YX`*@=A)@=:I8[TAP+N8O\#'3:?N")85=,&6L41#.`!68`$##`"\4$%?\!Y
M6O@"/2@'!'I%?B!U`\('?Y")*#`'T@ABU5$?(\4&=?B8#2"HDEFB?U"*4F*9
M'@JB=2&BEREL$65BD@F61R`'H9:;U*@[+T&C#I!!`R``.X:H'->"/_H'@,<1
MD>9F\6$$+>H'(O!XS&F5?L"DVI@`-X`C"6";N6,!HO=J]+<"3S8&MD=Z`["!
M'5<"60`&?1![/%D#;0D@K?8`"_![DA./G;<`PZ<C&]&?/?E["7`;/`!0*Y")
MHS:H=S0#"$!ZGUB'4F`!$:4'$"H(PQ<!1O![1O`'+'5(;C8$$<50DLFIG>FI
M<A'_!4>`>!S1!$<P;2)@IS6`!7/`!@%P!"JV!T<0`94H`0#UBBMQ`D=0?,)V
M!!-@!D?0!4OY`3(+`3BPL1PQLBS[!Q9PH!YW!+F)`A!E`5-P!$[P!V`0!1H1
MM"9SL01)M'_@`IYG!%IP!!<G`F"5`$RPCFXPEP70!9^X*E&9`5;`LS$043V0
M`U3+!@MP4&#0'0)@`:H9`P_0!7W*LTJP3`G0!([7$64P`=*'`&DF"">P3`80
MF$,+<',"!@1`5"E7BPM0`S$:K!W&LY6V@6"0!$<@.1?04%,P`E2;J1Z+`W,P
MM-*CL3]+L8SQ3BZY)7/"KJYK(2#@0G:F);-;NQC2!QIE_X]9LKN\:R%O0`0P
M\(A;X@9JH)C#V[S.^[S0&[W2.[W4JQC)95W8F[W:N[W<V[W>^[W@&[XZ]137
M*[[F>[[HF[[JN[[LV[ZYM8!(`0/>.;_T6[_V>[_XF[_ZN[_\V[_^^[\`',`"
M/,`$7,`&?,`(G,`*O,`,W,`._,`0',$2+,&36[T6?,$8G,$:O,$<W,$>_,$@
M',(B/,(D7,(F?,*'(0'`(0*TJ,+`,0*/)0@,H`1"0`2%5HN_$3=L8`-GX$X;
MH0;:M!'9)!P:P08B``1`0`(_'!PC0)0=D0<H8`,W+`@7(`/`VXY*J1%M,`(R
M`)H>T0!GT(\7$\3K>087ETT<B_^Y9X"YJ'D&&"L(8"S&?Z8&K<N.OU&V<C`"
MOY&0Q&$I?>S"P3%/>OR3(C`")?E-92L((U`&-/`#4]P1=)`#9G`"2*81PY'(
M&D$'>J`#E`S'Q,%A$``#0C`$R*L1(U`%+I#(AT:+&G`&2JS"CRBH;'PH)Z`#
M.=!3#D#':QD<$K".92P<B'=HP-$#I2P'*"`$W]E@W),%-6!G158`#Q!W@C`$
M.P90`=!D1^H'0M,'`"6?JJ.BX-&0OJ*;"T"7.!"XAX-".=<1VP9038!U90`>
M'G":`H"/!7"=R)([$<"\'#%\YZB2@Y>+?I!+`X)LCU<`@I!E-(E]&^'/&T$#
M!9"['9'_EMBVGK`2(-OA'!DMB=.(I`<=(9S:8;\'4!00PQJA`5]H'36@8@E]
M+AP1!_NGTO.D9,<"`AED'1,@QG(P!0\H!4O+=4(#`?$A.?XQ3#2(T(*``IEH
M'0%PFA`MT0>''16'=2?$T*^CFALG``$`)T?0A0?F'T=0`M6,=/XQ!GCU>P^0
M!]@9)@^P!9EH`#_Y`Y`'`70@>DKP!U^8`097H;$+(I;4&H+`>5G0!<YFAQP7
MUF#P>Q9`!QMQ!^"A`!FDMPT@??X!!H+0AA80AT3@/^;H:!/@$6P`*XG<(>?C
M+@2]LBB)U`H--$(K9:*M$5GY$11=`.NH!->!T2SR&K>A++K-_P2M$2:+!7H>
MG3N#V:%OYU`*\'N?S1$'`!XUL`49E`68FV6O`=5?.`$$D$$&(`<P\"KFV!HH
M(`&Y,P-;(':8"P"=QQH`=3?:;)L9A+(),]"%L]HC$"83@``[)@41&-L+754/
MD#MC4`=<AV*N\6KN0N#5_(EO-P-:0'\%H&]?7:R"0'],$-_#)`#@(0-MT(DE
M0S-^<-=]^FA%XP,RW'YJD`:$.T\;,2!>N9X`I>(D$"8DAB,10IJ:MQ'::-D'
M\*#]F;#QD09UT(-MH)%_`%9YT`;@T9I4#%!W!]`]N8ZFK39V%E$)C=11W=I@
M&29O*`C\/=&=YP<ZA]YA@ML>81T@\?_CP7F,UO&)EID&8<+2&A`F_'QZED>4
M/$GB?Z"6(`$>/QD'X0PBP_0'+5H"OMR)('8'N7.)>.T'MMK>PV<`IE34\XW4
M++J.<5",;]CE4:TC&Y#H0-T1[N)+H1:8&=2/F8AT$1XAK?9JDEZ61#`"D-=3
M;#<#Z^F6^5B'`5`=K\81+,X1K;:?@H"/?$KCU)8%/;`1#.`"+#VG;W>)G&<#
M*MLB!S"-"B@(G3B3&[%_3A!0E;A]UF$Q4?X@\7K05;[0K=V&3)`%\`V+.,D1
M:=F)*<>8<4CF'6'F'X'F0*KF=FB9W,*@@A`#,,81;<BG@B`'OZ=]>G[O<OB3
M:B`#TS8@@1[_'\>>=UE6!_.ZW)-R`SZJS=[\QJU^U'\``EG&V/Q9T9J>ENR*
MB`3PZ1P1ZB#"IVEW`Y7X`3)0R@2V=?@X:OYQ`FG``#"0!3Y0`6RGMQL1)LG8
MB9;GRW\6)K^'R3N"!<!!8D_F;1I!/2V((S^0!@V`>AY@TJ;L!Y^]?\Y1'3`0
M!`&=YP@M!<OZ!YVXY1H1Y`4P!SB"ZM7!.EQWVC@">E2.]N8N"'`?!]J*ZIK^
MP^F3!0E;`!Z0)[B=3NED9];!^!0@T?B.J\;X>&"0)WILBNB-!"-1`P7PQD4N
M>7E^!"_<$9P'4%PPYQ`O"'%@'24I".`!`M(H.:".5>!AF/&=ZPO`_U((+9^6
MK1$7D*(GG_#E2.ON,@&0CV3N<@,]KP:_%ZQ(@$(*((H(!M8E4(Q^<.R2F`46
M@WJX[YE^=VW^N1&G3_2\GAT_TXDM/G+2E!U9X-4<D089A'?^X1S1CTMG;^;H
MG008``@)?E-_A84\?A9_"WY&A8PT'GX\&7YK?Q1^,5E9%04%A7Z@A6I^1X>)
MBXV%9GX+AK"DK@]2('X41WYI?WZ]OB6AOKW`A@:ZAKEJ?P4K97X/9[=_`WYF
MA5$KV4&Q4@9HL%M^9;S"I[%Q",(`L)F7?PZBL6-^:DA^&;&%E;X%#H8KPGJ!
M@N%G!2P'8T"U>@6K%+$_:>+M$Z9LHJ\`;?_^"`C@*PN"C/E"BAQ)LJ3)DRA3
MJES)LJ7+ES!CRIQ)$Q;`CC@*`>0PPT^6$86<!8@EJ$*A+KT,@"R$P4`!$B$S
MK5A`]0,F/S1@Z?#3Y$\)/Q&DB+H@TDU/+7+^*/#SC5&9'`6#_8%0H%>6:K&B
M^!'R9X0?'X_$??"30(NEJV>H9?@4:M2?4N;T\O4+^,_"D:464(/B1T>N7;W6
MB%XC(MAHTK",[2J4;-D*.6(94?A3Z09K7^-2)R!K:&T27@:H+L@:4H(90>(,
MM2L4,4LL'WXDW+@7<E^)"'ZP_/.CI4P9&O'6@(55P4<"RZYB.30$P8\4VEQ/
M'X`_@4.O(;%`X##_Y@=_S?\`!BC@@`06:."!,P%DQADDY+'=&FQPQ`$;?Z#@
MAP>P8.#3'7^$P(D@,,"2QA'>1)4<+`"L8HAA3'CEQQEN6."'`B(9X<<,JS7A
M!UE6^)&#"'YT\<<<\?Q!0A-&$."'"_*(\DDO(*A2!AL3^&',)9F<(4$6"3#&
MBW.R/%#(/)_4Y4>4EXF4V58S9,'#9^2$U,M(JB%#CVM_?&&E-#AP54@.98!Q
MHB$/^`C+/#SP\E`^!Z`@0R$"4(.`<H?]T<9=1A5"QUT0.$-C(7?<T`!\1UP0
M`V$"Z%1I1*"0\!<L/&0Q!GH,&;)>(1KX`4PEUL3"ZQ\IC@'!'W>@X-\=_QQ9
M@>"RS#;K[+/01KL20&?D`]`E)MP5(@2YQ-`;=Y:F$T`K,XA(XC?Y9)*;(>))
MX48A;@CRZ%?5VN+'H[&(5P"Z?]CCK8QJ5.#'!'\T8,H?;I3V!T`]D!=0+SI(
M^8=XH2'V1Y]%BL5`(3^D(O##$:<94F8]]')$'G#.F8_*(=5YFS+,:"26-'X5
MD&HAZOHZHR$M^&2'HB-=0!A(<!F$<Z4N(F%($C=V*,H;A;@0)'S6M/'5%JJZ
MP^H?;]RE\!]<^$$`K>KI:HB255"=SZ]T(*7(&SXY^(<0U$EK]]UXYZWWWC:]
M:&VEU(`Q[!6$Q?#"#7>]\`<,7#(`@3'KCEABNO^#0BJ(`CSP$(X4=+A8K5I!
MWFRY'^.:84W'7>#QR1MM))!%".!UQ82/&'SRLR%2$Y#&[@1U48=;"/.'I=\.
MU#7*5P$$@4(N6OPQ^Q2[I[&5D*T$<-K&MKK2GA^3IFS):?Z$!GXQQ[R,YQ\G
M]#);&_.L0(0(4-2U;B&#97'#"#'T-$`HB\8BAR``^,`/<M&BH[GC#U40!15&
M`(38_($-DJ!`#YQ0EQ^H[0_1>-W"5E6D%!F@#!\PPUVJ5;WKE6(,:QC"`C@Q
MJDHTX31$N*`-?!*"/TAB"R,(0D^(P[<>^O"'0`RB2:CU-W?((1?:<0-V.G*%
M/\BA)X3X`Y`ZP9QSF6C_?DSA3R]JL(="T`M2T+&-(4X5$"?.HQ?K^`,-[F(E
M?V"`C7YHHB'J4`,_9*H0;4(!\!Y3L2P5`@M%DL#,>N$!`=2A*(9@0)LJT(J`
M')"/KZ@C(;P7D&H]S&^%<-D?6A,S2_5D-@4KE#"ZX(]8K'"4:0':2'Y@IEY$
M()57.>`<9B>,`4#M,5HD'85^50A!#>5:S"G2'-;2$66AQY&E$$86@*"/AX&"
MEW]`RE!B)8PQW$Z(V,RF-K?)K!NL0`+Y\*95"N&$%33O#PRPP@0,P($RO`L-
MV<!>&RBP`GS9(0H#*&4L=+"";>3C`P$8PQ@"`)1",.&;N%N!=@PQA&PXU&@B
M_XA`#2A0RC8L8`830($AS"#0!<0!%@Q8`0(H9(@IK``&,>CGV59@%7Z"\P\7
M$*DA]A"!&0P4G"$=*2Q,^H,?/#0;XRP$'E;@K06P]`_8^-E/LP'.I2*T$`-8
MP36Q@8<_($",?RC#"B)6"#0,P`,SB``0/IJ/.YR``SZ80`9,\(\"CD0/):C!
M$0:P`:T<U1!RP`$8?`"&!73.$!((P`R.$`7LN6`%%BP$#$0:JKO:0::%<(`1
M'E"#$I3AKS[]Z0>&ZM`!P``DA_WII`Z;V#_L805;@!H,(N"#,6CAI=R,K6QG
M2]O:VO:VN,VM;G?+V][Z]K?`#:YPATO<XAKWN,A-KO]RE\O<YCKWN="-KG2G
M2]WJ6O>ZV,VN=K?+W>YZ][O@#:]XQTO>\IKWO.A-KWK7R][VNO>]\(VO?.=+
MW_K:][[XS:]^]\O?_OKWOP`.L(`'3.`"&_C`"$ZP@A?,X`:_%P/>B7`9&)"#
M$QCB!#F`:1F,\@87```'&(B%&P#E'11`C0$2_H$^YP`#(]R@#X5H0!G\B8<R
MB,`)[BQ$IS0*J3*0A0T?8`(6>!R+!N```&40G1M:?`,-&$($,80%#$+T0!%0
M!2KH+`,&U"!A[[CA!%UF@``B?`+8QN(".,!"$N0&8=YT:EB&J("$14!2,$OX
M#Q`.\6,F_.0RC*H0%R#"?`S_\8$PQZ(.)\`"#GB#/@E3N1`HZ'(.4*P,/&MY
M<5V^HQ3)7-`83P$++I#;A9-`4DQ[YP15U;!W8,#6D*``"0OX`4B"T&4E1S@)
M(T@EK=T`8>\D`05UT$B7<_P'_61`UIMV=*H.0`,CZ*"48X[P$+#WAP_<``LG
M@*6#&^R,2A[!,04X12O6D`:DW"4+I85(+G[!AF@((P$;4Z0PQD8'IVP,($'H
M$7&PD`4BHP$O3.#$710!"QD(XBY2\`<#M)B%L7G%,9DT0"'"YHNL1*,,C`A(
M&EK9BS/\6QA,6(IBX2B%JCI#3'RL="$HYHLN9(3C?LCJB1CQN3]`9Z&+*(#*
MX2.,_YK_`0T]\84Q.2YQ0WRE'-%@B#/&D4ND7448<J1!*PO0:0GT(JA-9U(C
M!>+S/]B!&BV?PP:%P:^("","P09(&KK=\C1\7!B[,$,KP>"&3`C#&WM`CD^\
M]7:!@),@/B&=Z+:]8`&@`0T%",#AW_!M0X0;/6M(7TYD,#5#C"@":&B!H#00
MC0R@`03IR(I>*/"&"A@#*%-P!1X&AL<9,*`/"3!:5_&2@!K$P0V2B)(A.!)B
M)3%I]*4__<-C80")#^9D%1`+""[N=B`I'@UM*,`,#K_X?^,`#23H";ZZFH4"
M].$.?=H"&[J=E5+L7#S7!X%]R%*`)E#_&TL/S.<TY(=9/?]"Y["H!`JH?\N)
M<^<.&"`((29]U/=GA<``:-`G,8`&#)!T09$<!B`%[T=61R,":-`'TO<'=%``
M62`";K`58&`(&.-6$7AX!$$PK1`#(,`X!1!LAD`W$>``#I`.$0,0$D!]L!01
MBB<!DN`$&[1V?K!_$H`4)_!OSW=X;2``W0<"=B`H0^``:``D"X`&#2`'D@`$
M;1`K!2`'1H@&>&`CZQ`!!=``=!`._D%X#E8`H+1)X"9NE@`$<9017V!AEG<$
M1D-Y,>"`?]`Q2N,4-S,"6:`L:3`#4A``68`N<+@`88-ELV<-TC<L/(`#!O@'
M%I`%X(0!-V`5Q7<S3A"(PY<:$L?_;^CB!%:`!A<W>VOX>+#P;[D1!'53"*G'
M559%==UF`&Y@?K`@'KG1(^R'#[`0?ZKP.2+$"-BS`/AG")6P<X8P!P7@+I#F
M!SFABB+A#)^CA_%7?".1">@R!N4R!"KR!TK2:AQ@`!'P`(.&C860`(#1"I]C
M&#XG*'6E@0GP'FH7$A$!2B^0`+.A=LY0:4K0&?^VAN3D!V+T`4TP3O_6*[;`
M`2MR+P%9"%;7%;008A*``S"&AFFXAD>0!130D5G@AFNP`="1`%LPB>IF-#;R
M`=%``6<0!-BQ!@)0>7@D)%+4"_M3"+#!@?V3D*"3!27P:"^X14B0%C$)!8;@
M`#,@)"4`_W%_@(T68'^P<(H_)PV%4`#ZV)&SP8HZ-AZ&H".,!H<NX`Q?40:X
MR"Y@D0$#4``30"'2AY6VX0Q@T)&Y4"VPP0$&XXO&N'.5,`!4X7,&,Q2&(`58
MTXS"L1J_B$G1<`0=*2A,IX9828%7T009P!&OP!E$1GF/P@!9P`=;X2U-*05G
M<`9]8A#L&#58`0NU!PLR`@$`@054\4CW6`A6(R;\N"1GL`9@D`4>YP<3U9&O
MT".)D@\\N8>#`%B#\&\1$)KA8`V,X),Y@9';IH9V4@Z0]P<\P!]9`)0C$FYB
M80!OX&YV80%W8#`".0'$$`=U`93-J0>QP),AP!&]X#NP8`>G9/\E&V`PO?('
M<6">GU@,$E<"_8-!)_*055E&6LD_L+`6_)(^9N`,25``#U"6*Q<05B!V'`<,
M;.<+U5(RKV`>8I>7^2<,M?('5B>0-6`0',<OAD"-A0">N-&4&L<.`6%A-E)S
MKC(./:(&$9E)PC`#5E&:$X,7AO"1L,`1\"0,`AF;.G$*M8D3<]!W![,8%]F>
M0OJ/ZP(/4Q@0#S`L>:``;*0`K0:="R:=K+$OA_=XXU8(<]`'AE%T550`!C`#
M%!!BT1``5I`%,3@7,OD',T!PC10!!S$#`5!JC6@(#:`$8L&>L7``/"`H&=`>
M6*5(BK"4Q"=Q$6`.43F@5+D,TT=]4YG_&S$)J(80#HP&'D!`C5+#&>?G!TB@
M!B\0#DJP#.YW>!OC#->'!I50+8"T!0N0"Z4!HLAHFQX'"[8`F(4@!9-2`#40
MFF?0?RN*F/=P>'W"=!)(?2*7"2B@!CW0)@XP.T1F(1;4)E3!)9F4`"?0)36$
M'I_SCSRT##4`"]CA``#Q`Z'):!"QJ1Q`,+7)!Y4`F%U(JW\`2%TDG$+JC<_)
M1]?G!QS0"F,P>!"0!)(PHF**8&3*AHX'DCI@`7(C*.8B>RWJ"FQ@#S>9``GP
M+L66!<T#`@7@`QP15",BD(T(`BO`3'_@!'L!#KYH`CN3`#-@LD2`LOT9<>!H
M,X5``RMP`5))_Z#+@*FSEQM6=Y.%8`_K,@!N0HT"(`5WL:JYX2J.4`"^^*RY
M07-_4"4BFG-Z>2?YX`99H!3TXP<M(HTAP:("JG00Z*:4@RX$(0),4RNS`P(&
M$Q`PAHU;,@8.`J3V$&6%X`%94$HYV0;UF`]*6AZ_I`O].`=5HE%*6P@)1!PV
M<`3X,IQ6)WL],@0/"8>`6@<!0(<AX`=<,+%CJI%M"'F$0P`,D(_G48<>.[<:
M:`Q.IB1-T`!JT!-0D0Y*4#P)<#,O2[!FH(12(`$.D`ET6`B%L@8.`![[X[O`
M*[P/IP;<JP9N@(TSQ`$@0`(&D`4-D+2;*GW=JP80\&^MR@/8@;@PE?\%4L`#
M##`%61``=<"BC;2JK3H"U&`;!8``ZSMF,_<B!I.<9Q`KLV*,3M"]`I",(I$.
M4=``'\"[2TL2<FN-$"@%ZZM/5Y&M(E`H%T`7!4`$#*`#62`F6[$`H8D#6=`B
MZ`B&Z.$"+Z`'4E``U_0'A-,%&H`!.M)$CQL+$=$%:D`":V%AM:D,(L"S&_!O
M1MR]=*"9!J`&&"`HGRND;+!##L!*"6`'#TDE0<BG!2`##$`X:>2Z%`N[%PMY
M%]`3,R`(4'N2L:"'LQ,%)%H7-2`()=`&#&"5J1(.N9&\5&H-:R$%/5$`U/8'
M*EP`8W`7,20!>LS'&?$595(`IB=Q<E`H3L'_J@*:&TK+@9=<A$YR%RO@K*J0
M!764!5#!HIJ)MA-:)CX!3J)<)B(`C#1W*DQ2"!RPN(QPR2(@P2'Q`8*PQY4'
MM_FPP>DA<TSG))_0KIGP"7<Q!F)G!-W7)GX0(KQW@#,0@NCH(9S3"D^R3+'`
M`-@QCS>B5.5#Q#[!@;R9*DML*8:1I=U7)N!$#0E@##-P2\/Y!TG`"0F1'@0J
M-31B#]+')5^CQ@:&;2*(<XKV!S:0`3@5!5V``$!@LIJ"`[ML"!B0`3PF`%>`
M!6D!`485`$#0.9206""0`5%$!S@0O>R1`3:@GTF@`%W`!*D&"SVP!5TP`/Y4
M,"5]`G^E`QE0U$4-_P%(H#0:(00*D+I,D0'C!`$9$+U88-1%_0%27=18``.$
M:@@YL`4KD`$7^0$9H&<PD`&3*`%6?0-Z5M56C0%D/4XH4-9.``!+H=9J,-=O
MK0=H/1(.@`4BI00F^]`C0=9ZUM$\%M?]8M4R#0LG8-1&@`.EQ`8B0$]:@&5,
M<+"+8P1QD-2&``09T`(17=0+H#CY\`8X$``!L`!PY@(9\%>Q0`>0?0)RX]IT
M0-9_Y@`9P-J,W==S@`(!H``X(#I2/=.&H`$$L`)<X$]238=M@`11(`#CAP#F
MI'L*?=W8G=W:O=W<W=W>_=W@'=[B/=[D7=[F?=[HG=[JO=[LW=[N_=[P'?_?
M\CW?]%W?]GW?^)W?^KW?_-W?_OW?`![@`C[@!%[@!G[@")[@"NZZ9E!\#@Y0
M_V&L)7$!CM`2$AZW@Y</%(X[2AT2`1!4%]#A*I$'%B"JAF`!1W`$8Q`!)G`'
M')"N!&`<016U#JX``M``4&L$5%8&'L`AE#@&*AX!&P,&6,,*@-D&'O`U,E`"
M,U`#(2(##FX`0V$!?^8"1N`"45XJ%D`6+S`!W/C3`S`I&F&W$#"./D``7?T'
M.3`!,S`#"O,"'L"-4](`8)#B8[`"NP`&Q3<#8G0"W#@#^"$`!F#G`]!J0^`#
M\V$!48X$&\X&-U`#,_``3@8#'O!76\X2`U!\8P#_!6(7"T8PX]DT`E9QX3(Q
M92]!ZH80XLU"ZA@`E"%A`U+@5A`1(F8`ZB-1`X:U?4]&%JB.$B\@!5]K=%AU
MZMJ$!L1P!@$*$\D>$G2@:2JQ[(YGF".SAF80[+%0`C6G!M:.$B(0@K%@#G*P
M`$9I!B'X`8H@9KY"EUI@!O"D'+FA``\0G$?P.0L@)`:0`!0R!UU`#!+P``P9
M/!8$`5*0!FO0/T>`+F8`2FC@ID>@!G^L#&]45VP0`6``-1$!"SB0%0)@`8QX
M@/B'`>72``6@.`Z0`#^`!N90=Q%C#A`P?0W@`QOC``;@`!?O1!Q@E'_0!!9P
MA@O@#FHP&T[@`ZEB`Q/@_P#.0!P-SQ(K\`T,(`6_$0LL&5L4,`YZ5A/>\1+0
MKNW-4O4;M>VQ@`0XUZ+`X,(HX0?>;@:/Y$75PO4KH0,^&`L5\`!0B?7%?NP/
M,)E6X0!:$`!$=F&C@@(8(`%#,``#X&07@`!:("9NP`0*H`1R(`$Z@``H``0K
M8`1TT``6]@,(\`4Z0`<GX`(*@/,N$`!,L#&'/UGYH`<!,``88`.>Z`0*H`7S
M(0$4L`42\/-_H`1Z8`8!0`$(,"HO@`!;0!;83@<Z$``W@`\CT/MUY0*?%@L.
M0``*\`-L,`!2`-.;9`@\,#9Q\``P(`4M4"%LGP&?(P,4T.XX,PYU4`)34.'S
M?O\(Y4*.,$8"*T`,7Q`#!3`L,)#&)P`(+VLE?X6%1VB%9A2%:`:&1VHX`89"
M%W\?&4@_?VE^AG\`G'\D$J!_.$*&5`Z3AB<*:$>&,%A_LX4$9S@TAGQ-GH9,
M!']L8'U-A@MKA6J,%J:%*T)E#T<"MVJGAC9;`2?;*XE_+UU_#4T!'W\49V\X
M"DUH92-_)Y=`;B@!`2)_.E.PQ-&Q`DJ;4VR&*,@09PZ2%3C8-(#1A(<+)@K.
M_(F#48@;"3H0K$&!($`."#,B--#QQ\$`!9QL\-@RH,&V0@P(K&""#84"+0?*
ME&&#PX$>%P&@8,L1@$"#'#+^H"#Q!P8&0@ZT!$#QAX[_C@`+,OSAH8#)%0AN
M%@2H\L<-@!6]3KG``87-E153"I',`((-+"/86%[,^">"AW6@7B#8<@'"@P>(
M"V&1HF<!DP``#NIINF';#!\\_IAA]F,+@1`8I`3P^@?#%@0:_HA`T,3FJ0NO
M^]`IT<7&J2HNQE1HK4<+EWHNS*P`AP(#)CU2^5$E=+.Z]>O8LQM"0_U,E@\?
M./P)$*/!#'^@*&A;<&:-%`D8#R20\"'+'R@+''31L:9`#A(*Y(&$"\Y`X$$+
M5&21!@4$,!!!"R(HL,$-`<@G@7>GM%$"`V64($`!%^0`!@,N$..!"",4,`(%
M-H!Q@!D&@%!%%'^,(8$:"3!0_\(N"C`00`9MC('!"`;$P8$ZIR!P`@,>P`##
M`PZ<<L099PP!1@R%@)!%7G^P=TH&&OUAA!EH^)#!F3.4\<</6+CAP2%FG,$#
M&#C\8<`->2%Q`R%Q)"#`%DK\@00,IZQAP`*(:H.((HS\X0@D:C3!TBE,H#!"
M,L$8(D$!$0PAQS9-1%8(`D`8$B0:8U`90PU<X2+`#!L@4$\A'_C@"95#2('E
M"`/<H@PS?SCS1PV@W-!$&2M8@4`VU7F`P0590'"*.(;,4)@-&W@@03LZ*`"!
M&5K@8(4`$[`4P1L3,/!"%FZ4H,X/%#@`0*^@G/```WS@`$0&$#0!@QI9Q*"!
M!S%`</^-%0"8$`$._>4@P00;K!M'`#BT^P<",#`Y`HP8#$#C34T0X0`8+J#@
M00,T,"&4%@O\D0$!>$0@A`P^3&3!!\L&8,0?%LA!"'GFB0`/`TUD\,88&YS@
M!QH!6-$``B+$@`,$$8!PB@=-C'""%A`0\$,%4ES`1Q?VDK@S(00[<,0("S2!
M#2AC7*"&!W*<^78A:SP`P0((^"B#!$=@0$0$VQQQP0.BK<%D"S!(\<8#,6CX
MQP-]7%!"'$=H($("!QFR^`5CM+$`$'?_T88!)++DW0@XB,>!#AO,D)9&960@
M0KHC@/$'==KU[OOOCG;W9F$UJJ'&%E"<HEZ7[2'QQQXER*#_^Q\3_,&!"&I\
M$<`:XC7@`0H.V.$,"BW34<""/3"/!!]JR."!](54#TH=,YQ@@@E_G$_J'W(\
M(($Y?\C!!R)PA,Z8(1D-H``&EL4S)^S(`H3J00;^9[SSE"`'VW@`&U"A"]Y!
MH@03*,`"YH"3`L3%2Z#(@!0,(`4P.*!,9\I`F@K#E2Y8[0A'F(`?1FBG((1N
M"R(@!`\01X(M=`E8AG`/!9;H#P^,8Q&->,0AG*&F4W#@`'4X0ALR90@1&,$'
M,["-(98'BA5$!1)HJ$$)/)``&FS0!P9@H5A68+5F&,`3):A!`89`PAM@:0NS
M6D8S&#$&4"P"60V0`AXB<9,YO*`._S@:AR&H58@Q8,YX"M!!.S"`!@><@`(,
M6`$)(C``HMU!`F](41HN*"8"P8!8H"!`7@[0@@DX9P0*4`/AT@"&.OR!`"ZX
MW!\N8`'N_>&4;E`E!=14`@QHD(-FJ%,0&K6-$;!A`RLP@Q7*-X(R=*$&<7!9
M^A"US?BQ@7`(4,`;S$&(,1@/>1#\@P1)()8Y%``-"4"!&G0`A1BHPP$D!,4#
M_!$!)ZBA#`.`09T.(((F($$-(T`<(7KYRRF802R@($DAH(&H4YR!$`O@!!7*
MH(.'SNU3H)A%%WHP&H46XP$AV-'N("`>V<S&>`:(1B%@8(%1A6`TIQB!M3!@
MCC,0HP^$*/^!'?ZP@C1XJ78FD(``/B!1X%GUJC?A3B$^*HW\E>"KDQKC>MIC
MAC]\=`@KZ.H$OEJ"#*PAK7_0@P$*@+UEEM5."QIK!M;Z5;1V]10B>$`6`)"_
M-'``6!Y(`C75X`<.<.*BG:"`"#!*`1WL2*9H`),!V!K$,(%B>&7(B`</48@!
M4,)T$=!!%A*!0D.`"11H@"L[RN`)/]@V+U/Z0Q).:X"YO8`"JQ23;?U0@#;H
M("ZDN,`@KM8"1D414D8@;"&(``(T#-</+N`B.0K!!BJT#!1&X$HA>,"``22O
M$-Z312$"H`72@F(`>S!$#CP0##<,@"5N*,!P=W;$0=;(#88P@A'_D/6'(32!
MD3<)0`$HD`!)2F,<!W@`/ME:AG;TP``U`,`S='"#+BA!31'(P@#.)U,*/."K
M`)QD%?^@($?50%AI@"NBAO<'#[RU$!$HP(@7Q$P1@%8!9E#3&:AYBC(4X,2+
MN.L?RA!"/+AL/6VKHH<"<($!D*UEA"@`6RVKD<RNX;L&L.Z6YP"%`OA`6J`H
M@38,`(:O9B#(DSRQNW;'U$(@"K*@@`)E3]!14'#UJ658P!'86CI?]4$*4%B#
M#JHH69GN2+9K4.-7M6$(31;"=D`%!1*&FX4XG*%E:DBJ-)Q*NPPT(`()R$!5
ML<KJJVK5K-1)*RY$H--"4.`%?X@"66%]_P;$3<YZ>1CF'FYL@A&T00E=<`8/
M""L`!2V//8(40`YZ70A?&T(`_K"!?1*0ABWTH@Y@N````<`#!%Q@!FF`[()`
M<-I./1I+F1!6@1T@TU-,8(,WT`)7I92EN-GC"'(``#%:>VG/.DJVR^1>&M(P
M@@C0(;=R<*>=U)"!^P;W`2!8>`!Z@,LW2`,(RP4%&$:1`5LX2HK9@,&]BW$$
M&$1WX6:(@'8CX&2IF)P6%-@@&SSP@AA,(*`$T()Z_["IX>#"$#'XV!\&0(-,
M@:`&%SC#&!:.@0)(2Y#!8L0`2O6'+`Z!P'(X@A0H?0H0<"`.;&CPM,:A`RV0
M:ZLA:,<6^/"'%O]H?04^B8`$<#F'.BA(IJ]UP!!.(<N6N.`!E\`9C$M`PB;$
M@`/84$,7;HQ+-_@]#<?:'0A6?H,W"YG(H$C7'YJ@S?(MV@53V%D&H,P$)L3O
M#Q2BP0`BP`E"S%H"*X!W!GC5EGO>\P\@D$`?&D"'PJ=9&VH^QP=<ZH`K4"!0
M;:C][AJO`QU@U!`R.*T%,-#G+HH'T'`.X`936@@.U&`-0[A!,3P`@@AHI`2&
M+<05SH#1$QP`%$/HZ7A`D&E#<&`$"]<$2O!IP2)J3.5400![&3`%"M!WJ]9J
M$-@[K[9O:64$%)`$!B`J_X``.E`#N_91;A`!-W`#!:!;$7`"$^`"-^;_``0C
M2\[@,UKA!P?P;&=P`1,`!`&P!2%X`PM0@O/C`56P`&\R`TQ@@TK0!'72!7HR
M`;^U=`"@;HRP,%/@`0*P(SGP`$G05FT`!CJ``U18;Z"P``20!(>Q;^2W4RMP
M`$)B.A/0`@3G,@876V-48>A1(T.06U4A!7306Q60!1BP2GB@?W_@3^-1`K^@
M`'_@'C$D%C10`S=@!$>`9H\R17+`!2O0+0A0!QF($W[H!S&$`2@P`UC`!$=0
M:_Q3`GBA`#O3!AF06DT`!B8P=']`!8QP=(70!A$`9!30!5OT";FP`AGP79/C
M`OV5=7_``#-``'S``3C0!@168'Z@!D1S"@S0_W)&4`"FN`)%LP(U8!--```N
MX`$7T`Y:L`4G4`*(&`-'X``+(`6M\0!Z0``%T``R%5$GT`7290@],`%*@#%!
M$`$P4`(?`&,>D`$NP`'.R`$G,`,P<&/.-`3RV`!8$`$ZTB49H`0G`V=#YC(,
M8$4N4`4^@`02@(44``1"P08/@`>KUR4+<`$UX`):0`P?X`<CX`)9@`V$8($8
M^`%7F`06D`'GI"Q9L`$+$`%)``8?@`)=``,1H(')!SU,*0,'8``A00![8`!)
M,`"NAS89``0<P``Q,`9]<`JI-07FT'V%`#KD0SMET`!4"0`I!@DX(05K0"Y3
MD`&ZHQ6[<3$X8`8Z./\!.(`$L@,*`J``4Z`#XM%_+3$]4F$`>P!J!MA4)Q`!
M-/``!OD`%#$+HQ6!G'D3$#`I&#`IQ.@`1A``3C!^A@`!`S``)X`!$N`;H7D.
M18-?:E$%<2`!Q*A;JG@`#0`.$K``0^`'<W`"-M$<NH4`6.!DZ```864(1!``
M`Z`-:T`C3&$$]U=E38`'O7F,5V`#T$$'OLD%%'`).H`!<Q`#2@(=?;`%X_D/
MSG$*:1`%6\$&L7D*=5((=&`%+;!B*-"?[VD(>O"??P`!N6D/'S`%=&`()8,#
M[TD'1E`!2&`32-`&7G$!T($3`#`'#'`#/V$3$K"(8A$'.$@!D0$!SE,(.&#_
M$P+`!"L``&EP!U&0H(4`!1_ZB6Q``XL!#MO0`!CAHH7P!E^P$!T)`??9"0M`
M%#N*$4;0D71P?1I@!>6)=-"!`M&PG:VA%3=P!YB0FV]@!`T``0P$"MU"`S00
M`G)Q)E#PG@U```$07ZT)`@/0!'W`$A7`%A^@"G:A`&4P!140I7]``V!1:&SP
M`TWC!D0!9!(!#JN$!`&`:W<`!0%`!1]!C'FZIQ4``@0``BR1!EK!%3:P#A@`
M#E'@8+*A,SQ`*#P0``(!'E)!`GI0G%R1JAG0D0*0`0+`?87`$J1IFFQPG@C@
M`M`1`@!P`E;G!A1B!FQ0!QC!!ZB9JS;!!@QX`R0D_P-;X#1LX$]1$"4L40)(
M@`"XQ@#Z=@H2P)Z7T)^GX`94D`3&R:JE00"78)^&D`2F(`,4H`7.T3$'P!(@
ML$160P(4T`2Q<0H80`%;H`TV4&MXH*-_D`<3Q!4K\0^%X`)T4*M;(`-Z<`!7
M@``QH`/&U9D>^[$@FR44<``_8"TA>[(HF[(JN[(LV[+8(0=<XK(J&UPI:P:^
M)+/7X0`!<`<^UK*;B;-`&[1".[3:$0!9X`/B1;1*N[1,V[1#VSE.VVH"<%HH
M"[5-VP198`"XQK)4&[5>^[5@&[9B.[9D6[9F>[9HF[9JN[9LV[9N^[9P&[=R
M.[=T6[=V>[=XF[=ZN[=\V_^W?NNR1S!XA:``]&(=;&`*9J"!O^,F*%<((9@%
M":"CIE@X;],`A;L-%O"N54$H)XLDH!``<>0#4Q!0K/:XD5L,DPL!L])J<T`5
M4GNYU=&U^%F'VS`@VZ`!!B!&-^$D3H(0!"`%31574A`!X703:0&\``8#";`"
M)*0&UM`9<0`&!I"TIV`$<72]O=N9+G"BV/$!2O8[%\"]-T$'M)M@V%>@V]"U
M1L"YV"$#L)L=V?L[\>L[[GL=X?L[APN^->`'4)<=`.`'\74=C6M(['L*@B@#
M9B```Z#`XW$*WINW":!_YB-;U6$#XO$!N@L\'S`&P58L3!`"/"`%&]`"UU<=
MY]/_"!0L)60G%"@+AH50`E!P!N[SO5=U`Q\<PAM@`\)H"%&P8JR6`REL53&6
M'9LI!"7\)32,"F.`7#=Q`1?`PO4R`&@P+R0P`?RWPZ"@/1M@!3<@`&"`!DC0
M"QP0`T-@+0'`!V:7!DU\!E#0#F<`Q9R)9]C1`(JK'11W'4:,';RS!DEL"!ZT
M3-IQ8[\#Q[Y#R+TCR-7A`+[A.SK\.R5P`FAP`HQI'0]@`C=K';ZX#0O@PV>8
MB`MP!S\PQ*-%@'A[!+G[!S*`B@/Z&K:!$?$U&7K0'"BP!CI3"-E7!N+KN`2@
M`%0Q`%*@L(4@I^.%`5KP/0L2`&:JF\1X/NR(!UV@%4Y6_UX(X!R1$`=0T`16
MH"8^T3(0<`)1@`)!\!,`=@H,&`4,@`$N4)K.P0`(8`0NO#O`@@,4@`)E$`!/
M41:8,'@;,P6?<@"!`@K"/!88$`#^TP!;H``R0`<>$`$8``&L_`<N$%I)J0"A
M85\(8`IZ,`0!P!(#@+35H1#W>08EX0_V%0`:D`;X&``U!UL!L"=_H,#+41B'
M4=*FX`8$L`6DMPT<T`*$`]'AG`12@10P\`&&G`/C``8@`*IA*A?U@`9;\`/.
MXP!2X`"(.#DMD`4'P3#6\66%$&@#H`6?PFX+?`ITD)MB@01HE9M8H#-B\0&8
M\08-X`),]P.JV`:@&!TP0(Q8@/\LH^#*A7`"`;`OFIQ[,OT!"[(%R0P`"N`/
MA/`!*H@#6C``T?P:P\$G3=`$"*`F2:``O8`!]4R]:_#,*GV,BQ$E+I`#A#4%
M*T`H9:!AZC<2N9HA6+`"7[!D:O(06-(&',K$OA``#S%,[(4-'Q`/<=``T"$#
M>FH++@`#"N`$_),!V?0'6`"/$(`%LO(';_`2Z7,UAE`J;Z`%*P`$;="?M.$&
M.B`%8L&ASHV;"*`&$>("F7P*FUP=1_=E92W*?Q#.!.`&9_#51A`E`I`.SN$"
M5$``UBQ9BVRV1X`Q73+;=O``?.`"/:5)3@`&9V`&,_`!T#8!)V`!/V`@-$`!
M/@@*6&#_!"?@`3T`!>=Q"C['H(4P!1&@!@AP`X>GJ27@<RU0``SP`)!<`"65
M#%U@!30@!=6H!D:@`$"0)@V`F4W@`F@@!4T.!C!``*H`"L@]!,]\!@6``PN`
MB`$@!#B0!08'SX6P!0"P``8``#8(`UM@!E*-`18`!`,`U#E`PRW^GK-=`>&=
M!#.@`1'0!"``X3304Q%``#3@`P.`!#[`!AS`!"[02]!=!E,BA&0'"B$@Y0A`
M`Q#@`TG`!_=F!%:@!/"WY4A04X:@AE5@!`GP2S?@!#7``Q3`T`C`!$K02U`P
M8`E`PPP@'@^0H!$0`7J@+8)F!#@@%)QL"#3`!;3R#=B1!`M`_^.%\!WM]0=:
M@`)9\"DWP-N@P-5+=@158`%.,P,N\`7)``I#_`>?8`"9/0.>M`4Q8"8A@)4$
M$`5J(`4$(,D4`6T-X`,N@`#NF`5C.`-S0.$6;B_V<L3T.@03L"UZ-P-7P`</
M,/`#X'-56(5XL`8)\!5-<`!'(`0T(&I&,#H%4`88&9#3E@!6L-UXX^,`D`P6
M0*8!8`<1P`%40`,*``,<$`)E,`8NT`4W<`)I!0%5W=T$,`20(10R@``*GP,W
M,,9@0+VR$0$QX`$KD$@NT/+64PL+0'$&`@,48!]0+@0S$`<+8`1WB`'*X=8#
MX`(S8*(+X'/I>X+X\P=6P`0PP)`+(/_N&QV*91`#S?T`--`?1A`"$Q`#`Q#?
M87CLA[`&C(\%"Q!CHFP,,*`%4W`&4C`%F%T'(GB0;+`"AAD%"N`"!M#'87L$
M#74Q?#T!QJ,2#S`":H`%3?!GGT8%<64&,4!W$(#XD[-!.-!!-R$#&6``$^``
M%/<&U$$`5U`""8@&%5``70#4:"`>Y^0`^@<`51`)MC2+)/50)%``&%`#;/`!
M,X`"$'!_L.4`)KH"9R`_\$<=$S#F)9``+&3/98\*A!('!1`'"YD9*``(''\6
M('^&AS(9!A,.9PM_(VX78V<993\3:FH1#24"?QX:;'X24II;(AD]?PL+:RN'
ML7](?&HR"0?_(7$?1Q@/AB(.@FQ9LC`6AA.0;2`<9689I:<B#W-_`V:R&3=_
M3$-_$0Q_,JTZ?V7H9;*&'S-XAB=;C^N'>CYI1NI_!8F&"V<#M,#P((2>H37S
MRI@CLD)'%TT>Y,1*`^N/GS\&-/S)H,:"@S]?,B!!`E&-AS\'QL!P`,$1#74@
MQEBT\V=%F@<CU&!I8@'&GQX99,4($,P--!DE#!$X4^(-)`=':J#X@_!GA&.&
M$(1(JNQ/@#(<4-@*<$;!NC7#(I#@H.G!CQ(-_B00JV-!F2I_-!@XD.#-%1>R
M+@AH0"!=C"[![#QPB@&!+`(C_IQH.`"BG#%K3$!0DR$&GS\0+DZ(_TL!#0DZ
M>+:<<71@0DXL)PA@`6%BW1L8`0H0@,1FPPHS"P#\Z1,TJ<=Q)=#^^6'ECX"+
M].P:/)*A>I<%%"G^*5%G!@P3:<Y@<0XFR`Q-"B2LJ/!GPCL7V0S*GT^_/OTC
M;2*D:5)F19D"1T1U00T!SC``4ZPXHLX:9NB@#W2Q=%4&64G)(LX?&*S@`F<-
M5+2`$9D<4D`-CZ!1T0H:4&!(&5`<H48):?PQ1!D+^!"@`1(D5<<44I3P@2P-
M(`#&!"L@N%V&AG1QABPE0'&&"'2P\LA2AA300!M2R`!:`@T8P$8L;5R8H0N.
M2%8"!PE4@@Z``E98`AH6G<'F#(FH(>4K!O]E0.`1!M0!0`D1&"!"5W]HMX\L
M+JCX1Q?C1%""`<]D(&>!2/D3WR%'S%!"#5K49`AQTJ6C3RP;/&!#+'2<9-`&
M'O#P!Q2`_9$%"9W^H44/#`30A16CGI60.F>LL$`"`=;PR2&&7F0`G!F\4*$+
MU>WIPXO^]"B"(TBL46A2T-FTIX$E+`E"4!-U(047#D!S@J(+T$"HK!,`QN`?
M:JQ`A:(9B)!4A5J4X4&`1Y"E:"QXUE0&L5'!4*$?`8Z1C[80%/`'!1^,$4)@
M790P1CII*'`N!EVE$8$L6\`9A+`V1B4`$%),L`=G#AIR$8P3HS&"!27,L-H"
M:,SI0@@/&,"$+'+_?-1&.PZ(@+,/P#W"V7;M&:+&!'C"5Z5!TM%SQ"$(90=+
M4CP^0,(9\77Q7X$?V`1*C//:Y_;;<&,Z,0%)]+=&A3+$L=@?$I`@@B#_2,?@
M$-PP`.$A$WQY@Q9&QO+`1W_$<(,$&;P!AB$#3,%!$'^\($,!#`AJHB$K.(#,
M'U&XX.(#%_SQDAGJW'$"'DF!($(=/(P<BQ9#L)%$D6X*4.$#2\:27"RM_#%%
M#,X5<(<1"%APP!\[#2"+`(\;(KD("T!P1!R@G/$PWG&X":<?:AA@"`D.<"3E
M#Q6MXXIS,0S1Q!V@^&*(#D@>2K#NOS@"!/Z@`(5P1'U_8!\8ZG"-2_T!_PT^
M@$`:'%`##41@@#^`0JC28:$::.D/,*""(52U#@D\H`6&V,-X6'4`"]2A#34P
M`0T8:(0?&:0JYP#6;Q25@R\ABU$'4!:SZB6.&V0@:SF@5AY(P(8<I&D!+C#'
M!69@$=+=Q"E]6P'S/D"N0[2@`70@P`!TD`$>7.X::W'*"4@`!@%X@`[SJM<0
M=!<`$"3E`5_Z"@<*(8`]G&%@7#M1L`R!@DY4"4X@D``Z_M""&OS!!DV@HBRZ
M\()9I..+81S``\!W@2UHXT<Q^,T\<G``'LQA!&#@#.'^8+CMQ(@"%RA`(8SP
MI`7D@0-8Q`,,W,``#K3N$`RHD%<N,`%Q-*%I]/\JSJ+$@0(.X$D&XQ%`,6*A
MA*%M00G3X1IV;/(U`8C@D04H4QK`P(.M_>$,!U#;!%JG`P?&[9WPC,76=%"`
M$/2G`5+H00B.0`<MX*`!%L#!U#`0N`69@0%N,<+A#+&%(6P`##!HW"$6L`4>
MH.`!(D"#!=`0@3U@P`,?`$`3&A"`SZ7!#`@8G:<>@()27,!%6P#`!9PQ`DZX
M8`5H2(H,'M``'C@F%@1P@@FZ8`$C)24"/?A`.)FDK8D^8@1=8(`9!N```X#`
M`C3X`P\*\$U94-2B&%5#`#`PAJ3Q8P$#T$`^)<!/\UF$#E)8`]`:X+Y6G,$#
M:%B##0_!@Q4T8`I7:8+_`UQ0@#H$``4@>%Q%)!:++JG!B7\80P-*484R6``/
MF$$#3[6@!`P8P(%*F,<?.*"#$F@!#Q'@GCI$)8L;6&`-:]@#"B:P`1C`(@87
M.L0`DJ-7[#$`!^8H`0Q00,4`Z.$"BV%`4V6!PT4&:P12D``U9.&&&4A`"$+<
MB!JF\`6$EG$&&(@!6Y(23!#D@!(+B(D,!B"Q;J7!GP#%P116L($M=-$00&`"
M`PA@%PM<(`$B&,$;`>""!H`!`TG)P`GBZ%<IC$`"'IA#4K:0@PM(H0Q,"$`#
M`&"%/Y[E1&[PP(,]<($*-0$`#&@"#"P;`B/L1@!2@,(Z+$"""DS`064`@A'V
M_XL%+1B!,$"0Q1`(X)L50%<"1'B``-P#5<X@5`0*=>7$+I"%"X1@##+HB"_X
M]X`/*`"WX8@%&R:`A0\XP0-W\``(0F"`*R3O:4G!`1*"9`4\Y>$!%:#"0G-P
M!!$88!59E84YJ;)-[7CB`6BP@0?N.@(^6"`/!I#!1_.@MB8,0`8U,,,;`AW/
M3L<-!W]H@(P_`!@0-`$!/XJ#%0*@!#>X@0I)0`$&4/`C"9SJ`U:(`6,GHH7#
ML@$#YI#%'/@0`"Y,I0U8B$$#!H#J/\2!"@$(,A:BA(,-Q`HP&"#`%O;PAW\>
MX`K\^1%NC'``"`2;"`$@0%P:VP0*\(!_P39'`YJ@!?_^R4('$H@%"J82.05@
M(0X\X+8&N'&'=QUBV,6>BAMJ&`,%W"`))+C``"1@ZBW\*-X##`H#M("`J>@A
M+ONV`Q9@<`)W_B$)`?BW&S(<`Q<(P`$$0,`+Z!"K\<@"!/+(J@Q2/@0B;/P,
M#NCU5.(0A2VXX%2'<`(&$.$"X0;@!'^@]1\^0/6]&H(&U<D`J(,0`"U\9`%V
MBD5(J@.8G3/!&AH08UP@,(`M5+(!4"\AOZF.(<",8`L#^&4L<.."\2!A@!^?
MPP*^HH<_Y``!&<!#`X*-&RTP8-93QT(9+D<N%]!!U:QVPQQB@(`3%#X6=6""
M`O@0)L9AH`E<2+41`N`J<SC_``LC.%4#L$V!+=C)'`<@0!.`\`$WZ"``2(@#
M!N(>"PE<^P\7J/WM#3&'&RC`#&P@-1=PT`9#E&"`LM```@B`@B10O0X+&/T!
M[/"%`$S!&O?^"F!XL`4"M([K30!!`PK_`2/$0`I_T$&43@"!#P0``$1``@N7
M!"````C@$S`7`#YA(>'G?G\@`@%@!#DP7%,Q?_GW!W*`!`%0!7%@?,`0`&9@
M<P=';($&:K)@@GR#`C1'<Q>(;@/0`!C@`EJ`!7&Q;`C`;9;G;&6`!#A@>3_E
M:4`8A''S`2(T`I(DA$B8A$I('VI@!$O8:1^P7$\XA5"#A#0`.528A>\D`^H@
M`X*@_X5@N(1N<#IA:!!$"`EF489JJ(5-T#I:(`-M(&-K.(<&00==``8/\$%T
MN(=9R`=2<#%\N`X-X$.!"$\!D(186(AJ>``<``9@P&^*&(F'0`)2P#R%:(<E
MP#J2N(GV4083\``(P$")R(FD6(JF>(JHF(JJN(JLV(JN^(JP&(NR.(NT6(NV
M>(NXF(NZN(N\V(N^^(O`&(S".(QJ"`((4`($P$>Y91`GP![OY`)=A3P40`%:
M\$UQ8`Y&,(T#P&VR<`+1F(0Z`#Z&<`.BE01.&#=.0'RM-8T4L`#B&`LW,(IN
MLW2R(`)Z&(A04`(7`@$@$`>[<8HWX(Q"N`9ZMPZ_1(]3*/\#E600$A`!1#`?
M#>`4];$`%>`&_<@-ZY`KP78(X4B068B0GN8"\K@.??`&,J".<2->WV@0%R"%
MLK!TGH,A]+!T"OF$L"4?-U"0L1`'3A@$/0$W,6D(+["1KU@"/X`&9G`Y_T`?
M[O-.%-`KAG`$JW$"4H`!=_`#D;4:.2`%HV@)3Z@VUI<%--$>/A`W;F``7[@.
M)2`6+]".:@DG<;,!@&0(%]`'D>@!#E!]J&,&:;!KI;@22;B4]'``$M,"][6$
M?5`(>:(';C`?]V`?)^``4<"7PA0+6&`$[VA%@CF%:>EII5$?!7!2APDW<-&8
M]%$F@RD((-`'Z;0.+2`(B?F$R6/_$.%B$&F@/@$@!!+I-FWS!R"`E;%(0H(5
M`%`0!PU``TY0?43P`32P=!F@!SK@*GRC`W#H`!\P!%2`?;'PE.LP:#2P`'7P
M(X/6!")P!TI@!I5D"2#``"[P`P)``SE`2&80G[%``F80`W,0!VJ@!T``/FG@
M`@P1(]:'`*<B`!&P-0(014OW`2,`=2)@!I%Q"$%0`@JPC(?P)H8@8%3!#G50
M`CE@!K\T`CKP`6S``",0`S3P"2"@`_C93"0J`SI@)Q4``A<@`4"0!.@G"S9@
M!C]R`"-``XH9:E1PA5,G`3K`;3(P/0*P5W.``CI@ES(P!EU5!UW0!!C`54+P
M2^_6.B;:_W)VD`0G0(B'T$1F\$$R8`9V>0@5H`;4Z6PCX`07\`9E0*0\@#\V
MT``B,#TB,*+`8`9(9PAL(`)"$`,,]`%ZD)W.D00PL)E1IP,Y\`9*M:==4`%S
M``,ZP!X@\*,@H`8QT)]_0`<Y4`4@T$0,9`(88`<N0*2'L)X5H`$T$*:KR@%\
M4`<7H`-`\`ETP)\,``()\'F'X`"M@P<_X@`8L`<.4*4()JAZ=P!5:CO`4!-I
ML)D7H`8TT#M_X``O\0;`^@?">JU+YZ1<^@%`4!O(-P;<M@="$':'@`<ZH`=?
M(@!*H`,+^:"100$V0`,B(*9]4*:^60!Z8`:%`01.D:`N`#X?0/\")W`L/R$$
M/U(Q>\!`?V`'*"H.P>";#"`^+K"`%T`%3@"I4KJKU"`"$C`]%W`!,3`&+[">
MP\&O=3`"(D`#ZV8A91"9G7-=?\H*1E"MAI`'0%`&^%,")Z`#_#8"0I`$=7";
M"(4%TT.7MOH)'V"D-K0'.D`#E\(`'Q`'>P"C`JF*`?!T><!**X`%)O``+K!J
M^S``GG@`&6`!,7`$-C,!)Q``_U``..!\Z\"=@K:N%J`=YC0'')!V..`$-<`#
MEF`&,^`",\`!2O``$@`#6Z`''""'?^`"%C`$`>`":)``5V`$U3`#;A::%PH#
MS;$&3O`]*W"C5+0"$3`%.A`!0P`&0:K_!33@`O_()!F%!T8P'NY%H3`P`2;`
M%#$0`4*P!@F@`U;0!&P`45HP!6M0'DC0!3$`!B/P#`M0`RZP!40YCCW!`3V@
M!E(```LI!P_@&5TP!Q$0`8@K`?UR<J."!2MP`A[0`S`P`_SF!A&``%1F"5NC
M!`H``V"0`\2K`TW@`2[0!?09"S1``$.`$S*``$,P`0=<!D>``@J``IG;!#[U
M%]4@9RW@`<+#IB7@!!%P!A?0!6BAKD!0`D/0!:!6`#=P!0HP!P'`!#BP5(;@
MN$/``4P@)RAP`Q&``3T&OSU@!E)@!"-0O-GH%0/@`F#`=MSV#P3P$A&@L&:P
M!F4P!B>@`-A$_Y=@@`0(-018<(@!,``T8`!]D`!)8"&'F`$RD0%K<`0?<+_$
ME`%),&@0<+_Z8GW0NID+8`!ZT`0T,`</``0W``9HL,8R00,(<8!@T`!K,`-&
ML`%2,P,Y$`,6X`0/P&D0,+[;$%DX0`/&8@.N>V`48`%*,`;`R3</,`0*<`*Q
ME`1FD``N,`!(,`A\0`,/8`<K\`!3((XQ\`!.,`$T8!XY8)H$``4'(SQ+4L5G
M(`4NT`1&D`=C$`--$`5G0+\,(@,>@`)U91<S\*!ZM<JMG`8)<$1E*0MOX`%N
M5@T4H$5N.U%2<`((0`-L4`(T`%@=6@))P+@S]<=7<)L5X`%:@'V;#/_&AS@&
M\SP#2>.Z'G`IK]`S6%`%O\"*."<%'L`\_P!E?W`'H5D`^88%B8"55F`#2!"?
M`L`!U_P';7!&VPF5?S!H>0`CL%`#TV@!#R`'0&`-`9`$A;L;`R`<.)`#,E`(
M-,`%AS`$D8$"/#,R)E``Q%1]'B"@VU'"?V`%:"!`@?8+*V`G$^`J,J`1A@`&
M:1`""9"C%RH%!F``8;:[JX`$+F`$WX0"$;`&OW`''!!B>6"=:*`B)?`1*(`$
MU&L]'Q`%ZS`#)!!U`*`&:6@(=H!-<@`&!U`"S',#.=`'UC,`"/D``X0"PE&9
M&<"761`CEZ,`[$$#3;`&RN!_()2]D5-$.5#_MG%``H!X#J,6`&B`2Q^0.,/D
M`%+0!:Y2`INP="1@!"@P`'4@`3&;`Y$A`H1-12L-`<K`!B.,"$3-!7V93'_P
M`%$"``!@!F;!47]@`CYP!TW\!S?P`SGP!34A`%TP`FR``N]8Q64@'.2PG6K0
M`%C)`#Y0!]ES`[<IU8?``0ZP!3X@!S.P`2[RV6DP`:(="Y^=4WIL$WS<!*SD
M7X?(!H8MX%LP!G*`4PE0VDJP!N=XH<,4.;IC>+4L``E`!PLP!VT0`!LP`%X]
M`A3P3010$(8`!<SS4OMP4H>(`5R0!P`D`@T1"P&0;S55A4F"`FP0`^6SS&L`
M$*%6`"##`&FP!VF0_Q0,HAW=3"U5'``[?@0W(0!WL%!3-P!L(`<!D'Q3@05_
MBE:AMAYF@>$Y`G5!K0'?1`)-<)LUL5SXS4IE.0:'30`M0`!:TDZ!U#.-.=&J
M6#0J;0,*_0]E8``!X@.QM")EX#YF\$<S`#!&=;<N/6@7P$U9>08?P$`RX"B0
M4KCJ\-E_4,4@H`!@<`0#@P%;@(<\HR)]&03SL`52_29=0`>.@1\GP`%H`JUR
M`9>'T#,E4`)^()W&@P9OD`&ULKLQ,@3M/`9',`9@4#!@DP!BL]=_(`4-DP_(
M]#2R$-H/%`#H?@A?`"@,7IM5_`=@8+X18@B'K.0;P9>,!0O_LNT!@"=/T_^;
MAU#"&K,&'?,QAU`&V@)IXCX9_L`\!"`3VZ$&>W($QKT%":``6'@!0L(!RK0=
M(%`14U`\OBGKM'[=3R,A(!@4XGZ;/5,@EC?%L$`"?$(%>)#6\&'%V>`(,)#6
MR:<&=6`$8!`H'1(+!@#@6:$'"```*.!("4Z9I./@9@#A4"/A)K\`\5$"1#`/
M[XL`3,\$3Y\&#+/M5>Q.7"$UA&(&E,XGQQD!'+`L,Z#LGZGUAV`!8><'`A":
MT%`H%*`&"%,#MB6%A*(,E<E&!@``'0KE9%,E:<`$!L#U64X5?`D+79X455P#
M>7_T5=2-\;$`/_#W"3)16W\&@8\42\+P`M`$CDC_`7R^`LLU]$6O/AC*$8;\
M!T'@T#B%0)6)BABPV!0@`?\0`R:(!G-0`%'"!S"@Z0`1H1?K)H>0`]]40-UY
M"$G`!'PK:$N'`)G^#*V>#54\`%`'!`,3`3)&#B]?`"3PCP'PZVBP`.OUTB10
M`Q]Q.6I3`\%*CR[`,V@`"$@`?X2%)6A_;085?WZ$%FDE)G\N``$8?W$,:RN$
M)7,.?SI2:!1_'H1Q:65F"PM_:AF%A0D-?QH#L;,7#VY_8)%G?V9K?TU``[,/
MA+A_);,99FD%A)V]?P(.G+"R:V:SA$<_?SAK`G$0$5J%93%_>!.E?S\1A``]
M;@9'$LYJ$VU_[D`0D&W+_Y1"`:#\&2'KF3,&]?X@$49HP(D_0"A,X_9GV1\J
M`\S(DI?&`(,N;/ZDB?/'PI`;?Q@LE"(##1H!Q%C].;-`@$TW%-3`"-#&@0$!
M$0".@&`@#3AR7*S`0"#K2"QI#CL5BH;&X;(5:190_+,`9IT2(@;]B4`$1]2I
M`>)D\470&[AG$>S\Z0&F$`T7A"HT2(`)`9H(%][UH8!HP;>*/?[8H58@C4B5
M%"YL(<3@S8IBA?+^<=/7(>>9/$H(*W?FRN@L`B#(P>$ATA]O:3IE4//'R@(U
MSXA-B#PY-R%'X'Y\L=<C*-FQ"UR3)K'N3P,WJO^464/#R$*-!OY\+H2"J%%G
MB/]V=]'PA\CCVRO0A'?VM+[]^_CSVV<S`<>')![<8<87($P@`0H)T%$`#FJ`
M8<)NPYPQ1!<@T-#%&0Z9ED,`(LS0`P,TS'+$&FM,,0,:QAT!SA@-2"!%%1FP
M4L8?T0RS!@(H,,`!`H6``00("&!!4@%T2!$$#Y49@H8(4CCQQQ$RC.&`"`4(
M`-8?!$3!0``?_#''&(G]`<$,?X2H)"%51"!'`2BXD$`D"^B(APM;;!`%`MLX
M(\`##=A0&Q@2;&%%`P,`P8HK'+WW!P5&,#``#+H4,L(*>90Q@PG9$?/'$`7D
M,,L6.&R```ST%;(`%VA0(]X?3##10`!6;*.+7=+00@+_/$X`T2@!6+`3`0-&
M)"%/'A&($(('=."`@P1''%""&EH,T```.`Q!`01?5%&(!3%4$`$!I9:01@1#
M?)#`6#CJB``;68R`A@4,;!'#!F#`<!E)X3V@`P86=#F%%/QT$40##W1)2$[?
M\#1+4%1H`0$2"?S!@0MJ&`!!"9XJ:JX>:&21F%6G=E4--&;D43""XH4%W1%H
M7($$'0:*8/'&'>O1TA>ORF#7+!.,@`,6#2!@12$A@($&#`]<X$,#0T@1P@E1
MF!#`&8R1]1X/"#B`Q"L&Y'!9&A3,X8$(+EXP7B$X2!M5J81T$4,#8WR@P`(D
M/+#&&1Z$P,<E'F`@0@1L1#""_S=L>*#&`E]<,,8":"1-S%0F;&U<([",E<<$
M(LB`K'-BF>H!&C=\0<<1(XP@10/9;:<L!`,H4))XH/T!@Q9Y0(P>C6H,08`)
M*[S'B7R>Z"?\\,0_U<($!7@@PQ\?U'#!*#.(\$<!"AB@`SDA_''"",8D,($:
M(S1!B/B$8)?`<B$$,$L`1QP1`0K81/&'^K,(D<`#"]"`0PXG>(K#12?8@\QJ
M@`/R_0$%-1@#'YC`@%<(H"\(G$`3!%"()G3&`[8(@!L`D``+&.$#4:"@'%:0
M`'#]80,>(40`I#8+"Q+B#3T3@A00H`4!-&$`"5!(&P+000SL07[&^,,-$C"#
M/DB,"_\-X$`"NN`&_M$@1"'`P1\F,`LY="$!"FA#%&?1ABL.8``7:`+W`O@'
M!V3!*86@5P*($L1"!.$(*.C+'^0G`"52P`$__,,6]W"1>!2""%(X`@Z4$(<2
M8-$6A"A#!);8A@828@0UD$(2V*``"C9!#TT(@0,LD(`(4'`%!2@!!0F!`A_,
M``:R(-\$7W"$Q7&/$`-,VQ^,H``Y/&!>'DC`#=IP`BDZ4@`6^(,('B"%ZIB+
M$"3P@12N5X@`\F\A9B+$`D*P)RD@090BF(`!`%.&95"Q$&_8`@A*%8`07`".
MY`,B(?[W!R5(@0/K""$-7DD6#D@!#!1T@@%J$)EPCM,A`C#_I"GX"`X*1.`-
MB[SC+(8X!DQ0(`$(6,`(VD!"<,6I3!<I!`Y%.<L']!(;KY"!#PS@CBCL819O
MN&(70F'`/Y!@#,7\PPO&X`$`[&$$`_#!`RAH!"G,8'E74`!!%1``$,S`!P"@
M@1RTD`$R;I0@0%11#I`P"Q?48`9)($OVYNF7`=R3@D,P@`'@)\8_Y&`/<#.`
M&2P`S#F>E!![2L`U;2@3'&0/`27,Z!]^R(!@MK%X@`VL8`F1I,$:]K"(3:QB
M%XL?JBZV!]YA;&-'.;PRS$BRF$WL"9B0V?HXMK-/011H1TO:TNJG`9<UK6I7
M.]K"LO:UL(VM?4*AV"04('NJI2WQ_RPKV]72H$JY9:UH>TO<XN('`G,PKG*7
M&QB`,/>YT"5N'M@3W4(0I+J,-<$XL7O8-*"1N^`-KWC'2][RFO>\Z$VO>M?+
MWO:Z][WPC:]\YTO?^MKWOH+%A`BD)UL!!,"`&&##!6*'6"/H%C\7`(Q@"<`2
M<&#"N-2%JTQNT&#$FD)X-P@38$_`W_H\F!!]>`.)]!/&S&`#"UO@1SL1H.`?
M!.`&R9T%$X:`V`$7X@4FCDD&7I`?$PB@`GHM7@.:,#1"O$`!'`!`*'R,GQ<P
M\S8=!H<#(DL(%QPXL%B8("$(0($NZX`-&#!"':3I`)@4P@A='L!)3P":.%QX
MEO`39I<I0/\`[JV!`@T6@$*UYZ07ZB`"[_M#!>9,`9B\`I8RD`&A+4H(##2A
M!%HXP)EM@.A9@"``)3#P+-A@(0N8:0XNL$`$J)`2'<QY4$+L<A.&D%P!`*`$
M`8C,+%6-@Q@[@``IX?*<=2`#!3L!T#J@PVU(10@S-YJRX'C!\M2K/M[*]F\\
M0,A.#IU8`R!"/Q)X,F!=*^WBFN";A-"!,,2E6.3HAPDJ!FR,[`,"M1"B!F&A
MMGT.T`4=X*`+']F"#CP@@`8!P6@0.`(5$`"$6<3!``I`K,((L88LF"D'62!P
M?8R`ACD)-@D%,\077`"&7E$</WDB2VK!`;Q"5&VP<1@##^1`"!__F,$,5ZC!
M".A@@'%\0'V<+80!!K```,R`(8=.`W(<((7-:&<,+]>"#_*P`#^0@!`V\,.U
M5S"#,?]A"F-(`@UFP("*N6(!,U)1(LWP@05D8`9E>9*89F"$H2P@)40WNDX(
M<0>AE<$"1B>$#!Y``QT<H4LP\`$-@#"!8JP``6;@`P<2#NL%6*$&.6C#`A00
M@P5((3$S>#D29O!6/1!&B`MPWP)B8`93O-10,S#T$5C.MOE=^RD[0Z_B9%`&
M()S`"12D@PNJ@.P/9-M@>S`##-@0!V67`0)#H`%+\F"H.\RB#DJ@@DP6T`05
M*VX/9P#`"<HP9C=L7R:%^,"87U"!"DC`_P4N\(4#@"`#:[M4!UURP`ATT``U
MZ``%H."Q`ZB`@BY]H`'P1P@AH`-$P!DZ8`/<]@<@,`;+XV1GD!*$<``C0`,@
MH'ME0$$O,'_L40$3F`=Y0`-EX'P,8%E.,0<G``0R<0$2P'X'E``&,S]0P`!H
MH0.\<4`ZH&',PQ+EYP`KF`3)A09`\`'(D0,Z,$X@0`(TD`9$R&,B$`I[``02
M<`$\F`0^B`U)X`(0X"4GX`($D%IMD`-"L#PQT`4\IH`%H`<]YP+<5T:VQWHN
M51U@X`8<,&8*,!07D0,XX`12)``%X%R;`@41(&D5@`=4R!(?\`,Z(!/\U81[
M)7QLL'"WL07TH_\%([(09L!?#``$>A`'%<`!97``$A`':I`$0,`2#I`$/W`!
MDO9"94`##E`'34`A<.40<C``G3@C&*`#0Y`2`E`&)Y`'VP`"$K``?$`#3I`2
M&%`%0]`&P%,'23`$6X`(*'"#@H8!-)`''V`&RT8(<S"-B=%-Z29V&.$:'W`$
M&``&C!!E!E"#30`%&1!TR.$".%`"SE<&6O$'#+@`'G!HE(@(%Z``)0`_=C`&
M#98$0@`<X"".<X<&]Z@BCD<(<A``&T`).)``]?@>$H`*8A(1A#`!X/<!,#$&
M>4`(#E``#;`"EX4!6>`,H($$3;`&'N!<1*`^X@@#O?(+4T`_B_(8I2?_!PGP
M2F]P!!"P`#-`/J91`6.`BSJ0`Q!X&X/T`[Z@>[PG7FL@!490!F.``#.@`VV@
M!2NP!>K4$180`#-`![R0`6-``FAP!"O@`2L0`!,`&$T0`"N0<X1``Q$0BVS0
M!1.0454I%C4`ER&2`1SPEK-P)11@63.P!1ZU*`K0!06`!F<P`0/P``QP!C5P
M2S6@!9!'-7:P!5L0`6,@'A%``0:``1(`!@0`!D^G`+%X1N`@`U9Y`3L'>86@
M!CJ5`PBP`ET@/Q3@06```65@`!X``DVP!2O`!W_`!2N`=_4DB611`EM0`]E8
M`$_F/B_@`Q$0`#70C0]``"6@%]6`")9U!F-`_P$>\`.!\YB.<`(/,``1X`9F
M<`0>0`,>,``6HQI!X`%<@#_F&0#U^0=;,);B`P,E8)JI)00E,``U@`=$J6`R
MD`5:L``U0`$3X"D!$``64&3EDPBHX!`9@`,/\'1J0`#HEPA^D(6$8`0]8`7P
M4P9@@``^<#UCL`*N&2YG0`3?F9:0N`8+$!$(,`!KP``3H`5)0QH!P`$+(`(U
ML`6Q@`:!60)2%)I=\``U*$01L`4(0*0_Q8TS$`.TQ:1;0`</T`1\]P<(8`'P
MQ`D,,*(+,`8#\'-D&@`/``7`8P418`&D\`'?60(.T$T>L`</D`%YTTPUP*!H
ML`4&H%?B"``*M@4E8/^4L[".A(``5Y`!6.!=&X`<3:`!!-`E]D@(:9``+T!]
M"C`';U"CB```7[``O?(".OD&;("0(L(.C\&0A:`B7:!APF8,&J``H/H>$``&
M+C`)LR``HPF1=3"LL^`!.8"2A$`$X5$"H&$%!,`$U?$'=4`F8M<&7W`0%9``
M#%``SK>3!T,!(%``,68,(A`=XLHV3+(%O#``%UH(:S`#"#`!7.F58#E>SU`&
MG`4#"B`"&@D)A9"66-("9*,]0H`&">`&*$`FCE8!"<<&,V!]'L!R`R`"L4<?
M9R`^(^`!%7`$=<`&`Y!NB&E9ZA,"7-!7?Z`@:#`V!S01XL,##Y`'$C`"5'/_
M`OAV!^&Q`NR!`$G0!-?#``IP`3R2![!Y%W\P`$'P!R)#"&J0<-GT"&`C/3>@
M!67``8)6L8`R`6?P!B<0KF-VLJ/W!U<0!24G3<)PL5/DL(Q``TI0"/&A'65P
M!LD`0A\`+@W@!W=0`%EX`S]@!M>C!4@P!Q_@`*HQ`=$&!&*1MQX@`4DQ/Q?`
M40J06GPP83D0*805%B`;!1(@/G-P.K,P!S=`51[A"C/`&Z70![^2!%EP;2C4
M!A\@/F6@/A*0<#,`$,N0(6>@!/QP`D+0HV:G`0X0!0NP!E;@*21PH;T24$"!
M!D]:#R:P-$QT!SY0@W(P`2D1`#1P&870!R0$!M'&_Q@Q`!/3\`%@T`8",`5K
M(&K+LP`*`0-"<+XJD0`28!(%X`L<@`<*$+=-4`;X1@,!<`<7@`>%\`!9&`,`
M@*NT(%8&@`!O0`AG4`#\91I_8`!=0`$K\``@D`&!U$J.X`;+(`/>408%(%8S
M,"-F9P$]H&AU:P`2(`"H<`:R,`MJD`40_`T*>:L-Z0S?10@M4,(GK"B7=C^>
M0@A1>YMY)Q[VF`!BA1;.P`$40)8D0`%2E*M_,%(&X`.5]`="D`PE,`[F.@P4
M8)ZSL`!HN`8G`"X8?`@#@+ZFL0;)(`&84[!!C%W_.B-G@)(I;``%<*6'@#MN
M4`60:08B@R%0>\9_''&DY/\09E`.BO(,"K.6%2Q6!1`[*5L&(T$!+W##8Y`J
M4F``4G#&KQ`'1U``7^``5...P9.RAB161Q`$AR8%>4P?$8!&X*8+*(S):J`1
MFX*2IG#)!A!Q6)`%7'(&.@S(/BH,(K&VSP'$BZ(&?B!6"4!M=5N>KQ`+0_`8
MI+#,"?!RQ5#!23D'JI$`B,`3"J,&(_+'!>`"#L$$J<4`.(`\:\"YTQ-O4)L!
M:]#(8X&V,^`+#N$;5O$'&,`%\^,'*R`%M.4"/K``3!`>9?`*N)HA."H`5<`!
M!6`&Q.L$+J`',)"\)3#*4K#14`S(I2"]&8`O(G##SA$36M%SX&MP`.`#BP(Z
MH&'_`%-`;0W'T"*W$V9P`Z`1D`;`2H2@!>QLS24PT7^0JCDTP83@$6@0``X<
M#GJ4`!UFH4:'P3OG&"SQCJ+J""Z`=D8PFJ&:!&#`<F:'!3BP`"@0'R"0!:X@
M!2#0`\E`""E!JX6@D=KAPUK\*X60$B:R`&7=UT\A!PN0!>+I`"GT!P)VCVMQ
M`B@I`%N@$,X0`&61A3PW"]PJ:#-`QEV`V>I`"!3`DQ3P`?-A#S^0O&U0`QCP
MQH<!&N"V!C,B!V#0RX!\I=RUQSNQ`C'``3;Q`;UZ.[MA!%:@`:27R,]0"E=L
M$R*`1C;@$5_`9I,\;5![!"30!38Q`M]U)0A@69U\`7==_P,.:P-H<`$8H##H
M@%-34]KD0T4I&P$T4'$C0`)J\29/\0P*@$@II`LQ$!]H(-P4(!-)\-VFQQAH
M0`)Y8`(.H`-L<B)HP-V=\\RI'<WDEAE9@`%H(`&()!Z(8"CKG`$HL!QS4`#C
MB@?2RP":8@)T0`\GH!HR/`]BL<UP-`#!?8[VD%K6TP#E@,^5@2AH(.):8!-G
M0%EKT`6()$<4X`)LL5=,(``,P`9\Z%P!8`0D,C%,7='!XQ488@4@0'K$R]@9
M,)1'_@-H$`(?0`-7$-S1^Z2F4!)J0#X14(,'$!$`@`0SW:Z&H&=H(`09E0!)
M<,-!,`1@@)<_?09FX.>$$#T&</\!-5`1O*#A$B`!3!T;(E!HA?!-&M`$5:UV
M?W`!`:T=O_(`/,;5N@W6*N$($<`$)/(`*!"J<_0*9L<#"K`9\:$#5KX&6H`#
M!\#7,:``>DT(8`!^9J!@5:TB`*`MCOT`?\/J:_``(3!WLG/7OQ".HW0!`2`'
M8U"NDV$V,[*M\$.ML["U-U8/8I<#/B``;^`!)*('NUO&I3<9"-R1#9"\E#`!
ML*T`&95":Z`M)O/;P3W<W,4!;,!;?8P!E3$',R">Q*T&$=`E`S`%RKW(=A#0
M?/A@=E`"#<`&EMFQ*W``E7P$=I#A=?1A"/`!^0#>B_PE`H`!4F<!4F1O"C,$
MP=0"%T+_`2TP!@)``M20LE;`(R*``';@`8CK!VF``1]&'SC@'33`(U(K"PB?
M!FZP\!2050&P?:90\6X@`#-P+'C@!E)0`1DN,1@PX1F0!PG0E'S@*1>.!F-`
M*FU7"`AP`MAQM]N<`28`##+@"#1A##*@*5MP$50`SQ]K!7004>M\!"9@XFTP
M`29P\FV0E(60!0Q@!RZ!!PBM<QL`Y'A_!&Y@1L::OPW@76W`!20P!XU^!>O@
MHGT@/D"0^9'_8#1PVQ3="18-!B`P#6?@`Q]0BU-`O/A8#\D+!$.3!"4P`C,0
M!Q+0G1G0`FZN$@;P)2,@A%<Z`<@%)3,M`)_W`:/9_".@/B0@_P4'4``\R.XK
M(`<S4'9\;`;?[P;A+Q\E'@('AP8$`/==^`I((`LH8)<6``@_?P%5:"M_B']'
MB0%)=@4??RA=?R6)?P9JEQD+B&E^;UD.B#==98=_#'X2"QEO%DU_*VA=&(@7
M8&\*!&UQ8Q]J8&G#`FU&*W4"$Q*(AHF+$ED7?TE=`AZC?S=;93?#!R$&)'\?
M!6^)2%%T`@$N?U@6='):&;)EB#0^;"5KEZ])?QHD&*(HT0`=/+0DBC#B#P4S
MB,Q0^#,E@ILY32@MZ-=FPJ)$'%K@"/"'!()$:R:X21(!0X$T<V;8N42SILV;
M.'/F!#`A1XX_(Z+\&?)@`HU+31C\P?\10L2#+DP6,(@U(A:#3F4\/#AQZ<.#
M!SC^[.&:2`?#HPQ(.OG*Y%*0&26:^`Q[]8^3"5TL,&"PXFF:$4??('A00L2(
M3BA*4/#P)XJ`/PMR0-!">)J+"0HX",`!X-*`!^P>1)B&*$38/RX>>#A*0<&#
MSCDZ_2DSX8&>/S1J0_DCHVA;&@U/X)@3(!:B'C50-'DLM4*$!PCJ)`IRI(25
M'(#_F/YC!GJ$/Q=*/&C2YL2>/\'`=$G39$0<`A&V7,D>@F1J#V%!E"BQY2>B
M!1,$@,4)=#Q0#R*4T8!66#H<\<`]B"1QQ(1','#!5^[(0<$#%,S!Q@!@*/`8
M>)TU,X$3:`G_95PL)\P0P0`CI+8"$SADA\@>1RWP!6Y[O!&`:$H!"(82?\`P
MAFEU"6"!)!8L%L)TM=%0WFF(P#"#%&"<4>08?Q@Q00DOH$88#'L(18(5-/PT
M`E=&$"8#`TM^``9_>SV'0!PY!!8`&!QLD(@$'#RP11P,",5((B]PH,-I;`1P
MAG&(6/!D(C@<]8<`1XQPX!\2@*&'H5W>0$-84\#06`,*7&+!!PULX8,/.FA'
MX1%ZI66``3<D4NBA14Y@0`0-C+`;(IWJ02$8?]APA`$/$'%)'!3,4$,&<_P1
MAQ$S^##`'8WY%T<$'S1QWB4-=.'#$4`@0A(B&`0P!0J)E.'.`F2=_]`)&TC4
M4$,3)O!([+J(`#"&`&V"09I86I3`T%!%6:K3PQ!'+/'$%%=L\<5=A24'LA,+
MP`?&B%"`!L@DEZP3$]/0`*')++?L,L:;_2&'%&F\;//-..>L\\X\]^SSST#W
MC`88`'1!9<0B*`6RR$'_/$4)44R@=--4-\T&&`,HD&K57'?M]==@ARWVV!>_
M(8(M33L@!]DNH_'!B&S'7?8(!\MM]]UXYZWWWGSW[???@`<N^."$%V[XX8@G
MKOCBC#?N^$WPWG1!!;IJ(O$'961>AAN)H#"U&FA+K(;E%#.PQNG97#("%0T%
M1,,X?[0!@Q-T(/(#$!#D=,XE%S2`"`-5:/_)>Q6DQ>'"&FRT''G$#)#^!QUN
MF%KR&VLG(@(-(Z-'`QZ78)!Y$JV3+,<YNR/"QA!(`)%-^0^WP?DE$H"`2!#,
M\$8YR>SG]`&1B-BQN<D7B(3%SC$^D*$`;C7)G\E@X`;/_4R!%/O`!3`@@@?B
MY`YL:![)!'"#VU1L>7:SQ$W,T`]$G$$V$<M`"1;`PO(QH7Z065G$6&@Q'2@@
M`QD('3XB<((2].`-8'"!!=PA("QLX0\Z:`<'XG"3$Y30$T?0DGY<H``9)`($
M'G#!&&0@&!UHX6@D$V'$3EB6,]AA`"8+0,T0H0<%G.`(=&A!$!\`N]E$8`%,
M@%7)FK`&.P!,&^W_P(('YJ"&84&L!-E#"1+^\`8I'!$3D\+8#P`"L0SX@31E
M\,,:26:&34U,!+'B(\@0>1,=",]E!DC#"WU62))EP`Q!B)7/_DB3&OR!C"#3
M00;"-S$QAM`!$F@#(B!P`6&2\%(2X`$*_W``"53K#7?`0"+_P(E+V($!#1#`
MVAR`A@7<(PXM\-,;I'.IY-&$A768R:7^8(=F5D\`$G@?(J(`0YH\H((H6(`-
MK%"2"1R@`,(L`1U*,`HL0"01>)#`&^9P@Q-4CP$&J(&6A$``\*!1`&P0@JE@
M,``;6$(.OH3GU/YP!S=(('<70"!-1-@`9R*B#A(8$034,`I<ON,';GB,_QWL
M<`$WY,&E?ZC`!<Q)$P&HP7=W`(/O$#&&?@D!!`NPX@U*-)N#_B`"=8@#!AX#
M`NXU`P/"#*H&DL>&"W!O#A8X`0/``+<('``1"L``"K!`!SND02EI4$/M_N"&
M"XS"#0:HYQ\P<)(7*.Q2"6C#'#"P5`%P\P]I:,'[B!E6$[2`6PKBE@,F]08!
M%',3-7#''Q[@@YHYH`6Y8Z0:U.D`O2*BM:DMZR@ZB0>TC:@8`<%`M5+ATAC<
MP`YI=5\+4H>(!JB!B7=X`PCD]P<V:,`!I$Q$""2P-BS\@)S6:L']KCG6.3"1
MK_($IY]B=X$\I%*;R'QK+YK[5L<R`)H8&(4<KO]I"S0PMPT@:"P=U/"8N>ZU
MN;WK'S8O,=WJ-0`$KW0#$\O:V/[5X0UO*"8=T(`V.]`AF`)H`3D9H`%APG=D
M0'P,`R2`W3?X00`GQ`!S`^)5`:1!?F^(J71MT0;KRC,1QGV,&^J`AJGYU9=R
M2\`*5D`2'3R`"QZP`PD9X`$">`"%)ZC!`&K0S3$L1A"(J&8B+""H$IQ!BPB8
M01DNE($)P"`V`3$`41/!PC6@PA(/L$```D`'/<Q@`!5*1!<6,(`^U.0BU.`#
M#6(`V0*0X`$A.S0BIO#(/W0A`%OP0`5*P`'2H.$P6AK`4>:`K"X<8`#3<`,8
M:(#&T2;B`D?0PABH9`;_K,T`TE)8:DTLT<,!<,"^1QB`#TB@!#!H8082L.D1
M(A`$`_QA#`J(0`D4T`6%F(4+%E!G(BHP@0P<`04RD()"`N(#&2R`&0%0RAJ6
MA(@R'!0%%EB#`3P`A(RL`(T#6`$"2%(&#C3AB`%`@`6,L`$#<``'4L@5(@8`
M@(-9^P0<:/(')J`%,$#`#F#80A!%4(!&F\\2-+""B$1@!#EP0`$E0*-X2D""
M(Q!@#"`P,I+M0`(.4$8.*P"##)`@*#"X80$S\,"*J3F`(^9A#"5(0Q!*H(4:
MP$`"8]""`48P!%][(`Y#+WH0[""H([C`#`;8P@,`(D(#H`$>"EB2$T+>A390
M_V`".O#W!UP^@5/JH`L$`+899A!IKE"``ETX0O;N8`$N!(`2PP[3'X*0]".8
MR@`KV#<='/X'&-W"0&;^@P(0T(67>%D$'AB`!RZ`AHFDH0"8>(`"%L"?&GS@
M#`8(@`<@?00>M,$"*X@`/PW0I!G0X>"(.``'ME""7''YD7SW.R5@``8*&,`,
M9:"`[GF?*Q&N8`T+.,($+E"#`)0@+$_I@N@A38V0!P`""QC#%F;P@S5(P0@R
MX``!2K#4-?AA`6?85T_^T`0.$+D2'O"`!.[\`!G0@<A=@`4.,&P5=`DN$`%Q
M)P"T$68Z(`?Y9BYYDUARD`77T`)_@`1#0$($D"XZ@/]"8"`_.``%"W`2')<(
M&5``MV($E:`!E7`&8*`4#R($7$$"1I`&WW$")U$3;?9F?U`#C[$,'&`+,3`%
MB3`&6``%,[!SB?`&$X`'.%!"?B`#(I0!:M`%T[`%J'``Y!8!`G!,EP!_?X``
M$")&")`]UW<@8A0#//`')[`UW)$K3>`$?Q`!6#9K?P`&>=!X4(`$"O$!4T``
MD4`#26!3\)<&QB8%'U`!/F`";8`L'K`V$4`0ET`$_8`"BQ1TB*`&4A!R,^`&
M%E`S9R!&92"&0&``3VA+$,`!L2,%(!!K?_`%:0`:?[`%&_`=;2`%$O!\:>!+
M#7`$?N!EM]0)1Q`)1V`#N.'_`D/0"1=@;%Y7$Q8!(TQP/3#0`VB4!Z!1`L[2
M'N_@!!Y@@1AX!<Y"`Q"0.6W@`7Y"`$&P`%1E@@OP'2@`!4$W!=-P`T90!6@D
M`SR``%Q1!@T@C]I@!#GP'0PP`&;P'1(0"UV'!C.@`7+P!6]0`+D#(VL`$<_G
M!"0A`75(`)S3"&:P)`<I`,B2!U16&CF(:&"X:`1!@W\@!3(#&G0H``"%"#)8
M$D;0`$O2`)KD93PD"4;0>86&"<ZR`%5P@49P!BPI`8A&!%#P`ER`6&]@`%;4
M!,$&9;8X!OO`@B2)"(@6`?W"`<A'`2=0E?N`",^W`"2!!HC6`+:4'`+@!T^"
M:`_`_T3M,()_4(*6@`4]0!$6B`A^<$LDP7&I&`<=H1]4`!D_$0,K0`03@`A'
M<'.GI&=O-0`24`8*H00*T`-<TDAYTW4",60/``4DE"GD@$*+^0<@$``TI`:;
MD@$#,#J44P+)XV6(AD1E4!X$``;U$`$.0`$"=$X;P8,B5`)J@'@K8&^)D%H4
M`$9_,("%R0?]4`=^L`<B1``M\`$U$"`Y6!(+H``)D`9>R&9:0@$0PC$.D3U@
MP`<'0IYNX`):X`&HP!T$086R\$0K]0>EZ0)SMH;#I`-<,`9E0(AG8(B5``&[
MB`@E(`!"M@(^8$B(,`<N0``/T`F8^`<MD`4U8P0\L`(UD_]^\7)'2(`";>!F
M=>D#0Y8`/V`%!C``(K!PG=,6CH:8:U"@--$`-%`#&D!&(I0%L`<&1D!S0W9B
MS4@31K`&E/`#33``%4`#HJ4%)%`"W/,`886@G@D%?6``"B"'F=,`4C!D'M"!
M,I1E"]`$(@``#!!T`C`%`S`#.30#7BD`,F"E2<`&9YJF&7`#HL4=]0`!$Y&0
M`#<`,B`!!3!D8W`#$SF?#<`!8/`%>5A<VR`%YE8/G?<"VV8!B?0!6+`"QG:2
MEP($GU$/P9D&4Z`%0P`PMHF;0>"B$["+1BD_$!`!/OEYF,`]8-A)H?@'/GE"
M2C`&)2H!S4B%-H4%+MH%9;IFEHK_J:;V!U;PE<"*",+J?-#7":]J;"4@/WU9
M"7^0H#-@!*GIJ769`%V0`]C5EV2$8")`HBM`?B5P'LE6G#-P`]NV!1>@J8E@
M`MN0"9GS!V[F`H]$;G?3=14`!GB`!FC@G6O@`0UQ&(DPFQBP!=O*CI<0G+6*
M&Y1I`1+P`?6`!.U($R`0"0#PF[%C"<&I!AX@L&B0#6V`-CU:$UU`24G@#@+1
M`EPR"$K!!FS`!RJ8"@40`VF@H=_Y'UH2!6%A!]\Q3PWA`!&0!(]$GB/Q`C#P
MGL<DG\]W$W"&"/JZ!6LX!Q#P`%H``B[PGRA4B-(Z#,$)DB2[28A0!0'0`MY6
M"6O$`*#W_P=\H`=<8`LG`##F=@DB*@(#0+),Y`!64``V,)L0(`/!.@2ZZ$O\
MR@>#**%\J0$""P%(X`(DVP9!>@E*H`6IP@`U<`@NL*2&-3)@($P"T```*[`U
M(P`G(`4CD#D50*D"*P#>5!.<H`3WQK8$@`47,`7UT`8R,`-M00=*8``\<+L8
MH+LX(%H.T$F0M:>(T(P0@`4%\*9E6ZA1RP8VX'*)``9`L`'BJ;R=)P';U@79
M4PXR(`"6H*D$8(6:8JUL*P$E0`#^\0=:0+$6*P(N^@"J:@"VX`#B.Q$0`'K-
M.*L94*NWN@!)L``D"U@CXZLHQ`3!"@&^1+[FR[Y,\)4.S*P0S/^LSVJKGB>M
M(U.MEJ!WC]NP(A0'3I``=RJNT)H!>LNWP*@`)""P_?BN4/68?U`'!J`##4"%
M]^IF2,NLF]F\:>`!,L`&UD5"2)`K-X!"$3`.1L`'#0NF#VN@9P`N=>`!]49H
M7D0.TP(4U6,#6@!S.H`"#\`&B<&^PAD!\.("#C,&:>`&#X`"+94(1K`%PT`'
M%W`2)]`%=Y``V80L<SL'HX$((D`)#F``$``$9`&>?Q`#E)!/Z"$',=`)+'0A
M;H`JB=`$3DP):B`'3ZL)SS=BZ+%)EN"J@\`'.-"4:Q`%"3`-3>`"-H4#,""@
M02>CEH`-;-`%/S#'`P<O4,!/[)<()1#_"0H0`C00*P-`A.5V4(@@H@XP`0)@
M!V.``6.@%!8``A'``)P6`B4P!VF0`""@CW7``;OU!QP``\F@`!\P`ITA0@]@
M*E1P`CF@D2++!F/`@KWY!QH@!8N$"2?1`@$0!V@P`79`2EH0!'_`!4)`Q$;\
M`S=@158@`S!`!7,PC'.@HK$;7^Q8`09044''`0S0*%K@`BHH`@0P`*8BRR`M
MTCSP`',@`1&@O&DP$1[@!AN0!0,=`G.``)HX#00P`C,7AB?`48.5G59Y!V-P
M=9!*`7'P`&Y0`2/Y!TKP'5JZ%,Z""!SP`FR``PKQJ6R``*H($EJL!=#55Q;J
M90I0F/;"`-]!_P0`/#("3,`3<4(28`$'P``#TZMJP,Z)D`,NG0>+Z4M3'1`L
MJ0`=]@!?Z==S`-ASR`!Q8``;'*V5\,$&.EJ4LP7VT@FJ:<YLL`"10`!4D@!V
M0$9HD`'/7`%VP`'ZH25(`!%*L`4V,`8*]HA@^`%KU``%(`=R\`"K>P]NQJMQ
MX``LB3==EP8\<"M@4`<DY'%LBD(2D``&``9Q$,74M$P0^]P&P`5E(`,),`-:
M<`AL,`-6=`1K)`=CD`4<\'!@(`5_A\9J(`%2X`,UL$E#(`520`-L8`;O60!^
MT-_U0`'GHA395@"FT@)28``?@PAT,`-PL0)[[0>2Z+,WG`$^,`.Y$_]T=3`!
M/O``N5,&!I``6#EXW;U^;/O)\WD*+2C,G`+=`Q`'`F`N4G`5\4T`\(=",N`'
M-!"VMOP'/(""%*#<[SD""9!TEF`!"3!M$:40<2`M6P`W=XL2J&`&!9``N4(#
MT!T+'P#=$($#"3`02W%)$)H(&"`%69`%*I@'!3``(N0`#/YT;*``]@TO`)`%
MF'`);9``5D1_+DH`75Z8I,0`4E`#76`'QQW==:"E8_``=1`"67`#]4U[;1"[
M&?!$U60!IA)T92`%=[8"`S@#!7`!RS@&3Y?IF\X&!/#A'R#3$P$`"3`!,X`&
M,0#=J?+<U1<060``..`''Z``-9``X9,!-7#_!*CIO1/A`E)P!+?V6F,P!HB:
M!C=.:+-1`#.P`(?PJ6Q848G`W=Y]"%P^`1Z@JA"@X3-0,Q'`WF\-&5I"JY90
MP-34Y4.IUVA>:C5F``4@"+[D`,O>["``W27PE?->[VR(@AP0V1T\V7\`PN2`
M@BW>L`A0`"$@[5R9"'%'VO5@!EVN@L`H`&-@`#/0$`"7`%P!A@8@/&R@=#6P
M!6O0PX>0NCY`GG9S6\ES`)]U!](18<EE39\%87\P!_]%!^QS6VLC`!O@!IS#
M`'Z"4>;]5E-0/O"T.WW%!C-Q6]42!QIP8W^P`<QE`HTV#'<L,Q?P5L4E:PV@
M0XQT`0\F'0QP8]2#_PAMH`&IA5$RHP'<PBXC%51HT`:/@5$T_SS58@=UX`8S
M@0+A,R(F\%D[?P&[`P(0X%T%A&,N7DYRB@@C8B')0Z_DL@%L4#-T,%(0$$R(
M\`8:@%U\-?<O)6T-D$AC'U8,$#KYQ?;:7`?]D@@F=3]_0*!P`T][)0<:W5R^
MLR.7(`"[!4ULCP:QCUN7<@&[)?-AU?ES;P*/`0%H\P:<\P'Z^3SD$_3)@P$,
M(`<Z)@'JE`82L%<88`+<SRZ/<0>UPP9,U`8QA5L,``*[!4SQ?P!MH,UR<%)V
M+@%Y<`=Q``AW=']M<7]_&!!V;8=_;Q>%<W\-@X<-#'\"F8<";'\N,8V'#/\;
MF9X@:9U@(G]T&G:';Q)N!YF,;W)_@G*:A7]R;W]L%9BVK9(0>:(8)IRBCI!Q
MR"!O=RY-A\R-&`YQ=6_!OFR:`HQISG\.D([!<X-WF!`2=:)S#,"$E0QHG+F_
MKXU`E'*4Z\N(1FPNV'%SQXV;/W5@_0&AZ)G%BQ@S:MS(L:/'CZ(8<,#VAP1(
MD!**G5S)LJ7%,YY<NI1P0:;-FS)-XG3YP=_.GT!_&O%@J*.2!"J#*CT4XH&+
MI5!!DH@9M:I5H`)P.+C*M:O7KV##BAU+EJ,+%!]A)"G+$@.?8&SCRIU+MZ[=
MNWCSZMW+MZ_?OX`#"QY,N+#APX@3TX7+DC%'$1C_U*C)6&9IFRHT1-7AL8!&
M4:L"=""1$>N.1@:3.0I@U>C$PT80<F`,)@+"SLH=@U1@^<%V2Q&[1Z4^E,.W
MRV`7=@=#BQ'U,\<@H5^$\.&/B`4JD0</B@&#*#;P6-L%#KFK].A_4!BW&>[U
M3NA)^&2L!4-3RSO#:A(>T-+$@H\4E+'`?QCYL=0("5PABA$&$``&%U?)<00'
M6TC1PQ\##'?1&01NA`8%HAA02R-J''$1'OQ1H*%,!G:$`!$L9;`B2!2LT0B'
MHAPQXTG\T4`$'C?\44)&.#92AHTKF=`%1Q)@\8<'6C1PR`'\F8%D4&7@=D@4
M:IP!XETU!L@5E2X!*>2._RL=`,`?-_"S$PH=(E)`G*)(@(T!;K+$WQIF$/8&
M&)JX(<&(C=CGAB$0:#!(#P0$XX`$DCS3P"Q_!#C@=QK@<8@?`DA05`-J:-+0
M!6RT(8&4CJBQE:20_G%"`)7\$0(8S;`!!C\"M#!('7$TX!TI$+EQR40#W='"
M5N/D<8%[?WPPPR$?4%#'*G_,(<&JLH+P!XYOV)<)/73D8@<(%#"@WP&>,.!=
MB8_ZE!X8=%`P0@N^R>+M(7$P0L<==[P!@K:_2"!`BPZ$0,\=`FC`A@FMVD%/
M'AC,\8;$_S;2@*:6H"%C(W&8UM`Q"6%L'RXU9H(!9SE^H(9$<0QJT0$2>.RO
MMO]_"G!''2A@0<>0?Z2A`2,FHWS('`B<T$;(SP@@21N:0*!KLV,@&O-%[@@`
M:",7@&&'&7JDA#6R`N31`K,!ZV<''1+XXP`:6392QQ@B>%F!?I-XEPD$NZ4A
M0:R'V-&I/_;F\XHL(]9Q;=\,*#R*P)6N$>`!C/@RM``,`&P'`U+Z##3#IJ4S
MCRYR@(!)UA(]0X<:MK5!AP-V-Y+SSB.X_(>@V)8V*!L:%`6!JG]<@(``"+2*
M03$'8(X[QJ),&FGBC-Q`@'LH@&$(`P;KDG`,"+QA0&3G/(,'J7_888<$I?\"
M1AIZF-'`!C%UUY<960`J10U2D-;(`Y(8<0,,"?@PPQW_$RB`&4A0@!E,P#$W
MZ%\"[&"I.&F!?FOQPQ&D,*0?2&$,!JB#&8[@!PP@H`8)$`$;/'"$!+3N#S)(
M0`V65(,"(*$1.M!!(P:Q@0(F0`-K.((!"I`!*10`AQS8809V>($Y>&`,-TR#
M!T"H`%%<H`!YDD$6I""`([20-#>0@A3*P"$C[J$1%`#"'P(@&PM@P`=22,!3
M"I`&&B3```I0@Q0,D(`,B&(%64`"!68P`RFX00!2F($/^B`*"O`C`V8P@P=V
M*!L%S,`#!EK#&R/P!S/,P`]E*.`1W+""->Q!"CYXP`+4L,@"R,8*"9""%OZP
MAS?68#@+L,(?"""$2C%`"P:0_\)3>+8`+ZTA#0:HP0SB9,4QC$%B-:`?J@Z!
MA@(^@`&*-$`6<@`_,%AI!2X<D@P*4`,/R`&8PNS0$Q/0`%SJ4A160(L(M+"!
M!/!1`Q3(@A$PX,X'4(5$&;!`_!J1@2P,P`S"+``#V%`".IX@#?.#HR@$$`$D
M!HD#6N1`&Q`43"U)40IG\`$=*X.#`JCR#T>8@4`#.0;'=&$&1PC`'=`04H&B
MX9(XN*`4;.```XBT.F-(XPL3Z(,%AJD,#R!-$%YX"#7X`(1!ZH(4)K#-;LHA
M!X&<P!\DD(`Q4-(,`9!F#OK)GZ35H(0;8&D""M#50V`3"6"8`1W=8"LDGG`!
M$_#!&/\"`,HWG,"=!<!#``JP5RE<8`5IS(Q')_!`*:RE$3P(9`!0R$T+R&&'
M,&C$!.3I@C>6@`V6]$,+S6"`,=3`!T`[!`VTN,H5/,``'E#)![)@@"1,8(=]
M8H(6,\.7(>%@"G^(`0=$`0`>@+0/#T`!&VX`!#78T0+\V`(51#&`-[#A"#UH
MH"CLZ9\_^.$#5K,#`C"Q!0V8@0`"H,)B&6#&+;#2!H7B0"D"X`+'B6(!0WB&
M%F!4!@2LP0=NX$$)VN`"+:PA`FY@PF5=0`,8..D##\B#'T#@``\\8PI2$*4F
M2J`&'"``$1P0P`3^V`046$%,C5@#`1HP`23(H0MH."8&QO#_AP+DP0-J>$,$
M]N#B.SQ`%&<84AAG28(O/,4%BP7C(1-YV0\,``,K*(D?VI``2&FA!V8``!T(
M4!TLX*&3%D@"&S(PRB)W(0^TLH,'0%`#$+3A`<-!01?JX`-L1$`-)9C#`3R`
M`5[Z<@M\&"XQQ8B%-5!!AD.@9",&P`HF`,`,1>;/D*R$HR&50`,8.@&>]5S(
M-<!9SG1N!`F,\(<%[$$+:+D!`DKTAQD4&D;/,*Z01(&&1<L2!R<@0A/F,(+S
M+7B$HI#!FB!`R1HT8`X&R)H>ZC``+8&T2RH.P!L>(``WU$`#1Z"!``#P@S],
MH:Q"JLX*7#``*/R!!P!(L1MRL"88_PR!"7:\P)(2$(?L'ID-6XBNX\IP`R=9
M02=_4$,!(*!A.92`!#N#]`!.8('X3B$-`9#`'[2@`S-8@`U`&$"K+[*%(*&`
M`"QU`SUQ_)\C`($-`2#!"3@]`D$?8@$X^$,7:,"&,9`@"NB=P@D^5"DT]&`%
M&G]`&_Q``CM0-TX$>$&GA=2,+IS`#':\40GJD(!E#4`&4::#>PT06030#0-2
M.,`<2L"`%?C6`B<0Q9#64`(WP"`"/9B!0W1>VS%J"P)2;80-(L``#_Q)$B/(
MD!T-L((5>(`DATC#%/;J)0'%"0$&,((F6K2%-,C!#!1(@!JX]H<FC*'O!G"#
M`1X@PT9\(/_N0'9O(Y`0V>E&:@)K6)*J';<&W"+]#WS*@&];?`$#'()GFA%!
M`,Q+X0#8#_7F/<09"E``Z$1@"`-0P`@60/,VV+X`ZB:1B52.8QU/9@IG4$`$
M5L"!9PGY#XA\_8?6D/(6-Z``??=`P_7P!R=D00$*[^0$M!6$4=JQU2+P0=]G
MH`,I',(*P\%0+]`%7>``%(`%3'`(71`#=E8C1W`0'T!,WB$#2-`$'+`"$9``
MHN`!??<`$2!^(+)H:]!H?Y``?0<&1O"`S1(G-8*`"A@*A]`&NQ4!<H`_?S`"
M$U`B`].!WI9J=H1[?S!Q5O('0U`&2/``?4=.!7![SW`!&1`!CG;_"#I2`%L!
M`\:F(UY"""L@`7RW`@9P`D=`2!Q@`2L`!G&G@(>``T,!!BM@`1%`<Q!0`!,0
M`W(0`78C53Q3`FG01@&0`+X4(&^@AQ$06FH`!H>``!5P625X@D;@`GPE`@TP
M`^D7`&90&5XR<18Q`P<Q!P]P`2"2!DMX(_]!8=9V!A&`A"O`*8VP`$%0<T)R
M!F\0`UM0`V5`<X:D`QP(6`W@!YZ`>(HG"DZ0``FWB"LP`T;P>DIW`3=&A#=`
M>5/'#Z/4"#&P)'_`!"BP`N<`8DS()W\P@#K0A5*P3'DQ)`C@'0YPAJV0`$E0
M!7<`!KDP`@2@:C.0)64@'K:2`4XP`85W_RF-8`=*$``>0`<M0@$.$`$$4%^3
M9R--L`59$G8-,`43H"#0`GKV]26'<`)$]0=50`(/X`^HEV2K5R-]\GI\8@2S
M5P`88'NKYCKV<P='T``4A@#,`7R'X``\L`)80%N-H`!64`5=L``_0'-_\'S1
M]P=Y,`+3EV1*5RF380;9-P594GJ'8$@+ETCW5R/E5P`5L$59<@%#:!U&D`![
M('_>P1FJAG\10(\BX'_5J"'=Q@0*,`0ZX((J!P,\PP2^I(++ER/:@@)0T`10
MT)"B,`'TB`(@N&J,-HI_X`/T^`%ZR8)K0)==()5CA`9-U)$WF(-'(`!90(\S
MHFI`*(0VL@9&F/\!].@`H0B$.>`!."`#47AL5/@'5I@C7?(E6U@"](@!.O('
M'$`#62(;C4"-:C@!5I`E*""4>#`%QF@!^H&'MP=F%.`$!/"'E6%T0594AO@'
M"`"3A\"865(=/8!+/'`$]!@$E;@MA@2$C:")O_``(?")H2A\H]B4IFB:6>(>
MO>2*)7`&`;`"2<`$M0@BMUAL63(P??./`2D**(!+>>"=9?`!R"A\)=`4AP`#
M.#"$S]AIP^$$U,@$,H"-E6)L8]<G:K`".H";!<H7NW4%:Y$#ZCF+4C(!K*`#
M58`!_`$&4F($M11X0\)D^]@A;:"42#&0^G8(')"0?X`#BR4`7=`'_R'_`=08
M/B5@&TU``Z(W)3YP$`)@`&E``*R`/6L`DG;$>B,YIF;@!"\D`1X`3$SH.@:@
M"6C``6_``1]P!=@``240!U)5@S"P`'8P`XX!!6/P`I$G`$+Y?$KD'1,``TDI
M"B.P6RI226=@!:$P!-=9>0K'`589A!2``8LE`7XP!]#W!U``=38R8I5'`YW4
M!4]!`/87A"7@``^0!FT0`1(0CG_P9J)P`E*``0L@!1(@`;LE(4WQ!FTP`[Z$
M`#*D`\047U;P`SB0&3Q@`:*``-6A`\=XE;Q926LP`DXR)![`#P"JK'_`K+P5
M`\+Z"T<0`J+@`A&P7%Y:KN7X+%)PK?'E@RM9_Y.[A:%E``/\@0$<D`>I*0I<
M-E6OJ2,/4&U&8&Q@\`%9^`<K$`<L]@<-NYL$@!9E@&T3JG+U%20C8`0T]P-5
M\`<_$`%8L"8;0*UYV&JE@JP_5:XS($8D4@`/<01MP#/A6HUEL`(F@00_P)RD
M"@7GZ24.L%L60:XB@''PZ:C?2I]SB0A@0!7Y297[>02:LK`.L%@$<`$RL"0,
M$`%U8"!!>@A(T0BHV@07L*884@815WUR4`"E8`2FBD))AB<:V@@AD`"YP`$F
M`*+:^`<6\`;<6*(RX'U@RQ<6T`61R`4>`(.>5P.'4`83L`4>X`!Y8``TH`='
M8'GL>@AL\`!-$``E$/\#TM4(7!```=`$;#"01;L%%/``Z6,CY+4%'``$;S`!
M`U`"S'$(0P`&31`!@FN1AP!0Q9AR+3`&35`#-A"F^3:F(EE)9FHU`Z"/;)JO
M$+$%!M`%-8`6"#`&:/``7#`&H0``"F`!-(`C1D``"OH`<8`#SW*H+98&-X"$
M"M`'C6HQ'L`'D>J49,:XCNLJ!A``1["I-!<`%*!/Y>H!",!L0S@$8S``1X!D
M:]`##\`!8/`%9SDD`P`&71`!<R`#8(``,Z`A%^!_,%``N=`$"!`!.,`&`'`$
M7<`!OH0!#T`!8$!,(U$"=%!WE.L$HN`L3>`!(G"8B6LE#6``?#`D25`#7.#_
M:S1LPW$2`[ZFPBQ\3R#@!Y#6`A,0Q#:0!U*`!"C@`0-0N24J"J`I"G=@`8<V
MFF5@!Q,0``_`!*#8IKQ[!`0`QRN)A6_L`<:6`6,@`[;Y!P#P``'``2XY&1*P
MN1Y0'8U0`A%``0AP`)]G>2)`<R;09@\`!+H9Q-66AWE`R`$0`:0[;W^@`;UJ
MQB;X`$'",TO<Q`U0!AY```\``3P0R\\TM!20Q@#PL-GP``3@`2-`<W-L,4A,
MBD[I<P/P`,!Y<F>@G]D7`5L0`3=P!P:P`%?@`2W``5T`!JO4(J>;NE31NP2P
M=*[%N`T@`P90;1+Z!WQ`R&#P!D/X1$!@M]'8"$P0_P&[!['9:&RR7`8DBG-;
MT`4*L$I\`0^_H!`6P0:E(P`7T#EYT#0:$"F-("@+\09QX`;@\`P8X";=$P=L
MD!!I<"@WX[D74`RT8Q$FL`Z\8A%H8QQQH`&F$1'5LBO>X#&[$M,2H`SC@`ZB
M8`*A<@AUT`"E<@'>`@)2@@]R0"B$``LR+3F:@"[IP`]S8!_E$SYY(`V@\P]5
M_0>84PV"0`B&D!`","(0@`$'0P]&V3!UD`,,\`9)``3N0`CVL0^-X``5,#%)
M4RW>@@'+1!%W(`?>X`@8T"\+]08:\!J/<"^<`-.Z,`B^``\CG0SVP=!`\P:#
M#1T,(`E\?1'=DPF,W0JV`?\SIC$'0=((<:W8=^``(UT'K\$-PC`BBIT&(##5
MFY`)DB``&^`0DK+2X7,()@`P2K/8?",DCQ`3;J`!O5`4<L`XU:(!W3/9;.`&
M"O$-WG#1$X%M^78$)E`,WD+9AR`/G2,/!_,0@*T+#E`'Y=<(=\`XXJ#4?R#9
MDO#7`5,[!/$'^9()<M`&()`'<V`(!P`!PT`/>-`,/;,->=((#-`JZ;`.1EDZ
MO%"3LZT+:`T!!U`.CB#1EF`YGF#=IET!_%(M$H$'`*,8)%[BB+$%6I`#:&;B
M<I$&NVOBZ@D5(L`%]RI]2L$`S<SB.K[C/-[C42$`2G`#!^'C1`X6+QX59\!R
MSQ#_&T7>Y$[^Y%`>Y5(^Y51>Y59^Y5B>Y5J^Y5S>Y6"1%`YP'EX^YF1>YF9^
MYCL>I962XVC>YF[^YG`>YW9!`6PNYW9^YWB>YU-.5S?@!`_P`#C0`(*V`!A`
M!!/P`&$7!0H`!A=0`F!@1QKPYPO`&"(`!H!>>27Q`"6@CQ"PS8JKYZ`>ZJ(^
MZH%1``?@``E@`G9@`2+!KN`J#0_P`2L0!720`2:1`6Y@`9J"`",KA0.EOGG*
M`0Q0!S5P!E@@1BZ@OJ2^[,S>[,[>%8;HF(D4`3*0!"[0``A@`C.02!X`!"L0
M64GP`#2`"=MN!EV@[']@!!:@!+91`A*PC$UP!A:`!&:`_P/+^.SXGN_ZON\<
M,20B@*)E4`$0$`!5``,50)A=V4F'$`2X%(EJB1!KD+P[4XB'H`5GT)N_R>\:
MO_$<W^Q#0F;.10.EX(:4X`&>``4CH/!3("5>^@"UD`3L1PB-`K@PZ0#PDJMG
ML`6LH`&XU?$^__-`[^8\DP$<[,&=%G=0P`$(L`4"H/`R,`$.8@>:VP1@T+E_
M0`,E\+L$]0=Z4`(!4.Q<F+PP,GU!7_9F?_93SAIF5P:HL@%#;E=`8!L?@`EL
MH`<Z4!-L\`-4@#P0<0(T("6LP`9JP3LM0`4]X`E?A/:*O_B,W_B.__B0'_F2
M/_F47_F6?_F8G_F:O_F<W_F>___YH!_ZHC_ZI%_ZIG_ZJ)_ZJK_ZK-_ZKO_Z
ML!_[LC_[M%_[MG_[N)_[NK_[O-_[OO_[P!_\PC_\Q%_\QG_\R)_\RK_\S-_\
MSO_\T!_]TC_]U%_]J,]9!I#]P78$I+&EUVX`#<!068!^GW$(+J#])5`*VA_`
MAB`!>)0%6^``<S"&K;"Y6C`#YX#.ZBP,8P`(2']$!@M_20\P!@(T37^/?PM1
MD)1_+@:8'CQ_2)B8`90"/CB/908-!RM960H@?T>>!BYFL4@RGB4HE8\H/E>0
M4P5^'B25`IZ)?Q\&'YV927]&L0-_#A%^!4QN`[%'M[%_%I@U"VV[D%]2?@9#
M?PV>/@3_)I4!H.*88)5&-0Z6!H^7UM$X-\2`GQDM_K"!H<Z'CD<&!H:#0<L3
MF&.89E"HP\L`D4?+QB%),T/+HP$EZ%"Z1X[-'P-FOAF8,:#..T]'_K3)4"!+
MA`:*8MV"H6Q"E@(#W/P),$$IDGR4+@EP4.(H`8Z4D%`#L^*DF9>8QD![1W3$
MC'53(.$PT.</-YPA/0E@6>X<B1H?_F0P($*O%C.@`DR"9"''N3\5#7`8$2V6
M"THC#*AYA,-"T:-)XV)J<`_3AZ`^(F#8!>N3NPBKNO23AFF"84JL/5TP(.//
M,1<R,57*_<^"(4BE-_^!<=9`$+">8!@!Y4!+SP@OAONH,'Q1_Z4#`7J"<978
MP(7#X,.+'W]839D(!<J445-@S9\T?LR@\8-&QXPA5!)(A&3&#XVUU/BQ0ADZ
M%%#%'#48`$,,4DSPQP59$&%&%A_,9D@),\A!"1@1_`&`'_E$8$$9?J2Q0`F4
M4-#5.?W14(8"6>3!DWIEZ$+)`P[^H<`,<T1@P`D,.G@"#@DT4<8%"\Q`XP=K
M^(&$"QQD@<8N%/@QQB,09*&###X\4`E\3UH@Y1E^G#'C>7XP0$$"-`91!QA'
MY+"`'SH$4088;)[0)!(TON)!&3=D8=(Y.60!``H#9('!?$;BX`<6E92`XA$(
MJ$=4BH\BYL<?:OA!``H$9-$7)3+XD?\!"B44X$`2@A+1A!\__.%'%M\=L5X9
M"!A0!@Q@EI%!%DX\4H*5CY")11E8^)$#%HI"."IP?RZ0Q0FR+K"GKWXX,1\.
MZE$+1`%4G%"``A@@ZP>W+_A1QAL-KJ%#`E#\,>Q`>U727QI6>"##%7[$4$D&
M71FDRPJ&".B"%ED,,5\9<1B`0`X!^"'!'W,D8.H?=N)9Q@G&TNC&$7\&.F@E
M#HQ!Q1\UG/L*$">^LB)$91R69!DN^,#!'Q2`0>-WE,SPQ1]O)```NQ.X"R\#
M92!Q;AD"4$HCTFSJ<(27E100@7JZ<.!#$C',$,`;:ZH'1A8"4"+">>FMYX=[
M\)EQK7J5O!W_LP$44&(UC0)`^'``4DB@7@%&8D`!B@H4X,(/'B1P`(E=M$%B
M&I4T`6X..#(P)XT0D*?YYIP_PM,C[+$=WWQH(#'!!G/0L`DE]_Y!0(=^_#8!
M$A?XD=8?3*3Y1P0>4.H2%C-@D,5CE#3A0QOB)/!2!H^W#(F*A[5^0IJ?'V9$
M%BK17?OMCC+P!QJZ/N+\(TU.-H(?T%3B0U43-^#')D-^Z<=D:220!)EF%O#(
M]!)0\`\D?4#?'^2PA=?XCWSSH\015M0%'QQF`%")0P*TL+!'%"E2D_K*.:KD
MG?Y$P@<<D<,1"/"O`I3-!@1@0``2$(?W2"%`F;+5(\R0D_<DL`$U_WA(!;)0
ME7[@SS9^@`*$;K`C<RB0@;"SU@WI1#I(S&$%7'C$#7[Q!S)-:6$D\`//M/``
M`0S+2_5B78D&P($\Q`$+/?A7P/P`"H)5:X`&4,#"DD"?/X2@"=^1@!]*D("R
MX>Q_/P0.`QUX#@48@0X\;`(;"K"'EBV0$N$[A_,"X"4*U.TP*IK#^=:0Q2UV
MD5-U?(4&2_$_'L2H:AF`Q`&R<"D7%(`$!_R##OQ`G1*";FTV=%L"SU$^2%[R
M$05()23X("4[#H!GZ7G$X-Q0@"T\8@A^0`&)_/"!QU&"#0D0Q!]XT*\Y=>Z;
MX`Q/]=CS@!588'3T:<$J2H"#.=@+5B>8@?\C]KB`7P4A!@5(R#:C^8=TJ>H1
M:2A``KJP"RI0,P%3\,/YDM`\%#WO9>^TP`JD<`.]\%!2,:.$`[*`@MHMR`_Z
M?`,_P9?1!11`4B4002_9D"E*J+,7H&##`]9AA`W(;S+RR@#^?K6`!1Q!"G2@
MP$5+``,E^&$TE8AEDR:`49>)SP]OV`4='O";/W1A!O,A6*(R"@E)O6("EG1/
MBF8@A0!X\`A1?(1S*L$!J$!B!@J`!!:\Y`<+J$J&B*DA?`:P`%4P1@A9T.-`
MR$2!!63'%:[T0SLJ\<A(0#5V3>*K7^?S`$DQH0$^`,(NK/@]=='@?\.A4`D>
MD`4HA)$_)1+!*B+_H`274`)@+TG4!=P8NT>L`*OJ:H(4=F'2\_GKC\7RPQ$D
M5='&SBFJN_A"!$1@@#4<`0]^.(`C(1I)WB;`G-/"F110BE1(P*``'P@4(T`+
M`PJ!<DJOJ`%*_V"*1^2!FE73"`5$D,4#/`(#_J%``7HZ`Q[M8IQ^*.<Y=<G4
M$@@3$DN55"KI9K?ME@`43<A1U3(ZN-JESP%^N$$9I%"#JY6($@P`Z2/D\*@Y
M6;*JX4QQY\99``,<80SHG%(54*/8=_IA5L>9U8V-,(<-(Y5,AJD="R'!!5SN
M)@M,R`((G$3-AJ8(HF(<PQ$*$``!_`JE7(7$[)3@@P:0J+O*^EXD38I2_Y7N
M\F*4D!H$MB`%<Z@!`18C*"7@@],24&"G.O9`7X2*4AB0"+TI^E^"2Q`SXW[X
M2T<@A6T-,!]A9`$'=L#@*Q*`B5$J\P@\R=U+2.BY+$@:D@B`Q`(\(*L@2$%J
M&:4A0+'AAP0LP"4*R(D!0$$F8=@/H`4`*FE6-"?X*-'6-V`#92U+TLW6<6%F
MF`&"_6"#$JQ@!08@`&AG6"(V\(&T6:C-:P-6!@\T@;:_@?;"8DD)#EA`#DA1
M)B"%2URG.A9RNX!!9B,0@O;L=KJ0S#(E3/KB+$"*`@XN07<?X3X=*(#4R5ZV
M#<[[B".HUZOMM>$9JM9B!9%)*9T50I6R$."V_/]7?Z!T,8P)K."X^:'`"_[E
M'W(M*5`,[AS)Q%D).G4I7YMB0DJ#]R/F`^8HS`D3EE&QT#?'8M')ASX_6+@)
M5@`*,?Z`!/.HU@BR0`U3OH:.C%&`%!)@!$A8DV1CD$).?(0])S\T>A].EPNJ
M)S,P*""5W'R-"!0JYI(Z%('T4UFY6RP,$8!@('+XD!]7C=-$[[0`=8A"`J9$
M[C_DP`^C6D`Q@/N'7@K2<R#?11<<\0@/<&!A>BA`L"5]!$NGZ`@,2-RF`G"S
M1RB`:I!0`"$O,`4(@('4C^``0><W(3;-4*_S"X*__T"'`O"]`'3`'S%_*R^5
M7UXORH/L_&20A8HV$:#_'M!F#JA5Q6.KZ[O(%8(!0.#L/F2!TN]T0!7RTH`+
M;OLE96B2J]\H+S`L['H<@<`-*I`E2I_?G;$42`VW(FQ7"?@U`:^6`$=@&?@&
M"=55"<YS`WX``984'D>`'A4%?H\@?J[0*>A5>I00<3R'2I"`7Q/S!S:@6/X#
M-E+0#Q]W2T9G>;L@@R^A<L%$"5&`>'^@?[44<X.#8=K4`G[@`NW%1X?V"&^0
M!:^Q`;;C34/WA)I3=+E$.EO``0?@!EO0=*BE<V_4!%G``&F0!5TP!W+``07@
M!B"0!3&0+"?X=?3@!\Z44#7`7B4R/C@#95OX!UD$!`6X"]3'2N]1`&-8AF=8
M_W?B<W>5ET!`X`=[,&=B:$E9@`2F-!H2.'@V-!E[D`5[<'BV<5*4]P@,D`6I
M5#M,H&YX=T2V,0,H@@:6^`<W4`#?<3XG4$$\D1>4X%4@N$$Y,4U_<`)9P!@C
M4`#[01E^T!8?@@$?DA?<5%'S(P#"D&K`-QE5D0;"9TE5(@+XXP:W941V=@Z/
M=``S``#5TDO3>'V/0``3$`<-`Q6<M3#N\VH",`&@X&S1L`[OE`92$%<2Q'F0
M`%OA8Q`%8PAH4`!&L#"=H@=_0`/O,P0%8$D1,S$!6":H*`"J^`<5P(4ZP7%$
M,2SBV(`P(S,.-2<.4('@$2I9T`_OR`;QV'0>V'"6UO]><F!21@0)-P@)";`%
M;]`&6U`##7!`H1AJ+PA*,;A+,TB4-6@W!S8<?H"0-)`%J^.#*%(#-5`V6J!%
M[=4D1_@($S`!>8`[K^2$4!B6X"&%;4,Z/7!^ZB!6>0@)M44'^=@&4'!^"5``
M)R`'_24'#E``*^*&E``%\?$'<T="S7,4QD<$0F5\!?`LFF)\!\$`&8`-QN=6
MD/`&/9$Y?T!]"9``62`1Q18)A%D`!-`DC*D`KO4(6%``R$4`'E`'1Y`%*1-7
M<P:9=<4&G,@)?B`#58*8!*4'62`%63`##6"*B8B8!7``K=D3!C`Q?TD)>5`#
M66`0%M`&%<0`!1!T795!F)3_$VY@$'_@!C-E$![00I1P`%%B$&G!`*AA`+\)
M.0GDE]!(>("9`%9@!*WW!P_`!3\DA%W7?-YX%.LP#](W&7-G!8V&F'^P`7/9
M$S;2CNI2CYH)B_+2%7DY;9J2!BC0FYIY'.\7/H]7,/X)!F]000#0FR#2!A$`
MFW\P`U9`>;6&F!5PG,\Y,?NU"Q-01T;@!]3B2)_Y$HA)H=+"F`1UF,974950
M*/5YHP_*,RWY"I])!"32$_ZQ"S7Y"'1D?$I(>3=JBZ\%<ITRE,1I7\OVI>II
M?,G9$X@I`7)0%>J`!48$E94WE[[9=>W5!F>!D:8D4%$*EF*YIY3P`=P'`2=`
M'6YP_R0"P#1_T`(`8`1:"@D74`885PHX-0)ED#D8H`5&0!U(@U-VHA3E\JB4
M``)E$)QO4`;4T:GF02,5<#9/0PF-BC5154TT\AJ5\`.+=5]&4)"0(``P@%2G
MJAXB4`$[LPM$\!$$YZ@"@`--,`0:0@F#JAYJ8`Y(PP!^^@AV4`8BH*I8\PA]
M,``X@%R`>2G`2B..F@/JD0.1Q@D/80PNT`1U:1ME@%1[X*B4@`*ZD`,\LPLB
M\!K5]`AN<`)-$`,JL0MSL*ZK,T#KVJ[L99DG@%07\!J#:ID]X`1.P!B/(*E>
MYCU_\`/<AP**"0GD6@8R<*[K`:R6*0,P4*CB^@@F``5&@/\'D(`T95.H2/4!
M!``%&(L"&AH$E\*H\OH!6@``P5D)'W`<N_H(.3`9-"("&B*SCZ`'`P`#;T`'
M97""?]`#U"("EX(TXBH`'VNNCZ`#VD0)9Z`$]U4&_:`&]9JR?M8ME="K(L`1
MV+H>NQ`'0T"Q(%&S&+N#ANIXXEH!Y;(KKK`+)["H=I2H/(.U[E4&A*L,?TJJ
MW7DDX>HQE!"YZN$&:[LQ@"JNENFT.]N+2"4"-N(`3#``T?$'&'`IYN&I!(<$
M6C!YYL&GL!N[LCN[M%N[M@L>;:``^G2[O-N[OON[M<L%'0N\Q%N\QGN\R)N\
MRKN\RINWS/N\T!N]*N:\TEN]UGO_O=B;O=J[O=S;O=[[O>`;ON([ON1;ON9[
MONB;ONJ[ONS;ON[[OO`;O_([O_1+O*5Q!"=S##`0%#-Q`VW0'991!UZ8!0C@
M`,X@%Q(P4_ME7[$!!L7P`2EC`(IV&)?@"7GA`NH0$;8!#QL1;['P#]Y@&Q;@
M`ACA">?`OT>@6>)3`]X3&P9@`;3`";'0`&#0==9P%$V`<2WP(_X@%`JB#*V9
M`$FQ%$W!"5IX35/0$.V@&=10"16,"4=P##SC#3<!Q8=1`0SV"&`0%H;PQ!9@
M4PU0%8*X&OEP!$T7``/0'=Z!"2UL`((0'*=@!A/P'3*0#Q_<N=YE$%*@:-.P
M"W,Q#EM0_S9;;``>0$4C^1Q!6PERX!P\-`^#C`D4T1OCL`#V%0`&8!A!\0AS
M<`03X%I@$'0#<,2[4!@O&R>,BA/:M@N]0$5_$`S#,'FA\,%(8`10$<.6[`EA
M"PEDH0AYL0P7$!<1P!BY`0J#/`-='`M=I\%S<;*>X`%$,1L6X19C4#9F``::
MP0R[$!L/4`QO`<E_,`)=L`H(H!(U_`<Q8#%'P`/0[`DNT!DPP;\SX+]/;`!V
M'!9)X$Z[,,CD$`>*4#;+\`&),0$QLP>2.0`!+#D^X8+66P`<0`$U4`!X`!_J
MP484X`%9T`<F=F*R1'5;X"0G0`%'X`>6!`$U(#0!D`6_X-`4@/\`6=`5`7`$
M3#!E8,HB"8``EG0!U/D``#`&!0`"\`$&%*``L(*O%!`E%=@>[U%Z/VV-YU`&
M#0EP"9!_'I!AE@!P4E!8WK07UN@`#+8`0GP-KT$`>W29.4/1<U<&;?``4I`!
MJ!$LPZ(+&8"(D*!:#X`%'E``$D`F$6!)Z4HJ.=.0!$!GP+0&\['7%,!INV!4
M"8#/]$P!/O"%9I``%-`%M34`1;(%!?!O_]`3U.%L:T`!-6K3^/4^]GDQ!0#4
MEN0`<P(I:_`/D-C0PUL_'@``I*6<1\#7NY`&G#S9_?(20#T#@>4A<)@!U[6L
ME)!%6V`$HO<2-6"-(N!-L$`!J$$*PQ+_:F*]*7^@1W[@LB^A17^P`G)="=55
M0;?$`;D2WH]PHPX5!U1F!8(XMY8D7!3PT?_C325PU9;$?92P,"0R`&U`)FI`
M6-GA)6OPB!1048W]V`P0V=;X&'[0@KI=!C^]!08@!0?0*0U-`5VW`KV]`-[!
MVPU]K\_3W`B@E]\MV98D`FP`!L$D5#_#8#70!0L@=A5``1$#U#(0W6%%(@%0
MT1?='S:MX;)RVQ-0`*D,2<U-6D-@3?B3T3709FN0>=^=$T.0!5O0T;DLO4C=
M!D<P$NKR9]F-/GH:!UDP&$:0KDXX/:O3!<I#D@/@0!YP2!)@!8F\"S2D<[(7
M0D<``!+]"#7`_X]QDWE(K=MFT.?@$7$Q0$M_H`0\="7"$I*;`EL.2`%N<&MR
MT`2&47S#0K%@OC"S-!IMP$7R$F!Z@=XKU$(!-0`">!@1)]@K1]@2&1X*4.2O
M$3ZE\@.JEJ(1L$.+Y4IQ<$#"T#CT6*$V9`!?4`?/F4HQ]U2JTMHTJ9:5H`5#
M]@=@$"`HAFA?T0;5!W^V4</,Y$Q_`$TV0@E&E1<QH%E9_%3NUD#R8@#*XP'<
MR0DL?CL&\0#:B-X.R%7D+92A=1CK$]SN`S\3O`NU17GVC>\[]^6S$@,`3B:/
M$`02$^4X]9$"`"NYSI:/$N%]'C1)T*64P.$ST`8>#H.8=$DZX$`K4/]#CZ!:
MW#<%#\%@K-0&*+``[D3>C54*=:1'2=`Z;&D(<A!'Y\!@;N`'1L#D9>*$!A4'
M4?[Q1Q`')3`8--#7U8O4?W#E$DTB#'^C)#`G/;4`'=7;$(C=5N`'&">!(QD!
M9R`#4M`A8FT`54"]]A(1N_('4@"4;M$%\($%9U!>^AWH--D$9G`#4E#H`M)3
M^E8*4G`&>X`>2D$!,S!+&.M5CJ47?U(C-7@^(OX'>Q!-VTZ'5Z0N"+!;CX!/
M\G(6'Q#7YS`&6O@`8-`Q>[L+K>X'`&`&$P+K6,U\E-`&!6`%;04S<L`O/:!J
M#4!E"NF"M8,"P'X69S#LK0,?%A``&B`%%J#_[`2S`%^1)(/O[(-]&&-@G5@`
M!B0V((Z+:`I@!J$2'9&D!5V`7['R!R$V\(]0.U:^.B[64Q4%W;SF!VEZ3@T`
M"%D6?G]W)3=-$7]_!C-^:RLEBY.4C&63:'Z7BVJ/`E8)E8MX?C$)`W]M4GX<
M/W6BDWX+BQ0)9F81A"4&"[T7HIEE97XS)6=^:L>3!3!K60.]9Y9R)WX]9E*]
M"VI_Q`D.1V5IFHLE6)T!O6M_*S59/PL&G(^P?Q019S(3BBO9O6DT:C2H9(#"
MGP=^/`QILRC8HB,SM/T9%N.,$3\DS/C!HJ[;K#]=QL`J^*>'GR_#TOPY=F:!
MGULS./Q94X#2BB,7_Q+$J,>SI\^?0/\46&=OQ3AA?@KX,0#CC\L24'5T(DK)
MY:(,-1=IW$`A2Q8_73#\.0#`40(3/,UD,6``C%`"DS)P&*<TRP(V]6@N,W!D
M3!8SXXJ5R`!KF%(/*/[,29`!A!\:Y20Y)825;0!&%(ZAJ60DP1PP#Q8-VQQL
MQ8Q):W2M6&&`@&2"1B:5\'!,"MN!A>7]"7SD2)8UF8Y`90)+1!8(4_PP8.2G
M^0,Y&IMG">+234,_22C(*\"D1H02*[3Z43G.2HTO7;00+B#X\H(59@R<T"V4
M*D$$DQ9X.)"4K0Q1:1PAQ1$&%/"?`9MD4$(G$BPRSD>5[+'"5[,8(`547?],
M]L<1X4V61@D`9/&%'TP0\D,6:O"0106,9.#!`Y'TA"`FY,S3W$FPZ'`$!%M(
MP9`:""0`%D^RT))%;ZO\44(!4)4@`C":#%-&%C<@H\PB!93AS`1076+`C<^9
MP214B?D1A!0WA'-4.11T,@94-[!30BU&Z#95/5U]Q8%8*XQ9`@-F[%A!`81B
M]@<>"*SBP1Q_.+1A`DU.E-1236D$!IP>+<+:2&"BD=)*?K3D1V\%</"&7I/<
MI,900;7JZJM8$H5`$T>-UD0!&V@XR05^N+!(#[A9]0<4XRWBDAT44)#&A77(
M(8$=?PB1Q4[U!*K2(C5T^,<6`1P%1*\\H5K?;D?_`%9C/67(8X$4N;9`3`E9
M*!"9L91IBUDG(RQ"@DH>,"E%%@=(2IHFM^+UAPNA@(>"'SZ\1LD^DQR!3Z@^
MI>L@,K%F(@U/"S!YA!]*,++"`FO$\0<V"TPQ4`Q^;/;'"WY\H)U0"]#`<(<:
MD>='-3-@D<%ZFQB[0AY9U$`?J[!P.8D6BA193X!FI.*#(C/^04``#6"WB&-4
MB,)`OFD,\@9)^1'"X2)89*'D`C7,D,`P?T3A1PD(`=!B:@W+&+2C?Z!S0V*P
M*'"A#WY(($`+?[S1A1]OU./TS!I"U5,PP[P1`>')$))*`3_0Q,TD!HP<@\F!
M5H(,%CX@N.9!4-R9:@D?_S!L)SVP)+NL!Z_<1$D9"4@`008(899&OFTTX<<O
MCIX]R6A=X'IRL;%\9,$$(QVQ`!`F#\/B,2((ZPP*XK*#DQ2^_H$!;K"FK_ZX
M%T@!1*TMRS&#!W0(N\@<4E@PQP$&***K#7Y`PFYJX`%[&*0:0I!#`:;PASY(
MX01Q0!\EK)6?`OQB!`D0PE'8P(4"7$L4XF(5U%:'+GG@(5[#*@@%+%```2A)
M,E;)@+U(4@,`U"$$!<!"UA"0K`+L9#2-TD00_%`%-C0`#/("#QLX,#=81"$+
M+_B#"&3!DHKI9AR?&XK&>)*'"8`A60FX3-6T<@1*O"$!1GB#'08@CYD58!:Y
MP/]9L<:Q!D<XX6=""9I3P@.`I2S#/I1P01;RU;Y9.`T64/N#',;@EAF]P`<X
M8,017-A'Q%7""EG(E4L$0#9Z;2@\`CB"6TJP`"WX00MP:UNRVM:B/P2@B0QP
MH2C&R#?7(;(`74@6E620!;$D1Y:B>)QNK"(YGE".$"1H3N;^P`8D9($!GJ/$
M&$]61DH@PP%*$0<Y7I`%&=A23G]`@!_[1CM1).L/"!0?)2KP##;(80N$*,C"
M/B"I!B7/7J-YP_SHD#-KSF(#!8#++`TRB87]X`]4\`,&A(6"+#0C*YHZPAP"
M8`$W'.`!_EN?1EM%**4D(`[PVTP2>N62CI9Q#WY(@%+_AN#)<OA!"@7(@A,,
MR$RCM8$+2XEI`]9`GPD>X8-N^->7$F"'-3D@"UO("T1%6"ZZ=#1@E;#8'XR'
M`3!@81$0".`+/2E#:1KD6PGP"@9<((5)="&I0'3(*\,:,R6%AP%-!(97#)`%
M*4"@BCV1*A8SEI2.BF((;?T#$PK0AFF6CA)5(A01[;&=62Q,CCI;PRLO@,>.
M$DH"[_D#`];RQWJTP1%T+0`$,O4TW\14JP52BFC_8+,"K`)"E.A$`6K@!U2$
MEE`WL(IIO;(34DXQ!L-P3!46D1P0&(`PL9-$":(VRXX:(!,F_68EG&FR<(*A
M#F&E;6@<]Q'($3,+'14H)8ZY_PB$9$ZQETE-1QNI1[5T%#\8&X`FG$H,-LB6
M4/*(D0`X2TY`3N*<2S2`'";44<@8+P%".@U)/%"TNC(D>>`E%!:`.%(7:,2Y
MW0#O2S4P$H(N0@`QI:L!V%#2ND!`O;C57>P4R]*-NO@G/LO`#<1"APQ\X`,9
M&*T;`$`#%/SL9P+\PP\0L(7_+,+'DW##%!3`!7JB\P2+T$!C#F`%!0R`!W^0
M@,,F80,<T($2(,B``@#PBQH[V05&^+(H)'!5M#6(#CBP08U_G`$U4^(#018`
M`'(`@,_]X0N0T8$.CDP8/91O$4B`,AMH@(`!/`D(0)B$#+YP`!R/]G?T%,`-
M`C``P/_IH'R"K@<&HK`"`#C`?!D02T_PO(@:XP8+OJ,S82J1`R.\0K,98``2
MG+R(+E=B#E0@L@OP<@(!8B$Q;<!"^6Q0YS_46`(_R(`<]*"'/\3X9PU`0?G6
M$&1K-Z@>#3""`C+PN0P`#A9P_ID1:&`=)/SL"AQFY@^X10-&P>(,7%``$K[L
M[A^C`,DX^)D5HO@'':!``!G8`(Y'```6'2H#(T!"M9TRZ`4,6A3]S@`6?O=C
M)#0@`]^&!0WBM`B&RZ$%`U"`#GEB[D44F]`%IS.4*X%I'"]B#QEH``;4709H
M28#.D=PU)9C]8U_EW'Q&^,"<,X"#Y7S\QU=UP<6!$.2/A[S_$B>8^<[/X`(Z
MVR!Q3D```EP@AS\DNE$#*#4>L&KC103\QWJP]!]V3`.B_^RJ'<\5+,Y.B0UH
M805&0(N/?[:`)_W<WRZ(I)`IL(69O_CQD(\\3RZ`"LE;_O*8S[SF-\_YSGN^
M'G)(^N='3_K2F_[TJ$_]Y2L@0=6[_O6PC[WL3T^"V=O^]KC/O>YWS_O>^_[W
MP`^^\(=/_.(;__C(3[[RE\_\YCO_^="/OO2G3_WJ6__ZD!=`$R8^=QI$(`+4
M:H,9.&`!(\_A!N1W@75.4#X9S,(%`[".#&[@@&39_P(+D$']B4*`=2SZ^Y16
M"3)@?Q2`?SK@`$:0+$TP!=9!`!2P_W8_0`$71PE*\'TX,%HO0(!/,@D.:'\N
M<`*Q\0?N%P<N0("'M@AQ``3?EP.+X`;H9P$Q8!UK0`'#Y0;)X@`ZD"Q<<&A,
MQX$7=P,Z0`04``)S-P"040D+8'\A6`46$`%6X$(#F"P$<'5_D(#VMP;NMP@O
M`!<S:'^.-PDT0`&C)47VMP`!TX$9\'5=2`%&H&HRPP%;X$MV\P=UT`1-001<
M\#G,9F>5\`%;,"<-4G]>B%@$:`09R"(50`$O(`*%N&84P()_<`$4$`6(1@$B
M((A26'!:P!!K$!M)2`$#8&16F"PR$(44@`/6(0I8H`7Y\1$N\'[),@`M%DCV
MAP7+D8/V]_\D)]"$2!`':WB#UL:*54B`6&B"!D0!L"8*>]!H+`(!4+`%6/8'
M,*``D;1S/Z9JBW`#-Q`'"S!S-Z!H--"$%]>!-SB#I_8"1H")R2("GP8#"Z!F
M5C`%)T",E6!_6D!/AB8*&3"'!:<#G#B!?Z".BO@'5?!]5P!,6FB/3V**%.`K
M(Q``):`%F_&+$&1_35`&GP"))D`!##"*%.!PD]`&T#`)H383`)E[6)!2U:4%
M64``XL2""E``&=`%69`$;$`!`=4$+?D'&4!0I4,!CW$R)5!_XO1%%U`NF6``
MUO%&?X!)`S``67`9$Y0`]\<A:-`6*_020@$NXF0O<8-445``#\#_!LZ0BY3@
M@+/5D!F@&]:"DQY8"5M0`%J@`%E``FSP`#*IDW#A$B*13"VS`E2Y.)'4"7ZP
M=D*Q(FZ%30:!,!M("4<P`<D2&S00E5J0`!;P/#PT!@9`A).0@`D`F6MP6'KA
M$H-("8M1(V50`!1`EZQ8*MI1``>P`%+`>`E01BUP)`#P`%*`!E6R'%/T`W3`
M1+/63Z(``@4P!@!P!`7``)GP113PA3>@'51I!*G!#5,Q##S$AJ)P$9)Q#,<S
M!]G4G)FX`J7@%/)`(!3``5G@*P90`_8G`QHA=F)I;Y-0`<W1!P_15A101A3@
MGB7@!Y%&"?U)`0A0`.'1#KFH`<]@2B1#_P%@X`<\Y`#VZ0?XZ9F@:094F2R^
MX@<1L`4%@A:3D`8%T`10H7U2,"$.<$*=\0,C@"19\`NR40(!D@#T-!A_,`59
M0*`U*10S8'\.X!)7Q5-HH$M?)`(K0`$-E1A$PP<9D*/)`D@<VB,)<`==10D2
MT!R&.2$[D5F34'^Y$`&*B*,4P)*720EE^9H"@*'9Z0+X8P%,`"E.,9O)<@+C
MD$NY<`8#X#])D`"%Y9P?60E3E`6GQ@YUN4>]YP&$@V7@F51_P`%:D%7$\5D+
M<*4D%P`%X`8]24;V,"I">3&;@)3-L0YO9)\?D:>5<%@/L0)7N0GN*12,`0%C
MD`#VX@8%()55(O\!X3-05\&6/P4YHD`'62",$S"I?E"IE[H`854'H/"7U>0=
M?S``A%,^2C$+X.$462``#S!KE5`NDR``$U!Y"],`_31%_L6MU+0(HZDYL'"E
M/K!=4C4`H<$JU?`!"R`9U5"%63`0$#"B4\12.)`%:2`"!>`#(O$\'U054M`X
M<5``.L`WHJ`[,X$QUPD]L.`!?O%EQY``2.`8;^.PY"D)\?!)Y55&G62P!.D'
M!#<)2D!7#+0A'-H&^TE3?_`F]4A0.I!?'C83/N)*;?8I?["R6="R&\)<J+H(
M%/,!!7"":B`205``:E`#!(`!?I`#.'`:LS()`9`AE``5`>('!F&C8S#_:ULP
M"S)9%2GE!D**)9MPI`\B@M>*%40B#2Q#65ZI`VM1/A]KJ)501?M5>2XA0:@R
M16I`01<C%C>@"/5*"7OU!SY@!DE0`&47`/(R3=,E!0G08GG+I;J7-;S#BKS"
M:W^P,(UY,,>S"+&C!IEZKA3P+RA@!I*Q.J!:`P^`30L``QA3+0A2!HEAE0:`
M!6<0`UD@0`5@`0_`2Q%@+S`S<QKP-C0A#'H$.@25`;9@!@K0JV_4"\LQ";%S
M4)/@`J6+3LBP`+GP`3.0"VAP$T:4``IP!P6`!$>@M;.5``Q0K750`V"0K[!P
M!`@@#&H0!%D`.'.0!66@$3\0!-)+A4.K%5)P_PNW,AG:`*.3\`4ZX0?Y8C$F
M4`(R,11UX!*8=01GP`.7HR3"^`<1<`1U(`5P$0%P`0`)X+U$2)R5(`65YTHE
MD`D7609C:!/5E!H`8`9]M`;#P!$DTX=^``*7"RH18`%.4`!@4`:9,#(+L!.L
MD07T>IX=@DERP!>]<`.`4BQ2JT=M$`!&``!NL2&T%0,Q>TZL!5&T@`\R@,'B
MHPUI<$)2D`&-^2EM<`1C7,8)?#+^L`W=L#$6H*V4(`0[$KP"X`<Z8`$R802G
M83[R6PE<>P3N4`&#00=^,+I"\0"]$#7(*@4TD+9YI"D&\0"A00"*T*3:X#*Q
M<`9N8`5^4`%5.@D1T/\%&5`#N>,.].J5H"(-0P0X;O`;9EH`9X!OQX$-0JP&
M;%`#!;`%0]`X\?#`X^`"9Y":/P!7-+!9D!$Z6RP*$R`$#HH7[1`SFIM[WLL`
M`>`#Y,3*$>MGSS.&&I.Z/WD$JXL#KULCH,H'Q?I&0`0&A`)5XM$<DL"[-S))
M0D$#!7`#V6(OQQ`$#6$`9I`:-])A5W$CHY(&0'DC[HQ7XC&&J=$2%#`#.N`'
M?72^-Y(%/<`#&!$BK\`=852MSY.SCGDC)(.RR[``T>$'TY*_1&O1->$2-P)(
M8``%B2Q`PW`CD*$4S3$#)'8C!4`$&R*TFW(%8\`&!C*S6%,#@P;#_O1?SV7_
MT>X<4>AJT8]PU,TATUMP&@'0!*!B!%*`!5SBQ!9]H.`QK%9,+VGP)<WAM/V4
M"<Q5<@6``E/$(O1\!`^0Q@0%-P)Z(PD01>1Y(YN!,,W!7)\R`GX@V'X`5>::
MT^1`,>P@TW^@`0S;#5'S$M4:LF;'UI(LHT>``T>`!8.QN,MP(_(0S3-``\^E
MMJ3<E`"3!5?`DQ:],;$`)CQI+V^0!2+P`YG,#DRP`NG`RU64&BF;)69ZTI'$
MV9?P`GH='D`=JN-P(PJ`%V-@`;8;`LRQUY7@`,=3#0VR`DPP`\_->Y:ZG\?#
M*QLS`FFP,!O3`PXP#)9T##\GE69`/?O9!^_BJ0]A_P:9``D%L@"`57LXD`L'
M:P8S@`9HL!R\BP2IV;).FP`>$`"K$5M:TS<%D`0T8>'L#+V[F@9ID"88W5-W
M1CL?(`#^+1J%DX1,X`$[\Y?9<`/YTD<(D`N)<;U%TR&.T13YNP`6G@9GD`60
M&,PGH!$\\``U`*+;2K1CP.(G\-/J6@D'D`4<@).AD9H+<`-#@!>UN@`N,!`+
M,`$D($HJ40*JK20%9-D-90=9XP':H0A<#3I<D"H1D`DX8.&IJ,-C+0(!6]84
M2PFJ4!`"<@'',%(>8,]RK4>1<`PS<-?6E@59G+/]%`+G\@=5$@#B!!?TK"(S
MP)\VR\;VT`5GD#^YD[,.@/\!<[`'?6'C*C'JXM2RFUU-K<Q,@UP)&Y``8&`=
MB*S(C%R%IQ$'8/"%D1$@PI``88O)&R,!IU:V^6$`FY7I+D/=G_T'*E(B^0*W
MCD,!UX,6LQRZ$*H`&\$."]#DQRL*570,D+A?D(BN!3`"IO$+A/L'<8"?&O!*
M/^HPX^`$"^!0BZ`%<EE6EE`/.."UBQ,G(P/OO#Q["B0<2X(#BW$9A64!$)`%
M=@-B30#J<Q@!D/L%'I`'4Z4(,;LX]_RI"OX(+R`D"W!4E??P$^[KG[2JVU*Z
M3IL+7Q#BDZ!`_M-'(9"K!!&]O/KB]0"LJ.`&IT#RBV#R<I"$RIT`F@&QBY#I
M4!'_1C0C`*O0(0M>#^;Z!W;P`%)9#2:0,Q@D7HY)M#O,Y?7`!UD`%6/@!_T-
MXTAC+)*@TE>5-@VR`3O)!@@F$PA]*0SF`'V^"%^PG`%9`%7@L)4`L=797SY+
MQ!CO!S@`X,VA`250Z3:A7'ZD/!-`/27;3R-]=0\`*24@!65%SSVOZJE0OC5+
MNL-UI(A5`XM@!;KQ*:L/%:Z?X)IJ3=(@L,[.`3NR"#Y``(Z1`S=P&EO`UCV0
M!8:YM:Q=!G)`.(1Q!*H-!FR-[<8B#Z:4VZ/\[6[``060`'A![K#@V5=A+_W0
M]2(Q,DKB!]!-,780E8M``'X`""9_@W]K!7\F619_9D=I_X0D?@U_,GYH"R6$
M?VE^:FQ'!6]_.7X%38,&99J:4E(E)0E@?RL+?R5^*ZNZN[R]OK^$-ED0@P,1
M=P!9"B59+7];60@3!3Q_&5D!%GX`?T%^$PI9M11'?Q<%F9M^JG]'9FA^:W]8
M?K4T62OA"72:C9I'*]"D^O,BBY8_!=1H\9-C12Y-"_Q$")`E0J%#O0Q0&)3!
MP*!&:2@4<+B"R:H!V!X40/,G`C9MW!90`.''PAE+*\H-8N!GQ*`O61@4J'4"
MUR!X\I`86>5.DQ(_',(%8.3GT0)JNIHRTFGH3T22.C3->"B@0(PR'C45D$<(
MTY\V8*0("%'`P)8:!A@,6E'O3_^`C9O$F:GI,(BF!@6D;&D%`1Z[73D'K>GT
M1TV\,H17(-!T8]B@&A%NH@&3I4Z),O`\D)R5B406CT>DK)B0!<8?`P9(QAAL
MP4*!"&P('1`WB(J?"T<V?O!3CD)N#WYBK**P,8Z'(VU6Y';XHT^6"5RB#<*<
M9OB5XL?;F?DXTN&-/W[`=$F0X!$A"7YJE.B"H8D4B@Z`D`4`">3P1U%UZ/)*
M&D>H<H,?&?Q!0TVW5%.`#R3AL8!'%^#&$D+LK`#85QSAXY`+J_AQAB89R.:0
M#%FL]X<0?C!`RQ\Q&+7*32O^X4)-4JW2U1\HA6!&`1:X]X84!@S`I!P+)``6
M)VI0D@7_BA!DX8=AMZGFD`2$7+#.(%9D<<"-.3X$S)ILMDD('R8-\L$`&,QQ
M@@</B$"("S-$`.8?;``QQ@1#S#%(#!',`(4;/M;BXWM_Q$&!GE[)X``%+_QQ
M*5LYE'`$#H)H(H.C@RR@@P-&4`K#`&X04,$>&3"@0UBKH##!#$`(0!`!OAB!
MXH%+4;)`'"Y01QVDA+@1PQ$E^/06$#-,@(*A:Z`X``\74."`#J220$!P?X!`
M@;?RM*$%K9=F>@)@;<FPRA">WB"*#!3$\8<`3=`*D;O"#O("KVL82\&O?T!`
M`0J$3.&"",$20D"FA*P!J<%Z7C!`#5M,,@@*%&CPAQ:4_H'$_P+T&AOR(!;[
M,``(FD[:"[?^4E#!'Q5@*H+`O!*"`PV$)#&`!MH28<4?-XAPJ<!_Z`"I#DO)
M1($1$!LA\!HE-Y%$&YJHT<0%.U'`PP*_+E!+L10`T(,N+OP:`@42Z""PNRB4
M,,,"NOYQ<QQ:V_L'`UY7.DC)U(5EK!`;O&NLJPYD,`&_2=3`1'`RY+S*#3?$
ML8">^)XPR`E@@*''(`0(7,$:P9+N`.B4ZO`KT'ML+K#FFE#`-2'K&EOLAW(,
M0((.Y6*A;YBR$S+$`T?0((HF_PXBAQ9``$Y!6"$$T"0&A0CL@J0S)TVWA%$0
M(K6QL__!@[:#X*L&[V_Y[N;Z[+?O_O_[\,<O__STL_D!LO7GK__^_/?O__\`
M#*``!TC``AKP@`A,H`+Y-P)&+?"!$(R@!"=(P0I:\((8S*`&-\C!#GKP@R`,
MH0A'2,(2FO"$*$RA"E?(PA:Z\(4PC*$,9TC#&J807Y\;Q.'`=#0*1*%PV<J6
M]5P0K"$H@`-&T,L+FI"I2YWN#T2@0)7^@(((\2(.`/B`)N3`!`14XP])0`#/
M]M:$`>!!$R'(``&H]X<I!,`V5-P"$N2PB@LTH01;8,D)<D8OO4V!"_RH'G4`
M0+W:44<>,K``!ZQ`#$+<3&#98HNO)`5)LI4-3)8<6+9F=BD1!)%F!+A`S:AC
M!;T(D3JU<!K_!:"@-TU\@`(:$\$`N%8S2A@+!P[41!L&0"H)#*`$`0C!*M[`
MA`BL0`F$$!<)4":[VG&!!N`BA-LHP`44G7(`,@A.'+#`@2Z<@`UNT()M&)"!
M(20OD^[20P"06#="W(`Z!.#7]ZA3`>>A*'1G_,'S=`$#"K#1F=#D&[\X]DJN
M`2$"$:"!`T$P`.F`CCI-@%T&$#8(2AI+%RCH`A)G]DE)/9$09K!`!'!@J%"6
MREUNH`%"I=-)';*%$`)8``<LD(,YO$!@F/+5("CWAWE.*F#4`=DJBC6$O6F!
M732@`#&F&3B?ZL"0%+A!#YO@`D9)(``ER(#&-"$NA]H-JQEH9ZDH_^"35SKJ
M#DC`P1\D0('6>04+FC#D%.9@T2:P8PXWF&E5!=F$*[C!HM3QD;%*Z2/8B8M+
M-\A`-#$X!3\8P%#PJ<MKW@"/!$@A"P]P`(]P4PH#2,TC$LA"`:!CD<EL!!X?
M4H`?XA217CSHI8RHBQ3FP(`LU,`/1)B%%`JP&4)8@#X/^(,PQF"F-TB65(.8
M02P*H(`Z9``C@WE$&Q+@AR\NX#4&@(HUZH(;,QAW!@_P0\/^``,#4)=)RW&4
M1CB1`-P8X)78M2T;*(!=S]ZD2HZYR18J4X`S6*85$OG#39AD@$6`P@!2\,,4
M=-$$/PSM#YB)D&6H8EX_P'45^,E"(%4""_\.K*(*W[ALX6:D70&K*`..I:Y:
M-;&"UQ3`#S`8L`$*4``1L`$`S,FN=%#B@`>IH2OT=:\+AF,`Z"!A%260;!8\
M-F/W7L`,]5W*BS778#41@@,*YDB*_8`#.11@`#I,`(]"\(TQ^`&928L/(0K0
M7NH*LR^#X`2!TT((#&1!"A/PPP/8<)-<<.)#<O+##&;@AQ\@I$=-P8&@#9`%
M"3AF$'`F1`3\X`%&TT`&"/8#DS`-F%?<AKL&@$%$<"-:.\3.#U/Y@1_\0`@?
M^*&H`YAQ708`!D;/&L7N#4!E*ZR$`SS``,SP\"ITH.8_$)DT%R;$$?SP'B@P
M9Q`BH+$;WI``BS3_P,(LVO(/V%MAVT2!.;=]SW5G?&8YN_</(LGT*40TB#88
M(+AIR,**-?AK/U"J+T*YP:,OD`4H\&@0!;"B<]CP`##,JR>3R4(%4/N'.]3%
M`Z5B]2ZF4(`LP%8*`(A#`4A`@PD(`*%B(L(9"D#'/]@A"U0H"@/`,)4:G``%
M"=#`Q31Q`#_P[`<6P,!S/U*5/Y"@+L%R"Y&R8`TKM\`/IA[`*81$&?BHEP*<
MD)$.T_*@!I!#$_?]0WY7C0(U]-<R+*F$!/ZM;,`$8`:KJ*UY#869`CA@PM']
MPQ7\\*>V9-?0\'G/&4J0RS]PH0M_P$`$$'8')GF&1SO_`P&RD`<6E\,-_P7^
M-T^@`*,J-/P!8_@#'K)``-E<!-UT%N[&O6)%0I2@%@SPP2D,@%R0J"4!2SF"
ME%9!9&$G?O%YZ((/4+$%'C7N#W.(`*0BP&@VKN4M!M!<I*G$BR,<X0Y0S((,
M;G*</VM""!.PPQTB$);^#L(=<TB``OY0AP<`X-%.U\0(_'`>.<0E.&37R"`\
M;8#2>T7B.3H9!1+@@P9$2>(:<&=+AV[L<AN`D7A',2;&U00VX`?+-`4<`%F#
ML'V,1@P-^(`1(('M('ZSD``Z02`%P`?B0W<M\E';!2@/$`!1]P=R\!\8@&UM
MT`4%X`9N$0<U@`#,1PB!Y1<U,`M(96\9,`-8H_]!$&!S67!A<&8!'H!^,Z``
M9!=P4U<!?J`O!L`[;(8%#(<"9E$C]\<+5L`#!O!2<>`'ZY%\`)`+%%`#*-`)
M\*`Q8K(&-R$""1`A)0`%-.`(UZ4);)``1S@[SZ4&:H!C5F$!.H!V7I$)<_!;
MU@`&9]"(:9`'=X8#8A4Q3><'`P"(4@!U?J`%C;@BS@$H!.`'`I"&G<@`6;=U
MU>9U_F4)@R`%2G`39M"(U),<D2(?0^4'/Z)%94`?-P!W/?>":#:!!7`%"0!F
M?^`#69`!=4<(2*!G(I`@W8"+T6%B9Y!XE7`RD<$&D:<B?[`<--",=>,-NK(%
MI:`G0"8%G2@`4I@`.M#_2)IP>H.``Q"G$8VH)V90`S_0B'J!#ASP!EG``5;V
M!T`@!5.0!:9FC?:6!)*P`;C((R(@:"<`C7>0!<1HC"&H!D[0:.D79PWI7YH@
M`'YP9(/@`?[&9@-@?82@:C4P!`[D?>KQ@CV2@$@`B)&69AI#(Y,0?UT`B!.0
M"080`)WX!JU%-.FA@Z31$%@V"%OP`$ZB@P4H?]O5B6CP:`TP(!7@`PF`!7JQ
M"D%P)0D@'>N(`UOY#R7@$0;``3IQ!`@0`<%E"[X!1X20>"RW@@[P90KY)P\I
M`6XA!P:`@QU9)8%U!QXP`3Y("'40+7X`!!R4(R!@`9FWD=J!?LSRA`)G`)8!
M_Y='L`!KP'I?R8K[T092@")#N0L"\5*<@"(-D@'[U1&3`0)YP(J5L25]H")#
M,0L+8`8ET`9\('&$@`++M@UO@&*KMFJ/\`!3\(+N$A&KE@"**9RKMB)4\&)9
M\#N248G#Z0>:>)WH-IP)<!X4<)UE<(KK<!/W<`)?!YL&$(O7&2&_Z5@>HPD!
M,`8"D`4F40:9F7RL%G?P('54U!,`8`#!82NK9HR$``%=H"7]-P\%4`>*08V)
M=Q.PM0+H@(Q#0'U^D`5-D`<("';=B&K!`637624WD%U9\!CSYRAF8);#>0B#
M,9RJ4``XD``NL!VK,`-;H'%%]:#QX`8)<`(G8`!HP/\C;'`-F@8W!3`""`"@
M"#&<-7`ZRW>=Z9"`BCE_&3!R>E``RP%HP-<$+U8`9^.2[L"AA``/UXE<$>%`
MF%$E\0>EMW&=E["BDJ-#GK(A*-9P!<`$EN$L.X@*!UBF9+IJ8'!&*$"B]J>@
M=8``^^4C)$J=1[!X`D(`Y<`3+H`#67`ZDU$#)1>762`W?H`"G#"<'.``@_%$
M\'`&5U&6T?&IJY8)W[F<AL9NA#!@@:1!"%``Y.`'+`-G73`&Z#<&74"94_>"
M5$`(-<`'FXD!4K!L:.``E.8<!M`&HZD+I0E34_@'-5`&1C!^36``I"`!U_8A
M^/$##WD&L-<2IN(!`N!LNZ#_`4;P:L^5!FGP(&F`'Q9`7X"W`!/0`S[0!8R2
M`0'Y%A\`"KHP&5-D8?"Z7F08.^A88#JD$X-P$V>S=6D0`:"PBA\2FF3W?5W@
M!-BF2P50`R*1>?8I%,M&%8_P@@2C>-C9!3U19Q'!+S1'`PE@$F.0B3Y0`&V`
M>!C!`]7%8E*P`#?@$S<!!`I0`,+$!$@';7[0>&!PH08"9*'7;CU`?$CF*#B0
M>:S7#XZ@%E[W``K@$)KP@@^P?ZNYLSV[3F5$C8-0!S(0"XJ7B7GF$P5P`FD`
M`A[0/4\Z1:O`K%]`"!.P`"/'!C.@K+IP!S\@!8!7`+FE'F*R3'NC=38'KS6I
M:!I#_VQG%'\XF`9@X)/V%Q$DD!.32`$E0`$/D`4*20E0(1+!LJ<&R!$8(9-8
MD`4ATP8:P!<L0P@U2P'34')M,`*V^P\9<`0#X`'!*Y#X,&DHP@9WJ@O7`+2&
MP0D`D`RY]2/ON1Q]L"$+<`7NDH,Z]*NVNA<%>!L'L4&@26!9H)A]`7E:\&AY
M4````*R@QY>`9P[2MYEHX&R6D".XD6`C$*VK,*UK=F0)(`,XP`%R$`!@L'XB
M$%K'PZQ)H&H8,`:G,`%```,^4`%&(`6N5``(XQB)%UV+AQLT5@=NH9!AX:^:
MP`<^0$=?P)N46+!/MX(ZZ!$/.0X.2Q`%4%3KEX]5H6HJPO^A54D"&=L.&T$1
MMQMH[N4')F"?:="N^=ES'.NXR<5=67`#YR`=G&"B'%`+;+`"L:)IG#4".CL(
M<S>6LW##/!(',Q``=``#KP8H*Z#!ZY?!F0"UFN`"1Z`70V)ZM>`&P'0;K;>U
M:Z8&I6L%8$L($X(;EJ5S&%'&27-GFH-XBW#&#*!<I*96Q_<'"#`5><L+KA`<
M+5`;(Y=FL,D1"$!'5N"3*.)N)Z!Q!\$&$]`$Z%>3E?`K$DI'\==IG`L1K&9G
M4Q$[)3!W8[!^\X!="5``NL*Z4(F`D*L*'"`%#.`"!:#'3;<W?M!>V04$+A`4
MA5#-[9`!"!`-P=L&`<!=O`5PR.7_NIH0=7&@`#/P!NNW8'_0!%D04U&J#GI+
M@")3:(6I"?7'0<+02,9P!X+6!350'ZG1!08P!B``OY]X!EF@EIC5!O;[<98@
M/7%VA%]Q(O\;AEM!)#>(S"U@"@4P!74P!FSI849P9(,)!C[`!BZ0`%&0!2#@
M`-@@!0/X!TLB!0-P!`9P`1_L!Q"0B8-`!)WJ%FW@`7+1(B3A`D+!E`4@"TP'
MPWS*"6-`$J^4%BUF=>VQ`O+2!8HQ`T%Q$\7YPQ+A&WMV$V#@$&!&BS;(`;E$
M`.DP733`Q`X07E0A4K8:36+2(P!0`!!PT`,P`0E@@LVH`"X!`S1`9Q-``(AW
MO%G0/8Z'_W7<.!E3X`9<BE5^,*P<,`-I0&P_`&1='0-V-@--D`"3;'IC(=9Z
M8@!C\25'DB1>C1`*P1"'/`@1`'%_<&V)!=F2#0^52HT-:`'00``3\B$#$%P%
M\``KX!(\(V@.$06<`)`.86K!@%FU.@9N,,IN$%Y:2@K`E`5#`PT!0!O4DPS+
MT`RSC%QM0!MKF05]J[:M:PL^B2'<,90HYBQRVI6RS&JF/0@],(W*?(`FL@)1
M\&@OL(D84`,S0`#FU4J+_2$3\`"E'6LST$K?W%@Z$+P?D,GF"7VUN0K,O()V
MQ@5^\1+;<(CK#!4D80>!%0?)FAW;L0*G\\\;M`"I#2\AX'Q'$/\!AL8`SN<!
M%K!,(W`$S@(&*X;C@(($RA4!/K$'%J`7>I#'%D`J"M`$=\CC\[83%M`Z,HL(
M#R`%[\$&6R!^]B("/N`#"&,%$3($8U`#MD$'OY4S6.`*6@I%*C$#\H`#4GT"
M1[#CL`,!'D`#-+!T/W`$(H`#//XI26->)7`VJ[`'?_Y]8U3E`K#H1[`'2BX^
M1Q`#"[#HW3,">8XB1:XK26#D.WX$'A``??`'1<[CBQ``CD(%1]#J#5<"\Z8%
M39`#`6#JY>#G1Q#+)M@I0R@#1AXW'PL[A.``*]!>3?`&3=`P-_#H1J[HP9X!
M&/X'4?#+@U#D/G$''+`9#3`?GA4'$D#_*)H2``"P![+PZ3S.,S>@7`\`,830
M!,['`680'!:PZ",`[,[7/6`0`GZ.`5$@V6]1`E/:$E%@[1.`[8/`!B4PR=X^
M!RV2``&@(24`+C+P`'<`!LXW`5MP`.W`X[V.Z9,X!5@9`7HR`E+-`WFL"6X0
M:U)B2K!@`''B`$XB!><!Y`;2#F-$"-'37D@@\JYNY(-0Y8/0!*>P[SQ^`G>(
M,D<@SZ72!`Q@`4``Y`?@`8Y+!Q.@5F*C"4C_!];N?`'`\X`2`!$@!R@P`\N=
M0Z5B!.!R`QS/)\NMWX,0`#@@Z3:``P'@YUM9`4?`-6#P\SHCU>5S!+##!6!`
M!VE0YE*@!:=3_^@?:?)?CR-'0/"+KA<6L.4V1$`2<,]K@@*$W_FD7_JF?_JH
MG_HAE`,GLR9)X(ZJ'_NR/_NT7_NV?_NXG_NZO_N\W_N^__O`'_S"/_S$7_S&
M?_S(G_SN\[DKH-]JT-QNM0:7\P=YP`>U8*IBHYF$P`#9/P5;F?UB\P;2G_V/
M4`%K"4?<+S9F,`D7`/Z/\0'@+VX]8@9JD`;QKPDTL`#4T_X\`P@Q"X,+:FB$
M"S2'B&EF:@P+#7]_"PR3-A%=(Y.<DRB(-)!I?V^5BX,TG3>#4!><$EL1,&R<
M(TAHDQ^$-'9_GPM(+9V3$#<E1KUIB&N<%X0_DVH+;V>$+F^^B&>3,O\1`9*"
MA#%_<3HE6A"3A,&3;E@E2'.=9^-_9V9_:SJY99Q*-YS*`/&$[P8*2@L$_-FS
M@-D?$9DVV:NG!M^?(=XD_!%0QM*?)#=H"5@@@].Z#Y-H(,)%!TD)'-C^%"MA
MI5>I!6ZR'5SEX`^)!3$:(6)P!D>T!?8&W1`V"2,%C<-^3.L48PHG'$,V:BDQ
MY<`?781N*$/420":.1I7#>KW1\:*%7LFK2%T0EZ9-2@L_CDU*`T-E'_,[&3D
M:T6`/NH0Q?P3#HG&4SA,<#K!88O'<#A`3))C)H*1#9/HX#BF<)(M7'_4L.4T
MI`L"B<-BRYY-N[;MV[ASZ[[MQ$^-!%F$4?'_?<0/0`I^$/C*XH>2'P/0C7!2
MXR>!@0(%-/N1`MV```H%NC<0D4#*!#\KV%"'GJ4`A#7;H0?@Y,(`<"E'_OA!
M^L=`&33509<?)\4!=(,?^:V017<PG!&?`19\8(`4SQG0@'_413")'VK\`0""
M-61AU3!(7+>@!=3AD@:'#G('82?835C`.",4D(`'?@PP21L!^('$)&94N"`$
M&3P''$"<'!#B`PD<D0:`UAD@G5SQ^=&%'&7XH<R"!F31Q1\9<&D`/E8@6%X>
M`UP7W@!R/)#%!.'UY$=XP"4Q1P0)E%"``K2HLX(Z!OR!W$%FE##)'07X`54)
M?KB20:`%9*"?'R7U_TC!15G4,(-QE/SY1QF!GN#'!%(4T`"`V_PA*C,X2('8
MAG3Z8=4141KP01M@9(&C!7\HF<4#!1SQQHI^H!2!'Y(F"L,?`Z"'AGW=.>/'
M05E2LF"B)Z@Z:JF2=+(I-)P@X8<E#?BA`P1'%#!!I@+45\""1P#H8J"<:`&"
M#@?%:,!\PVGJ1[84</DK&R50\"@G$E((70-'6&1`LK6.E\41/F2QR8/><:*@
MB1>T>)T4#K"QQ:A=0K-">.^Z$H"N"12@<@$E9&'H)#W^Z%PG1.C:I2N[]>SS
MST`';=L,6K`AQP1&M%%`!&W\880?((!7`P-()'IS;-0QLX$?2>B7ZB04>/\Z
MR1$SW/&'#G[L0=TH#63QPQH%="@;J*CM-XE_`*[62;IC_*%`L'^L,.`D#GX=
MC99WET$=A_JI@8$?6/R!:]^R+3!SBG^LJ$;ALD7Z!QL^--&&#Q'(\8<+4/]1
MHQ0/`(DX"G[\D$$!DS2116E_\)&`"'\P4``%><<&7X>BHI"E,C.?D`68]$XB
M0!:2"E``%&!?^H<>6?`N@`$`Z(<4&S-$L'56:&-@DJ<+!(J<H85.PL.1DS!Z
MZ<&>SWE#`S[\[D`637RN0!9Q6("G0/4'+BC'#0EP`:IVY`,PR$$*>O'>Y\+W
MAX9U0@99D`3:*J`[WOF."2LJ0"I:EBPI=,\#!5C_P;/TMH#M<*0YEOM#'08P
M@P(J1P()[,3CI*`CA/WK(WX(`7@L01X^`&H2`)+;,,"`@B;LPW,[*@``FF8$
M`T2-7@=J``:TT``N#&-M8W-8LEC8!38\CPE>DXW@_N`&`^"`<PPPSA[,]8<[
MS"!!DKJ`'W`P`C]L@P$3N%0!D,(#/_1$#@5@G3J:PXDH;.$/#:B!481&R4I:
M\I*9*]8D*B"'$/B!"+GP`PPHL"X9!.`!,/3C&<[0D\/Q036:](,95KD)"D0`
M#6A(0QRR8(5)F&"/8/Q`%FP`-Q>L$C4!,4#=!J`&-4CA/Y!;)53&ADH3S.`!
M":K!*L]`#5FNTGRI05Q__Q3W'!UQ2%10<4`<9A/#<*)`#2)@D3?/`,Y)%``!
M\$P`#CPYD#\@<EE7R`(2LI".((U""7ZPP>PFD0--3@(!".B3!<8`(!S@,B=4
MZI``_'"%X\5P#CB@70:DL,TTV"`+K<1#GRA@/2RT;A($2(`$MZ<``=R(!ACH
MDY^.2(&=M>\/!%@!!S@0/^R@@'Z2\L,#$(""-U%`!I2:A`3\,`(!3H*`5BB`
M$430BP42+@L(*$`K-X04FE90"]O\`Q->Z@;00%2B8UC1`Q3@NP<D*P(60.0#
M5&@`+*R2=PM(%`VJU<YXTB&K1OA`+SIAA",@P`>=N(,4M`#4!+1A!KSZ'$2/
MN/\7/QCS#$K\`QA.0(#(%:`)N!2`)\'Y`5'V]'-/RP,!/E`%%WQ1G$<`0#.E
MD"R_G@$E0#CM&4HS3]@$+C]L,,`-.#?5)%S!D)-@0A;>L`))`>@&1I!"GZXP
M!@>,P0!"N(#I_D`#@1+T:I/`00*TT`/<8?*]\(UO;`"$3'OX(28`,@,%2C"&
M+_B``*GT@X`=$DX!(R@G!D:0H`R\``#9=D,96)R`']`&^#!X&'3;4(*A:6"Q
M59``65`>`1*48#0XR,"2"N<HQDF=IDZU(EIRP`#>PL[+)5B>*(:1@6O0,3_P
M@!-C$JT%-)``)00FP:);J'T)7`(T@JT``#*P$H<'88__)A@@13+P&>`F&Y:"
M[9&+)):`I:`980K8R3NEA/IL28'V[:\*9\C"*$JP@AF4`*GZ`4`-D#"&@F6I
MGGZ8RP`#!8$:"-@'$/#J)(X5N4XD.`LDJ&""!>7A/S29$^!9$8A/``8"),L*
M"9"`%-[R+`/3;@%'B(!_8&AC-!3ZT.F((A9:.\T_X*"&,^A>`2@[B0S,+'U(
M3/#,.F?@,CAHO/E%CH$G.1LP2CK'B1)PH.Z`RNJ8+\&#"QS,#$#5$PM80TK^
ME!_0L`(IE"`!5"T!&`(2MSTPQP]>%#*1C=S"LA1G.]V2K[[W7<ER\4PAK>49
M/_<;``MD@0:IW.98J8,%?60!_R#%%90'RJ"X.$[R#GZP`G5N\``IN**8Q\2P
M,C<4@#6L(0'0]&VMCY"!&G1A!C3(YC:[.4MZ'F[%&/*#'&IP+#4@O`(,L`"%
M:GPX(*Q!5)N;9SW_4(`N'-T`$6CMLB8A!2`\SP(N&,,C@[0`*8P!&TH.PK0X
M$0%>_P$!4@!0$R@>ZWPPK@V0\V@-;I``!X*)I*M,PP^RT+2-8-IZ`_C2)+"0
M!8Q'X'_@@F05P$!5DV06V"R%6P0,!0,_,`'A6:&S&;*@:J8GE019L$``"A:#
MQF^$4@O(+`'9B`("%&`*B@9B:/53]BSH86QH726S-.2\/Y2=$VA?T7"Z,(`,
M),L%6?\P0@1(W=>_4N((?<A"CR@QLQ>,B_5;>+T/"5"&`B`IE*!WA13`#-3'
MT\O!JYP]C")`<0RTMI4#3T!@YU,;9Q^A"29/0&]7"9@[B$`+64!9$:<Q,&,!
M0F!?(Y8`%?`'6.`'&(4V#E!N=)8**T`Y?U`%4F`^:5`&QX(!5Y=UCU1OG1`'
M03``!8!F_):"*I@;<Y``5#`)'(`$SQ-O?$!5^_5<8]!'Z-4)64-U\^%'G1`V
MG6!NM*`'HK0VOJ,A<*-^5S5R$C1.P1,;+(<`R;$&"9)MG,.#XI1SVL(AUG>`
M#,A(L=%.F*,Y63@,4(0`"2`]8!9/(Q`#7%(J<6!0+Z!58$+_.W_P7![Q!U90
M`^9C!U)@`5'8"5366C'@48:2!'1T,)R`!YY51U*P#X)B/<&E&7/@`3^X`'70
M!`8``3)0`)'6@Y,P!0."`!,PB6QP'H:R,M!1``]`,"M`!ST"*4F%!ILR&A3P
M./SQ(29`BNEP!:?(`?Q17;$''_4E0;8C#!84$`FP3C!@*GWXAU*``"NR!A0"
M!,;'=&7@)E;`?"R4'T_#:I.@`S(EC)]379Q`>-#1,KC3!M91`Y,@=+V``370
M2VH6;$R(ABFV$0<W"7Q0`"/P6O'T8,V&6V*DC4%(`+0@A$`8&VO$"86#`3,P
M'Y67%00C!8&SC]>3!7^X`H)8`#D@_T-90`\5(H<B.`D*T&A>MH(LV9*S00%2
MP`<`D`7+8@$%<`4T(`4SX`;[U5`!`"#.809".77AU`1F4"9HY`=:()1F\!T>
M9@19P`1`,`9B!49<P)%KD`4`()39T@D9]H1XDQQ,N3<9\%Q?8(6!`T%"V0<.
MLI1F\&#.QH4"L"EJ(`<S(`4TP`=2L#PWT)4FT6J9E'1N29!,5P)F<`52L&Z!
MA04TX`,^X`9:$`$@@`:M508&]0=;P)%A8@8W(`4>T`FM%0$N8#L_,(B<`!\`
M,`7`P@"(N!$>X`%MD`$)P)0VP`8>8`!``&)0L9(5\"8N`&(_9C=]A`5HP'DP
M0(6O\@<Y`_\`5%``\^%E"%<"R?63:"`N($!GOO`<GJ<?:*``GU0P;:``"<`'
M_[AN.=,$5+`O?]`$!:`#0C">`.*6T&",PR"<R%)!"L"4(-``]P0$/F``<A":
M+I"9+5"-'.`'/9"-!5`&3?`OS(<`3-D`J/8'>@1#-6`&3)``_<.>.H`$X\D)
M8,`!N)0E/\8)7>`'8)8#6<`%+A`!60`8P-996RF49M,Y&FD!"7`%4S!^/!DH
M;7`$4K!.!;EBR_@P3`>A0ND`4)``4*`#]>.63:DQ6`B$4Y`%+^``!3`#0"!=
ME(6.G&!3#U`%MN,"#S0#)Z`%4*,%/C"9E=E"^IE=.-`J"Q`'%##_5BYYIRIX
M`%O`'4Q`"PY``%*0`%LP"@O0!$$'!`R0'S%W!(S:/Y,0`HQZ!!,P`%X1J8P*
M"5$P#%-@'UW0(9"J$&Y@`0L0!)9*?YR0`Q;@$4>0"G]@`3F0J);:"0&``XEJ
M`WLP'U%@J2<P`I::69\:CSD`J;EP!"'P!W\J!>/7`^O);"GAJ)!J"0)`K+P:
MJ9DU"6#`J!ZP!1HQ!UC@`PE@`:Y@`7ZI`$UP`D>@$!O@`0N``XPZ`1E@IZH"
M!@4P!LR0J"$Y#'L0J0&@`7^0`^=*`XYZ`4>0`^P:J48!`@&0`#70-8G!"3)P
M;EHZ-JRJ!1.0!B2`0F.0>+!E'Q:@&8/`_T9:T`20^@*;=`0GT`29^@<%)UI&
M<00,0`-=P`!-@!1Q,`#(V@22P`9&\!L<H!D16!Y-\`:PRJB9FJ][*+&30+%I
M$`"6&A<H,`$)$`$2P6G!P@S1N@?L:@=Q*EHY8*X8$`51$'26.@(T0']:H*B,
M^@!:X!4_:P!!.PD'X`&1]@=T,`',:J[W>CU4.5J<0`.9-;2,ZEZ=``;,Z@!H
M-WY>D7KN<P3U(!N_JK)=:0%&<:V1&@)QL*=2$`#I8*DNVTBFJCI'L`EWP`'*
M`0)=8!US^@=1P*RJ<VYC@`2T<`;R6@-5T*KCV@2+RJA[<``*@*P((`#1>K1X
M.KS$6[S&>[S(F_^\RKN\S-N\SON\T!N]TCN]U%N]UGN]V)N]VKN]W-N]WON]
MX!N^XCN^Y%N^YGN^Z)N^ZKN^[-N^[ON^\!N_\CN_]%N_]GN_^)N_^KN__-N_
M_ON_`!S``CS`!%S`!GS`")S`"KS`#-S`#OS`$!S!$CS!%%S!%GS!&)S!&KS!
M'-S!'OS!(!S"(CS")%S")GS"*)S"*KS"+-S"+OS",!S#,CS#-%S#-GS#.)S#
M.KS#/-S#/OS#0!S$0CS!`B"4*T8.G-E*%P`8#<!-VW1,(R`!;_`!'O$!N"`"
MHR`'(R`)3WP&<H`!_+<8G$`-"[@1(M!*9\#%JR2\$O#$4/$"#1$;(K#_2B1+
M.$\\7I/0`%``!*;C`,,U"2*P`%E!.%D\`@P@!UU,H72,49W0!DF`!/_&382#
M.T0A39.0!D\\`A?`.Z;A.$^L!M2P2B2`QV6P`#S3,=M47P)``S=0QEL<RF>@
M&9G3Q7@\Q+:<P7V`;K[1$S9`(=41!`OF"D$290QV!'Q%?P:`%`6P#6E@03>6
M!EFV'3S#&GY`?VI0`#TD2Y/B!_S3"2N08.D1,`(6`'UG3P8V`Z/PS)R`/0)6
M`A7&(74`!08V`0KA!_W3S&4@9@*V8(<&&IQP!\?"S=)!';S&.%>%;0+@;0C2
M0CWA!I$2S7Y0`L1<'8C1H'-B%<HF8/Q!MV,@_V`%P#L-,]$_HM#B=,LF;<%@
M$`$-(`')S`8U,`85D`9=@%+($0!N$"1R@`93U6#-S%=^$)+)S'3,[,P9@$MH
M$)MI1P(<4*T/U3)F<\V0IA_XX`<Q``(+D`4E,0D.@`:GA`8.L'=($`=G4`!?
M`"-`@`:P,PY4;=3E'`%@4`>M10+#HP-9H`1O4'FI(&`H@,\K8E&X)"@/8&)+
MU0E:4``?$`<?(@+4D04+:-#B)@)H``2BY"!&S0`U8F1S)`.S4]D5A08CD`4$
MX`!^,,HX*BBWA$M'C`()P`#H,A\AO4<8(-D_X"`QP-8G?=L3_`99<!"^<`'E
MPJJP@P(!4P!YP4@K8O\1QOPLO](?RCS44[W1S#,))R!3G)!<0O"BJ?$N&J+-
M0'@`$V`SF#8S`/``7N%[\,@)!<`,>@0-#3D,%F``9S`',O`>'*(`!M`T;5`&
MH,'-`<#7?J`W^S6.D,4)"4!_##`#-[#8$*=$68(+?4#5#M();\`!E(4#69`'
MX=99_=""`P`!6;``&'`!<2&$L?&)-``!$J",9A`\[M@$9XC;,`[!`(('G1!/
M*P8@.D`!1^`!#Q`DEZS-%<17@Q+4RYPYSFQ@^<&(#K*'PB0`GI'=R-%:4YTJ
M*^"HX8V2/00FRX/>V)$I=;#-"L8)>X!N6O7.:G`$7](`0ED2?C"3)'`$^2S_
M;((R,UGYI9PR"55.'2ZPAHZ=)0]0`LCJQPDF*7P`CQ$`;@G68'Y@9S,P3&$X
M*EF1T>TM!XR7!6#`KZ_-%JFFT-83XYZNP``BRX!\?7\``GY`!3J.<,CQX\C-
M5T/@`2M`Y#_6S%-=`J@0W?:UAP%`45$P!A!PS2A@`,@QY7ANY6`S,P%@Y0`(
M(UV0`=[9#WY``;=>%E'@`SXV/![`*R=V*1SR`#H>YRNP%G,N%UM^>N!-?-3Q
M!@4@+@SN!QR0I:/@((1P$'TD`2"IY81P!@#B`3,0-ZRQ,@4@!Q0P`X107W*0
M!#'S)9D^-A'@(-(>QY\>\0>LV_<:!4D01V7]!Y4G_P,Z3@?_8]Q`GMP&L`9J
MD`4?_@<)L"P';EMVPPF,F`34S8\;=LUG(`+,0>QYX`'?=^R#-P8>`086R'0.
M\0`_:#C`EPIL,`9F,#QJ>`=RD`9@P.UJH*)9$.<`/C-"<-Y4EUD8X$;4\0<#
MU>?C=@%9<"D1W@DM""QT<(>=D#=OH"ET``,*8#J2C08D/@Q.T&@T$"@+S^$O
M+O&`3\`1`'U$T)X5E``?<`$H]!WY<6*L/C9\Q0R,@A03$`$7L'ELSDS-Y`8C
MI08HX`'*P0WFLDJ"2O.2-M4N\`(`!AA7;E]<``**V$_V]$H8)(`NT$QJP,@4
M`P(?4``N,#Q.$)5HX`2_T_\X_?'?*X($N#\'I#3U,T``G7#5,("P'/+U^R/V
MN/`_1%']:L`SWSPSLX/[(1`\:!,##A(*R.$`%,`!N)]O9;#;&\"T%;3B/F(+
M%N,@M[_Y@;__``P(%P9^?B5Q?R-CA`8C?Q1'?W\/?I%I?F:11RMH!FM_*'X+
M?VM9A"5N?X2J:!FJ1WB1?UH%=Y%;"2,%9W\QEZF$"5BQL10EL48%A`-LP\F+
M(;^KL2@)A!,":WYJ;"[.'HW:?S1^99:J?FD4A%D/#,-S"(0%4']JE'\XX9%E
M?FA_$ED(G#EG()(./_3^M'*%AMP?.C[&M#$B3Y@Z51EBT0$CS],1,PWEZ?@S
M\)S_OV$H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`@]+$L(%9+`P:YD2*
M(R#2FS21V*2I]4>`G38"ZE1ZLU1#`Z-IPH9M0R<LUV$"FD:ZDZ;.`3E_I-82
M:Q0ETV%V6CA(>2#LH4IBT[095D<"!F9UTBBM*L%$+,5_L+J1&IA-G+!44S*0
M0"?2'*AQ(4=R(SA26CF!U:+6^C!UFS2H_CP=W$"-VLMB.\=B@T?"7P%W7J<Y
ML!AUX,%"DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@PXL?3[Z\^?/HTZM?
MS[Z]^_?PX\N?3[^^_?OX\^O?S[^___\`!BC@@`06:."!_P@FJ.""##;HX(,0
M1BCAA!16:.&%&&:HX88<=NCAAR"&*.*())9HXHDHIJCBBBRVZ.*+,,8HXXPT
MUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGDDU!&*>645%9IY958
M9JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGGG'36:>>=>.:IYYY\
M]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKII9AFJNFFG';JZ:>@
MABKJJ*26:NJIJ*:JZJJLMNKJJ[#&*NNLM-9JZZVXYJKKKKSVZNNOP`8K[+#$
M%FOLL<@FJ^RRS#;K[+/01BOMM";45FOMM=AFJ^VVW';K[;?@ABONN.26:^ZY
/Z*:K[KKLMNONNU$&`@`[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
